

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number  
WO 2004/022722 A2

(51) International Patent Classification<sup>7</sup>: C12N MA 02139 (US). VAN PARIJS, Luk [—/US]; Scituate, MA (US).

(21) International Application Number: PCT/US2003/028111 (74) Agent: GERBER, Monica, R.; Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA 02109 (US).

(22) International Filing Date:  
5 September 2003 (05.09.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data:  
60/408,558 6 September 2002 (06.09.2002) US  
60/414,195 27 September 2002 (27.09.2002) US  
60/428,039 21 November 2002 (21.11.2002) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; Five Cambridge Center, Cambridge, MA 02142-1493 (US).

(72) Inventors; and  
(75) Inventors/Applicants (for US only): BEAR, James, E. [US/US]; 10 Rose Brook Drive, Durham, NC 27713 (US). DILLON, Christopher, P. [US/US]; 23 Princeton Street #2, Somerville, MA 02144 (US). RUBINSON, Douglas, A. [US/US]; 140 Magazine Street, Apt. 4a, Cambridge,

Published:  
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/022722 A2

(54) Title: LENTIVIRAL VECTORS, RELATED REAGENTS, AND METHODS OF USE THEREOF

(57) Abstract: The present invention provides new lentiviral vectors, including lentiviral transfer plasmids and infectious lentiviral particles. Lentiviral vectors of the invention were designed to offer a number of desirable features including reduced size, convenient cloning sites (including multiple cloning sites and sites for particularly useful restriction enzymes), loxP sites, self-inactivating LTRs, etc. Certain of the vectors are optimized for expression of reporter genes and/or for expression of siRNAs or shRNAs within eukaryotic cells. The invention also provides three and four plasmid lentiviral expression systems. In addition, the invention provides a variety of methods for using the vectors including gene silencing in cells and transgenic animals, and methods of treating disease.

**LENTIVIRAL VECTORS, RELATED REAGENTS,  
AND METHODS OF USE THEREOF**

**Cross-Reference to Related Applications**

5 [0001] This application claims priority to U.S. Provisional Patent Applications Ser. No. 60/408,558, filed September 6, 2002, Ser. No. 60/414,195, filed September 27, 2002, and Ser. No. 60/428,039, filed November 21, 2002. The contents of each of these applications is incorporated herein by reference.

10 **Background of the Invention**

[0002] Viral vectors are efficient gene delivery tools in eukaryotic cells. Useful viral vectors have been created from different virus families, including retroviruses. Retroviruses have proven to be versatile and effective gene transfer vectors for a variety of applications since they are easy to manipulate, typically do not induce a strong anti-viral immune response, and are able to integrate into the genome of a host cell, leading to stable gene expression. If provided with an appropriate envelope, retroviruses can infect almost any type of cell. Due to these advantages a large number of retroviral vectors have been developed for *in vitro* gene transfer. In addition, use of retroviruses for purposes such as the creation of transgenic or 20 knockout animals, or for gene therapy, has been explored.

[0003] However, vectors based on simple retroviruses (e.g., oncoretroviruses) have a number of disadvantages that limit their efficacy for such *in vivo* applications. For example, vectors based on simple retroviruses are generally unable to integrate into the genome of nondividing (postmitotic) cells. Furthermore, transgenes 25 expressed from simple retroviruses are subject to silencing during development (22). To overcome these drawbacks, attention has recently focused on lentiviruses, a group of complex retroviruses that includes the human immunodeficiency virus (HIV). In addition to the major retroviral genes gag, pol, and env, lentiviruses typically include additional genes that play regulatory or structural roles. Unlike simple retroviruses, 30 lentiviruses are able to integrate into the genome of non-dividing cells. Accordingly a variety of lentiviral vectors have been developed. However, existing lentiviral vectors remain less than optimal from a number of perspectives. For example, existing

lentiviral vectors are typically large in size, poorly characterized, and lack various features that facilitate cloning and uses of the vectors. Thus there remains a need in the art for improved lentiviral vectors. The present invention addresses this need.

5 [0004] Rapid progress in technologies for sequencing genes and characterizing their expression profiles has resulted in a growing list of coding regions within mammalian genomes that are predicted to contribute to normal tissue function and to the development of disease. Traditionally, establishing gene function has been accomplished by gene targeting in mouse embryonic stem cells. While this technology has been responsible for many key breakthroughs in our understanding of 10 the normal function as well as diseases of organs and tissues, it remains time-consuming and expensive to perform. Furthermore, current gene targeting approaches cannot be used to alter gene function in human tissues for the purposes of scientific investigation or gene therapy. For these reasons, alternative approaches to inhibit gene activity in primary cells and tissues have been explored.

15 [0005] Among the most promising of these new approaches is RNA interference (RNAi), which has recently emerged as a rapid and efficient means to silence gene function in eukaryotic (including mammalian) cells. As initially described in the nematode *C. elegans*, RNAi involves introduction of double-stranded RNA (dsRNA) into a cell thereby inhibiting gene expression in a sequence dependent fashion. More 20 recently it has been shown that shorter dsRNA species known as short interfering RNAs (siRNA) can silence mammalian gene expression in a specific manner, suggesting that RNAi can be used to study and manipulate gene function in higher organisms as well. However, the use of RNAi in mammalian cells and organisms is currently restricted by the limited delivery methods available. Accordingly, there is a 25 need in the art for improved reagents and methods that would facilitate the use of RNAi in mammalian cells and organisms. The present invention addresses this need, among others.

### Summary of the Invention

30 [0006] The present invention provides novel lentiviral vectors that offer a number of features and advantages. In one aspect, the invention provides a lentiviral vector comprising the following elements: a nucleic acid whose sequence includes (i) a

functional packaging signal; (ii) a multiple cloning site (MCS); and (iii) at least one additional element selected from the group consisting of: a second MCS, a second MCS into which a heterologous nucleic acid is inserted, a human immunodeficiency (HIV) FLAP element, an expression-enhancing posttranscriptional regulatory element, a target site for a site-specific recombinase, and a self-inactivating (SIN) long terminal repeat (LTR). The lentiviral vector may be a lentiviral transfer plasmid or an infectious lentiviral particle. In various embodiments of the invention the expression-enhancing posttranscriptional regulatory element is a woodchuck hepatitis virus regulatory element (WRE), and/or the target site is a loxP site. The invention further provides collections of lentiviral plasmids possessing the features described above.

**[0007]** In other aspects, the invention provides cells, including mammalian cells, and transgenic animals that contain any of the inventive lentiviral vectors or proviruses derived therefrom. The invention further provides methods for making transgenic animals the cells of which comprise an inventive lentiviral vector or a provirus derived therefrom.

**[0008]** The invention further provides a variety of lentiviral expression systems comprising inventive lentiviral transfer plasmids. For example, the invention provides a three-plasmid lentiviral expression system comprising: (a) a first plasmid whose sequence comprises a nucleic acid sequence of at least part of a lentiviral genome, wherein the plasmid (i) contains at least one defect in at least one gene encoding a lentiviral structural protein, and (ii) lacks a functional packaging signal; (b) a second plasmid whose sequence comprises a nucleic acid sequence of a virus, wherein the plasmid (i) expresses a viral envelope protein, and (ii) lacks a functional packaging signal; and (c) a third plasmid whose nucleic acid sequence includes (i) a functional packaging signal; (ii) a multiple cloning site (MCS); and (iii) at least one additional element selected from the group consisting of: a second MCS, a second MCS into which a heterologous nucleic acid is inserted, an HIV FLAP element, an expression-enhancing posttranscriptional regulatory element, a target site for a site-specific recombinase, and a self-inactivating (SIN) LTR.

**[0009]** The invention further provides a four plasmid lentiviral expression system, in which three of the plasmids are as described immediately above and the fourth plasmid encodes the Rev protein.

5 **[0010]** The invention provides methods of creating infectious lentiviral particles and of creating producer cell lines that produce infectious lentiviral particles. The lentiviral particles may, but need not be, derived from the lentiviral transfer plasmids as described herein.

10 **[0011]** The invention further provides a method for introducing and expressing a heterologous nucleic acid in a target cell comprising introducing a lentiviral vector of the invention into the target cell and expressing the heterologous nucleic acid therein. In various embodiments of the invention the heterologous nucleic acid is operably linked to a constitutive, an inducible, or a cell type or tissue specific promoter, allowing conditional expression of the nucleic acid.

15 **[0012]** In another aspect, the invention provides a method for achieving controlled expression of a heterologous nucleic acid in a cell comprising steps of: (i) inserting the heterologous nucleic acid into a lentiviral vector between sites for a recombinase, thereby producing a modified lentiviral vector; (ii) introducing the modified lentiviral vector or a portion thereof including at least the sites for the recombinase and the region between the sites into the cell and; (iii) subsequently inducing expression of 20 the recombinase within the cell, thereby preventing expression of the heterologous nucleic acid within the cell.

25 **[0013]** The invention also provides a method for expressing a transcript in a mammal in a cell type or tissue-specific manner comprising: (i) delivering a lentiviral vector to cells of the mammal, wherein the lentiviral vector comprises a heterologous nucleic acid, and wherein the heterologous nucleic acid is located between sites for a site-specific recombinase; and (ii) inducing expression of the site-specific recombinase in a subset of the cells of the mammal, thereby preventing synthesis of the transcript within those cells.

30 **[0014]** In another aspect, the invention provides a lentiviral vector whose presence within a cell results in transcription of one or more ribonucleic acids (RNAs) that self-hybridize or hybridize to each other to form a short hairpin RNA (shRNA) or short interfering RNA (siRNA) that inhibits expression of at least one target transcript

in the cell. In certain embodiments of the invention the lentiviral vector comprises a nucleic acid segment operably linked to a promoter, so that transcription from the promoter (i.e., transcription directed by the promoter) results in synthesis of an RNA comprising complementary regions that hybridize to form an shRNA targeted to the target transcript. (When an RNA comprises complementary regions that hybridize with each other, the RNA will be said to self-hybridize.) According to certain embodiments of the invention the shRNA comprises a base-paired region approximately 19 nucleotides long. According to certain embodiments of the invention the RNA may comprise more than 2 complementary regions, so that self-hybridization results in multiple base-paired regions, separated by loops or single-stranded regions. The base-paired regions may have identical or different sequences and thus may be targeted to the same or different regions of a single transcript or to different transcripts.

[0015] In certain embodiments of the invention the lentiviral vector comprises a nucleic acid segment flanked by two promoters in opposite orientation, wherein the promoters are operably linked to the nucleic acid segment, so that transcription from the promoters results in synthesis of two complementary RNAs that hybridize with each other to form an siRNA targeted to the target transcript. According to certain embodiments of the invention the siRNA comprises a base-paired region approximately 19 nucleotides long. In certain embodiments of the invention the lentiviral vector comprises at least two promoters and at least two nucleic acid segments, wherein each promoter is operably linked to a nucleic acid segment, so that transcription from the promoters results in synthesis of two complementary RNAs that hybridize with each other to form an siRNA targeted to the target transcript. The nucleic acid segment(s) present within the lentiviral vectors may be part of a larger nucleic acid, e.g., a heterologous nucleic acid that is inserted into the vector as described herein.

[0016] The lentiviral vectors of the invention may be lentiviral transfer plasmids or infectious lentiviral particles (e.g., a lentivirus or pseudotyped lentivirus). As discussed further below, lentiviruses have an RNA genome. Therefore, where the lentiviral vector is a lentiviral particle, the viral genome must undergo reverse transcription and second strand synthesis to produce DNA capable of directing RNA

transcription. In addition, where reference is made herein to elements such as cloning sites, promoters, regulatory elements, etc., it is to be understood that the sequences of these elements are present in RNA form in the lentiviral particles of the invention and are present in DNA form in the lentiviral transfer plasmids of the invention.

5 Furthermore, where a template for synthesis of an RNA is "provided by" RNA present in a lentiviral particle, it is understood that the RNA must undergo reverse transcription and second strand synthesis to produce DNA that can serve as a template for synthesis of RNA (transcription).

[0017] The invention further provides pharmaceutical compositions comprising  
10 any of the inventive lentiviral vectors and a pharmaceutically acceptable carrier.

[0018] The invention further provides a three plasmid lentiviral expression system comprising (i) a lentiviral transfer plasmid, wherein the lentiviral transfer plasmid directs transcription of at least one ribonucleic acid (RNA) that, when present within a cell, hybridizes to form an shRNA or siRNA that inhibits expression of at least one  
15 gene expressed in the cell. (ii) a packaging plasmid; and (iii) an Env-coding plasmid. In certain embodiments of the invention the lentiviral transfer plasmid comprises a nucleic acid segment operably linked to a promoter, so that transcription from the promoter results in synthesis of an RNA that hybridizes to form an shRNA targeted to a target transcript. In certain embodiments of the invention the lentiviral transfer  
20 plasmid comprises a nucleic acid segment flanked by two oppositely directed promoters, wherein the promoters are operably linked to the nucleic acid segment, so that transcription from the promoters results in synthesis of two complementary RNAs that hybridize with each other to form an siRNA targeted to a target transcript. In certain embodiments of the invention the lentiviral transfer plasmid comprises two  
25 promoters and two nucleic acid segments, wherein each promoter is operably linked to a nucleic acid segment, so that transcription from the promoters results in synthesis of two complementary RNAs that hybridize with each other to form an siRNA targeted to a target transcript. The lentiviral transfer plasmid may, but need not be, any of the inventive lentiviral transfer plasmids described herein.

30 [0019] The invention further provides a four plasmid lentiviral expression system comprising a three plasmid lentiviral expression system as described above and a fourth plasmid that encodes the Rev protein.

[0020] The invention additionally provides a method of inhibiting or reducing the expression of a target transcript in a cell comprising delivering a lentiviral vector to the cell, wherein presence of the lentiviral vector within the cell results in synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA that inhibits expression of the target transcript. Note that where presence of the lentiviral vectors, particles, or plasmids of the invention results in production of an shRNA, the shRNA may require further processing within the cell to form an inhibitory structure. shRNAs that are so processed are considered to inhibit expression of the target transcript.

5

[0021] The invention further provides a method for reversibly inhibiting or reducing expression of a target transcript in a cell comprising: (i) delivering a lentiviral vector to the cell, wherein presence of the lentiviral vector within the cell results in synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA that inhibits expression of the target transcript,

10

15 wherein the lentiviral vector comprises a nucleic acid segment located between sites for a site-specific recombinase, which nucleic acid segment provides a template for transcription of the one or more RNAs; and (ii) inducing expression of the site-specific recombinase within the cell, thereby preventing synthesis of at least one of the RNAs. The vector can be a lentiviral transfer plasmid or lentiviral particle.

[0022] The invention also provides a method for reversibly inhibiting or reducing expression of a transcript in a mammal in a cell type or tissue-specific manner comprising: (i) delivering to the mammal a lentiviral vector whose presence within a cell results in synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA that inhibits expression of the target

20

25 transcript, wherein the lentiviral vector comprises a nucleic acid segment located between sites for a site-specific recombinase, which nucleic acid segment provides a template for transcription of the RNA; and (ii) inducing expression of the site-specific recombinase in a subset of the cells of the mammal, thereby preventing synthesis of at least one of the RNAs within the subset of cells. In any of the above methods, the cell

30

may be a mammalian cell, the site-specific recombinase may be Cre, and the sites may be loxP sites.

[0023] The invention includes a variety of therapeutic applications for the inventive lentiviral vectors. In particular, the lentiviral vectors are useful for gene therapy. The invention provides a method of treating or preventing infection by an infectious agent, the method comprising the step of administering to a subject prior to, 5 simultaneously with, or after exposure of the subject to the infectious agent, a composition comprising an effective amount of a lentiviral vector, wherein the lentiviral vector directs transcription of at least one RNA that hybridizes to form an shRNA or siRNA that is targeted to a transcript produced during infection by the infectious agent, which transcript is characterized in that reduction in levels of the 10 transcript delays, prevents, or inhibits one or more aspects of infection by or replication of the infectious agent.

[0024] In addition, the invention provides a method of treating or preventing a disease or clinical condition, the method comprising: (i) removing a population of cells from a subject at risk of or suffering from disease or clinical condition; (ii) 15 engineering or manipulating the cells to contain an effective amount of an siRNA or shRNA targeted to a transcript by infecting or transfecting the cells with a lentiviral vector, wherein the transcript is characterized in that its degradation delays, prevents, or inhibits one or more aspects of the disease or clinical condition; (iii) and returning at least a portion of the cells to the subject. Suitable lentiviral vectors are described 20 herein. Without intending to suggest any limitation, the therapeutic approaches may find particular use in diseases such as cancer, in which a mutation in a cellular gene is responsible for or contributes to the pathogenesis of the disease, and in which specific inhibition of the target transcript bearing the mutation may be achieved by expressing an siRNA or shRNA targeted to the target transcript within the cells, without 25 interfering with expression of the normal allele. According to certain embodiments of the invention, rather than removing cells from the body of a subject, infecting or transfecting them in tissue culture and then returning them to the subject, inventive lentiviral vectors or lentiviruses are delivered directly to the subject.

[0025] This application refers to various patents, journal articles, and other 30 publications, all of which are incorporated herein by reference. In addition, the following publications are incorporated herein by reference: *Current Protocols in Molecular Biology*, *Current Protocols in Immunology*, *Current Protocols in Protein*

*Science*, and *Current Protocols in Cell Biology*, John Wiley & Sons, N.Y., edition as of July 2002; Sambrook, Russell, and Sambrook, *Molecular Cloning: A Laboratory Manual*, 3<sup>rd</sup> ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2001.

5

### Brief Description of the Drawing

- [0026] *Figure 1* shows a map of pBFGW.
- [0027] *Figure 2* shows a map of pLL3.0.
- [0028] *Figure 3* shows a map of pLL3.1.
- [0029] *Figure 4* shows a map of pLL3.2.
- 10 [0030] *Figure 5* shows a map of pLL3.3.
- [0031] *Figure 6* shows a map of pLL3.4.
- [0032] *Figure 7* shows a map of pLL3.5.
- [0033] *Figure 8* shows a map of pLL3.6.
- [0034] *Figure 9* shows a map of pLL3.7.
- 15 [0035] *Figure 10A* shows schematic diagrams of the HIV provirus (upper panel) and relevant portions of representative packaging and Env-coding plasmids (middle and lower panels, respectively) for a three plasmid system.
- [0036] *Figure 10B* shows schematic diagrams of the HIV provirus (upper panel) and relevant portions of representative packaging, Rev-coding and Env-coding plasmids (second, third, and lower panels, respectively) for a four plasmid system.
- 20 [0037] *Figure 11* shows the siRNA structure found to be active in the *Drosophila* system.
- [0038] *Figure 12* presents a schematic representation of the steps involved in RNA interference in *Drosophila*.
- 25 [0039] *Figure 13* shows a schematic diagram of a variety of exemplary shRNA structures useful in accordance with the present invention.
- [0040] *Figure 14* presents a representation of an alternative inhibitory pathway, in which the DICER enzyme cleaves a substrate having a base mismatch in the stem to generate an inhibitory product that binds to the 3' UTR of a target transcript and
- 30 inhibits translation.

[0041] *Figure 15* presents a schematic diagram of a nucleic acid that serves as a template for transcription of an RNA that hybridizes to form an shRNA and also shows the RNA before and after hybridization.

[0042] *Figure 16* presents a schematic diagram of one example of a construct that 5 may be used to direct transcription of sense and antisense strands of an siRNA.

[0043] *Figure 17A* presents a schematic representation of a portion of the lentivirus vector pLL3.7. Key: SIN-LTR: self-inactivating long terminal repeat;  $\Psi$ : HIV packaging signal; cPPT: central polypurine track; U6: U6 (RNA polymerase III) promoter; MCS: multiple cloning site; CMV: cytomegalovirus (RNA polymerase II) 10 promoter; EGFP: enhanced green fluorescent protein; WRE: woodchuck hepatitis virus response element.

[0044] *Figure 17B* presents the sequence of the CD8 stem loop used to generate pLL3.7 CD8 (See Examples). A sequence known to silence CD8 as an siRNA (11) was adapted with a loop sequence from Paddison et al. (39) to create the final 15 sequence. The presumed transcription initiation site is indicated by a +1. Nucleotides which form the loop structure are indicated in green font (Loop). The pol III terminator stretch (a stretch of Us in the RNA) is indicated in red font.

[0045] *Figure 17C* shows the predicted structure of the CD8 stem-loop RNA produced from pLL3.7 CD8.

[0046] *Figure 18A* shows density plots demonstrating specific silencing of CD8 expression by pLL3.7 CD8. CD8 $^+$ CD4 $^+$  E10 cells were either mock infected (No Virus), infected with a pLL3.7 (Control Virus), or pLL3.7 CD8 (CD8 RNAi virus). Density plots indicate the expression levels of CD4 and CD8 48 hours post-infection. 20

[0047] *Figure 18B* presents histograms showing staining for the T cell surface markers, CD3, TCR $\beta$ , and CD28. The histograms show that other surface markers are unaffected by silencing of CD8. E10 cells infected with pLL3.7 (green 25 histograms) or pLL3.7 CD8 (pink histograms) were stained for CD3, TCR $\beta$ , and CD28. Solid histograms represent the level of these surface markers on uninfected cells.

[0048] *Figure 19A* shows stable silencing of CD8 by pLL3.7 CD8. Sorted 30 populations of infected E10 cells were maintained in long-term culture. E10 cells pLL3.7 CD8 (CD8 RNAi virus) were sorted four days after infection for GFP

expression and low CD8 expression, while cells infected with control virus were sorted for GFP expression only. Each population was cultured for 1 month and analyzed for CD8 expression via flow cytometry at weekly intervals. The CD8 and GFP levels expressed by infected cells 4 days following infection and after one month 5 of culture are shown.

[0049] *Figure 19B* shows a Northern blot showing specific degradation of CD8 mRNA induced by pLL3.7 CD8. CD8 and CD4 mRNA levels in uninfected E10 cells, or E10 cells infected with either pLL3.7 (Control Virus) or pLL3.7 CD8 (CD8 RNAi Virus) and sorted on the basis of GFP and CD8 expression, were assayed. The bands 10 representing CD8 and CD4 mRNA species are identified by lines (top panel).

[0050] *Figure 19C* shows generation of processed shRNAs in cells infected with pLL3.7 CD8. The cells analysed for CD8 and CD4 mRNA levels described in the legend to Figure 18B were also assayed for the presence of shRNAs by Northern blot. The location of 21, 22, and 23 nucleotide RNAs are identified by arrows.

[0051] *Figure 20A* presents flow cytometric analysis showing specific silencing 15 of genes in primary T cells by pLL3.7 CD8 and pLL3.7 CD25. CD8<sup>+</sup> TCR transgenic T cells were activated for 3 days with cognate peptide and then infected with pLL3.7, pLL3.7 CD8, or pLL3.7 CD25. The efficiency of infection was determined by assaying GFP expression by flow cytometry. The expression of CD8 and CD25 on 20 infected T cells was assayed by staining with specific antibodies that bind these surface markers.

[0052] *Figure 20B* is a bar graph showing functional silencing of genes in primary T cells with pLL3.7 CD25. CD8<sup>+</sup> TCR transgenic T cells were infected and activated as in A. and then cultured for 48 hours in the presence of increasing 25 concentrations of IL-2. Proliferation was assessed by <sup>3</sup>H-thymidine incorporation.

[0053] *Figure 21A* shows flow cytometric analysis of expression of GFP from pLL3.7 CD8 infection in the AK7 ES cell line. AK7 ES cells were infected with pLL3.7 CD8 and sorted for GFP expression (green line) and compared with uninfected control (purple peak).

[0054] *Figure 21B* shows fluorescent imaging of paws of ES cell-derived mice. 30 The paws of control and pLL3.7 CD8 ES chimeric mice were imaged with standard epifluorescence for expression of EGFP.

[0055] *Figure 21C* shows flow cytometric identification of ES cell-derived thymocytes in chimeric mice. Thymocytes from noninfected (purple peak) and pLL3.7 CD8 (green line) ES derived mice were harvested and analyzed for GFP expression.

5 [0056] *Figure 21D* is a photograph showing expression of CD4 and CD8 in the thymus and spleen of ES cell-derived mice. Thymocytes and splenocytes from week old control and CD8 RNAi (pLL 3.7 CD8) ES cell-derived mice were harvested and stained for CD4 and CD8 expression.

10 [0057] *Figure 22A* shows flow cytometric analysis of EGFP expression in cells infected with an EGFP-expressing lentiviral vector in which the promoter and EGFP coding sequences are floxed. The solid purple peaks represent uninfected cells. The population of cells expressing EGFP is shown with a green line.

15 [0058] *Figure 22B* shows flow cytometric analysis of EGFP expression in cells infected with an EGFP-expressing lentiviral vector 10 days after induction of Cre expression. The solid purple peaks represent uninfected cells. The population of cells expressing EGFP is shown with a green line.

20 [0059] *Figure 22C* shows a direct flow cytometric comparison between pLL3.7 infected D7 cells before (green line) and after (pink line) Cre delivery.

[0060] *Figure 23* shows flow cytometric analysis of CD8 expression in T cells transfected with transfer plasmids that direct expression of either an shRNA targeted to CD8 or an irrelevant stem-loop sequence, demonstrating silencing of CD8 by the CD8 shRNA. GFP expression is on the x-axis, and CD8 expression is on the y-axis. The upper panel shows lack of GFP expression in untransfected cells. The middle panel shows CD8 expression in GFP<sup>+</sup> cells transfected with a transfer plasmid targeted to an unrelated sequence. The lower panel shows reduced CD8 expression in GFP<sup>+</sup> cells transfected with a transfer plasmid targeted to CD8.

25 [0061] *Figure 24* shows flow cytometric analysis of expression of transfected human CD8 in wild type ES cells or ES cells infected with a mouse CD8 shRNA virus, demonstrating that the mouse CD8 shRNA specifically silences mouse CD8 and not human CD8.

[0062] *Figure 25* is a Northern blot showing that higher expression levels of CD8 shRNA in cells that did (left) versus cells that did not (right) exhibit silencing of CD8 following infection with a mouse CD8 shRNA virus.

5

## Definitions

[0063] The term *defective* as used herein refers to a nucleic acid that is not functional with regard to either (i) encoding its gene product or (ii) serving as a signaling sequence. For example, a defective *env* gene sequence does not encode a functional Env protein; a defective packaging signal will not facilitate the packaging 10 of a nucleic acid molecule that includes the defective signal. A nucleic acid may be defective for some but not all of its functions. For example, a defective LTR may fail to promote transcription of downstream sequences while still retaining the ability to direct integration. Nucleic acid sequences may be made defective by any means known in the art, including by mutagenesis, by the deletion of some or all of the 15 sequence, by inserting a heterologous sequence into the nucleic acid sequence, by placing the sequence out-of-frame, or by otherwise blocking the sequence. Defective sequences may also occur naturally, i.e., without human intervention, such as by mutation, and may be isolated from viruses in which they arise. Proteins that are encoded by a defective nucleic acid and are therefore not functional may be referred 20 to as defective proteins. It is to be understood that the term “defective” is relative. In other words, the function need not be completely eliminated but is typically substantially reduced relative to the comparable wild type function. Generally, a defective sequence exhibits less than approximately 10% of the function of the comparable wild type sequence, preferably less than approximately 5% of the 25 function of the comparable wild type sequence, yet more preferably less than approximately 2%, less than approximately 1%, less than approximately 0.5%, or approximately 0%, i.e., below the limits of detection.

[0064] The terms *deleted* or *deletion* are used herein in accordance with their standard usage in the art, i.e., meaning either total removal of the specified segment or 30 the removal of a sufficient portion of the specified segment to render the segment inoperative or nonfunctional with respect to at least one of its functions.

[0065] The term *heterologous* as used herein in reference to a nucleic acid, refers broadly to a first nucleic acid that is inserted into a second nucleic acid such as a plasmid or vector. In particular, the term refers to a nucleic acid that is not naturally present in the wild type version of a virus-based vector or plasmid that is used to

5 deliver the sequence into a cell. The term also refers to a nucleic acid that is introduced into a cell, tissue, organism, etc., by artificial means including, but not limited to, transfection, transformation, or infection with a viral vector. Generally the nucleic acid is either not naturally found in the cell, tissue, or organism or, if naturally found therein, its expression is altered by introduction of the additional copy of the

10 nucleic acid (e.g., if the introduced copy is under the control of a different promoter than the naturally occurring copy). The term is also used to refer to a protein encoded by such a nucleic acid sequence. If a heterologous sequence is introduced into a cell or organism, the sequence is considered heterologous to the progeny of such a cell or organism.

15 [0066] The term *hybridize*, as used herein, refers to the interaction between two complementary nucleic acid sequences. The phrase *hybridizes under high stringency conditions* describes an interaction that is sufficiently stable that it is maintained under art-recognized high stringency conditions. Guidance for performing hybridization reactions can be found, for example, in *Current Protocols in Molecular Biology*, John

20 Wiley & Sons, N.Y., 6.3.1-6.3.6, 1989, and more recent updated editions, all of which are incorporated by reference. See also Sambrook, Russell, and Sambrook, *Molecular Cloning: A Laboratory Manual*, 3<sup>rd</sup> ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2001. Aqueous and nonaqueous methods are described in that reference and either can be used. Typically, for nucleic acid sequences over

25 approximately 50-100 nucleotides in length, various levels of stringency are defined, such as low stringency (e.g., 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by two washes in 0.2X SSC, 0.1% SDS at least at 50°C (the temperature of the washes can be increased to 55°C for medium-low stringency conditions));

30 medium stringency (e.g., 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C); high stringency (e.g., 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C); and very high stringency (e.g., 0.5 M sodium phosphate, 0.1% SDS at 65°C, followed by one or more washes at

0.2X SSC, 1% SDS at 65°C.) Hybridization under high stringency conditions only occurs between sequences with a very high degree of complementarity. One of ordinary skill in the art will recognize that the parameters for different degrees of stringency will generally differ based various factors such as the length of the 5 hybridizing sequences, whether they contain RNA or DNA, etc. For example, appropriate temperatures for high, medium, or low stringency hybridization will generally be lower for shorter sequences such as oligonucleotides than for longer sequences.

[0067] *Infectious*, as used herein in reference to a recombinant virus or viral 10 particle, indicates that the virus or viral particle is able to enter cells in a manner substantially similar or identical to that of a wild type virus and to perform at least one of the functions associated with infection by a wild type virus, e.g., release of the viral genome in the host cell cytoplasm, entry of the viral genome into the nucleus, reverse transcription and integration of the viral genome into the host cell's DNA. It is not 15 intended to indicate that the virus or viral particle is capable of undergoing replication or of completing the viral life cycle. The terms "viral particle" and "virus" are frequently used interchangeably herein. For example, the phrase "production of virus" may refer to production of viral particles and is not intended to indicate that wild type or replication competent virus is produced.

20 [0068] *Isolated*, as used herein, means 1) separated from at least some of the components with which it is usually associated in nature; 2) prepared or purified by a process that involves the hand of man; and/or 3) not occurring in nature.

[0069] *Operably linked*, as used herein, refers to a relationship between two 25 nucleic acid sequences wherein the expression of one of the nucleic acid sequences is controlled by, regulated by, modulated by, etc., the other nucleic acid sequence. For example, the transcription of a nucleic acid sequence is directed by an operably linked promoter sequence; post-transcriptional processing of a nucleic acid is directed by an operably linked processing sequence; the translation of a nucleic acid sequence is directed by an operably linked translational regulatory sequence; the transport or 30 localization of a nucleic acid or polypeptide is directed by an operably linked transport or localization sequence; and the post-translational processing of a polypeptide is directed by an operably linked processing sequence. Preferably a

nucleic acid sequence that is operably linked to a second nucleic acid sequence is covalently linked, either directly or indirectly, to such a sequence, although any effective three-dimensional association is acceptable.

5 [0070] *Purified*, as used herein, means separated from many other compounds or entities, e.g., compounds or entities with which it normally occurs in nature. A compound or entity may be *partially purified*, *substantially purified*, or *pure*, where it is *pure* when it is removed from substantially all other compounds or entities, i.e., is preferably at least about 90%, more preferably at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater than 99% pure.

10 [0071] The term *regulatory sequence* is used herein to describe a region of nucleic acid sequence that directs, enhances, or inhibits the expression (particularly transcription, but in some cases other events such as splicing or other processing, translation, etc.) of sequence(s) with which it is operatively linked. The term includes promoters, enhancers and other transcriptional control elements. In some 15 embodiments of the invention, regulatory sequences may direct constitutive expression of a nucleotide sequence; in other embodiments, regulatory sequences may direct tissue-specific and/or inducible expression. For instance, non-limiting examples of tissue-specific promoters appropriate for use in mammalian cells include lymphoid-specific promoters (see, for example, Calame et al., *Adv. Immunol.* 43:235, 20 1988) such as promoters of T cell receptors (see, e.g., Winoto et al., *EMBO J.* 8:729, 1989) and immunoglobulins (see, for example, Banerji et al., *Cell* 33:729, 1983; Queen et al., *Cell* 33:741, 1983), and neuron-specific promoters (e.g., the neurofilament promoter; Byrne et al., *Proc. Natl. Acad. Sci. USA* 86:5473, 1989). Developmentally-regulated promoters are also encompassed, including, for example, 25 the murine hox promoters (Kessel et al., *Science* 249:374, 1990) and the  $\alpha$ -fetoprotein promoter (Campes et al., *Genes Dev.* 3:537, 1989). In some embodiments of the invention regulatory sequences may direct expression of a nucleotide sequence only in cells that have been infected with an infectious agent. For example, the regulatory sequence may comprise a promoter and/or enhancer such as a virus-specific promoter 30 or enhancer that is recognized by a viral protein, e.g., a viral polymerase, transcription factor, etc.

[0072] A *short, interfering RNA (siRNA)* comprises an RNA duplex that is approximately 19 basepairs long and optionally further comprises one or two single-stranded overhangs or loops. An siRNA may be formed from two RNA strands that hybridize together, or may alternatively be generated from a single RNA strand that includes a self-hybridizing portion. When siRNAs include one or more free strand ends, it is generally preferred that free 5' ends have phosphate groups, and free 3' ends have hydroxyl groups. siRNAs include a portion that hybridizes with a target transcript. In certain preferred embodiments of the invention, one strand of the siRNA is precisely complementary with a region of the target transcript, meaning that the siRNA hybridizes to the target transcript without a single mismatch. In other embodiments of the invention one or more mismatches between the siRNA and the targeted portion of the target transcript may exist. In most embodiments of the invention in which perfect complementarity is not achieved, it is generally preferred that any mismatches be located at or near the siRNA termini.

[0073] The term *short hairpin RNA* refers to an RNA molecule comprising at least two complementary portions hybridized or capable of hybridizing to form a double-stranded structure sufficiently long to mediate RNAi (typically at least 19 base pairs in length), and at least one single-stranded portion, typically between approximately 1 and 10 nucleotides in length that forms a loop. As described further below, shRNAs are thought to be processed into siRNAs by the conserved cellular RNAi machinery. Thus shRNAs are precursors of siRNAs and are similarly capable of inhibiting expression of a target transcript.

[0074] The phrase *structural protein* as used herein refer to the proteins which are required for encapsidation (e.g., packaging) of a retroviral or lentiviral genome, and include Gag, Pol and Env.

[0075] The term *subject*, as used herein, refers to any individual to whom a lentiviral vector of the invention is delivered for any purpose. Preferred subjects are mammals, particularly rodents (e.g., mice and rats), domesticated mammals (e.g., dogs, cats, etc.), primates, or humans.

[0076] An siRNA or shRNA or an siRNA or shRNA sequence is considered to be *targeted* to target transcript for the purposes described herein if 1) the stability of the target transcript is reduced in the presence of the siRNA or shRNA as compared with

its absence; and/or 2) the siRNA or shRNA shows at least about 90%, more preferably at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% precise sequence complementarity with the target transcript for a stretch of at least about 17, more preferably at least about 18 or 19 to about 21-23 nucleotides; and/or 3) 5 one strand of the siRNA or one of the self-complementary portions of the shRNA hybridizes to the target transcript under stringent conditions for hybridization of small (<50 nucleotide) RNA molecules *in vitro* and/or under conditions typically found within the cytoplasm or nucleus of mammalian cells. Since the effect of targeting a transcript is to reduce or inhibit expression of the gene that directs synthesis of the 10 transcript, an siRNA or shRNA targeted to a transcript is also considered to target the gene that directs synthesis of the transcript even though the gene itself (i.e., genomic DNA) is not thought to interact with the siRNA, shRNA, or components of the cellular silencing machinery. Thus as used herein, an siRNA or shRNA that targets a gene is understood to target a transcript whose synthesis is directed by the gene.

15 [0077] The term *vector* is used herein to refer to a nucleic acid molecule capable of mediating entry of, e.g., transferring, transporting, etc., another nucleic acid molecule into a cell. The transferred nucleic acid is generally linked to, e.g., inserted into, the vector nucleic acid molecule. A vector may include sequences that direct autonomous replication, or may include sequences sufficient to allow integration into 20 host cell DNA. Useful vectors include, for example, plasmids, cosmids, and viral vectors. Useful viral vectors include, e.g., replication defective retroviruses, adenoviruses, adeno-associated viruses, and lentiviruses. As will be evident to one of ordinary skill in the art, viral vectors may include various viral components in addition to nucleic acid(s) that mediate entry of the transferred nucleic acid. Thus the 25 term *viral vector* may refer either to a virus or viral particle capable of transferring a nucleic acid into a cell or to the transferred nucleic acid itself. In particular, the terms “lentiviral vector”, “lentiviral expression vector” may be used to refer to lentiviral transfer plasmids and/or lentiviral particles of the invention as described below.

30 **Detailed Description of Certain Preferred Embodiments of the Invention**

[0078] *Retroviruses and retroviral vectors*

[0079] The retrovirus family consists of a group of viruses with a diploid RNA genome that is reverse transcribed during the viral life cycle to yield a double-stranded DNA intermediate that stably integrates into the chromosomal DNA of a host cell. The integrated DNA intermediate is referred to as a provirus. As used 5 herein, a provirus is "derived from" a virus or viral particle that delivers the nucleic acid from which the proviral DNA is reverse transcribed to the cytoplasm of the cell. The retroviral genome and proviral DNA include three genes referred to as *gag*, *pol*, and *env*, flanked by two long terminal repeat sequences (LTRs). The 5' and 3' LTRs contain elements that promote transcription (promoter-enhancer elements) and 10 polyadenylation of viral RNA. The LTRs also include additional cis-acting sequences required for viral replication. In addition, the viral genome includes a packaging signal referred to as psi ( $\Psi$ ) that is necessary for encapsidation (packaging) of the retroviral genome. As used herein, a packaging signal or psi sequence is any sequence sufficient to direct packaging of a nucleic acid whose sequence comprises 15 the packaging signal. This includes naturally occurring psi sequences and also engineered variants thereof.

[0080] Briefly, the normal infective cycle begins when the virus attaches to the surface of a susceptible cell through interaction with one or more cell surface receptors. The virus fuses with the cell membrane, and the viral core is delivered to 20 the cytoplasm, where the viral matrix and capsid become dismantled, releasing the viral genome. Viral reverse transcriptase copies the RNA genome into DNA, which moves into the nucleus, where its integration into host cell DNA is catalyzed by the viral integrase enzyme.

[0081] Once integrated into a host genome, viral DNA can remain dormant for 25 long periods of time. When activated, the viral DNA is transcribed by host cell RNA polymerase. The resulting transcript is both a genome for a new virion and a transcript from which viral *gag* and *gag-pol* polyproteins are synthesized. These polyproteins are later processed into the matrix (MA), capsid (CA), and nucleocapsid (NC) proteins (in the case of *gag*), or the matrix, capsid, protease (PR), reverse 30 transcriptase (RT), and integrase (INT) proteins (in the case of *gag-pol*). The full-length viral RNA transcript also yields transcripts that act as templates for synthesis of other viral proteins including envelope glycoproteins and, in the case of

lentiviruses, a number of regulatory proteins via various splicing events. Newly made Gag and Gag-Pol polyproteins associate with one another, with complete viral genomes, and with envelope proteins in the cell membrane so that a new viral particle begins to assemble at the membrane. As assembly continues, the structure extrudes 5 from the cell, thereby acquiring a lipid coat punctuated with envelope glycoproteins. Further discussion of the retroviral life cycle and features and descriptions of retrovirus classification and taxonomy may be found in Coffin, J., *et al.* (eds.), *Retroviruses*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1997, and in Fields, B., *et al.*, *Fields' Virology*, 4<sup>th</sup> ed., Philadelphia: Lippincott Williams and 10 Wilkins; ISBN: 0781718325, 2001. See also the Web site having URL [www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB](http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB), accessed October 11, 2002, providing a classification and information about viruses, of which retroviruses are entry 61 and lentiviruses are entry 61.0.6.

[0082] The ability of retroviruses to enter host cells and to mediate the integration 15 of heterologous nucleic acid sequences into the cellular genome (transduction) has led to their widespread use for *in vitro* and *in vivo* transfer and expression of nucleic acids, a process often referred to as gene transfer. However, the heterologous nucleic acid need not be a gene and need not encode a protein. As used herein, the term “gene transfer” refers to transfer of any nucleic acid. A transferred nucleic acid is 20 “expressed” in a cell if the introduction of the nucleic acid into the cell results, either directly or indirectly (such as via reverse transcription, integration, transcription, and, in some cases, translation) in the presence of an expression product of the nucleic acid (e.g., an RNA transcript and/or a polypeptide) within the cell.

[0083] Advantages of retroviral vector systems include: (i) efficient entry of 25 genetic material (the vector genome) into cells; (ii) an efficient process of entry into the target cell nucleus; (iii) relatively high levels of gene expression in many settings; (iv) minimal pathological effects on target cells in the case of many retroviruses; and (v) the potential to target particular cellular subtypes through control of the vector-target cell binding and tissue-specific control of gene expression (e.g., using tissue-specific promoters and/or enhancers).

[0084] In using a retrovirus for gene transfer, a foreign (not part of the wild type virus) sequence (e.g., a gene of interest) may be inserted into the retroviral genome in

place of wild type retroviral sequences. When the retrovirus delivers its genome to a cell, the foreign sequence is also introduced into the cell and may then be integrated into the host's cellular DNA as in the case of a wild type retroviral genome. The sequence may then be transcribed by the host cell's transcriptional machinery. If the 5 sequence includes a coding region, translation of the sequence within the host results in expression of the encoded protein by the host cell. The features described above have made retroviral vectors particularly attractive for gene therapy although they may be used in numerous other applications as described below.

[0085] In order to improve their safety, many recombinant retroviruses designed 10 for gene transfer are replication defective, i.e., the genome does not encode functional forms of all the proteins necessary for the complete infective cycle. For example, sequences encoding the structural proteins may be mutated or deleted. In particular, part or all of the sequence encoding the structural proteins may be replaced by a different nucleic acid sequence, i.e., a nucleic acid sequence that is to be introduced 15 into a target cell. However, the packaging signal remains intact. The nucleic acid sequence may include a promoter or its transcription may be under control of the viral LTR promoter-enhancer. In order to produce infectious viral particles that can be used to deliver the recombinant genome to cells, the required viral proteins are provided in trans. This may be accomplished using a variety of approaches as further 20 described below.

[0086] *Lentiviruses and lentiviral vectors*

[0087] Lentiviruses are a family of retroviruses that differ from the simple 25 retroviruses described above in that their genome includes any of a variety of genes in addition to Gag, Pol, and Env and may also include various regulatory elements. The additional genes encode typically include regulatory proteins such as Vif, Vpr, Vpu, Tat, Rev, and Nef. (For a discussion of various transcripts present at different times during the life cycle of HIV, see, for example, Kim et al., *J. Virol.* 63:3708, 1989, incorporated herein by reference). Further discussion of the lentiviral life cycle and features and descriptions of lentivirus classification and taxonomy may be found in 30 Coffin, J., et al. (eds.), *Retroviruses*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1997, and in Fields, B., et al., *Fields' Virology*, 4<sup>th</sup> ed., Philadelphia: Lippincott Williams and Wilkins; ISBN: 0781718325, 2001.

[0088] The fact that retroviruses cannot effectively direct integration into the genome of nondividing cells has limited their use for introducing genes into many important targets such as liver, skeletal muscle, heart, brain, retina, and various cells of the hematopoietic system. In contrast, lentiviruses are able to productively infect 5 and transduce nondividing cells, which has motivated the development of lentiviral vectors for gene transfer<sup>20,21</sup>. For example, lentiviruses are able to infect resting T cells, dendritic cells, and macrophages. Lentiviral vectors can also transfer genes to hematopoietic stem cells with a superior gene transfer efficiency and without affecting the repopulating capacity of these cells. Lentiviral vectors can also 10 transduce liver, skeletal muscle, retina, and neuronal cells. See, e.g., Mautino and Morgan, AIDS Patient Care STDS 2002 Jan;16(1):11-26; Somia, N., et al. *J. Virol.* 74(9): 4420-4424, 2000; Miyoshi, H., et al., *Science* 283: 682-686, 1999; US patent 6,013,516, and references 21 and 24. In addition, lentiviruses display reduced 15 susceptibility to developmental silencing relative to simple retroviruses (24). This feature enables their use for the creation of transgenic animals, which is impractical with simple retroviruses because developmental silencing results in low or undetectable levels of transgene expression.

[0089] As mentioned above, to enhance safety recombinant retroviruses and lentiviruses designed for gene transfer are typically replication defective, i.e., the 20 genome does not encode functional forms of all the proteins necessary for the complete infective cycle. The necessary proteins are therefore provided in trans. According to one approach, these proteins are provided by a packaging cell that has been engineered to produce the proteins. Methods for preparing packaging cell lines that express retrovirus proteins are well known in the art (See, e.g., U.S. Pat. No. 25 4,650,764 to Temin *et al.*, U.S. Patent No. 5,955,331 to Danos, *et al.*, Sheridan *et al.*, *Molecular Therapy* 2(3):262-275, Sep., 2000). Known packaging cell lines include  $\Psi$ 2, PA137, and PA12, among others.

[0090] In the absence of a nucleic acid sequence containing appropriate packaging 30 signals, the packaging cell produces empty virions. When a nucleic acid sequence containing appropriate packaging signals is present within the packaging cell (as may be achieved by either stably or transiently transfecting the cell with a construct

capable of directing transcription of such a sequence), the sequence can be packaged, yielding infectious viral particles. The resulting cell is referred to as a producer cell.

[0091] In the context of certain embodiments of the present invention, a packaging cell will comprise a host cell containing packaging-signal defective nucleic acid sequence(s) coding for retroviral protein(s). The cell is thus able to produce retroviral protein(s) but unable to produce replication-competent infectious virus. 5 Packaging cells may be created by transfecting a host cell (e.g., a human 293T cell) with one or more nucleic acid sequences encoding such protein(s) according to known procedures. Any suitable combination of expression cassettes capable of driving 10 synthesis of the required proteins is sufficient. Typically the packaging cell line contains (i) a modified retroviral genome encoding functional Gag and Gag-Pol polyproteins but unable to produce functional envelope protein; and (ii) a sequence encoding an envelope protein.

[0092] The various proteins need not all originate from the same viral species. 15 For example, the Gag and Pol proteins may be derived from any of a wide variety of retroviruses or lentiviruses. According to certain preferred embodiments of the invention the gag and pol proteins are derived from a lentivirus. According to certain embodiments of the invention the gag and pol proteins are derived from HIV. Many different types of host cell may be used, provided that the cells are permissive for 20 transcription from the promoters employed. Suitable host cells include, for example, 293 cells and derivatives thereof such as, 293.T, 293FT (Invitrogen), 293F, etc., NIH3T3 cells, etc. In general, any mammalian cell that supports transfection and can be grown in sufficient quantities can be used. One of ordinary skill in the art will be able to select appropriate host cells.

[0093] Although an envelope derived from the same retrovirus or lentivirus from 25 which the other viral proteins are derived can be used (homologous envelope) the use of a nonhomologous envelope protein such as the VSV G glycoprotein significantly reduces or eliminates the possibility of generating wild-type virus during vector manufacturing or after introduction of the vectors into host cells. Thus one useful 30 class of lentiviral vectors consists of replication-defective, hybrid viral particles made from the core proteins and enzymes of a lentivirus and the envelope of a different virus such as the vesicular stomatitis virus (VSV) or the Moloney leukemia virus.

[0094] Safety considerations prompted development of alternative approaches to the production of recombinant retroviral and lentiviral particles capable of infecting and transducing cells. According to an approach described in U.S. Patent Number 6,013,516 and also in references 19 and 20, three different constructs may be used to 5 produce the recombinant lentiviral particles. Two of these constructs provide packaging functions, one containing sequences encoding the core proteins and enzymes of the lentivirus and the other containing sequences encoding the envelope protein of a different related or unrelated virus.

[0095] The third construct, referred to herein as a transfer construct, transfer 10 vector, or transfer plasmid, includes a cloning site for insertion of a heterologous nucleic acid (i.e., a sequence not derived from the lentivirus) in addition to the cis-acting viral sequences that are necessary for certain aspects of the viral life cycle such as encapsidation, reverse transcription, and integration.

[0096] The three plasmid system, which does not require helper virus, and use of 15 a heterologous envelope improve the safety of the vector by reducing the likelihood that a replication-competent recombinant could be generated. In addition, removal of various non-essential cis-acting sequences and the discovery that sequences encoding certain viral proteins can be removed while still allowing efficient gene transfer further contributes to the safety of this system. These advances are reviewed in 20 reference 21 and articles listed therein, all of which are incorporated herein by reference.

[0097] The present invention provides new lentiviral transfer plasmids, new 25 replication-defective lentiviruses, and new lentiviral expression systems. Maps of exemplary lentiviral transfer constructs of the invention are provided in Figures 2 through 9 and corresponding sequences are provided as SEQ ID NOS: 2 through 9. However, the invention is not limited to these specific embodiments. Figure 2 shows a map of one of the transfer plasmids of the invention in which nucleotide 0 is indicated. For purposes of description, nucleotides are numbered in a clockwise direction with reference to nucleotide 0, and elements having lower nucleotide 30 numbers are considered 5' to elements having higher nucleotide numbers. Thus, for example, the CMV element is 5' to all other elements shown. Note that various elements depicted in the maps are not shown to scale. Also, the presence of a

particular element on a map is not intended to indicate that the entire element is necessarily present. For example, according to certain embodiments of the invention a portion of the 5' LTR is deleted.

[0098] According to certain embodiments of the invention the lentiviral transfer 5 plasmids are HIV-based lentiviral transfer plasmids. As used herein, a lentiviral plasmid is said to be "based on" a particular lentivirus species (e.g., HIV-1) or group (e.g., primate lentivirus group) if at least 50% of the lentiviral sequences found in the plasmid are derived from a lentivirus of that particular species or group, alternately, if the transfer plasmid displays greater identity or homology to a lentivirus of that 10 particular species or group than to other known lentiviruses. Thus a HIV-based lentiviral transfer plasmid is a transfer plasmid in which at least 50% of the lentiviral sequences are derived from (i.e., originate from), either HIV-1 or HIV-2 or, alternately, if the transfer plasmid displays greater identity or homology to HIV-1 or HIV-2 than to other known lentiviruses. In cases where the origin of any given 15 sequence is unknown, the likelihood that it is derived from a particular lentivirus may be determined by sequence comparison using, e.g., programs such as BLAST, BLASTNR, or CLUSTALW (or variations thereof) in a comprehensive database such as GenBank, Unigene, etc., can be performed using, e.g., default parameters and matrices (e.g., BLOSUM substitution matrix). (BLAST is described in Altschul, SF, 20 et al., Basic local alignment search tool, *J. Mol. Biol.*, 215(3): 403-410, 1990, Altschul, SF and Gish, W, *Methods in Enzymology*.

[0099] The invention provides a lentiviral transfer plasmid whose sequence 25 comprises a nucleic acid sequence including (i) a functional packaging signal; (ii) a multiple cloning site (MCS); and (iii) at least one additional element selected from the group consisting of: a second MCS, a second MCS into which a heterologous promoter or promoter-enhancer is inserted, an HIV FLAP element, an expression-enhancing posttranscriptional regulatory element, a target site for a site-specific recombinase, and a self-inactivating (SIN) LTR. It is to be understood that the target site for a site-specific recombinase is in addition to any site(s) required for integration 30 of the lentiviral genome. In other words, in those embodiments of the invention in which the additional element is a target site for a site-specific recombinase, the lentiviral transfer plasmid will typically also include target sites for the corresponding

lentiviral integrase (which normally exist within the LTRs). In particular, the invention provides (1) a lentiviral transfer construct as described immediately above wherein the additional element is a second MCS; (2) a lentiviral transfer construct as described immediately above wherein the additional element is a second MCS in

5 which a heterologous promoter or promoter-enhancer is inserted; (3) a lentiviral transfer construct as described immediately above wherein the additional element is an HIV FLAP element; (4) a lentiviral transfer construct as described immediately above wherein the additional element is an expression-enhancing posttranscriptional regulatory element such as the woodchuck hepatitis virus regulatory element (WRE);

10 (5) a lentiviral transfer construct as described immediately above wherein the additional element is a recombination site for a site-specific recombinase; and (6) a lentiviral transfer construct as described immediately above wherein the additional element is a SIN LTR. The lentiviral transfer plasmid may also comprise one or more heterologous promoters, enhancers, or promoter-enhancers.

15 [00100] The invention further provides lentiviral transfer plasmids containing at least two, at least three, at least four, at least five, or all of these additional elements. In particular, the invention provides a lentiviral transfer plasmid comprising a nucleic acid sequence that includes (i) a functional packaging signal; (ii) a multiple cloning site (MCS); (iii) a second MCS; (iv) a second MCS in which a heterologous promoter or a heterologous promoter-enhancer is inserted; (v) an HIV FLAP element; (vi) a WRE; (vii) two loxP sites; and a self-inactivating (SIN) LTR. The invention also encompasses lentiviral transfer plasmids as described above in which a heterologous nucleic acid is inserted at a site within an MCS. It will be appreciated that insertion of such a sequence separates the MCS into two parts.

20 [00101] According to preferred embodiments of the invention the transfer plasmid includes the cis-acting sequence elements required to support reverse transcription of a lentiviral genome and also the cis-acting sequence elements necessary for the packaging and integration of a lentiviral genome. These sequences typically include the Psi ( $\Psi$ ) packaging sequence, reverse transcription signals, integration signals, promoter or promoter/enhancer, polyadenylation sequence, tRNA binding site, and origin for second strand DNA synthesis. According to certain embodiments of the invention the transfer plasmid contains a Rev Response Element (RRE) such as that

25

30

located at positions 7622-8459 in the HIV NL4-3 genome (Genbank accession number AF003887). Of course RREs from other strains of HIV can also be used. Such sequences are readily available from Genbank or from the database having URL hiv-web.lanl.gov/content/index. According to certain embodiments of the invention 5 the transfer plasmid contains a 5' HIV R-U5-del gag element such as that located at positions 454-1126 in the HIV NL4-3 genome. According to preferred embodiments of the invention the transfer plasmid contains a sequence encoding a selectable marker such as the ampicillin resistance gene (Amp<sup>R</sup>) and an origin of replication that allows the plasmid to replicate within bacterial cells, such as the pUC origin. Various 10 features and elements mentioned above (and others) are more fully described in the following sections.

[00102] *Lentiviral genome sequences.* The lentiviral transfer plasmids may include lentiviral sequences derived from any of a wide variety of lentiviruses including, but not limited to, primate lentivirus group viruses such as human immunodeficiency 15 viruses HIV-1 and HIV-2 or simian immunodeficiency virus (SIV); feline lentivirus group viruses such as feline immunodeficiency virus (FIV); ovine/caprine immunodeficiency group viruses such as caprine arthritis encephalitis virus (CAEV); bovine immunodeficiency-like virus (BIV); equine lentivirus group viruses such as equine infectious anemia virus; and visna/maedi virus. It will be appreciated that each 20 of these viruses exists in multiple variants or strains.

[00103] According to certain preferred embodiments of the invention most or all of the lentiviral sequences are derived from HIV-1. For example, according to certain embodiments of the invention the lentiviral backbone of the transfer plasmids is derived from an HIV-1-based transfer plasmid such as that described in reference 29 or derivatives thereof such as those described in reference 24. However, it is to be understood that many different sources of lentiviral sequences can be used, and numerous substitutions and alterations in certain of the lentiviral sequences may be accommodated without impairing the ability of the transfer plasmid to perform the functions described herein, and such variations are within the scope of the invention. 25 The ability of any particular lentiviral transfer plasmid to transfer nucleic acids and/or 30 to generate a lentiviral particle capable of infecting and transducing cells in the

presence of the required viral proteins may readily be tested by methods known in the art, some of which will be evident from the Examples.

[00104] *Unique restriction sites and multiple cloning sites.* The invention provides new lentiviral transfer plasmids incorporating sites for a variety of different restriction enzymes. In particular, the invention provides lentiviral transfer constructs including 5 one or more multiple cloning sites (MCS), e.g., one MCS or two MCSs. As is well known in the art, a multiple cloning site, also referred to as a polylinker, or polycloning site, is a cluster of cloning sites such that many restriction enzymes operate within the site. A cloning site as used herein is a known sequence, preferably 10 the only one on the plasmid, (i.e., it is a unique sequence on the plasmid) upon which a restriction enzyme operates to linearize or cut the plasmid. Restriction sites for numerous restriction enzymes are known in the art and are listed, for example, in the catalogs of various manufacturers such as New England Biolabs, Promega, Beeringer- 15 Ingelheim, etc. For purposes of the present invention a restriction site is unique if it is recognized as such in the art or, alternately, if the enzyme displays at least a 5-fold greater likelihood of cutting at the unique site than at any other site in the plasmid under standard digestion conditions.

[00105] Typically an MCS is less than approximately 100 nucleotides in length (measured from the most 5' nucleotide in the most 5' restriction site to the most 3' 20 nucleotide in the most 3' restriction site, and including both of these nucleotides) and contains at least 4 unique restriction sites. According to certain embodiments of the invention an MCS is less than approximately 100 nucleotides in length. According to certain embodiments of the invention an MCS is less than approximately 75 nucleotides in length. According to certain embodiments of the invention an MCS is 25 less than approximately 50 nucleotides in length. According to certain embodiments of the invention the transfer plasmid comprises an MCS containing at least 5 unique restriction sites. According to other embodiments of the invention the transfer plasmid comprises an MCS containing at least 6 unique restriction sites. According to yet other embodiments of the invention the transfer plasmid comprises an MCS containing at least 7 unique restriction sites. According to yet other embodiments of the invention the transfer plasmid comprises an MCS containing at least 8 unique 30 restriction sites. According to yet other embodiments of the invention the transfer

plasmid comprises an MCS containing at least 9 unique restriction sites. According to yet other embodiments of the invention the transfer plasmid comprises at least two MCSs, each of which contains at least 7 unique restriction sites. The invention provides a lentiviral transfer plasmid containing an MCS that includes a site for a 5 restriction enzyme that leaves a blunt end after cutting. The invention further provides a lentiviral transfer plasmid containing an MCS that includes a restriction site that has an 8 bp recognition sequence.

[00106] The invention provides a lentiviral transfer plasmid having unique restriction sites for at least 4 enzymes selected from the group consisting of NotI, 10 ApaI, XhoI, XbaI, HpaI, NheI, PacI, NsiI, SphI, Sma/Xma, AccI, BamHI, and SphI. The invention further provides a lentiviral transfer plasmid having unique restriction sites for at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or at least 13 enzymes selected from the group consisting of NotI, ApaI, XhoI, XbaI, HpaI, NheI, PacI, NsiI, SphI, Sma/Xma, AccI, BamHI, and SphI. The 15 invention further provides collections of two or more of any of the lentiviral transfer plasmids described above. According to certain embodiments of the invention any of the lentiviral transfer plasmids described above are HIV-based transfer plasmids.

[00107] *HIV FLAP element.* According to certain embodiments of the invention the transfer plasmid includes an HIV FLAP element. This sequence contains 20 structural elements associated with the process of reverse transcription and encompasses the central polypurine tract and central termination sequences (cPPT and CTS). As described in Zennou, *et al.*, *Cell*, 101, 173, (2000), during HIV-1 reverse transcription, central initiation of the plus-strand DNA at the central polypurine tract (cPPT) and central termination at the central termination sequence 25 (CTS) lead to the formation of a three-stranded DNA structure: the HIV-1 central DNA flap. While not wishing to be bound by any theory, the DNA flap may act as a cis-active determinant of lentiviral genome nuclear import and/or may increase the titer of the virus.

[00108] *Expression-stimulating posttranscriptional regulatory element.* The 30 invention provides lentiviral transfer plasmids comprising any of a variety of posttranscriptional regulatory elements characterized in that their presence within a transcript increases expression of the heterologous nucleic acid at the protein level.

According to certain embodiments of the invention the posttranscriptional regulatory element is the woodchuck hepatitis virus regulatory element (WRE) as described in Zufferey, R., *et al.*, *J. Virol.*, 73, 2886, 1999. Other posttranscriptional processing elements that may be used include the posttranscriptional processing element present 5 within the genome of various viruses such as that present within the thymidine kinase gene of herpes simplex virus (Liu, X., and J. E. Mertz. *Genes Dev.* 9:1766-1780, 1995), and the posttranscriptional regulatory element (PRE) present in hepatitis B virus (HBV) (Huang, Z. M., and T. S. Yen, *Mol. Cell. Biol.* 5:3864-3869, 1995).

According to the invention the posttranscriptional regulatory element is positioned so 10 that a heterologous nucleic acid inserted into the transfer plasmid in the 5' directly from the element will result in production of a transcript that includes the posttranscriptional regulatory element at the 3' end. Figure 2 shows an example of a transfer plasmid incorporating the WRE downstream of sites for insertion of one or 15 more heterologous nucleic acid sequences. Figure 6 shows an example of a transfer plasmid in which a heterologous nucleic acid encoding EGFP has been inserted in the 5' direction from the WRE and the ubiquitin C (UbC) promoter has been inserted upstream of the sequence encoding EGFP. This configuration results in synthesis of a transcript whose 5' portion comprises EGFP coding sequences and whose 3' portion comprises the WRE sequence.

20 [00109] *Long terminal repeats.* According to certain embodiments of the invention the transfer plasmid includes a self-inactivating (SIN) LTR (29). As is known in the art, during the retroviral life cycle, the U3 region of the 3' LTR is duplicated to form the corresponding region of the 5' LTR in the course of reverse transcription and viral 25 DNA synthesis. Creation of a SIN LTR is achieved by inactivating the U3 region of the 3' LTR (preferably by deletion of a portion thereof as described in reference 29). The alteration is transferred to the 5' LTR after reverse transcription, thus eliminating the transcriptional unit of the LTRs in the provirus, which should prevent mobilization by replication competent virus. An additional safety enhancement is provided by replacing the U3 region of the 5' LTR with a heterologous promoter to 30 drive transcription of the viral genome during production of viral particles.

Appropriate promoters include, e.g., the CMV promoter. Preferred promoters are able to drive high levels of transcription in a Tat-independent manner. This replacement

further reduces the possibility of recombination to generate replication-competent virus because there is no complete U3 sequence in the virus production system. Thus in certain embodiments of the invention the transfer plasmid includes a self-inactivating (SIN) 3' LTR. In certain embodiments of the invention the transfer 5 plasmid includes a 5' LTR in which the U3 region is replaced with a heterologous promoter. The heterologous promoter drives transcription during transient transfection but after reverse transcription it gets replaced by a copy of U3 from the 3' LTR, which in the case of a SIN LTR contains a deletion that makes it unable to drive transcription. Thus all transcription is driven by the internal promoter after 10 integration.

[00110] According to certain embodiments of the invention one or both LTRs contain sequences that can be used to introduce insulator sequences into the vectors. In general, insulators are elements that can help to preserve the independent function of genes or transcription units embedded in a genome or genetic context in which 15 their expression may otherwise be influenced by regulatory signals within the genome or genetic context. See, for example, Burgess-Beusse B, et al., *Proc. Natl. Acad. Sci.* published August 1, 2002, 10.1073/pnas.162342499 and Zhan HC, et al., *Hum Genet.* Nov;109(5):471-8, 2001. In the context of the present invention, insulators "protect" the lentivirus-expressed sequences from integration site effects, which are mediated 20 by cis-acting elements present in genomic DNA, and lead to deregulated expression of transferred sequences. The invention provides transfer plasmids in which an insulator sequence is inserted into one or both LTRs.

[00111] *Heterologous promoters and promoter/enhancers.* Any of a wide variety of heterologous promoter and promoter/enhancer elements may be included in the 25 transfer plasmids and used to direct transcription of a heterologous nucleic acid sequence in cells infected with the recombinant lentiviral particles of the invention or cells into which the transfer plasmids of the invention have been introduced, e.g., by transfection. According to certain embodiments of the invention the transfer plasmids and lentiviral particles include a single heterologous promoter. In other embodiments 30 two or more heterologous promoters are included. The promoters may be in the same or in opposite orientation.

[00112] One of ordinary skill in the art will readily be able to select appropriate promoters depending upon the particular application. For example, sometimes it will be desirable to achieve constitutive, non-tissue specific, high level expression of a heterologous nucleic acid sequence. For such purposes viral promoters or

5 promoter/enhancers such as the SV40 promoter, CMV promoter or promoter/enhancer, etc., may be employed. Mammalian promoters such as the beta-actin promoter, ubiquitin C promoter, elongation factor 1 $\alpha$  promoter, tubulin promoter, etc., may also be used. If the plasmids are to be used in non-mammalian cells, appropriate promoters for such cells should be selected.

10 [00113] It may be desirable to achieve cell type specific or tissue-specific expression of a heterologous nucleic acid sequence (e.g., to express a particular heterologous nucleic acid in only a subset of cell types or tissues or during specific stages of development), tissue-specific promoters may be used. For example, it may be desirable to achieve conditional expression in the case of transgenic animals or for

15 therapeutic applications, including gene therapy. As used herein, the term "tissue specific promoter" refers to a regulatory element (e.g., promoter, promoter/enhancer or portion thereof) that preferentially directs transcription in only a subset of cell or tissue types, or during discrete stages in the development of a cell, tissue, or organism. A tissue specific promoter may direct transcription in only a single cell type or in

20 multiple cell types (e.g., two to several different cell types). Numerous tissue-specific promoters are known, and one of ordinary skill in the art will readily be able to identify tissue specific promoters (or to determine whether any particular promoter is a tissue specific promoter) from the literature or by performing experiments such as Northern blots, immunoblots, etc. in which expression of either an endogenous gene

25 or a reporter gene operably linked to the promoter is compared in different cell or tissue types). For example, the nestin, neural specific enolase, NeuN, and GFAP promoters direct transcription in various neural or glial lineage cells; the keratin 5 promoter directs transcription in keratinocytes; the MyoD promoter directs transcription in skeletal muscle cells; the insulin promoter directs transcription in pancreatic beta cells; the CYP450 3A4 promoter directs transcription in hepatocytes. The invention therefore provides lentiviral transfer plasmids as described above

30 comprising a tissue-specific promoter and methods of using the transfer plasmids and

lentiviral particles derived therefrom to achieve cell type or tissue specific expression.

Preferred promoters are active in mammalian cells. According to certain embodiments of the invention the tissue-specific promoter is specific for brain (e.g., neurons), liver (e.g., hepatocytes), pancreas, skeletal muscle (e.g., myocytes), immune system cells (e.g., T cells, B cells, macrophages), heart (e.g., cardiac myocytes), retina, skin (e.g., keratinocytes), bone (e.g., osteoblasts or osteoclasts), etc.

5 [00114] It may be desirable to achieve conditional expression of a heterologous nucleic acid sequence (e.g., to control expression of a particular heterologous nucleic acid by subjecting a cell, tissue, organism, etc., to a treatment or condition that causes the heterologous nucleic acid to be expressed or that causes an increase or decrease in expression of the heterologous nucleic acid), for which purpose a variety of inducible promoters and systems. In particular, it may be desirable to achieve conditional expression in the case of transgenic animals or for therapeutic applications, including gene therapy. See, e.g., Haviv YS and Curiel DT, *Adv Drug Deliv Rev*, 53(2):135-54, 10 2001, describing approaches for achieving conditional gene expression in cancer cells. As used herein, "conditional expression" may refer to any type of conditional expression including, but not limited to: inducible expression; repressible expression; expression in cells or tissues having a particular physiological, biological, or disease state, etc. This definition is not intended to exclude cell type or tissue-specific expression, since the type of cell or tissue may also be considered a condition.

15 [00115] One approach to achieving conditional expression involves the use of inducible promoters. As used herein, the term "inducible promoter" refers to a regulatory element (e.g., a promoter, promoter/enhancer or portion thereof) whose transcriptional activity may be regulated by exposing a cell or tissue containing a nucleic acid sequence operably linked to the promoter to a treatment or condition that alters the transcriptional activity of the promoter, resulting in increased transcription of the nucleic acid sequence. For convenience, as used herein, the term "inducible promoter" also includes repressible promoters, i.e., promoters whose transcriptional activity may be regulated by exposing a cell or tissue containing a nucleic acid 20 sequence operably linked to the promoter to a treatment or condition that alters the transcriptional activity of the promoter, resulting in decreased transcription of the nucleic acid sequence. Preferred inducible promoters are active in mammalian cells.

Inducible promoters include, but are not limited to steroid-inducible promoters such as the promoters for the genes encoding the glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormone), metallothionein promoter (inducible by treatment with various heavy metals), MX-1 promoter (inducible by 5 interferon), etc. The invention therefore provides lentiviral transfer plasmids as described above comprising a tissue-specific promoter and methods of using the transfer plasmids and lentiviral particles derived therefrom to achieve cell type or tissue specific expression.

[00116] Another approach to achieving conditional expression involves use of 10 binary transgenic systems, in which gene expression is controlled by the interaction of two components: a "target" transgene and an "effector" transgene, whose product acts on the target transgene. See, e.g., Lewandoski, M., *Nature Reviews Genetics* 2, 743-755 (2001) and articles referenced therein, all of which are incorporated herein by reference, reviewing methods for achieving conditional expression in mice. In 15 general, binary transgenic systems fall into two categories. In the first type of system, the effector transactivates transcription of the target transgene. For example, in the tetracycline-dependent regulatory systems (Gossen, M. & Bujard, H, *Proc. Natl Acad. Sci. USA* 89, 5547-5551 (1992), the effector is a fusion of sequences that encode the VP16 transactivation domain and the *Escherichia coli* tetracycline repressor (TetR) 20 protein, which specifically binds both tetracycline and the 19-bp operator sequences (*tetO*) of the *tet* operon in the target transgene, resulting in its transcription. In the original system, the tetracycline-controlled transactivator (tTA) cannot bind DNA when the inducer is present, while in a modified version, the 'reverse tTA' (rtTA) binds DNA only when the inducer is present ('tet-on') (Gossen, M. *et al.*, *Science* 268, 25 1766-1769 (1995)). The current inducer of choice is doxycycline (Dox). The invention therefore provides lentiviral transfer plasmids as described above comprising a tetracycline-controlled transactivator or reverse tetracycline-controlled transactivator, lentiviral transfer plasmids comprising operator sequences of the *tet* operon to which the tetracycline-controlled transactivator or reverse tetracycline-controlled transactivator specifically bind, and methods of using the transfer plasmids 30 and lentiviral particles derived therefrom to achieve conditional expression, including the generation of transgenic animals in which conditional expression is achieved.

[00117] In the second type of system, the effector is a site-specific DNA recombinase that rearranges the target gene, thereby activating or silencing it. These systems are described below. In order to achieve conditional expression in cells or tissues having a particular physiological, biological, or disease state, a promoter that 5 is selectively active in cells or tissue having that particular physiological, biological, or disease state may be used.

[00118] As described further below, one application for the lentiviral transfer plasmids and lentiviral expression systems of the invention is to direct transcription of RNAs that hybridize or self-hybridize to form siRNAs or shRNAs in cells, e.g., 10 mammalian cells. For these purposes in certain embodiments of the invention it is preferred to use a PolIII promoter such as the U6 or H1 promoter. Therefore, the invention provides lentiviral transfer plasmids and lentiviral particles optimized for siRNA, i.e., lentiviral transfer plasmids and lentiviral particles comprising a PolIII promoter, e.g., the U6 or H1 promoter. According to certain embodiments of the 15 invention the PolIII promoter is inducible. It is noted that Pol II promoters can also be used to achieve intracellular expression of siRNA or shRNA (Xia, H., *et al.*, *Nat. Biotech.*, 20: 1006-1010, 2002), and the lentiviral vectors described herein may be used in this manner.

[00119] *Transfer plasmid size.* As described in further detail in Example 1, by 20 removing certain dispensable sequences the inventors have created lentiviral transfer plasmids having reduced size relative to previously known lentiviral transfer plasmids, which results in a number of advantages. First, the reduced size of the transfer constructs adds to their ease of manipulability. Second, the reduced size adds to their flexibility. As is known in the art, there is a limit to the size of retroviral 25 genomes that can be efficiently packaged. Generally it is preferable to limit the size of the transcript for packaging (distance between 5' and 3' UTRs) to less than approximately 8-10 kB. Thus removal of the dispensable sequences allows the insertion of larger heterologous sequence(s) without compromising the ability of the resulting genomic transcript to be packaged during the production of lentiviral particles. As used herein in reference to retroviral and lentiviral vectors, a "genome" 30 or "genomic transcript" generally refers to a transcript that contains sufficient packaging signals to allow packaging. It does not imply that the transcript need

contain all or even most of the genetic information found in a wild type virus. In general, the sequence of a genomic transcript will depend on the location of the promoter upstream of the packaging sequence and the location of the polyadenylation site downstream of the packaging sequence.

5 [00120] The invention provides a lentiviral transfer plasmid having a length less than 10 kilobases (kB). The invention provides a lentiviral transfer plasmid having a length less than 9 kB. The invention provides a lentiviral transfer plasmid having a length less than 8 kB). The invention provides a lentiviral transfer plasmid having a length less than 7 kB). The invention provides a lentiviral transfer plasmid having a  
10 length less than 6.5 kB). The invention provides a lentiviral transfer plasmid having a length of approximately 6 kB). Generally, unless otherwise evident from the context, the term "approximately" means that the value may deviate by 10% or less from the numeral given, and the ranges listed are assumed to include both endpoints. The invention further provides collections of lentiviral plasmids having a length less than  
15 10 kB, a length less than 9 kB, a length less than 8 kB, or a length less than 7 kB.

[00121] In particular, the invention provides a lentiviral transfer plasmid having a length less than 8 kB and comprising one or more heterologous nucleic acid sequences. According to certain embodiments of the invention the heterologous nucleic acid sequence is a promoter or promoter/enhancer such as the CMV promoter, 20 the CMV promoter/enhancer, or the Ubiquitin C promoter. According to certain embodiments of the invention the promoter is the U6 or H1 promoter. According to certain embodiments of the invention the heterologous nucleic acid sequence is a reporter gene, e.g., a gene encoding EGFP or dsRed2. The invention particularly provides a lentiviral transfer plasmid having a length of approximately 6.0 kB  
25 comprising at least one MCS, two LoxP sites, an HIV FLAP element, and a WRE.

[00122] *Transfer plasmid sequence information.* The inventors have recognized that prior art lentiviral vector systems suffered from a dearth of sequence information. As will be readily appreciated by one of ordinary skill in the art, regardless of the particular nature of a transfer plasmid, it is desirable to have complete and accurate 30 sequence information. Such information makes it possible, for example, to readily determine the identity of all restriction sites, to design primers for amplification of particular plasmid sequences or for other purposes such as the introduction of

mutations, etc. In addition, the availability of complete sequence information makes it possible to identify determinants of plasmid function, e.g., by engineering mutations at specific sites and observing the effect on, for example, packaging, integration, transcription, etc. Accordingly, the invention provides a fully sequenced lentiviral transfer plasmid, wherein the sequence is deposited in a publicly accessible database. By "fully sequenced" is meant that the complete nucleotide sequence of the plasmid is known. By "publicly accessible database" is meant Genbank, or any other database that can be accessed by the public without requiring a fee. In particular, the invention provides a fully sequenced lentiviral transfer plasmid comprising the sequence set forth in any of the following SEQ ID NOS: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. In addition, the invention provides a collection of lentiviral transfer plasmids including at least two of the plasmids having SEQ ID NOS: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. In addition, the invention provides a lentiviral transfer plasmid having a sequence that differs by not more than 100 nucleotides from the sequence set forth in SEQ ID NOS: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. The invention further provides a lentiviral transfer plasmid having a sequence that differs by not more than X nucleotides from the sequence set forth in SEQ ID NOS: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, where X represents any number between 1 and 99, inclusive. By "a sequence that differs by not more than X nucleotides (where X is any number) from the sequence of SEQ ID NO: Y" is meant any sequence that can be obtained from SEQ ID NO: Y by either inserting, deleting, and/or altering less than X nucleotides of SEQ ID NO: Y.

**[00123] Recombination sites for site-specific recombinase.** According to certain embodiments of the invention the transfer plasmid includes at least one (typically two) site(s) for recombination mediated by a site-specific recombinase. Site-specific recombinases catalyze the introduction or excision of DNA fragments from a longer DNA molecule. These enzymes recognize a relatively short, unique nucleic acid sequence, which serves for both recognition and recombination. Typically the

recombination site is composed of short inverted repeats (6, 7 or 8 base pairs in length) and the length of the DNA-binding element is typically 11-13 bp in length.

[00124] In general, the transfer plasmids may contain one or more recombination sites for any of a wide variety of site-specific recombinases. As mentioned above, it  
5 is to be understood that the target site for a site-specific recombinase is in addition to any site(s) required for integration of the lentiviral genome. According to various embodiments of the invention the transfer plasmid includes one or more sites for a recombinase enzyme selected from the group consisting of Cre, XerD, HP1 and Flp. These enzymes and their recombination sites are well known in the art. See, for  
10 example, Sauer, B. & Henderson, N., *Nucleic Acids Res.* 17, 147-161 (1989), Gorman, C. and Bullock, C., *Curr. Op. Biotechnol.*, 11(5): 455-460, 2000, O'Gorman, S., Fox, D. T. & Wahl, G. M., *Science* 251, 1351-1355 (1991) and Kolb, A., *Cloning Stem Cells*, 4(1):65-80, 2002, and U.S. Patent 4,959,317. See also Kuhn, R., and Torres, RM, *Methods Mol Biol* 2002;180:175-204.  
15 [00125] These recombinases catalyse a conservative DNA recombination event between two 34-bp recognition sites (*loxP* and *FRT*, respectively). Placing a heterologous nucleic acid sequence operably linked to a promoter element between two *loxP* sites (in which case the sequence is "floxed") allows for controlled expression of the heterologous sequence following transfer into a cell. By inducing  
20 expression of Cre within the cell, the heterologous nucleic acid sequence is excised, thus preventing further transcription and effectively eliminating expression of the sequence. This system has a number of applications including Cre-mediated gene activation (in which either heterologous or endogenous genes may be activated, e.g., by removal of an inhibitory element or a polyadenylation site), creation of transgenic  
25 animals exhibiting temporal control of Cre expression, cell-lineage analysis in transgenic animals, and generation of tissue-specific knockouts or knockdowns in transgenic animals.

[00126] According to certain embodiments of the invention the transfer plasmid includes two *loxP* sites. Furthermore, in preferred embodiments of the invention the transfer plasmid includes a cloning site, e.g., a unique restriction site, between the two *loxP* sites, which allows the convenient insertion of a heterologous nucleic acid sequence. According to certain embodiments of the invention the transfer plasmid

includes a MCS between the two loxP sites. According to certain embodiments of the invention the two loxP sites are located between an HIV FLAP element and a WRE. According to certain embodiments of the invention the plasmid contains a unique restriction site between the 3' loxP site and the WRE.

5 [00127] As described above, positioning the heterologous nucleic acid sequence between loxP sites allows for controlled expression of the heterologous sequence following transfer into a cell. By inducing Cre expression within the cell, the heterologous nucleic acid sequence is excised, thus preventing further transcription and effectively eliminating expression of the sequence. Cre expression may be  
10 induced in any of a variety of ways. For example, Cre may be present in the cells under control of an inducible promoter, and Cre expression may be induced by activating the promoter. Alternately, Cre expression may be induced by introducing an expression vector that directs expression of Cre into the cell. Any suitable expression vector can be used, including, but not limited to, viral vectors such as  
15 adenoviral vectors. (The phrase "inducing Cre expression" as used herein refers to any process that results in an increased level of Cre within a cell.)

[00128] The invention thus provides a method for achieving controlled expression of a heterologous nucleic acid sequence comprising steps of inserting the heterologous nucleic acid sequence into a transfer plasmid of the invention between 20 sites for a recombinase, thereby producing a modified transfer plasmid; introducing the modified transfer plasmid or a portion thereof including at least the sites for the recombinase and the region between the sites into a cell and; subsequently inducing expression of the recombinase within the cell. According to certain embodiments of the invention the cell is a mammalian cell. According to certain embodiments of the 25 invention the recombinase is Cre and the sites for the recombinase are loxP sites. In accordance with the invention the transfer plasmid may be introduced into the cell using standard techniques such as transfection. Alternately, the transfer plasmid may be used to generate a lentiviral particle that includes a lentiviral genome comprising the recombinase sites and the region between them. As described elsewhere herein, 30 the genome integrates into the cell's DNA and directs expression of the heterologous nucleic acid sequence. The cell may be used for any of a variety of purposes as described in more detail below.

[00129] The lentiviral transfer plasmids comprising two loxP sites are useful in any applications for which standard vectors comprising two loxP sites can be used. For example, selectable markers may be placed between the loxP sites. This allows for sequential and repeated targeting of multiple genes to a single cell (or its progeny).

5 After introduction of a transfer plasmid comprising a floxed selectable marker into a cell, stable transfectants may be selected. After isolation of a stable transfectant, the marker can be excised by induction of Cre. The marker may then be used to target a second gene to the cell or its progeny. Lentiviral particles comprising a lentiviral genome derived from the transfer plasmids may be used in the same manner.

10 [00130] As another example, standard gene-targeting techniques may be used to produce a mouse in which an essential region of a gene of interest is floxed, so that tissue-specific Cre expression results in the inactivation of this allele. The transfer plasmids may be introduced into cells (e.g., ES cells) using pronuclear injection. Alternately, the cells may be injected or infected with lentiviral particles comprising a

15 lentiviral genome derived from the transfer plasmid. Tissue-specific Cre expression may be achieved by crossing a mouse line with a conditional allele (i.e., a floxed nucleic acid sequence) to an effector mouse line that expresses *cre* in a tissue-specific manner, so that progeny are produced in which the conditional allele is inactivated only in those tissues or cells that express Cre. Suitable transgenic lines are known in

20 the art and may be found, for example, in the Cre Transgenic Database at the Web site having URL [www.mshri.on.ca/nagy/Cre-pub.html](http://www.mshri.on.ca/nagy/Cre-pub.html).

[00131] *Internal ribosome entry sequence (IRES)*. The transfer plasmids may also include an IRES. IRES elements function as initiators of the efficient translation of reading frames. An IRES allows ribosomes to start the translation process anew with

25 whatever is immediately downstream and regardless of whatever was upstream. In particular, an IRES allows for the translation of two different genes on a single transcript. For example, an IRES allows the expression of a marker such as EGFP off the same transcript as a transgene, which has a number of advantages: (1) The transgene is native and does not have any fused open reading frames that might affect

30 function; (2) Since the EGFP is from the same transcript its levels should be an accurate representation of the levels of the upstream transgene. IRES elements are known in the art and are further described in Kim, et al., *Molecular and Cellular*

*Biology* 12(8):3636-3643 (August 1992) and McBratney, et al., *Current Opinion in Cell Biology* 5:961-965 (1993).

[00132] Any of a wide variety of sequences of viral, cellular, or synthetic origin which mediate internal binding of the ribosomes can be used as an IRES. Examples 5 include those IRES elements from poliovirus Type I, the 5'UTR of encephalomyocarditis virus (EMV), of Thelier's murine encephalomyelitis virus (TMEV) of foot and mouth disease virus (FMDV) of bovine enterovirus (BEV), of coxsackie B virus (CBV), or of human rhinovirus (HRV), or the human immunoglobulin heavy chain binding protein (BIP) 5'UTR, the *Drosophila antennapediae* 5'UTR or the *Drosophila ultrabithorax* 5'UTR, or genetic hybrids or fragments from the above-listed sequences.

[00133] *Transfer plasmids incorporating heterologous nucleic acids.* The invention provides new lentiviral transfer constructs incorporating a variety of heterologous 10 nucleic acids (also referred to as heterologous sequences or heterologous nucleic acid segments), preferably operably linked to a promoter or promoter/enhancer element. These sequences may be inserted at any available site within the transfer plasmid including, but not limited to, at a restriction site within a MCS. In general, the 15 inserted nucleotide sequence may be any nucleotide sequence and may be a naturally occurring sequence or variant thereof or an artificial sequence. Heterologous gene sequences of the present invention may comprise one or more gene sequences that already possess one or more regulatory elements such as promoters, initiation 20 sequences, processing sequences, etc. Alternatively, such regulatory elements may be present within the transfer plasmid prior to insertion of the heterologous sequence.

[00134] According to certain embodiments of the invention the inserted 25 heterologous sequence is a reporter gene sequence. A reporter gene sequence, as used herein, is any gene sequence which, when expressed, results in the production of a protein whose presence or activity can be monitored. Suitable reporter gene sequences include, but are not limited to, sequences encoding chemiluminescent or 30 fluorescent proteins such as green fluorescent protein (GFP) and variants thereof such as enhanced green fluorescent protein (EGFP); cyan fluorescent protein; yellow fluorescent protein; blue fluorescent protein; dsRed or dsRed2, luciferase, aequorin, etc. Many of these markers and their uses are reviewed in van Roessel, P. and Brand,

A., *Nature Cell Biology*, 4(1), E15-20, 2002, and references therein, all of which are incorporated herein by reference. Additional examples of suitable reporter genes include the gene for galactokinase, beta-galactosidase, chloramphenicol acetyltransferase, beta-lactamase, etc. Alternatively, the reporter gene sequence may 5 be any gene sequence whose expression produces a gene product which affects cell physiology or phenotype. In general, a reporter gene sequence typically encodes a protein that is not normally present within a cell into which the transfer plasmid is to be introduced.

[00135] According to certain embodiments of the invention the inserted 10 heterologous sequence is a selectable marker gene sequence, which term is used herein to refer to any gene sequence capable of expressing a protein whose presence permits the selective maintenance and/or propagation of a cell which contains it. Examples of selectable marker genes include gene sequences capable of conferring 15 host resistance to antibiotics (e.g., puromycin, ampicillin, tetracycline, kanamycin, and the like), or of conferring host resistance to amino acid analogues, or of permitting the growth of cells on additional carbon sources or under otherwise impermissible culture conditions. A gene sequence may be both a reporter gene and a 20 selectable marker gene sequence. In general, preferred reporter or selectable marker gene sequences are sufficient to permit the recognition or selection of the plasmid in normal cells.

[00136] The heterologous sequence may also comprise the coding sequence of a 25 desired product such as a biologically active protein or polypeptide (e.g., a therapeutically active protein or polypeptide) and/or an immunogenic or antigenic protein or polypeptide. Introduction of the transfer plasmid into a suitable cell thus results in expression of the protein or polypeptide by the cell. Alternatively, the heterologous gene sequence may comprise a nucleic acid segment that provides a template for transcription of an antisense RNA, a ribozyme, or, preferably, one or 30 more strands of a short interfering RNA (siRNA) or a precursor thereof such as a short hairpin RNA (shRNA). As described further below, siRNAs and shRNAs targeted to cellular transcripts inhibit expression of such transcripts. Introduction of the transfer plasmid into a suitable cell thus results in production of the siRNA or shRNA, which inhibits expression of the target transcript.

[00137] *Three and four plasmid lentiviral expression systems.* The invention further provides a recombinant lentiviral expression system comprising three plasmids. The first plasmid is constructed to contain mutations that prevent lentivirus-mediated transfer of viral genes. Such mutations may be a deletion of sequences in the viral env gene, thus preventing the generation of replication-competent lentivirus, or may be deletions of certain cis-acting sequence elements at the 3' end of the genome required for viral reverse transcription and integration. Thus even if viral genes from this construct are packaged into viral particles, they will not be replicated and replication-competent wild-type viruses will not be produced. The first plasmid (packaging plasmid) comprises a nucleic acid sequence of at least part of a lentiviral genome, wherein the vector (i) contains at least one defect in at least one gene encoding a lentiviral structural protein, and (ii) lacks a functional packaging signal. The second plasmid (Env-coding plasmid) comprises a nucleic acid sequence of a virus, wherein the vector (i) expresses a viral envelope protein, and (ii) lacks a functional packaging signal. The third plasmid may be any of the inventive transfer plasmids described above. The first and second plasmids are further described below, and schematic diagrams of relevant portions of representative first and second plasmids (packaging and Env-coding) are presented in Figure 10A, which is taken from reference 21. The third plasmid (not shown) is a transfer plasmid.

[00138] *Packaging plasmid.* In certain embodiments of the invention the first vector is a *gag/pol* expression vector, i.e., a plasmid capable of directing expression of functional forms of a retroviral *gag* gene product and a retroviral *Pol* gene product. These proteins are necessary for assembly and release of viral particles from cells. The first plasmid may also express sequences encoding various accessory lentiviral proteins including, but not limited to, Vif, Vpr, Vpu, Tat, Rev, and Nef. In particular, the first plasmid may express a sequence encoding Rev. In general, the *gag* and *pol* sequences may be derived from any retrovirus, and the accessory sequences may be derived from any lentivirus. According to certain embodiments of the invention the *gag* and *pol* sequences and any accessory sequences are derived from HIV-1. It is noted that the *gag*, *pol*, and accessory protein sequences need not be identical to wild type versions but instead may contain mutations, deletions, etc., that do not

significantly impair the ability of the protein to perform its function in the viral life cycle.

[00139] The first plasmid is preferably constructed to contain mutations that exclude retroviral-mediated transfer of viral genes. Such mutations may be a deletion 5 or mutation of sequences in the viral *env* gene, thus excluding the possibility of generating replication-competent lentivirus. Alternatively, or in addition to, deletion or mutation of *env*, according to certain embodiments of the invention the plasmid sequence may contain deletions of certain *cis*-acting sequence elements at the 3' end of the genome required for viral reverse transcription and integration. Accordingly, 10 even if viral genes from this construct are packaged into viral particles, they will not be replicated and replication-competent wild-type viruses will not be generated. Any of a wide variety of packaging plasmids may be used in the three plasmid lentiviral expression system of the invention including, but not limited to, those described in references 21, 24, 29, and 40.

[00140] *Env-coding plasmid.* This plasmid directs expression of a viral envelope protein and, therefore, comprises a nucleic acid sequence encoding a viral envelope protein under the control of a suitable promoter. The promoter can be any promoter capable of directing transcription in cells into which the plasmid is to be introduced. One of ordinary skill in the art will readily be able to select an appropriate promoter 15 among, for example, the promoters mentioned above. For example, according to certain embodiments of the invention a CMV promoter is used. The Env-coding plasmid preferably contains any additional sequences needed for efficient transcription, processing, etc., of the *env* transcript including, but not limited to, a polyadenylation signal such as any of those mentioned above.

[00141] The host range of cells that the viral vectors of the present invention can 20 infect may be altered (e.g., broadened) by utilizing an envelope gene from a different virus. Thus is possible to alter or increase the host range of the vectors of the present invention by taking advantage of the ability of the envelope proteins of certain viruses to participate in the encapsidation of other viruses. In a preferred embodiment of the present invention, the G-protein of vesicular-stomatitis virus (VSV-G; see, e.g., Rose 25 and Gillione, J. Virol. 39, 519-528 (1981); Rose and Bergmann, Cell 30, 753-762 (1982)), or a fragment or derivative thereof, is the envelope protein expressed by the 30

second plasmid. VSV-G efficiently forms pseudotyped virions with genome and matrix components of other viruses. As used herein, the term "pseudotype" refers to a viral particle that contains nucleic acid of one virus but the envelope protein of another virus. In general, VSV-G pseudotyped viruses have a very broad host range, 5 and may be pelleted to titers of high concentration by ultracentrifugation (e.g., according to the method of J. C. Burns, et al., Proc. Natl. Acad. Sci. USA 90, 8033-8037 (1993)), while still retaining high levels of infectivity.

[00142] Additional envelope proteins that may be used in accordance with the present invention include, but are not limited to, ecotropic or amphotropic MLV 10 envelopes, 10A1 envelope, truncated forms of the HIV env, GALV, BAEV, SIV, FeLV-B, RD114, SSAV, Ebola, Sendai, FPV (Fowl plague virus), and influenza virus envelopes. Similarly, genes encoding envelopes from RNA viruses (e.g. RNA virus families of Picornaviridae, Calciviridae, Astroviridae, Togaviridae, Flaviviridae, Coronaviridae, Paramyxoviridae, Rhabdoviridae, Filoviridae, Orthomyxoviridae, 15 Bunyaviridae, Arenaviridae, Reoviridae, Birnaviridae, Retroviridae) as well as from the DNA viruses (families of Hepadnaviridae, Circoviridae, Parvoviridae, Papovaviridae, Adenoviridae, Herpesviridae, Poxviridae, and Iridoviridae) may be utilized. Representative examples include FIV, FeLV, RSV, VEE, HFVW, WDSV, SFV, Rabies, ALV, BIV, BLV, EBV, CAEV, HTLV, SNV, ChTLV, STLV, MPMV, 20 SMRV, RAV, FuSV, MH2, AEV, AMV, CT10, EIAV. In addition to the above, hybrid envelopes (e.g. envelope comprising regions of more than one of the above), may be employed. According to certain embodiments of the invention the envelope recognizes a unique cellular receptor (e.g., a receptor found only on a specific cell type or in a specific species), while according to certain other embodiments of the 25 invention the envelope recognizes multiple different receptors. According to certain embodiments of the invention the second plasmid encodes a cell or tissue specific targeting envelope. Cell or tissue specific targeting may be achieved, for example, by incorporating particular sequences within the envelope sequence (e.g., sequences encoding ligands for cell or tissue-specific receptors, antibody sequences, etc.). Thus 30 any of a wide variety of Env-coding plasmids may be used in the three plasmid lentiviral expression system of the invention including, but not limited to, those described in references 21, 24, 29, and 40.

[00143] *Variations on the three plasmid system.* The invention further provides a four plasmid lentiviral expression system comprising a three plasmid lentiviral expression system as described herein and a fourth plasmid comprising a nucleic acid sequence encoding the Rev protein (in which case the *rev* gene is generally not included in the other plasmids. As mentioned above, the presence of Rev increases the level of transcription during production of lentiviral particles. It will be appreciated that a variety of alternative three or four plasmid systems may be employed while maintaining the feature that no sequence of recombination event(s) between only two of the three or four plasmids is sufficient to generate replication-competent virus. For example, either Gag or Pol or any of the accessory proteins may be encoded by the plasmid referred to as the Env-coding plasmid. Alternately, Gag, Pol, or any of the accessory proteins may be encoded by the transfer plasmid. In addition, sequences encoding Rev may be provided on the same plasmid that encodes Gag, Pol, or Env. According to certain embodiments of the invention sequences encoding a functional Tat protein are absent from the plasmids, and sequences encoding Rev are provided on a separate plasmid rather than on the same plasmid as sequences encoding other viral genes, as described in reference 40. Schematic diagrams of relevant portions of representative first and second plasmids (packaging and Env-coding) and fourth plasmid encoding Rev are presented in Figure 10B, which is taken from reference 40. The third plasmid (not shown) is a transfer plasmid.

[00144] *Applications of the lentiviral transfer plasmids and expression systems.* The lentiviral transfer plasmids and lentiviral expression systems of the invention have a wide variety of uses, some of which have been described above. As will be evident, the transfer plasmids may be used for any application in which a conventional expression plasmid is employed. As described in Examples 3 through 6, the transfer plasmids of the invention are able to drive expression of heterologous genes (e.g., EGFP) when transfected into cells and are also able to drive synthesis of shRNA when transfected into cells.

[00145] The presence of one or more MCSs means that the plasmids may conveniently be used for insertion and subsequent expression of any heterologous sequence. In particular, the transfer plasmids that include an insertion site such as an MCS between sites for a recombinase such as loxP may be used for easy assembly of

a promoter-site-sequence-site cassette, (where "site" indicates a recombination site for a recombinase and "sequence" indicates a heterologous sequence of interest), e.g., a promoter-loxP-sequence-loxP site that can then be moved into another vector. It is noted that the transfer plasmids can be used to direct expression of a heterologous

5 nucleic acid in a variety of eukaryotic cells other than mammalian cells, provided a promoter capable of directing transcription in such cells is employed. Thus references to "mammalian cells" herein should not be understood to exclude non-mammalian cells, as long as an appropriate promoter for transcription in non-mammalian cells is provided.

10 [00146] *Introducing plasmids into cells.* In general, the plasmids described herein may be introduced into cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA or RNA) into cells, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, injection, or electroporation.

15 [00147] *Production of replication-defective lentiviral particles.* In general, the transfer plasmids and the three-plasmid recombinant lentiviral expression systems of the invention may be used to produce infectious, replication-defective lentiviral particles according to methods known to those skilled in the art. In the case of the recombinant lentiviral expression system of the invention the methods include (i) transfecting a lentivirus-permissive cell with the three-plasmid lentiviral expression system of the present invention; (ii) producing the lentivirus-derived particles in the transfected cell; and (iii) collecting the virus particles from the cell. The step of

20 transfecting the lentivirus-permissive cell can be carried out according to any suitable means known to those skilled in the art. For example, the three-plasmid expression system described herein may be used to generate lentivirus-derived retroviral vector particles by transient transfection. The plasmids may be introduced into cells by any suitable means, including, but not limited to, calcium phosphate or calcium chloride

25 co-precipitation, DEAE-dextran-mediated transfection, lipofection, injection, or electroporation.

30

[00148] The transfer plasmids of the invention may be used to produce infectious, replication-defective lentiviral particles in a similar manner using helper cells that express the necessary viral proteins as known in the art and mentioned above. In general, the transfer plasmids may be used to produce infectious, replication-defective 5 lentiviral particles in conjunction with any system using any combination of plasmids and/or helper cell lines that provides the appropriate combination of required genes: *gag*, *pol*, *env*, and, preferably, *rev* in cases where transcription occurs from a *gag/pol* expression cassette containing a Rev-response element (or alternately a system that supplies the various proteins encoded by these genes).

10 [00149] Infectious virus particles may be collected using conventional techniques. For example, the infectious particles may be collected by cell lysis, or collection of the supernatant of the cell culture, as is known in the art. Optionally, the collected virus particles may be purified if desired. Suitable purification techniques are well known to those skilled in the art. Methods for titering virus particles are also well 15 known in the art. Further details are provided in the Examples.

[00150] *Producer cell lines.* As will be evident, when a host cell permissive for production of lentiviral particles is transfected with the plasmids of the three-plasmid system, the cell becomes a producer cell, i.e., a cell that produces infectious lentiviral particles. Similarly, when a helper cell that produces the necessary viral proteins is 20 transfected with a transfer plasmid of the invention, the cell becomes a producer cell. The invention therefore provides producer cells and corresponding producer cell lines and methods for the production of such cells and cell lines. In particular, the invention provides a method of creating a producer cell line comprising introducing a transfer plasmid of the invention into a host cell; and introducing a packaging plasmid 25 and an envelope plasmid into the host cell. The invention provides another method of creating a producer cell line comprising introducing a transfer plasmid of the invention into a helper cell that produces viral proteins necessary for encapsidation of a lentiviral genome and subsequent infectivity of a lentiviral particle resulting from encapsidation.

30 [00151] The inclusion of appropriate genetic elements from various papovaviruses allows plasmids to be maintained as episomes within mammalian cells. Such plasmids are faithfully distributed to daughter cells. In particular, viral elements of

various polyomaviruses and papillomaviruses such as BK virus (BKV), bovine papilloma virus 1 (BPV-1) and Epstein-Barr virus (EBV), among others, are useful in this regard. The invention therefore provides lentiviral transfer plasmids comprising a viral element sufficient for stable maintenance of the transfer plasmid as an episome 5 within mammalian cells. Appropriate genetic elements and their use are described, for example, in Van Craenenbroeck, *et al.*, *Eur. J. Biochem.* 267, 5665-5678 (2000) and references therein, all of which are incorporated herein by reference.

10 [00152] The invention further provides cell lines comprising the transfer plasmids described above, i.e., cell lines in which the transfer plasmids are stably maintained as episomes. In particular, the invention provides producer cell lines (cell lines that produce the proteins needed for production of infectious lentiviral particles) in which the transfer plasmids are stably maintained as episomes. According to certain 15 embodiments of the invention these cell lines constitutively produce lentiviral particles.

15 [00153] According to other embodiments of the invention one or more of the necessary viral proteins is under the control of an inducible promoter. Thus the invention provides helper cell lines in which the transfer plasmids are stably expressed as episomes, wherein at least one viral protein expressed by the cell line is under control of an inducible promoter. This allows the cells to be expanded under 20 conditions that are not permissive for viral production. Once the cells have reached a desired density (e.g., confluence), or a desired cell number, etc., the protein whose expression is under control of the inducible promoter can be induced, allowing 25 production of viral particles to begin. This system offers a number of advantages. In particular, since every cell has the required components, titer is increased. In addition, it avoids the necessity of performing a transfection each time a particular virus is desired. Any of a variety of inducible promoters known in the art may be used. One of ordinary skill in the art will readily be able to select an appropriate inducible promoter and apply appropriate techniques to induce expression therefrom.

30 [00154] The invention thus provides a method of producing lentiviral particles comprising introducing a lentiviral transfer plasmid of the invention, which lentiviral transfer plasmid comprises a genetic element (e.g., a viral element) sufficient for stable maintenance of the transfer plasmid as an episome in mammalian cells, into a

helper cell that produces proteins needed for production of infectious lentiviral particles and; culturing the cell for a period sufficient to allow production of lentiviral particles. The invention further provides a method of producing lentiviral particles comprising introducing a lentiviral transfer plasmid of the invention, which lentiviral transfer plasmid comprises a genetic element sufficient for stable maintenance of the transfer plasmid as an episome in mammalian cells, into a helper cell that expresses a protein required for production of lentiviral particles, wherein expression of the protein is under control of an inducible promoter; inducing expression of the protein required for production of lentiviral particles; and culturing the cell for a period sufficient to allow production of lentiviral particles.

[00155] *Transgenic and knockout animals.* The transfer plasmids may be used to generate stable transgenic or knockout animals, wherein the transgene is a heterologous nucleic acid contained in the transfer plasmid. Transgenic animals may be generated through standard (non-viral) means such as pronuclear injection of the transfer plasmid. In addition, the lentiviral particles may be used to create transgenic animals wherein the transgene is a heterologous nucleic acid contained in the lentiviral particle. For example, lentiviral particles of the invention may be injected into the perivitelline space of single-cell embryos, which may then be implanted and carried to term. Alternately, the zona pellucida may be removed and the denuded embryo incubated with lentiviral suspension prior to implantation as described in reference 24. This approach offers a more efficient method of creating a variety of transgenic animals, e.g., birds, rats, and other mammals. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like. Transgenic animals typically carry a gene which has been introduced into the germline of the animal, or an ancestor of the animal, at an early (usually one-cell) developmental stage. In general, a transgene is heterologous DNA, which preferably is integrated into or occurs in the genome of the cells of a transgenic animal. Integration of the transgene may lead to a deletion of endogenous chromosomal DNA, e.g., by homologous recombination, such that the function of an expression product of the DNA is

impaired or eliminated. In this case the resulting animal is referred to as a knockdown or knockout animal. Note that transgene sequences may include endogenous sequences but typically also include additional sequences that do not naturally occur in the animal.

5 [00156] As described in Example 7, the inventors have generated transgenic mice using a lentiviral particle comprising a heterologous nucleic acid encoding the fluorescent protein GFP, which serves as a transgene. The lentiviral particles were able to induce expression of GFP within embryonic stem cells (ES cells), and these ES cells gave rise to transgenic animals whose cells expressed GFP. These results  
10 demonstrate that heterologous nucleic acids contained in the lentiviral particles of the invention are not subject to developmental silencing.

[00157] *Constitutive, conditional, reversible, and tissue-specific expression.* The transfer plasmids and lentiviral particles of the invention may be used to achieve constitutive, conditional, reversible, or tissue-specific expression in cells, tissues, or  
15 organisms, including transgenic animals. The invention provides a method of reversibly expressing a transcript in a cell comprising: (i) delivering a lentiviral vector to the cell, wherein the lentiviral vector comprises a heterologous nucleic acid, and wherein the heterologous nucleic acid is located between sites for a site-specific recombinase; and (ii) inducing expression of the site-specific recombinase within the  
20 cell, thereby preventing synthesis of synthesis of the transcript within those cells. According to certain embodiments of the invention the cell is a mammalian cell. According to certain embodiments of the invention the step of inducing the site-specific recombinase comprises introducing a vector encoding the site-specific recombinase into the cell. According to other embodiments of the invention a nucleic  
25 acid encoding the site-specific recombinase is operably linked to an inducible promoter, and the inducing step comprises inducing the promoter as described above. As discussed in more detail in Example 8, the inventors have shown that introduction of a lentiviral particle comprising a heterologous nucleic acid encoding the fluorescent protein EGFP between loxP sites into cells results in expression of EGFP  
30 within the cells. When the EGFP-expressing cells were subsequently infected with an adenovirus containing a nucleic acid encoding Cre, thereby inducing expression of

Cre within the cells, expression of EGFP was eliminated in a significant proportion of the cells. Thus expression of EGFP was reversible.

[00158] In addition, the invention provides a variety of methods for achieving conditional and/or tissue-specific expression. For example, the invention provides a 5 method for expressing a transcript in a mammal in a cell type or tissue-specific manner comprising: (i) delivering a lentiviral transfer plasmid or lentiviral particle to cells of the mammal, wherein the lentiviral transfer plasmid or lentiviral particle comprises a heterologous nucleic acid, and wherein the heterologous nucleic acid is located between sites for a site-specific recombinase; and (ii) inducing expression of 10 the site-specific recombinase in a subset of the cells of the mammal, thereby preventing synthesis of the transcript within those cells. According to certain embodiments of the inventive methods the recombinase is Cre. According to certain embodiments of the invention the step of inducing the site-specific recombinase comprises introducing a vector encoding the site-specific recombinase into the cell. 15 According to other embodiments of the invention a nucleic acid encoding the site-specific recombinase is operably linked to an inducible promoter, and the inducing step comprises inducing the promoter as described above. In certain embodiments of the invention the nucleic acid encoding the site-specific recombinase is operably linked to a cell type or tissue-specific promoter, so that synthesis of the recombinase 20 takes place only in cells or tissues in which that promoter is active.

[00159] *Gene and transcript silencing.* As described in more detail below, the invention provides methods of reducing or inhibiting the expression of target genes and/or transcripts (which need not necessarily encode proteins) by exploiting the phenomenon of RNA interference (RNAi). For example, the invention provides a 25 method of inhibiting or reducing the expression of a target transcript in a cell comprising delivering a lentiviral vector (e.g., a lentiviral transfer plasmid or lentiviral particle) to the cell, wherein presence of the lentiviral vector within a cell results in synthesis of one or more RNAs that self-hybridize or hybridize with each other to form a short hairpin RNA or short interfering RNA that is targeted to the target 30 transcript. Such lentiviral expression vectors may be used therapeutically to silence disease-causing genes and/or render cells resistant to infectious organisms. In addition, lentiviral expression vectors may facilitate the creation of animals deficient

in immunogenic xenoantigens as sources of organs for organ transplantation. It will be appreciated that in those embodiments of the invention in which the nucleic acid segment that provides a template for synthesis of the one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA is floxed,

5 inhibition of the target transcript may be reversed by expressing Cre, thereby excising the template for the siRNA or shRNA. Thus the invention allows conditional and tissue-specific expression of target transcripts in cells, tissues, or organisms. RNAi and methods of using the plasmids and expression systems of the invention for achieving RNAi are described below.

10 [00160] *RNA interference*

[00161] Small inhibitory RNAs were first discovered in studies of the phenomenon of RNA interference (RNAi) in *Drosophila*, as described, for example, in WO 01/75164, etc. It was found that, in *Drosophila*, long double-stranded RNAs are processed by an RNase III-like enzyme called DICER (Bernstein et al., *Nature* 409:363, 2001) into smaller dsRNAs comprised of two 21 nt strands, each of which has a 5' phosphate group and a 3' hydroxyl, and includes a 19 nt region precisely complementary with the other strand, so that there is a 19 nt duplex region flanked by 2 nt-3' overhangs (see Figure 11). These small dsRNAs (siRNAs) act to silence expression of any gene that includes a region complementary to one of the dsRNA strands, presumably because a helicase activity unwinds the 19 bp duplex in the siRNA, allowing an alternative duplex to form between one strand of the siRNA and the target transcript. This new duplex then guides an endonuclease complex, RISC, to the target RNA, which it cleaves ("slices") at a single location, producing unprotected RNA ends that are promptly degraded by cellular machinery (see Figure 12).

20 [00162] Homologs of the DICER enzyme are found in diverse species ranging from *C. elegans* to humans (Sharp, *Genes Dev.* 15:485, 2001; Zamore, *Nat. Struct. Biol.* 8:746, 2001), raising the possibility that an RNAi-like mechanism might be able to silence gene expression in a variety of different cell types including mammalian, or even human, cells. However, long dsRNAs (e.g., dsRNAs having a double-stranded region longer than about 30 – 50 nucleotides) are known to activate the interferon response in mammalian cells. Thus, rather than achieving the specific gene silencing observed with the *Drosophila* RNAi mechanism, the presence of long dsRNAs into

mammalian cells would be expected to lead to interferon-mediated non-specific suppression of translation, potentially resulting in cell death. Long dsRNAs are therefore not thought to be useful for inhibiting expression of particular genes in mammalian cells.

5 [00163] In contrast, siRNAs, when present in mammalian cells, can effectively reduce the expression of target transcripts and genes in a specific manner without activating the anti-viral response (9, 10). Preferred siRNAs typically include a base-paired region approximately 19 nt long, and may further comprise one or more single-stranded regions, typically 3' overhangs on one or both strands. Figures 11 and 13  
10 presents various structures that can be utilized to mediate RNA interference. Figure 11 shows the siRNA structure found to be active in the *Drosophila* system and likely represents the species that is active in mammalian cells. This structure consists of two 21 nt strands having a complementary core region of 19 nt and 2 nt 3' overhangs at each end of the double-stranded region. Figures 13A, 13B, 13C, and 13D represent  
15 additional structures that may be used to mediate RNA interference. These hairpin (stem-loop) structures may function directly as inhibitory RNAs or may be processed intracellularly to yield an siRNA structure such as that depicted in Figure 11.

[00164] Many different RNA species having structures such as these have been introduced into mammalian cells and have been shown to reduce expression of target  
20 transcripts. For example, siRNAs targeted to transcripts encoding the HIV Gag protein or the the HIV-1 cellular receptor CD4 reduced the level of the corresponding mRNAs and proteins Gag in cells infected with HIV (Novina, C., *et al.*, *Nat Med.*, 8(7):681-6, 2002), resulting in inhibition of virus production. Studies such as this, demonstrating siRNA-mediated inhibition of cellular genes as well as genes of  
25 infectious organisms, demonstrate the therapeutic potential of RNA interference for a wide variety of conditions. In addition, the ability to selectively reduce or eliminate expression of particular genes has profound implications for the study of gene function.

[00165] In general, preferred siRNAs reduce the target transcript level or level of  
30 the encoded protein at least about 2 fold, preferably at least about 5 fold, more preferably at least about 10 fold, at least about 25 fold, at least about 50 fold or to an even greater degree relative to the level that would be present in the absence of the

inhibitory RNA. In selecting a target sequence for any particular transcript it may be desirable to test a variety of siRNAs in order to identify one with an appropriate efficacy.

[00166] In general, an siRNA includes a double-stranded region (the "inhibitory region"), one strand of which is substantially complementary to a portion of the target transcript, so that a precise hybrid can form *in vivo* between one strand of the siRNA and the target transcript. The portion of the target transcript to which the siRNA strand hybridizes may be referred to as the target or targeted portion or site. In certain preferred embodiments of the invention, the relevant inhibitor region of the siRNA is perfectly complementary with the target transcript; in other embodiments, one or more non-complementary residues are located at or near the ends of the siRNA/template duplex or elsewhere. As will be appreciated by those of ordinary skill in the art, it is generally preferred that mismatches in the central portion of the siRNA/template duplex be avoided (see, for example, Elbashir et al., *EMBO J.* 15 20:6877, 2001).

[00167] Generally any portion of a target transcript may be selected as the target site, to which the antisense strand of the siRNA will be complementary. It may be preferable to select siRNAs that hybridize with a target site that includes exonic sequences in the target transcript or hybridizes exclusively with exonic sequences. Hybridization with intronic sequences is not excluded, but generally appears not to be preferred in mammalian cells. An siRNA that hybridizes with a target site that includes only sequences within a single exon may be selected, or the target site may be created by splicing or other modification of a primary transcript. Any site that is available for hybridization with an siRNA antisense strand, resulting in slicing and degradation of the transcript may be utilized in accordance with the present invention. Nonetheless, those of ordinary skill in the art will appreciate that, in some instances, it may be desirable to select particular regions of target gene transcript as siRNA hybridization targets. For example, it may be desirable to avoid (i) sections of target transcript that may be shared with other transcripts whose degradation is not desired; (ii) sections of target transcript that are identical or homologous to other transcripts whose degradation is not desired. In general, coding regions and regions closer to the 3' end of the transcript than to the 5' end are preferred. The 3' portion of target

transcripts may be less likely to exhibit secondary structure that may inhibit or interfere with siRNA activity, e.g., by reducing accessibility.

[00168] In general, preferred siRNA sequences have a GC content between 30 and 70% or, preferably, between 40 and 60%. In general, it is preferred to avoid target 5 sequences that contain strings of >2 identical nucleotides (e.g., AAA, GGGG). siRNA sequences may conveniently be identified by scanning the cDNA sequence from 5' to 3' until an appropriate 19 nucleotide target is identified. If it is desired to include a 3' overhang in the antisense strand, the 19 nt sequence should be preceded by nucleotides complementary to the desired 3' overhang. For example, according to 10 certain embodiments of the invention an siRNA sequence should correspond to:

AAN<sub>19</sub>.

[00169] Certain siRNAs hybridize to a target site that includes or consists entirely of 3' UTR sequences. Such siRNAs may tolerate a larger number of mismatches in the siRNA/template duplex, and particularly may tolerate mismatches within the 15 central region of the duplex. In fact, some mismatches may be desirable as siRNA/template duplex formation in the 3' UTR may inhibit expression of a protein encoded by the template transcript by a mechanism related to but distinct from classic RNA inhibition. In particular, there is evidence to suggest that siRNAs that bind to the 3' UTR of a template transcript may reduce translation of the transcript rather than decreasing its stability. Specifically, as shown in Figure 14, the DICER enzyme that 20 generates siRNAs in the *Drosophila* system discussed above and also in a variety of organisms, is known to also be able to process a small, temporal RNA (stRNA) substrate into an inhibitory agent that, when bound within the 3' UTR of a target transcript, blocks translation of the transcript (see Grishok, A., et al., *Cell* 106, 23-24, 2001; Hutvagner, G., et al., *Science*, 293, 834-838, 2001; Ketting, R., et al., *Genes Dev.*, 15, 2654-2659). For the purposes of the present invention, any partly or fully 25 double-stranded short RNA as described herein, one strand of which binds to a target transcript and reduces its expression (i.e., reduces the level of the transcript and/or reduces synthesis of the polypeptide encoded by the transcript) is considered to be an siRNA, regardless of whether the RNA acts by triggering degradation, by inhibiting translation, or by other means. In certain preferred embodiments of the invention, 30 reducing expression of the transcript involves degradation of the transcript. In

addition any precursor structure (e.g., a short hairpin RNA, as described herein) that may be processed *in vivo* (i.e., within a cell or organism) to generate such an siRNA is useful in the practice of the present invention.

[00170] Use of RNAi in mammalian cells, tissues, and organisms is currently 5 restricted by the limited delivery methods available. siRNAs can be delivered to cells by various means, such as electroporation (11), use of lipofectants (10), or expression of short hairpin RNAs (shRNAs) in cells from a plasmid template (11-16). shRNAs are precursors of siRNAs, and typically comprise dsRNA stretches of at least 19 bp separated by a loop of several non self-complementary nucleotides. shRNAs adopt 10 stem-loop structures, thought to be recognized and processed into siRNAs by the conserved cellular RNAi machinery (17; Ketting, R., et al., *Genes Dev.*, 15, 2654- 2659). While the approaches mentioned above have been successful at targeting gene expression in cell culture systems, in general they are not as readily applicable to primary cells, which are difficult to transfect by standard methods such as those 15 mentioned above. Their use to target gene expression in mammalian subjects is also problematic. A further limitation of introducing siRNAs into cells by standard means is that the inhibitory (knockdown) effect is transient, as mammalian cells appear to lack the siRNA amplification mechanisms that confer RNAi potency and longevity in lower organisms (10).

20 [00171] The present invention encompasses the recognition that use of lentiviral expression systems offer a means of overcoming problems associated with delivery of siRNAs into mammalian cells and tissues, including primary mammalian cells and tissues, nondividing cells (including neurons and naïve T cells), and cells at early stages of development such as embryonic cells (including embryonic stem cells). The 25 invention further encompasses the recognition that use of lentiviral vectors offers a means of overcoming problems associated with delivery of siRNAs into mammalian subjects.

[00172] The invention provides lentiviral vectors and expression systems capable of directing transcription of RNAs that hybridize to form shRNAs and/or siRNAs in 30 mammalian cells. In particular, the invention provides a lentiviral vector comprising a nucleic acid segment operably linked to a promoter, so that transcription from the

promoter results in synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA targeted to a target transcript.

[00173] The invention further provides a three-plasmid lentiviral expression system comprising (i) a lentiviral transfer plasmid comprising a nucleic acid segment operably linked to a promoter, so that transcription from the promoter results in synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA targeted to a target transcript; (ii) a packaging plasmid; and (iii) an Env-coding plasmid. In addition, the invention provides an infectious lentiviral particle comprising a nucleic acid segment operably linked to a promoter, so that transcription from the promoter results in synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA targeted to a target transcript. In other words, the nucleic acid segment(s) provides template(s) for synthesis of an RNA that self-hybridizes to form an shRNA or for synthesis of two complementary RNAs that hybridize to form an siRNA.

15 [00174] According to certain embodiments of the invention the lentiviral vector comprises a nucleic acid segment which, when transcribed, produces an RNA that comprises two complementary elements that hybridize to one another to form a stem and a loop. The stem-loop structure is also referred to as a hairpin. Figure 15A schematically depicts such a nucleic acid segment 10 operably linked to a promoter element 20. Nucleic acid segment 10 comprises complementary elements 30 and 40, separated by element 50. Preferably the nucleic acid includes a transcriptional terminator element 60, e.g., a terminator for RNA polymerase III such as a string of T residues. However, such a terminator element may also be provided within a vector into which the nucleic acid segment is inserted. Figure 15B schematically depicts an RNA 70 transcribed from nucleic acid segment 10 prior to hybridization. RNA 70 comprises self-complementary elements 80 and 90.

20 [00175] Figure 15C schematically depicts the RNA following hybridization of the complementary portions, resulting in formation of stem 100 and loop 110. Termination within the terminator sequence results in a 3' overhang 120, which may comprise one or more U residues. Preferably, the stem is approximately 19 bp long, the loop is about 1-20, more preferably about 4-12, and most preferably about 6-10 nt long and/or the overhang is about 1-20, and more preferably about 2-6 nt long. In

certain preferred embodiments of the invention the overhang is 2 nt long. In certain embodiments of the invention the stem is minimally 19 nucleotides in length and may be up to approximately 29 nucleotides in length. One of ordinary skill in the art will appreciate that loops of 4 nucleotides or greater are less likely to be subject to steric 5 constraints than are shorter loops and therefore may be preferred.

[00176] Figure 17A schematically depicts the sequence of a nucleic acid comprising a segment which, when transcribed, produces an RNA that comprises two complementary elements that hybridize to one another to form a stem and a loop, inserted into the MCS of a lentiviral transfer plasmid of the invention.

10 Complementary portions are indicated with arrows in opposite orientation to one another. Figure 17B depicts a nucleic acid which, when transcribed, results in an RNA targeted to the CD8 molecule. Figure 17C depicts the shRNA that results following hybridization of the complementary portions of an RNA transcribed from the nucleic acid in Figure 17B. The RNA forms a stem-loop structure in which the 15 stem is targeted to CD8. As described in more detail in Example 3, the inventors have shown that lentiviral transfer plasmids comprising a heterologous nucleic acid whose sequence includes the CD8 stem-loop sequence inhibit expression of CD8 when introduced into cells. In addition, as described in Examples 4 and 5, lentiviral particles comprising a heterologous nucleic acid whose sequence includes the CD8 20 stem-loop sequence inhibit expression of CD8 at both the mRNA and protein level when introduced into cells. Furthermore, the inhibition of expression persisted over the length of the experiment (1 month), demonstrating that RNAi mediated by the integrated lentivirus was stable. The inventors were unable to detect shRNA structures in the infected cells but were able to detect approximately 21 nucleotide-long RNAs comprising the CD8 stem loop sequence and having a typical siRNA 25 structure. While not wishing to be bound by any theory, this results confirms the hypothesis that shRNAs are processed into siRNAs within the cell. The inventors also demonstrated that shRNA-mediated inhibition of CD8 was specific. In particular, shRNAs targeted to the mouse CD8 RNA did not inhibit expression of 30 human CD8.

[00177] The invention therefore provides a lentiviral vector, e.g., a lentiviral transfer plasmid or lentiviral particle comprising a nucleic acid segment that provides

a template for synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA, wherein the shRNA or siRNA is targeted to a target transcript and reduces expression of the transcript. For example, the invention provides a lentiviral transfer plasmid comprising the following elements: a nucleic acid including (i) a functional packaging signal; (ii) a multiple cloning site (MCS) into which a nucleic acid may be inserted; (iii) at least one additional element selected from the group consisting of: a second MCS, an HIV FLAP element, a heterologous promoter, a heterologous enhancer, an expression-enhancing posttranscriptional regulatory element, a target site for a site-specific recombinase, and a self-inactivating (SIN) LTR; and (iv) a nucleic acid segment that provides a template for synthesis of an shRNA or siRNA, which shRNA or siRNA is targeted to a target transcript and reduces expression of the transcript. In certain preferred embodiments of the invention the nucleic acid segment provides a template for synthesis of an RNA that self-hybridizes to form an shRNA.

[00178] Any of the various embodiments of the elements included in the lentiviral transfer plasmid or lentiviral particle may be selected as described above. In particular, the invention provides a lentiviral transfer plasmid comprising the following elements: a nucleic acid including (i) a functional packaging signal; (ii) a multiple cloning site (MCS) into which a nucleic acid may be inserted; (iii) a second MCS; (iv) an HIV FLAP element; (v) a WRE; (vi) two loxP sites; (vii) a self-inactivating (SIN) LTR; and (viii) a nucleic acid segment operably linked to a PolIII promoter, wherein the nucleic acid segment provides a template for synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA, which shRNA or siRNA is targeted to a target transcript and reduces expression of the transcript. In certain preferred embodiments of the invention the nucleic acid segment provides a template for synthesis of an RNA that hybridizes to form an shRNA.

[00179] Identification of sequences for design of the stem portion of an shRNA may be performed as described above for siRNAs. See also the Web sites having URLs

[www.mpiibpc.gwdg.de/abteilungen/100/105/sirna.html](http://www.mpiibpc.gwdg.de/abteilungen/100/105/sirna.html) and  
[katahdin.chsl.org:9331/RNAi](http://katahdin.chsl.org:9331/RNAi) (visited October 23, 2002). The first step is to search

for potential target sequences, e.g., by scanning the cDNA. According to certain embodiments of the invention a potential target sequence corresponds to any sequence of the form GN<sub>18</sub>. According to other embodiments of the invention a potential target sequence corresponds to a sequence of the form AAGN<sub>18</sub>. According to yet other 5 embodiments of the invention a potential target sequence corresponds to a sequence of the form AAGN<sub>18</sub>TT. Once a potential target is selected, the sequence GN<sub>18</sub> is used as the sequence for the stem (duplex) portion of the shRNA. Thus in certain embodiments of the invention the GN<sub>18</sub> is preferably be surrounded by AA---TT in the context of the mRNA. Where the U6 promoter is used, a 5' guanine is generally 10 required due to the constraints of this promoter. It may be useful to test 4-5 targets for each transcript or gene of interest. It may be desirable to perform a database search (e.g., BLAST search) using the GN<sub>18</sub> sequences to verify that the sequence is unique in order to avoid silencing other genes in addition to the target gene. As lentivirus pseudotyped with VSV-G is capable of infecting human cells, if the lentivirus is not 15 intended for use in humans it may be desirable to determine if there are human genes that may be silenced. If so, it may be preferable to avoid sequences that would target such genes.

[00180] According to certain embodiments of the invention the sequence TTCAAGAGA (SEQ ID NO:10) is selected for the loop. Thus to design the 20 complete hairpin sequence according to certain embodiments of the invention, a 19 nt sequence suitable as the inhibitory portion of a typical siRNA is selected, optionally including an additional two nucleotides such as AA at the 5' end in order to generate a 3' UU overhang in the resulting shRNA. A loop sequence is added at the 3' end of the 19 (or 21) nt sequence, followed by a sequence complementary to the 19 nt (or 21) 25 sequence, resulting in a stem-loop after hybridization. See Example 3 for additional information. Any of a variety of other sequences may be selected for the loop including, but not limited to, loops used in the shRNAs described in Brummelkamp, *et al.*, Paddison, *et al.*, Sui, *et al.*, Yui, *et al.*, or Paul, *et al.*.

[00181] The invention provides a method of reducing or inhibiting expression of a 30 target transcript in a cell comprising: (i) delivering a lentiviral vector to the cell, wherein presence of the lentiviral vector within the cell results in transcription of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or

siRNA that is targeted to the target transcript and reduces expression of the transcript. The lentiviral vector comprises a nucleic acid segment that provides a template for synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA that is targeted to the transcript and reduces expression of the transcript. In certain preferred embodiments of the invention the nucleic acid provides a template for synthesis of an RNA that hybridizes to form an shRNA.

**[00182]** According to certain embodiments of the invention the cell is a mammalian cell. Any of the lentiviral transfer plasmids or lentiviral particles described above may be used, wherein presence of the plasmid or particle in a cell provides a template for synthesis of one or more RNAs that self-hybridize or hybridize with each other to form a shRNA or siRNA targeted to the transcript of interest. According to certain embodiments of the invention the delivering step comprises delivering the lentiviral transfer plasmid or lentiviral particle to a mammalian subject, thereby delivering the lentiviral transfer plasmid or lentiviral particle to a cell that is present within the body of the subject. According to certain embodiments of the invention the cell is a primary cell. By "primary cell" is meant a cell that has been removed from the body of a subject and maintained in tissue culture for less than approximately 1, 2, 3, 4, or 5 doubling periods or a non-immortalized cell. According to certain embodiments of the invention the mammalian cell is a nondividing cell, e.g., a terminally differentiated T cell, neuron, hepatocyte, retinal cell, skeletal myocyte, cardiac myocyte, keratinocyte, macrophage, etc. The mammalian cell may be a human cell or a nonhuman (e.g., mouse or rat) cell. According to certain embodiments of the invention the mammalian cell is an embryonic cell or an embryonic stem cell.

**[00183]** The invention further provides a method for reversibly inhibiting or reducing expression of a target transcript in a cell comprising: delivering a lentiviral vector to the cell, wherein the lentiviral vector comprises a nucleic acid segment that provides a template for synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA, which shRNA or siRNA is targeted to the target transcript and reduces expression of the transcript, wherein the nucleic acid segment is located between sites for a site-specific recombinase; and (ii) inducing expression of the site-specific recombinase within the cell, thereby

preventing synthesis of at least one of the RNAs. According to certain embodiments of the invention the cell is a mammalian cell. According to certain embodiments of the invention the recombinase is Cre. According to certain embodiments of the invention the step of inducing the site-specific recombinase comprises introducing a 5 vector encoding the site-specific recombinase into the cell. According to other embodiments of the invention a nucleic acid encoding the site-specific recombinase is operably linked to an inducible promoter, and the inducing step comprises inducing the promoter within a cell containing the nucleic acid, as described above.

[00184] In addition, the invention provides a variety of methods for reversibly 10 inhibiting or reducing expression of a target transcript in a conditional and/or tissue-specific manner. For example, the invention provides a method for reversibly inhibiting or reducing expression of a transcript in a mammal in a cell type specific or tissue-specific manner comprising: (i) delivering a lentiviral vector to cells of the mammal, wherein the lentiviral vector comprises a nucleic acid segment that provides 15 a template for synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA, which shRNA or siRNA is targeted to the target transcript and reduces expression of the transcript, and wherein the nucleic acid segment is located between sites for a site-specific recombinase; and (ii) inducing expression of the site-specific recombinase in a subset of the cells of the mammal, 20 thereby preventing synthesis of at least one of the RNAs within those cells.

According to certain embodiments of the inventive methods the recombinase is Cre. According to certain embodiments of the invention the step of inducing the site-specific recombinase comprises introducing a vector encoding the site-specific recombinase into a subset of the cells of the subject, e.g., by utilizing a vector that 25 requires a receptor present only on a subset of the cells. According to other embodiments of the invention a nucleic acid encoding the site-specific recombinase is operably linked to an inducible promoter, and the inducing step comprises inducing the promoter within cells containing the nucleic acid, as described above, whereby expression of the target transcript is restored only in cells or tissues in which the 30 promoter is active.

[00185] In certain embodiments of the invention the nucleic acid encoding the site-specific recombinase is operably linked to a cell type or tissue-specific promoter, so

that synthesis of the recombinase takes place only in cells or tissues in which that promoter is active, whereby expression of the target transcript is restored only in cells or tissues in which the promoter is active.

**[00186]** In certain preferred embodiments of the invention, the promoter utilized to direct expression of the one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA is a promoter for RNA polymerase III (Pol III). Pol III directs synthesis of small transcripts that terminate within a stretch of 4-5 T residues. Certain Pol III promoters such as the U6 or H1 promoters do not require *cis*-acting regulatory elements (other than the first transcribed nucleotide) within the transcribed region and thus are preferred according to certain embodiments of the invention since they readily permit the selection of desired RNA sequences. In the case of naturally occurring U6 promoters the first transcribed nucleotide is guanosine, while in the case of naturally occurring H1 promoters the first transcribed nucleotide is adenine. (See, e.g., Medina MF and Joshi S., *Curr Opin Mol Ther* 1999 Oct;1(5):580-94; Yu, J., et al., *Proc. Natl. Acad. Sci.*, 99(9), 6047-6052 (2002); Sui, G., et al., *Proc. Natl. Acad. Sci.*, 99(8), 5515-5520 (2002); Paddison, P., et al., *Genes and Dev.*, 16, 948-958 (2002); Brummelkamp, T., et al., *Science*, 296, 550-553 (2002); Miyagashi, M. and Taira, K., *Nat. Biotech.*, 20, 497-500 (2002); Paul, C., et al., *Nat. Biotech.*, 20, 505-508 (2002); Tuschl, T., et al., *Nat. Biotech.*, 20, 446-448 (2002)). Thus in certain embodiments of the invention, e.g., where transcription is driven by a U6 promoter, the 5' nucleotide of preferred RNA sequences for formation of shRNAs or siRNAs is G. In certain other embodiments of the invention, e.g., where transcription is driven by an H1 promoter, the 5' nucleotide may be A. The lentiviral transfer plasmid may be created by inserting a cassette comprising the RNA sequence into a transfer plasmid optimized for RNAi that already contains a suitable promoter, e.g., a plasmid such as pLL3.7. Alternately, a cassette comprising the RNA sequence operably linked to a suitable promoter may be inserted into a transfer plasmid that lacks such a promoter, e.g., a plasmid such as pLL3.0.

**[00187]** The invention thus encompasses administration of a lentiviral vector to a cell, e.g., a mammalian cell, to inhibit or reduce expression of any target transcript or gene, wherein the lentiviral vector comprises a nucleic acid segment that provides a template for synthesis of one or more RNAs that self-hybridize or hybridize to form

an shRNA or siRNA that is targeted to the target transcript or gene. In general, the nucleic acid segment may provide a template for synthesis of any RNA structure capable of being processed *in vivo* to a shRNA or siRNA, so long as the RNA does not induce other negative events such as induction of the interferon response. In 5 certain preferred embodiments of the invention the nucleic acid segment provides a template for synthesis of an RNA that self-hybridizes to form an shRNA targeted to the target transcript.

[00188] As discussed above, in addition to their use for synthesis of RNAs that self-hybridize to form shRNAs, the lentiviral vectors of the invention may be used for 10 synthesis of various other RNAs that mediate RNAi. In particular, two separate approximately 21 nt RNA strands may be generated, each of which contains a 19 nt region complementary to the other, and the individual strands may hybridize together to generate an siRNA structure. Accordingly, the invention encompasses a lentiviral vector comprising two transcribable regions, each of which provides a template for 15 synthesis of a transcript containing a region complementary with the other. Generally each transcript will be approximately 21 nt in length and the complementary regions will be approximately 19 nt in length, as described above.

[00189] In addition, the invention provides a lentiviral vector that contains 20 oppositely directed promoters flanking a nucleic acid segment and positioned so that two different transcripts, approximately 21 nt in length and having complementary regions approximately 19 nt in length, are generated. It will be appreciated that appropriate terminators should be supplied in these cases. In cases in which the RNA structure undergoes one or more processing steps, those of ordinary skill in the art will appreciate that the nucleic acid segment will preferably be designed to include 25 sequences that may be necessary for processing of the RNA. Figure 16 presents a schematic diagram of such a plasmid.

[00190] A large number of variations on the above are possible. For example, the lentiviral vector may comprise multiple nucleic acid segments, each of which provides a template for synthesis of one or more RNAs that self-hybridize or 30 hybridize with each other to form shRNAs or siRNAs, which shRNAs or siRNAs may target the same transcript or different transcripts. In addition, according to certain embodiments of the invention the nucleic acid segment provides a template for

synthesis of a plurality of RNAs that self-hybridize or hybridize with each other to form a plurality of siRNAs or siRNA precursors. For example, a single promoter may direct synthesis of a single RNA transcript containing multiple self-complementary regions, each of which may hybridize to generate a plurality of stem-loop structures.

5 These structures may be cleaved *in vivo*, e.g., by DICER, to generate multiple different siRNAs. It will be appreciated that such transcripts preferably contain a termination signal at the 3' end of the transcript but not between the individual siRNA units.

[00191] The present invention encompasses any cell manipulated to contain an 10 inventive lentiviral transfer plasmid, lentiviral particle, or lentiviral genome derived therefrom (e.g., a provirus), wherein the lentiviral transfer plasmid, lentiviral particle, or lentiviral genome provides a template for synthesis of one or more RNAs that self-hybridize or hybridize to form an shRNA or siRNA. Preferably, the cell is a 15 mammalian cell. According to certain embodiments of the invention the cell is a human cell. Those of ordinary skill in the art will appreciate that intracellular expression of RNAs that self-hybridize or hybridize with each other to form shRNAs or siRNAs according to the present invention may allow the production of cells that produce the shRNA or siRNA over long periods of time (e.g., greater than a few days, 20 preferably at least several months, more preferably at least a year or longer, possibly a lifetime).

[00192] In certain embodiments of the invention, the cells are non-human cells within an organism. For example, the present invention encompasses transgenic animals the cells of which contain an inventive lentiviral transfer plasmid, lentiviral particle, or lentiviral genome derived therefrom, wherein the lentiviral transfer 25 plasmid, lentiviral particle, or lentiviral genome provides a template for synthesis of one or more RNAs that self-hybridize or hybridize to form an shRNA or siRNA in one or more cell types or tissues of the transgenic animal. The invention therefore provides a transgenic animal, one or more cells of which comprise a heterologous nucleic acid segment provided by a lentiviral vector, wherein the lentiviral vector 30 comprises (i) a functional packaging signal; (ii) a multiple cloning site (MCS); and (iii) at least one additional element selected from the group consisting of: a second MCS, a second MCS into which a heterologous promoter or promoter-enhancer is

inserted, an HIV FLAP element, an expression-enhancing posttranscriptional regulatory element, a target site for a site-specific recombinase, and a self-inactivating (SIN) LTR. According to certain embodiments of the invention the cells of the transgenic animal contain a heterologous nucleic acid segment that comprises sites for 5 a site-specific recombinase.

[00193] As described in Example 7, the inventors have generated transgenic mice using a variety of lentiviral particles each comprising a first heterologous nucleic acid segment encoding the fluorescent protein GFP, and also a second heterologous nucleic acid segment that provides a template for synthesis of an RNA that self- 10 hybridizes to form an shRNA targeted to a target transcript. The lentiviral particles were able to induce expression of GFP within embryonic stem cells (ES cells), and these ES cells gave rise to transgenic animals whose cells expressed GFP. Furthermore, expression of the particular target transcript corresponding to the second 15 nucleic acid segment was reduced or inhibited in cells of the transgenic mice. These results demonstrate that the lentiviral transfer plasmids and lentiviral particles of the invention may be used to generate transgenic animals in which expression of a target transcript is reduced or inhibited. It is noted that the lentiviral vectors of the invention may thus generally be used as bifunctional vectors, leading both to expression of a heterologous nucleic acid and silencing of an endogenous gene.

20 [00194] *Kits*

[00195] The invention provides a variety of kits comprising one or more of the lentiviral transfer plasmids of the invention. For example, the invention provides a kit comprising (a) a lentiviral transfer plasmid comprising a nucleic acid sequence including (i) a functional packaging signal; (ii) a multiple cloning site (MCS) into 25 which a heterologous gene may be inserted; and (iii) at least one additional element selected from the group consisting of: a second MCS, an HIV FLAP element, a heterologous promoter, a heterologous enhancer, an expression-enhancing posttranscriptional regulatory element, a target site for a site-specific recombinase, and a self-inactivating (SIN) LTR; and one or more of the following items: (i) a packaging mix comprising one or more plasmids that collectively provide nucleic acid sequences coding for retroviral or lentiviral Gag and Pol proteins and an envelope 30 protein. The packaging mix may contain two or more plasmids. According to certain

embodiments of the invention the packaging mix includes two plasmids, one of which provides nucleic acid sequences coding for Gag and Pol and the other of which provides nucleic acid segments coding for an envelope protein; (ii) cells (e.g., a cell line) that are permissive for production of lentiviral particles such as 293T cells; (iii) 5 packaging cells, e.g., a cell line that is permissive for production of lentiviral particles and provides the proteins Gag, Pol, Env, and, optionally, Rev; (iv) cells suitable for use in titering lentiviral particles; a transfection-enhancing agent such as Lipofectamine; (v) a selection agent such as an antibiotic, preferably corresponding to an antibiotic resistance gene in the lentiviral transfer plasmid; (vi) instructions for use; 10 (vii) a lentiviral transfer plasmid comprising a heterologous nucleic acid segment such as a reporter gene that may serve as a positive control (referred to as a "positive control plasmid").

[00196] According to certain embodiments of the invention the kit contains a set of lentiviral transfer plasmids comprising a variety of different heterologous promoters 15 and/or reporter genes. For example, the kit may contain a set of two or more vectors selected from the group consisting of the plasmids of: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

[00197] *Therapeutic Applications and Pharmaceutical Formulations*  
20 [00198] The lentiviral vectors of the invention are useful for a wide variety of therapeutic applications. In particular, they are useful in any context for which gene therapy is contemplated. For example, lentiviral vectors comprising a heterologous nucleic acid segment operably linked to a promoter are useful for any disease or 25 clinical condition associated with reduction or absence of the protein encoded by the heterologous nucleic acid segment, or any disease or clinical condition that can be effectively treated by augmenting the expression of the encoded protein within the subject. For example, lentiviral vectors comprising a nucleic acid segment encoding the cystic fibrosis transmembrane conductance regulator (CFTR) or encoding  $\alpha$ 1-antitrypsin may be used for the treatment of cystic fibrosis and  $\alpha$ 1-antitrypsin 30 deficiency, respectively. Lentiviral vectors comprising a nucleic acid segment encoding Factor VIII or Factor IX may be used for treatment of hemophilia A or B, respectively. See the Web site having URL [www.wiley.co.uk/genetherapy/clinical/](http://www.wiley.co.uk/genetherapy/clinical/)

(visited October 19, 2002) for a representative list of current gene therapy clinical trials involving expression of a therapeutic protein in a subject in need of treatment.

**[00199]** Inventive lentiviral vectors capable of causing intracellular synthesis of inhibitory RNAs (siRNAs or shRNAs) are useful in treating any disease or clinical condition associated with overexpression of a transcript or its encoded protein in a subject, or any disease or clinical condition that may be treated by causing reduction of a transcript or its encoded protein in a subject. For example, many cancers are associated with overexpression of oncogene products. Delivering a lentiviral vector that provides a template for synthesis of one or more RNAs that self-hybridize or

hybridize with each other to form an shRNA or siRNA targeted to the transcript encoding the oncogene product may be used to treat such cancers. The high degree of specificity achieved by RNA interference suggests that it is possible to selectively target transcripts containing single base pair mutations while not interfering with expression of the normal cellular allele. Lentiviral vectors that provide a template for

synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA targeted to a transcript encoding a cytokine may be used to regulate immune system responses (e.g., responses responsible for organ transplant rejection, allergy, autoimmune diseases, inflammation, etc.). Lentiviral vectors that provide a template for synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA targeted to a transcript of an infectious agent or targeted to a cellular transcript whose encoded product is necessary for or contributes to any aspect of the infectious process may be used in the treatment of infectious diseases.

**[00200]** Gene therapy protocols may involve administering an effective amount of a lentiviral vector whose presence within a cell results in production of a therapeutic siRNA or shRNA to a subject either before, substantially contemporaneously, with, or after the onset of a condition to be treated. Another approach that may be used alternatively or in combination with the foregoing is to isolate a population of cells, e.g., stem cells or immune system cells from a subject, optionally expand the cells in tissue culture, and administer a lentiviral vector whose presence within a cell results in production of a therapeutic siRNA or shRNA to the cells *in vitro*. The cells may then be returned to the subject, where, for example, they may provide a population of

cells that produce a therapeutic shRNA or siRNA, or that are resistant to infection by an infectious organism, etc. Optionally, cells expressing the therapeutic shRNA or siRNA can be selected *in vitro* prior to introducing them into the subject. In some embodiments of the invention a population of cells, which may be cells from a cell line or from an individual other than the subject, can be used. Methods of isolating stem cells, immune system cells, etc., from a subject and returning them to the subject are well known in the art. Such methods are used, e.g., for bone marrow transplant, peripheral blood stem cell transplant, etc., in patients undergoing chemotherapy.

[00201] Compositions comprising lentiviral vectors of the invention may provide a template for a single siRNA or shRNA species, targeted to a single site in a single target transcript, or alternatively may provide templates for a plurality of different siRNA or shRNA species, targeted to one or more sites in one or more target transcripts. In some embodiments of the invention, it will be desirable to utilize compositions comprising one or more lentiviral vectors, wherein presence of the lentiviral vector(s) within a cell or within different cells in the body, results in production of a plurality of different siRNA or shRNA species targeted to different genes, which may be cellular genes or, where an infection is being treated, genes of an infectious organism. Also, some embodiments will provide templates for more than one siRNA or shRNA species targeted to a single transcript. To give but one example, it may be desirable to provide templates for synthesis of one or more RNAs that self-hybridize or hybridize with each other to form at least one siRNA or shRNA targeted to coding regions of a target transcript and at least one siRNA or shRNA targeted to the 3' UTR. This strategy may provide extra assurance that products encoded by the relevant transcript will not be generated because at least one siRNA or shRNA will target the transcript for degradation while at least one other inhibits the translation of any transcripts that avoid degradation. The invention encompasses "therapeutic cocktails", including approaches in which a single lentiviral particle provides templates for synthesis of one or more RNAs that self-hybridize or hybridize to form shRNAs or siRNAs that inhibit multiple target transcripts.

[00202] It may be desirable to combine the administration of inventive lentiviral vectors with one or more additional therapeutic agents. The invention therefore encompasses compositions comprising a lentiviral vector of the invention, preferably

a lentiviral particle, and a second therapeutic agent, e.g., a composition approved by the U.S. Food and Drug Administration.

[00203] Inventive compositions may be formulated for delivery by any available route including, but not limited to parenteral (e.g., intravenous), intradermal, 5 subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, rectal, and vaginal. Preferred routes of delivery include parenteral, transmucosal, rectal, and vaginal. Inventive pharmaceutical compositions typically include a lentiviral vector in combination with a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" includes solvents, dispersion media, 10 coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.

[00204] A pharmaceutical composition is formulated to be compatible with its intended route of administration. Solutions or suspensions used for parenteral, 15 intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such 20 as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[00205] Pharmaceutical compositions suitable for injectable use typically include 25 sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition should be sterile and should be fluid to the 30 extent that easy syringability exists. Preferred pharmaceutical formulations are stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. In general, the

relevant carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethyleneglycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance 5 of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in 10 the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

15 [00206] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.

Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are 20 vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[00207] Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, *e.g.*, 25 gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin, 30 an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a

flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

Formulations for oral delivery may advantageously incorporate agents to improve stability within the gastrointestinal tract and/or to enhance absorption.

[00208] For administration by inhalation, the inventive lentiviral vectors are 5 preferably delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

[00209] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the 10 barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or 15 creams as generally known in the art.

[00210] The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[00211] In one embodiment, the active agents, *i.e.*, a lentiviral vector of the 20 invention and/or other agents to be administered together with a lentiviral vector of the invention, are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such 25 formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those 30 skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[00212] It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound

5 calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

[00213] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the

10 dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD<sub>50</sub> / ED<sub>50</sub>. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in

15 order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[00214] The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED<sub>50</sub> with

20 little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC<sub>50</sub> (i.e.,

25 the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

[00215] The pharmaceutical composition can be administered at various intervals

30 and over different periods of time as required, e.g., one time per week for between about 1 to 10 weeks, between 2 to 8 weeks, between about 3 to 7 weeks, about 4, 5, or 6 weeks, etc. For certain conditions such as HIV it may be necessary to administer

the therapeutic composition on an indefinite basis to keep the disease under control. The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the 5 subject, and other diseases present. Generally, treatment of a subject with a lentiviral vector as described herein, can include a single treatment or, in many cases, can include a series of treatments.

[00216] Exemplary doses for administration of gene therapy vectors are known in the art. It is furthermore understood that appropriate doses of a lentiviral vector that 10 provides a template for synthesis of one or more RNAs that self-hybridize or hybridize with each other to form an shRNA or siRNA may, in general, depend upon the potency of the siRNA or shRNA and may optionally be tailored to the particular recipient, for example, through administration of increasing doses until a preselected desired response is achieved. It is understood that the specific dose level for any 15 particular animal subject may depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

[00217] Lentiviral gene therapy vectors can be delivered to a subject by, for 20 example, intravenous injection, local administration, or by stereotactic injection (see e.g., Chen *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). In certain embodiments of the invention the vectors may be delivered orally or inhalationally and may be encapsulated or otherwise manipulated to protect them from degradation, 25 enhance uptake into tissues or cells, etc. The pharmaceutical preparation can include the lentiviral vector in an acceptable diluent, or can comprise a slow release matrix in which the lentiviral vector is imbedded. Alternatively, where the vector can be produced intact from recombinant cells, as is the case for retroviral or lentiviral vectors as described herein, the pharmaceutical preparation can include one or more 30 cells which produce the vectors.

[00218] Inventive pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

## Exemplification

**[00219] Example 1: Generation of pLentiLox Vectors**

5 This example describes generation of the pLentiLox family of vectors. Unless otherwise indicated, standard molecular biology techniques were generally performed in accordance with guidance found in *Current Protocols in Molecular Biology*, edition as of 2001; or in Sambrook, Russell, and Sambrook, *Molecular Cloning: A Laboratory Manual*, 3<sup>rd</sup> ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2001, or according to instructions provided by the manufacturer of the relevant reagents or kits. It is noted that a variety of different approaches to generating the constructs described below as well as alternative sources for the elements incorporated into the constructs may be employed. In particular, the sequence information provided herein enables one of ordinary skill in the art to 10 chemically synthesize part or all of the constructs, thus offering considerable flexibility.

15

**[00220] Characterization of pBFGW.** Generation of the pLentiLox vector family involved extensive modification of the plasmid pBFGW. Accordingly, the first step was a thorough characterization of this plasmid. pBFGW is a third generation 20 lentiviral plasmid based upon the pCDNA 3.1/Zeo plasmid (Invitrogen) that was incompletely characterized and lacked sequence information. pBFGW is a member of the same vector family as pFUGW<sup>24</sup> but contains a Beta-actin/CMV hybrid promoter rather than a ubiquitin promoter. Lentiviral elements in pBFGW are derived from HIV-1. We sequenced this plasmid in its entirety. The sequence is 25 presented as SEQ ID NO: 1. A restriction map of pBFGW was generated based upon the sequencing information and verified (for several enzymes) by digestion and agarose gel electrophoresis and is shown in Figure 1.

**[00221]** pBFGW includes a cassette for the generation of lentivirus inserted downstream of the CMV promoter of pCDNA3.1/Zeo. The cassette consists of a 5' 30 self-inactivating (SIN) LTR, the required packaging sequence (Psi), the HIV FLAP element (FLAP), a hybrid promoter consisting of beta-actin and CMV promoter sequences, the open reading frame for enhanced Green Fluorescent Protein (EGFP),

the Woodchuck Hepatitis Regulatory Element (WRE), and the 3' SIN LTR. There existed only three unique restriction sites for the introduction of transgenes and/or promoters. In addition pBFGW was 10,441 base pairs in length without the introduction of a transgene. Plasmids of this size are more difficult to manipulate 5 then smaller plasmids. There was also no mechanism to eliminate transgene expression after infection.

10 [00222] *Elimination of elements between FLAP and WRE.* pBFGW was sequentially digested with PacI and EcoRI. The 7,930 bp fragment representing the backbone was purified by gel purification. The overhanging ends were filled-in by reaction with Pfu polymerase to generate blunt ends.

15 [00223] *Introduction of a MCS-LoxP-MCS-LoxP cassette.* The plasmid pBluescript Lox (pBS-Lox) was created by amplifying two LoxP sites from an unrelated vector (pML2MIG) by PCR. The two LoxP PCR products contained a 23bp overlap region (containing the restriction sites EcoR1, NotI and HindIII) at their 5' and 3' ends respectively. These two products were combined in a splicing overlap extension (SOE) PCR reaction (Horton, RM, *et al.*, *Biotechniques*, 8(5):528-35, 1990) using standard PCR conditions to create the LoxP-MCS-LoxP cassette, that was cloned into the filled-in HindIII and NotI sites of pBlueScript (KSII+) as a blunt ended fragment. The following primers were used in the PCR reactions:

20 20 [00224] PCR product #1 was amplified with the following primers:

[00225] L1/5': 5'(tggtgggtacctagtggacc)3' (SEQ ID NO: 32)

[00226] L1/3': 5'(aagcttaagcggccgcagaattcgtcgaggacctaataacgtatag)3' (SEQ ID NO: 33)

[00227] PCR product #2 was amplified with the following primers:

25 25 [00228] L2/5': 5'(gaattctcgccgcgcttaagcttggaaacccttaatataacttcg)3' (SEQ ID NO: 34)

[00229] L2/3': 5'(cgcttcacgagattccagcag)3' (SEQ ID NO: 35)

[00230] The LoxP-MCS-LoxP cassette was used in the LentiLox cloning described below. The second LoxP site of this cassette contained a three base pair deletion.

30 30 This deletion was not identified until later in the construction of the LentiLox vectors (see below).

[00231] pBS-Lox was digested with Asp718. A 209bp fragment was isolated by gel purification. This fragment contained a 5' multiple cloning site (5' MCS), a LoxP site, a 3' multiple cloning site (3' MCS), and a second LoxP site. The overhanging ends of the 209bp Asp718 fragment were filled-in with cloned Pfu polymerase, and 5 ligated into the 7,930 bp fragment of pBFGW. The orientation of the insertion was determined both by restriction fragment length polymorphism and by sequencing. A plasmid containing the MCS-LoxP-MCS-LoxP cassette with the expected sequence in the correct orientation was named pLentiLox 1.0.

[00232] *Elimination of plasmid backbone restriction sites.* Several of the sites 10 found within the two MCS's were present elsewhere in the pLentiLox 1.0 vector. Specifically, NotI, ApaI, and XhoI cut both within the MCS cassette as well as once elsewhere in the vector. In order to gain the use of these sites we intended to destroy each site within the plasmid backbone.

[00233] pLL1.0 was partially digested with NotI under conditions of limiting 15 enzyme activity (.0625 Units of enzyme per microgram of pLL1.0 incubated at 37 degrees Celsius for twenty minutes). The 8,142 bp band that represented linearized pLL1.0 was isolated via agarose gel electrophoresis followed by gel extraction. This linearized fragment was phosphorylated on its 5' ends with T4 Polynucleotide Kinase (PNK). The overhanging ends of this molecule were then filled-in with cloned Pfu to 20 destroy the NotI site. The ends were ligated together to circularize the molecule. To determine whether a NotI site had been destroyed and to determine which NotI site had been destroyed the plasmid was digested with NotI and with PstI. Destruction of the NotI site in the plasmid backbone yielded fragments of 7830 bp and 312 bp whereas destruction of the MCS NotI site yielded fragments of 7253 and 889 bp 25 respectively. We accidentally chose a plasmid in which the MCS NotI site was destroyed and named it pLentiLox 1.1 (pLL1.1). This was later remedied (see below). It should be noted that the creation of pLL1.1 was problematic due to recombination within the vector resulting in large deletions of required sequences. To verify the presence of an intact backbone it was necessary to perform an additional 30 restriction digest. An enzyme that cut in three places was used, and the digestion pattern of pLL1.1 was compared with that of pLL1.0 to make sure that the two bands representing the backbone were the same size.

[00234] We designed a strategy to destroy the ApaI site that would also eliminate a 2197 bp fragment between the 3'SIN LTR and the pUC ori that we deemed non-essential for lentiviral production. This ApaI-PciI fragment contained a BGH polyadenylation site, an SV40 promoter/ori, the Zeomycin resistance gene, and an 5 SV40 polyadenylation site. We digested pLL1.1 with PciI to linearize the plasmid. The linearized plasmid was then digested with a limiting amount of ApaI (between .25 Units and 2 Units per microgram of linearized pLL1.1 for twenty minutes at room temperature). A 5,945 bp fragment representing a single cut with ApaI adjacent to the 3' LTR was isolated by agarose gel electrophoresis followed by gel purification. The 10 gel purified fragment was phosphorylated with PNK, filled in with cloned Pfu, and circularized by ligation. The ligated DNA was digested with StuI prior to transformation into bacteria. Digestion with StuI was expected to specifically cut plasmid that contains the 2197 bp fragment that had been eliminated, and thus was used to select against contamination with uncut pLL1.1 vector. The elimination of 15 the 2197 bp and the destruction of PciI and ApaI were verified by restriction digest and a correct plasmid was identified and named pLentiLox 1.2 (pLL1.2).

[00235] To destroy the XhoI site, pLL1.2 was cut with limiting amounts of XhoI (.0625 Units per microgram of plasmid for twenty minutes at 37 degrees Celsius). A 5,947 bp fragment representing single-cut linearized pLL1.2 was isolated via agarose 20 gel electrophoresis and gel purification. The fragment was 5' phosphorylated with PNK, filled in with cloned Pfu, recircularized with ligase, and transformed into bacteria. Destruction of the correct XhoI site was verified by restriction digest. A correct plasmid was identified and named pLentiLox1.3 (pLL1.3).

[00236] *Expansion of the 5' MCS.* The 5' MCS was intended for the insertion of 25 promoter sequences, among other purposes. After destruction of the sites mentioned above two unique cloning sites (ApaI and XhoI) remained in this MCS. We derived a list of restriction enzymes that failed to cut pLL1.3 to generate a list of candidate sites to engineer into an expanded 5'MCS. We then designed complementary oligonucleotides to allow us to introduce XbaI, HpaI, NheI, and PacI sites between 30 the ApaI and XhoI sites. The oligonucleotides were designed to include two nucleotides between adjacent restriction sites. The sequence of the sense oligonucleotides was 5' cgctctagacggtaacgcgctagccgttaatcgcc 3' (SEQ ID NO: 11).

The antisense oligonucleotide was complementary to this sequence but contained an additional four nucleotides at the 5' end to produce an XhoI overhang and four nucleotides at the 3' end to produce an ApaI overhang. The antisense oligonucleotide sequence was 5'-tcgaggcttaattaacggctagcgcgttaaccgtctagagcgggcc-3' (SEQ ID NO: 12). We chose restriction sites to include based upon the following criteria: (1) Inclusion of a site for a restriction enzyme that leaves a blunt end after cutting; (2) Inclusion of a restriction site that has an 8 bp recognition sequence. (3) Inclusion of sites for which enzymes are widely available. (4) Inclusion of sites for enzymes that are known to be reliable cutters.

[00237] pLL1.3 was digested sequentially with ApaI and XhoI. The digest was then purified by Qiaquick PCR purification kit (Qiagen) to eliminate the small DNA fragment between ApaI and XhoI. The fragment was then treated with Shrimp Alkaline Phosphatase (SAP) to eliminate 5'-phosphate groups. The oligonucleotides described above were synthesized, 5' phosphorylated, and PAGE-purified by IDT Corp. (See Web site having URL [www.idtna.com](http://www.idtna.com). 60 picomols of each oligo were annealed in annealing buffer (100mM Potassium Acetate, 30mM HEPES-KOH pH 7.4, 2mM Magnesium acetate) by incubation at 95 degrees for 4 minutes, followed by 70 degrees for 10 minutes, then slowly cooled (.1 degrees/second) to 4 degrees, then maintained at 4 degrees for 10 minutes. The annealed oligos were diluted and ligated at an equimolar concentration with the linearized pLL1.3 vector. A plasmid containing the engineered MCS was identified by restriction digest and named pLL1.4.

[00238] It was at this time that we first realized that we had destroyed the NotI site in the MCS rather than in the plasmid backbone (see above). The second NotI site (adjacent to the LTR) was then destroyed in pLL1.4 as follows. pLL1.4 was digested with NotI to linearize the plasmid. The ends were 5' phosphorylated with PNK and were filled-in with cloned Pfu to blunt and destroy the NotI site. The plasmid was recircularized by ligation and transformed into bacteria. We checked for destruction of the NotI site by restriction digest and named the resulting plasmid pLentiLox 1.5 (pLL1.5).

[00239] We next sought to expand the 3' MCS. We designed primers to introduce NsiI, SphI, SmaI/XmaI, Ascl, and BamHI sites between the NotI and EcoRI sites.

We followed the same design criterion as described above. An additional criterion was that no three consecutive nucleotides would generate a nonsense codon. This would allow us to produce fusion proteins in which MCS sequence can remain between the fused proteins while minimizing the likelihood of premature termination of translation. In addition we wanted a minimum of sites in the MCS to be present in the sequences encoding EGFP and dsRed2, which we intended to include in many derivatives of our vectors (see below). We purposefully intended to make this MCS more versatile than the 5' MCS since we anticipated that most applications of our vector would require cloning into this MCS. The inclusion of an SphI site was fortuitous. The two nucleotide spacer between the NsiI and SmaI/XmaI led to the creation of an SphI site that overlaps these other two sites. More fortuitously, SphI is a unique site in pLL1.5. The oligonucleotide primers incorporating the desired restrictions sites are as follows:

[00240] 3' MCS Sense: 5' ggccggccatgcgtccccggatggcgccatggatccgc 3'  
15 (SEQ ID NO: 13)

[00241] 3' MCS Antisense: 5' aattcgccatggcgccatccggggcatgcgtggc 3'  
(SEQ ID NO: 14)

[00242] Because we had destroyed the NotI site that should have been present in the pLL1.5 3' MCS we had to use a different strategy to insert the oligonucleotides than was used for the 5' MCS. The pBS-Lox (described above) plasmid was digested 20 with NotI and EcoRI enzymes. The small DNA fragment that was liberated was eliminated by purifying the linearized pBS-Lox backbone in a Qiaquick PCR purification kit. The DNA was SAP treated. The 3' MCS oligonucleotides were annealed (see above). 150 fmols of annealed oligonucleotides and cut pLL1.5 were 25 ligated together and transformed into bacteria. A plasmid containing the expanded 3' MCS was identified by restriction digest and named pBS-Lox-MCS.

[00243] To insert the expanded MCS from pBS-Lox-MCS into pLL1.5, we replaced the EcoRI-XhoI fragment from pLL1.5 (containing the improperly destroyed NotI site) with the EcoRI-XhoI fragment from pBS-Lox-MCS (containing an intact 30 NotI site and the expanded 3' MCS). A plasmid containing the expanded MCS and intact NotI in the pLL backbone was identified by restriction digest and was named pLentiLox2.0 (pLL2.0).

[00244] *Production of useful pLL2.0 series vectors*

[00245] We next sought to produce constructs that would be useful starting points for many potential uses of our lentiviral vectors. One application in which there is enormous interest is the generation of fusion proteins in which a protein of interest (or 5 a portion thereof) is fused with a fluorescent protein. In particular, EGFP and dsRed2 are fluorescent proteins that are well characterized and for which sequences are widely available.

[00246] pLL2.1 was engineered to include the EGFP open reading frame. The EGFP open reading frame was amplified from pEGFP-N1 (Clontech) to include a 10 5'NotI site and a 3' NsiI site. The oligonucleotides used were:

[00247] EGFP/5'NotI: 5'-cggcgccgcgcaccatggtagcaaggcg-3' (SEQ ID NO: 15)

[00248] EGFP/3'NsiI: 5'-cgatgcacttgtacagctcgatggcg-3' (SEQ ID NO: 16)

[00249] The PCR product was isolated by agarose gel electrophoresis, gel purified, and cloned into the NotI and NsiI sites of pLL2.0 to create pLL2.1.

[00250] pLL2.2 was engineered to include the dsRed2 open reading frame. The dsRed2 open reading was amplified from pdsRed2-N1 (Clontech) to include a 5'NotI site and 3'NsiI site. The oligonucleotides used were:

[00251] dsRed2/5'NotI: 5'-cggcgccgcgcaccatggcctctccgag-3' (SEQ ID NO: 17)

[00252] dsRed2/3'NsiI: 5'-cgatgcacggAACAGGTGGCGGCC-3' (SEQ ID NO: 18)

[00253] The PCR product was isolated by agarose gel electrophoresis, gel purified, and cloned into the NotI and NsiI sites of pLL2.0 to create pLL2.2.

[00254] Because the pLentiLox series has a self-inactivating 5' LTR, the provirus has no endogenous 5' promoter activity. Therefore, it is necessary to include an internal promoter to drive transgene expression. This makes the system compatible 25 with tissue-specific promoters. We chose to clone a ubiquitous and constitutive promoter into our vector to create a transgenic system that should be active in most eukaryotic cell types as well as in all the tissues of a mouse. The promoter we chose was the Ubiquitin C promoter (UbC). We first attempted to clone UbC by PCR amplification of the promoter from the pUB6/V5/His vector. However, the UbC sequence was not robustly amplified via PCR (in several attempts). As a second 30 strategy we digested the pUB6/V5/His vector with BglII and HindIII which generates a fragment containing the UbC promoter. This fragment was isolated by agarose gel

electrophoresis and gel extraction. The fragment was filled-in with cloned Pfu polymerase and 5' phosphorylated with PNK. This fragment was ligated into HpaI digested pLL2.0, pLL2.1, and pLL2.2 to generate pLL2.3, pLL2.4, and pLL2.5 respectively. These plasmids were verified by restriction digest to contain the proper 5 insert. pLL2.4 and pLL2.5 were transfected into 293.T cells and production of the correct fluorescent protein was verified by visualizing the transfected cells under an epifluorescent microscope 24 hours after transfection.

[00255] As described in the following example, we later discovered that one of the loxP sites in the pLL2.0 series of vectors contained a deletion that rendered it 10 unusable. In order to generate the pLL3.0 series (which contain two wild type loxP sites) from the pLL2.1-pLL2.7 series we cloned ApaI-EcoRI inserts of various sizes (2.1-917 bp, 2.2-875bp, 2.3-1417bp, 2.4-2,138bp, 2.5-2096bp, 2.6-1519bp, and 2.7-1819bp) from the pLL2.1-pLL2.7 vectors into the 5,831bp ApaI-EcoRI backbone from pLL3.0 to create pLL3.1-pLL3.7.

15

[00256] *Example 2: Generation of Lentiviral Vectors for RNAi*

[00257] *Modification of pLL2.0 for use in RNAi* In order to drive expression of an RNAi-inducing stem-loop, we decided to incorporate a polIII promoter into a pLentilox series vector. In addition, we decided to incorporate a polII promoter to 20 drive expressin of EGFP as a reporter. Because we were concerned that the placement of a strong polII promoter near a polIII promoter might interfere with polIII function we chose to place the polII-EGFP cassette between LoxP sites. This would allow us to eliminate the polII promoter if we were failing to accumulate the stem-loop RNA.

25 [00258] We first inserted a cassette to drive expression of EGFP. A DNA fragment containing the CMV promoter upstream of the EGFP open reading frame was amplified from pEGFP-C1. The oligonucleotides were selected to engineer a 5' NotI site and 3' EcoRI site. The oligonucleotides used were:

[00259] 5'CMV/NotI: 5'-cggcggccgcgtggataaccgtattaccgccatg-3' (SEQ ID NO: 30 19)

[00260] 3'EGFP/stop/EcoRI: 5' cggaattcctacttgtacagctcgccatgccgag-3' (SEQ ID NO: 20) The PCR product was isolated by agarose gel electrophoresis and purified by

gel extraction. The fragment was cloned into the NotI and EcoRI sites of pLL2.0 to create pLL2.6. This plasmid was tested by restriction digest and production of EGFP was verified by transfection of pLL2.6 into 293.T cells.

[00261] The insertion of the U6 promoter presented an additional challenge. We  
5 needed to introduce a cloning site for the introduction of RNAi sequences. The U6  
promoter includes sequences required for activity up until the +1 transcriptional start  
site. Therefore, one cannot modify the sequences prior to -1 without incapacitating  
U6. We did not want to introduce a site after +1 as that would dictate that the first  
10 several nucleotides of the stem-loop would be derived from the restriction site. We  
therefore engineered the U6 promoter to introduce an HpaI site that cuts at the -1  
position of U6. The first three nucleotides of the HpaI site are present in the wildtype  
U6. We had to alter the nucleotides at -1 to +2 in order to engineer an HpaI site. As  
a result the U6 promoter is not functional when containing the HpaI site. However  
15 after digestion with HpaI and introduction of oligonucleotides to code for a stem-  
loop, those oligonucleotides can re-generate the wild-type 3' end of the U6 promoter  
thereby restoring transcriptional activity. We engineered oligonucleotides to add a  
XbaI site to the 5' end of the U6 promoter and HpaI, BstEII, and XhoI sites to the 3'  
end. We cloned the amplified PCR product from the pmU6 plasmid and introduced  
the product into the XbaI and XhoI sites of pLL2.6. The oligonucleotides used were:

20 [00262] 5' XbaI/U6: 5'-gctctagagatccgacggccatctctag-3' (SEQ ID NO: 21)

[00263] 3' XhoI/BstEII/HpaI/U6: 5'-  
gcctcgagggtcaccgcgcgttaacaaggctttccaagg-3' (SEQ ID NO: 22)

[00264] The resulting plasmid was verified by both restriction digest and by  
sequencing and was named pLL2.7.

25 [00265] *Repair of LoxP and engineering of new restriction site*

[00266] It was at this point that we recognized that the 3' LoxP site in the original  
pBS-Lox contained a three nucleotide deletion that rendered it unusable. We decided  
to fix the 3' LoxP site in the pLL2.0 plasmid and then use this plasmid backbone to  
clone in sequences from pLL2.1-pLL2.7. The repair of the LoxP site gave us an  
30 opportunity to engineer a new restriction site outside of the LoxP site (between the 3'  
LoxP and the WRE). This site would give our plasmid series even greater flexibility  
for engineering other additions such as IRES-GFP, or inducible expression systems.

[00267] Oligonucleotides were designed to amplify a fragment from pLL2.0 from the EcoRI site to a PflMI site located within WRE. The 5' oligonucleotide extended from the EcoRI site in the 3'MCS through the mutant LoxP site and into the region between the LoxP and the WRE. This oligonucleotide was designed to add the 5 deleted nucleotides to the LoxP site and to create a PciI site immediately following the LoxP site. The amplified DNA was inserted into the pLL2.0 backbone digested with EcoRI and PflMI. The oligonucleotides used were:

10 [00268] 5'EcoRI/LoxFix/PciI:  
5'-gcgaattcgtcgagggacctaataactcgatagcatacattatacgaagttatacatgtttaaagggttccgg-3'  
[00269] 3' PflM1/Rev: 5'-aaggagctgacagggtggggcaatg-3' (SEQ ID NO: 24)

[00270] A plasmid was checked by sequencing for the addition of a correct LoxP and PciI sites and named pLL3.0.

15 [00271] In order to generate the pLL3.1-pLL3.7 series from the pLL2.1-pLL2.7 series we cloned ApaI-EcoRI inserts of various sizes (2.1-917bp, 2.2-875bp, 2.3-1417bp, 2.4-2,138bp, 2.5-2096bp, 2.6-1519bp, and 2.7-1819bp) from the pLL2.1-pLL2.7 vectors into the 5,831bp ApaI-EcoRI backbone from pLL3.0 to create pLL3.1-pLL3.7. All plasmids were verified by restriction digest.

20 [00272] *Example 3: Specific Silencing of Genes in T Cells using a Lentiviral Vector*

[00273] Materials and Methods

[00274] *Cell culture:* E10 and primary mouse splenocyte cultures were performed as previously described (11). 293T cells (human fibroblasts) were cultured as described (21). *In vitro* T-cell proliferation was performed on 200,000 activated T-cells cultured in the presence/absence of increasing doses of IL2 (0 to 100 ng/ml) and pulsed for 6 h with [<sup>3</sup>H]TdR to assay proliferation.

25 [00275] *Oligonucleotide design.* The following approach was used to design oligonucleotides suitable for cloning into pLL3.7 vectors to generate vectors capable of directing synthesis of shRNAs for gene silencing in this and the following examples. As described above, we have engineered a multiple cloning site immediately following the U6 promoter. An HpaI site leaves a blunt end prior to the -

1 position in the promoter. The oligonucleotide design must incorporate a 5' T in order to reconstitute the -1 nucleotide of U6. An XhoI site cuts downstream of the U6 start site. The following oligonucleotide format was used:

[00276] Sense oligonucleotide: 5'T-(GN18)-(TTCAAGAGA)-(81NC)-TTTT

5 [00277] Antisense oligonucleotide: Complement of sense but with additional nucleotides at 5' end to generate XhoI overhang.

The loop sequence (TTCAAGAGA) (SEQ ID NO: 10) is based upon Brummelkamp et al. (Science 2002).

10 Oligonucleotides with 5' phosphates and PAGE purified were ordered from Integrated DNA Technologies (IDT), Coralville, IA.

15 [00278] *Generation of lentiviral transfer plasmids containing shRNAs targeted to CD8.*

[00279] Oligonucleotides having the following sequences were inserted into pLL3.7 to produce lentiviral transfer plasmids capable of directing expression of an shRNA targeted to CD8.

20 [00280] CD8 sense: 5'- tgctacaactactacatgactcaagagagtcatgttagtttttg -3' (SEQ ID NO: 36)

[00281] CD8 antisense: 5'-

gttacaaaaaagctacaactactacatgactcttgaagtcatgttagtttagca-3' (SEQ ID NO: 37)

[00282] The following protocol was used to clone oligonucleotides into pLL3.7 in this and the following examples:

25 [00283] Oligos are resuspended in water at 60pmol/λ and annealed as follows.

Annealing oligos:

1λ Sense oligo

1λ Antisense oligo

48λ Annealing Buffer

30

Annealing Buffer Recipe:

100mM K-acetate

30mM HEPES-KOH pH 7.4

2mM Mg-acetate

Incubate at 95° 4min

70° 10min

5 Decrease temperature to 4° slowly (.1°C/min)

Incubate at 4° 10 min

pLentiLox 3.7 is digested as follows:

Digest 1-2 $\mu$ g with XhoI and HpaI

10 Treat with SAP or with CIP

Purify linearized fragment

Estimate concentration

Ligation is performed as follows:

15 Ligate linearized product and annealed oligos at equimolar concentration. I typically use 60fmol of each component in a final concentration of 10 $\mu$ L.

Transformation is performed according to standard techniques. The use of an endA<sup>-</sup> strain of *E. coli*, e.g., STBL-2 cells is strongly recommended.

20

Clones are tested for the presence of inserts as follows:

We have had success testing for insertion of the stem-loop sequence with both colony PCR or by restriction digest. Insertion of insert causes a band shift of ~60bp in an XbaI/NotI fragment when compared to parental vector. This can be seen by 2%

25 agarose gel electrophoresis. RPMI. Cell viability immediately after electroporation was typically around 60%.

[00284] *Electroporation:* For electroporations, 10  $\mu$ g of LentiLox plasmid were added to prechilled 0.4-cm electrode gap cuvettes (Bio-Rad, Hercules, CA). E10 cells ( $1.5 \times 10^7$ ) were resuspended to  $3 \times 10^7$  cells/ml in cold serum-free RPMI, added to 30 the cuvettes, mixed, and pulsed once at 300 mV, 975  $\mu$ F with a Gene Pulser electroporator II (Bio-Rad). After electroporation, the cells were put into four wells of

a 24-well plate, each containing 1 ml of RPMI. Cell viability immediately after electroporation was typically around 60%.

5 [00285] *Flow cytometry:* For flow cytometric analysis described in this and subsequent examples, all cells were washed once in FACS buffer (PBS supplemented with 2% FCS and 0.01% sodium azide), resuspended to 200  $\mu$ l, and stained directly with the appropriate antibodies. The stained cells were washed once, then resuspended in 100  $\mu$ l FACS buffer containing 5  $\mu$ g/ml propidium iodide (PI).

10 Unstained and singly stained controls were included in every experiment. Cell data were collected on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) and four-color analyses (GFP, PE, PI, and allophycocyanin) were done with CellQuest software (BD Biosciences). All data were collected by analyses performed on at least  $2.5 \times 10^5$  PI-negative events (viable cells).

15 [00286] The following phycoerythrin (PE) conjugated antibodies were used in this and the following examples: anti-CD4 (clone RM4-5), anti-CD8 $\alpha$  (clone 53-6.7), anti-CD25 (clone PC81), anti TCR $\beta$  (clone H57-597), anti-CD28 (clone 37.51) and strepavidin. Allophycocyanin (APC)-conjugated anti-CD8 $\alpha$  and biotin-conjugated anti-CD3 were also used for analysis. All antibodies were from BD Pharmingen (San Diego, California). All plots shown are gated for viable cells, which were isolated by selecting PI cells.

20 [00287] *Northern blot analysis:* For Northern blot analysis, cells were lysed with Trizol reagent (Invitrogen), and total cellular RNA was prepared according to the manufacturer's instructions. CD4/CD8 probe hybridization and was performed as described (11). For the small RNA Northern, total RNA (60  $\mu$ g) was fractionated on a 10% denaturing polyacrylamide gel and transferred to nylon membrane. The 25 membrane was hybridized to a probe consisting of a 21nt CD8 siRNA sense strand 5' end-labeled with  $^{32}$ P. A 5' radiolabeled oligonucleotide probe to 5S RNA was used to determine equal loading of RNA. The probe for the siRNA CD8 was taken exactly from the sense strand in the pLL3.7 CD8 stem-loop as described in reference 11.

#### [00288] Results

30 [00289] To determine whether lentiviral vectors could deliver shRNAs and silence genes in mammalian cells, the pLL3.7 vector described in Example 2 that carries the U6 RNA polymerase III (polIII) promoter (Fig. 17A) was used. This promoter is

known to efficiently transcribe small RNAs that silence gene expression (2, 26). The pLL3.7 vector was also engineered to express EGFP as a reporter gene, permitting infected cells to be tracked by flow cytometry. EGFP expression was driven by a constitutive RNA polymerase II (polII) promoter derived from cytomegalovirus

5 (CMV) (Fig. 17B). This promoter is active in most mammalian tissues (27). The CMV promoter of pLL3.7 was placed between LoxP sites to allow removal of this genetic element if transcript levels from the U6 promoter were not sufficient to silence gene expression due, for example, to possible promoter interference that might decrease expression of shRNAs in infected cells.

10 [00290] To test whether pLL3.7 could be used to silence gene expression in mammalian cells, the sequence for a shRNA predicted to target the T cell surface molecule, CD8, was introduced into this vector to generate pLL3.7 CD8 (Fig. 17B). The CD8 shRNA duplex sequence (SEQ ID NO: 25: 5'-  
TGCTACAACTACTACATGAC-3' when expressed in DNA format) was based on

15 sequences that we had previously characterized in the CD8<sup>+</sup> E10 thymoma cell line (11, 28), and that we had shown will specifically downregulate CD8 in these cells when introduced as siRNAs. As a first test we electroporated pLL3.7 CD8 or a pLL3.7 vector containing a stem loop targeted to an unrelated sequence (CD25T, a stem loop targeted to CD25 but containing a mutation resulting in an early

20 termination site) into E10 cells, and quantified expression of CD8 in transfected cells by flow cytometry. E10 cells that took up pLL3.7 CD8 or pLL3.7 CD25T DNA could be identified by flow cytometry based on their expression of GFP, i.e., cells that took up the vector became GFP-positive. As shown in Figure 23, GFP<sup>+</sup> E10 cells transfected with pLL3.7 CD8 (lower panel) showed on average a 7-fold reduction in

25 CD8 levels relative to cells transfected with pLL3.7 CD25T (middle panel). This result demonstrated that pLL3.7 CD8 was able to silence expression of CD8 in T cells. Since we could detect GFP<sup>+</sup> and CD8-silenced cells, promoter interference did not present a major barrier for co-expression of shRNAs and a reporter gene.

An aspect of the data that should be noted is that although Figure 23 appears

30 to suggest that higher levels of GFP correlates with decreased CD8 expression, which would suggest that more copies of the lentiviral DNA result in greater silencing, this is an artifact due to the fact that when subtracting signal to

correct for overlap between signals, more signal from the PE (CD8) channel was subtracted from the GFP channel than should have been, which makes the cells with high GFP appear to have less CD8. In reality, it appears that any expression from the U6 promotor, regardless of number of integrants or copies leads to full silencing. A 5 further complication of this experiment is that GFP expression from the plasmid is actually highest after 24 hrs. As a consequence, at 48 hours, there are many silenced cells that have become GFP<sup>-</sup>.

10 [00291] *Example 4: Production of Infectious Lentiviral Particles using Lentiviral Transfer Plasmids Containing shRNA Sequences*

[00292] Materials and Methods

15 [00293] *Cell culture and lentivirus production.* Cell culture was performed as in Example 3. Lentiviral production was performed as described (24) using packaging plasmids pMDL g/pRRE, pCMV VSV-G, and pRSV-REV, described in references 21 and 40.

[00294] *Harvesting and titering lentivirus.* Lentivirus was harvested and titered according to the following protocol:

Harvesting:

- 20 1. Harvest supernatant from cells and spin at 25,000 rpm for 1.5hrs
2. Remove all liquid, add x volume of PBS (between 15 and 200ul), and allow to sit overnight at 4 degrees
3. Pipette up and down ~20 times
4. Use or aliquot and flash-freeze in liquid N2, store at -80.

Titering:

- 25 1. Plate  $4 \times 10^5$  293.T cells/well in a 6-well plate 12-24 hours prior to titering. It is helpful to have an additional well as a negative control that you mock infect with D10+polybrene but without virus.
2. Make a stock solution of D10 medium with 8 $\mu$ g/ml polybrene.
- 30 3. Generate a 10-fold dilution series of virus in the D10+polybrene. Using 1.5mls/well you should have 1 $\mu$ l, .1, .01, .001, .0001, and .00001 $\mu$ L of virus/well.
4. Incubate at 37 degrees O/N. Replace media with fresh D10.

5. At least 48 hours after infection trypsinize cells for FACS analysis. (Trypsinize, inactivate with media, spin, and resuspend in cold PBS).
6. FACS analyze for EGFP expression and record the percentage of cells that are EGFP positive.
- 5 7. Use a well that has between .1% and 10% of cells expressing EGFP to determine titer.

Sample calculation assuming 1% infection from the well with .01 $\mu$ l of virus: .01 (percentage of cells that are EGFP positive) x  $4 \times 10^5$  =  $4 \times 10^3$  positive cells.  
 $4 \times 10^3 \times 100$  (dilution factor) =  $4 \times 10^5$  viral particles/ $\mu$ l.

- 10 10 In general at least  $5 \times 10^5$  viral particles/ $\mu$ l should be used for embryo infections.

[00295] *Transfection of 293 cells.* The following protocol was used for transfection of 293 cells in this and the following examples.

- 15 15 1. Plate  $12 \times 10^6$  293.T cells in 20 ml on a  $15 \text{ cm}^2$  plate 24 hours before transfection. In general, two  $15 \text{ cm}$  plates per virus are used. It is highly preferred that the cells be well-maintained and of relatively low passage number.
- 20 20 2. Mix the following DNAs (preferably made using Endo-free Qiagen Kits according to the manufacturer's instructions) in a FACS tube. The DNAs should be in Endo-free TE at a concentration of  $0.5 \mu\text{g}/\mu\text{l}$ .

For 3 plasmid system:

- 25 25 20  $\mu\text{g}$  vector (transfer plasmid, e.g., pLL3.7 CD8)  
10  $\mu\text{g}$  pVSVG (envelope plasmid)  
15  $\mu\text{g}$   $\Delta$  8.9 (packaging plasmid)

For 4 plasmid, system (recommended),

- 30 30 20  $\mu\text{g}$  vector, (transfer plasmid, e.g., pLL3.7 CD8)  
10  $\mu\text{g}$  pVSVG (envelope plasmid)  
10  $\mu\text{g}$  RSV-REV (plasmid supplies Rev protein)  
10  $\mu\text{g}$  pMDL g/p RRE (packaging plasmid)

The envelope plasmid, packaging plasmids, and Rev-supplying plasmid are described in further detail in references 21, 24, 40, and 41.

Add 400  $\mu$ l 1.25 M  $\text{CaCl}_2$  and 1.5 ml  $\text{H}_2\text{O}$  and mix by tapping gently.

The following steps are done 1 plate at a time.

3. Add 2 ml of 2X HBS dropwise to DNA mixture while bubbling with a Pasteur pipette. When finished, continue to bubble for 12-15 seconds.
4. Take plate of 293T out of the incubator (plate remains in incubator for long as possible), and add transfection mixture dropwise all over the plate. Gently swirl plate from front to back, and return immediately to incubator.
5. 3.5 to 4 hours later, remove media, wash 2x with 10ml warm PBS, and add 20 ml warm D10 onto plate and place in incubator.
- 10 6. 36-48 hours after transfection, harvest viral supernatant and spin at 2000 rpm, 7 min at 4°C in a 50ml tube.
- 15 7. Filter viral SN through .45 um filter. Add 35ml of filtered supernatant to an ultracentrifuge tube. Balance tubes with additional media. Cover tubes with small piece of parafilm. (It is useful to titer some of the leftover supernatant to determine if there is loss of virus during concentration.)
8. Spin tubes using a SW-28 rotor at 25,000 rpm, 90 min, 4°C. Decant liquid and leave tube upside down on kimwipe for 10 min. Aspirate remaining media being careful not to touch bottom of tube.
- 20 9. Add 15 $\mu$ l cold PBS (for embryo infections, or any volume you wish) and leave tube at 4°C O/N with no shaking.
10. To resuspend, hold tube at angle and pipet fluid over pellet 20 times, being careful not to touch pellet with tip. It is expected that the pellet not be resuspended after this is complete. This pellet does not contain virus and can be discarded.
- 25 11. Aliquot or use virus. Virus should be aliquoted, flash-frozen in liquid nitrogen and stored at -80. There should be no change in titer with freezing concentrated virus. Avoid multiple freeze-thaws.

**[00296] Results**

- 30 30 [00297] To test whether pLL3.7 vectors could be used to generate infectious lentivirus particles, 293T cells were transfected with pLL3.7 or pLL3.7 CD8, and three lentiviral packaging plasmids developed by Miyoshi et al. (29). Our initial

concern was that a lentiviral construct containing shRNA sequences would itself be susceptible to RNA interference, thus preventing generation of viral (RNA) genomes and production of infectious viral particles. We failed to find any evidence of this type of auto-inhibition. We were able to generate viral stocks of pLL3.7 and pLL3.7

5 CD8 that could infect mouse fibroblast 3T3 cells, as gauged by GFP expression, and the titre of these viral stocks was always qualitatively similar. These results demonstrated that lentiviruses capable of mediating gene silencing can be generated efficiently. In other words, shRNAs generated by lentiviral vectors can target endogenous cellular transcripts but do not inhibit production of viral RNAs carrying

10 the same sequences.

**[00298] *Example 5: Stable Silencing of Genes and Production of Processed shRNAs in T Cells by a Lentiviral Vector***

**[00299] Materials and Methods**

15 **[00300] *Cell culture, lentivirus production, and lentivirus infection.*** Cell culture was performed as in Example 2. Lentiviral production and infection were performed as described (24) in this and following examples unless otherwise indicated. For some experiments, sorted populations of infected E10 cells were maintained in long-term culture. E10 cells pLL3.7 CD8 (CD8 RNAi virus) were sorted four days after

20 infection for GFP expression and low CD8 expression, while cells infected with control virus were sorted for GFP expression only. Each population was cultured for 1 month and analyzed for CD8 expression via flow cytometry at weekly intervals.

**[00301] Results**

25 **[00302] We examined whether the LentiLox system could be used to silence gene expression upon infection of mammalian cells. To accomplish this, E10 cells were infected with pLL3.7 and pLL3.7 CD8 viruses. A low viral titre was used so that only a fraction of cells became infected, as gauged by GFP expression (Fig. 18A). This allowed us to follow the fate of both infected and non-infected cells simultaneously. Infected (GFP<sup>+</sup>) cells on average showed a 16-fold reduction of CD8 expression.**

30 Figure 2a shows density plots indicating the expression levels of CD4 and CD8 48 hours post-infection.

[00303] Expression of CD8 and of other surface proteins was measured at 48 hours and at various times thereafter. Inhibition of CD8 expression in E10 cells infected with pLL3.7 CD8 was specific since levels of other surface proteins were not altered (Fig. 18B). Furthermore, in a subline of E10 cells engineered to express human CD8, 5 which differs from mouse CD8 by 4 out of 19 nucleotides in the region that we targeted, we showed that pLL3.7 CD8 selectively reduced expression of the mouse protein. Figure 24 shows expression of human CD8 in 3 populations of cells that either were (lower panels) or were not (upper panels) transfected with a construct encoding human CD8 (hCD8). The leftmost panels show expression of human CD8 10 in wild type ES cells, illustrating expression of hCD8 in transfected cells (lower left panel; cells below bar display hCD8 expression. The middle panels show expression of human CD8 in a population of ES cells that were infected with pLL3.7 CD8 and displayed effective silencing of mouse CD8 (low CD8). As shown in the lower middle panel, this population of cells did not display silencing of human CD8. The 15 rightmost panels show expression of human CD8 in a population of ES cells that were infected with pLL3.7 CD8 and did not display extensive silencing of mouse CD8 (high CD8). As shown in the lower right panel, this population of cells also did not display silencing of human CD8. These data show that an shRNA targeted to mouse CD8 does not silence human CD8, confirming the specificity of silencing. Cells 20 infected with a control virus (pLL3.7) or a virus that expressed a neuron-specific shRNA (pLL3.7 Mena+) showed no decrease in CD8 levels (Fig. 18A and data not shown).

[00304] To confirm that the decrease in surface CD8 expression seen in E10 cells resulted from mRNA degradation, we assayed CD8 mRNA levels in sorted (GFP<sup>+</sup>) 25 cell populations infected either with a control virus (pLL3.7) or CD8 RNAi virus (pLL3.7 CD8) (Fig. 19A). Consistent with results showing significant reduction of CD8 protein levels, the amount of CD8 transcripts in E10 cells infected with pLL3.7 CD8 was 13-fold lower than in controls (Fig. 19B). The same cells expressed normal amounts of CD4 transcripts (Fig. 19B), confirming the specificity of the RNAi 30 knockdown. We also examined whether the shRNAs encoded by pLL3.7 CD8 were processed into the approximately 21 nucleotide-long RNAs reported to mediate RNAi (12) by blotting cellular RNA extracts with a probe directed against the anti-sense

strand of the CD8 stem loop. Only the pLL3.7 CD8 infected cells produced CD8 siRNAs (Fig. 19C). The dominant population of siRNAs detected was 21 bases in length; although 1-2 bp longer species of siRNAs were also present (Fig. 19C). No precursor shRNA was visible on the autoradiogram.

5 [00305] To test the stability of lentivirus-mediated RNAi in mammalian cells, we followed expression of CD8 in long-term cultures of E10 cells infected with pLL3.7 or pLL3.7 CD8. Cells were sorted based on GFP and CD8 expression levels four days after infection with lentivirus, and subsequently monitored for expression of these proteins weekly. No change in expression of CD8 was observed and these cells

10 remained uniformly GFP positive, demonstrating that RNAi mediated by the integrated lentivirus was stable (Fig. 19A). In each experiment a small fraction (2 to 15%) of E10 cells infected with pLL3.7 CD8 showed no evidence of gene silencing, maintaining wild type CD8 expression (Fig. 19A). This was not necessarily the result of a low copy number of integrated viruses or poor expression of viral genes since

15 some of these cells expressed very high levels of GFP (Fig. 19A). As shown in the Northern blot in Figure 25, we were able to determine that these cells expressed little, if any shRNAs directed against CD8, suggesting that the activity of the polIII promoter was reduced.

[00306] *Example 6: Functional Gene Silencing in Differentiated Mammalian Cells*

20 *Induced by Lentiviruses*

[00307] Materials and Methods

[00308] *T-cell purification and stimulation.* Cells were harvested from spleen and lymph nodes. They were plated in RPMI with 10% FBS supplemented with 1 ug/ml ova peptide. Cells were infected 24 and 48 hours after plating and analyzed 72 hours

25 after plating. This activation method yields >90% purity of T-cells.

[00309] *Viral infection.* Spin infection was performed as described for retrovirus in van Parijs, L., *et al.*, *Immunity*, 11:281, 1999 using 50 ul of concentrated lentivirus.

[00310] We tested whether the LentiLox-based RNAi system could be used to silence gene expression in primary mammalian cells. In these experiments, we

30 purified CD8<sup>+</sup> T cells from the spleens of OTI T-cell receptor (TCR) transgenic mice, activated them with cognate peptide antigen, and then infected these cells with pLL3.7 or pLL3.7 CD8. After three days in culture, the T cells were harvested and

analysed for GFP and CD8 expression by flow cytometry. Between 68 and 82% of the cells were infected, as gauged by GFP expression (Fig. 4a). The infected (GFP<sup>+</sup>) population reproducibly showed approximately a 14-fold reduction in CD8 expression, demonstrating that lentivirus-driven expression of shRNAs efficiently 5 silenced gene expression in primary T cells (Fig. 20A). This effect of pLL3.7 CD8 was specific since infected cells showed normal expression of other T cell surface markers (Fig. 20A).

[00311] We next examined whether the degree of gene silencing achieved in primary mammalian cells using the LentiLox system was functionally relevant. To 10 accomplish this we performed an experiment aimed at studying the biological effects of targeting the IL-2 receptor (IL-2R) in T cells using lentivirus-mediated RNAi. IL-2 is an important growth factor for T cells, and T cells derived from mice that lack the receptor for this cytokine fail to proliferate *in vitro* (31). To determine whether we could phenocopy IL-2R-deficiency in primary T cells using lentivirus-mediated 15 RNAi, we designed a shRNA against the alpha chain of the IL-2 receptor (CD25) and used this sequence to create pLL3.7 CD25. The shRNA sequences were as follows:

[00312] CD25 sense: 5'- tgcattcacctaatcggtgttcaagagacagccgattaggtaatgccttttg-  
3' (SEQ ID NO: 38)

[00313] CD25 antisense:  
20 5'-gtcacaaaaaaagcattcacctaatcggtgtcttgaacagccgattaggtaatgca-3' (SEQ ID NO:  
39)

[00314] In most experiments between 70 and 85% of activated CD8+ TCR 25 transgenic T cells were infected with this virus (Fig. 20A). Infected cells on average showed a 25-fold reduction in IL-2R $\alpha$  chain expression, but expressed normal levels of other surface markers (Fig. 20A). These cells were challenged with increasing concentrations of IL-2, resulting in a 4- to 5-fold reduction in the response to this cytokine (Figure 20B). Therefore, the LentiLox RNAi system can be used to phenocopy loss-of-function in primary T cells.

30 [00315] *Example 7: Functional Silencing of Genes in Embryonic Stem Cell-derived Mice by a Lentiviral Vector*

[00316] Materials and Methods

[00317] *Generation of lentiviral transfer plasmids containing shRNAs targeted to Mena+, Beta-catenin, and p53.* Oligonucleotides having the following sequences were inserted into pLL3.7 as described above to produce lentiviral transfer plasmids capable of directing expression of shRNAs targeted to Mena+, Beta-catenin, or p53 transcripts.

5 [00318] Mena+ sense: 5'-  
tgtcctgtgcctggctactttcaagagaagttaggccaggcacaggacttttggaaac-3' (SEQ ID NO: 26)

[00319] Mena+ antisense:

[00320] 5'-tcgagttcccaaaaagtccctgtgcctggctacttctcttggaaagttaggccaggcacaggaca-3'  
10 (SEQ ID NO: 27)

[00321] Beta-catenin sense:

[00322] 5'-tgtccagcgcgtggctgaactcaagagtggtcagccaagcgcgtggacttttggaaa-3' (SEQ ID NO: 28)

[00323] Beta antisense:

15 [00324] 5'-tcgattcccaaaaagtccagcgcgtggctgaacactcttgaagttcagccaagcgcgtggaca-3'  
(SEQ ID NO: 29)

[00325] P53 sense:

[00326] 5'-  
tggcttaagtggagcccttcgagtgttagaagcttgcacactcggagggctcacttggccctttggaaa-3' (SEQ  
20 ID NO: 30)

[00327] P53 antisense:

[00328] 5' -  
tcgattcccaaaaaggcccaagtgaagccctccgagtgtcacaagcttcaacactcgaagggctccacttagacca - 3'  
(SEQ ID NO: 31)

25 [00329] *ES Cells:* AK7 ES cells were maintained and infected as described (23). Clones of ES cells were picked, expanded, and analyzed by flow cytometry for GFP expression. If the clone contained a mixed population of infected and uninfected cells, the GFP population was purified by fluorescence activated cell sorting.

[00330] *Production of transgenic mice:* Transgenic mice were generated  
30 essentially as described in reference 24.

[00331] Results

[00332] A unique feature of lentivirus-based vectors is that they can stably express transgenes in stem cells and are not silenced during development, allowing for the efficient generation of transgenic mice (23, 24). We tested whether the LentiLox RNAi system could be used to silence gene expression in stem cells, as well as 5 animals generated from these cells. To accomplish this we infected embryonic stem cells with versions of the pLL3.7 vector that expressed shRNAs against CD8 (pLL3.7 CD8), Mena+ (pLL3.7 Mena+), or p53 (pLL3.7 p53).

[00333] We found that these vectors could efficiently infect embryonic stem cells, and we are able to generate and maintain stable lines of infected ES cells (Figure 21A, 10 and data not shown).

[00334] To test whether ES cells infected with RNAi lentivirus were capable of giving rise to progeny that showed gene silencing, we generated uniformly GFP+ ES cell populations infected with pLL3.7 CD8, pLL3.7 Mena+, or the empty vector, pLL3.7, by cell sorting. Ten to twelve of these cells were injected into day 3 15 blastocysts, which were subsequently implanted into pseudopregnant recipients. To ensure that the lentivirus-infected ES cells contributed to immune tissues in the chimeric offspring, we used RAG2<sup>-/-</sup> blastocysts in these experiments. This genetic lesion blocks the development of B and T cells, so that any immune cells present in the chimeric progeny must be derived from the injected (wild type) ES cells (32).

20 Using this approach we generated mice derived from ES cells infected with pLL3.7 CD8, pLL3.7 Mena+, and pLL3.7. The degree of chimerism in these animals was between 50 and 90% as gauged by GFP fluorescence analysis of whole mice, as well as dissected organs (Figure 21B and data not shown). This result demonstrated that cells expressing siRNAs were not selected against during development and that these 25 cells were able to contribute to all tissues in the body.

[00335] In our chimeric mice, almost all cells in the lymphoid organs expressed GFP, indicating that they were derived from the injected ES cells (Figure 21C and data not shown). To examine whether lentivirus-mediated expression of shRNAs resulted in the silencing of CD8 *in vivo*, we harvested the thymus and spleen of 7 day-old 30 chimeric mice and stained the cells present in these organs with antibodies against CD8 and CD4 according to standard techniques. We found that developing T cells in the thymus of pLL3.7 CD8 mice showed a 7-fold reduction in CD8 expression

(Figure 21D). Furthermore, no mature CD8+ T cells were detected in this organ or in the spleen (Figure 21D). In contrast, thymocytes from these mice showed normal expression of CD4 and normal numbers of mature CD4+ T cells were found in their lymphoid organs. (Figure 21D). T cell differentiation and numbers were normal in 5 mice derived from pLL3.7 Mena+ and pLL3.7 infected ES cells (Figure 21D and data not shown).

**[00336] *Example 8: Cre-mediated Extinguishing of a Transgene Expressed from a Lentiviral Vector***

10 **[00337]** This example demonstrates that introduction of Cre recombinase into cells expressing a transgene from a lentiviral vector of the invention extinguishes expression of the transgene.

**[00338] Materials and Methods**

15 **[00339] *Expression of EGFP using a lentiviral vector.*** A 50% confluent 10 cm plate of D7 cells (See Bear JE, et al., *Cell* 2000 Jun 23;101(7):717-2 for description of cells and culture conditions.), was infected with 100ul of concentrated pLL3.7 B-catenin lentivirus, which expressed GFP as a transgene between two LoxP sites. Infected cells (pLL3.7 B-catenin containing cells) were sorted based upon expression of EGFP.

20 **[00340] *Introduction of Cre.*** A 50% confluent 6 cm plate of sorted D7 pLL3.7 B-catenin containing cells was infected with adenovirus expressing the Cre recombinase (Jackson EL, et al., *Genes Dev* 2001 Dec 15;15(24):3243-8. 1x10<sup>5</sup> infectious units were used in the infection. Cells were expanded for 10 days to allow time for expression of Cre protein, deletion of the loxP-CMVegfp-loxP cassette, and depletion 25 of EGFP protein pools. Cells were then analyzed by flow cytometry for expression of EGFP. Cells were also sorted based upon loss of EGFP expression and expanded.

**[00341] Results**

30 **[00342] *Figure 22A shows flow cytometric analysis of EGFP expression in cells infected with an EGFP-expressing lentiviral vector in which the promoter and EGFP coding sequences are floxed.*** Flow cytometry was performed at least 48 hours after infection. The solid purple peaks in Figure 22A and 22B represent uninfected cells. As shown in Figure 22A, ninety percent of the infected cells express EGFP. The

population of cells expressing EGFP is shown with a green line. Figure 22B shows flow cytometric analysis of EGFP expression in cells infected with an EGFP-expressing lentiviral vector 10 days after induction of Cre expression. The percentage of EGFP-expressing cells is reduced to 49%. Figure 22C shows a direct comparison 5 between pLL3.7 infected D7 cells before (green line) and after (pink line) Cre delivery. Induction of Cre extinguished expression of the floxed transgene in approximately half the cells. (The adenoviral titer was not high enough to infect all cells, thus cells in which the transgene was not extinguished were probably not infected with adenovirus.)

10

[00343] Sequences of *pBFGW* and *pLL3.0 – pLL3.7*. This section presents the sequences of plasmids *pBFGW* and *pLL3.0 – pLL3.7* in the form of GenBank files.

[00344] *pBFGW*

|    |              |            |                             |            |            |            |            |         |   |         |
|----|--------------|------------|-----------------------------|------------|------------|------------|------------|---------|---|---------|
| 5  | LOCUS        | PBFGW.gb   | 10441                       | BP         | DS-DNA     | CIRCULAR   | SYN        | 23-JAN- |   |         |
|    | 2002         |            |                             |            |            |            |            |         |   |         |
|    | DEFINITION   | -          |                             |            |            |            |            |         |   |         |
|    | ACCESSION    | -          |                             |            |            |            |            |         |   |         |
|    | KEYWORDS     | -          |                             |            |            |            |            |         |   |         |
|    | SOURCE       | -          |                             |            |            |            |            |         |   |         |
| 10 | FEATURES     |            | Location/Qualifiers         |            |            |            |            |         |   |         |
|    | promoter     |            | 212..816                    |            |            |            |            |         |   |         |
|    |              |            | /note="CMV 1"               |            |            |            |            |         |   |         |
|    | gene         |            | 9448..10308                 |            |            |            |            |         |   |         |
|    |              |            | /note="AmpR"                |            |            |            |            |         |   |         |
| 15 | rep_origin   |            | 8630..9303                  |            |            |            |            |         |   |         |
|    |              |            | /note="pUC"                 |            |            |            |            |         |   |         |
|    | polyA_signal |            | 6452..6666                  |            |            |            |            |         |   |         |
|    |              |            | /note="BGH pA"              |            |            |            |            |         |   |         |
| 20 | gene         |            | 7613..7987                  |            |            |            |            |         |   |         |
|    |              |            | /note="ZeoR"                |            |            |            |            |         |   |         |
|    | polyA_signal |            | 8117..8246                  |            |            |            |            |         |   |         |
|    |              |            | /note="SV40 pA"             |            |            |            |            |         |   |         |
|    | rep_origin   |            | 6729..7142                  |            |            |            |            |         |   |         |
|    |              |            | /note="f1 origin"           |            |            |            |            |         |   |         |
| 25 | promoter     |            | 7205..7530                  |            |            |            |            |         |   |         |
|    |              |            | /note="SV40 ori"            |            |            |            |            |         |   |         |
|    | LTR          |            | 835..1509                   |            |            |            |            |         |   |         |
|    |              |            | /note="5' LRT"              |            |            |            |            |         |   |         |
| 30 | misc_feature |            | 1533..2390                  |            |            |            |            |         |   |         |
|    |              |            | /note="psi sequence"        |            |            |            |            |         |   |         |
|    | misc_feature |            | 2416..2593                  |            |            |            |            |         |   |         |
|    |              |            | /note="FLAP"                |            |            |            |            |         |   |         |
|    | promoter     |            | 2612..2974                  |            |            |            |            |         |   |         |
|    |              |            | /note="CMV 2"               |            |            |            |            |         |   |         |
| 35 | promoter     |            | 2798..4229                  |            |            |            |            |         |   |         |
|    |              |            | /note="Beta actin promoter" |            |            |            |            |         |   |         |
|    | intron       |            | 4234..4327                  |            |            |            |            |         |   |         |
|    |              |            | /note="beta globin intron"  |            |            |            |            |         |   |         |
| 40 | gene         |            | 4373..5089                  |            |            |            |            |         |   |         |
|    |              |            | /note="EGFP"                |            |            |            |            |         |   |         |
|    | misc_feature |            | 5132..5721                  |            |            |            |            |         |   |         |
|    |              |            | /note="WRE"                 |            |            |            |            |         |   |         |
|    | misc_feature |            | 5737..6426                  |            |            |            |            |         |   |         |
|    |              |            | /note="3' LTR"              |            |            |            |            |         |   |         |
| 45 | BASE COUNT   | 2414       | A                           | 2697       | C          | 2911       | G          | 2419    | T | 0 OTHER |
|    | ORIGIN       | -          |                             |            |            |            |            |         |   |         |
|    |              | 1          | GTCGACGGAT                  | CGGGAGATCT | CCCGATCCCC | TATGGTGCAC | TCTCAGTACA |         |   |         |
|    |              | ATCTGCTCTG |                             |            |            |            |            |         |   |         |
| 50 | GCTGAGTAGT   | 61         | ATGCCGCATA                  | GTAAAGCCAG | TATCTGCTCC | CTGCTTGTGT | GTTGGAGGTC |         |   |         |
|    |              |            |                             |            |            |            |            |         |   |         |
|    |              | 121        | GCGCGAGCAA                  | AATTTAAGCT | ACAACAAGGC | AAGGCTTGAC | CGACAATTGC |         |   |         |
|    |              | ATGAAGAAC  |                             |            |            |            |            |         |   |         |
|    |              | 181        | TGCTTAGGGT                  | TAGGCCTTTT | GCGCTGCTTC | GCGATGTACG | GGCCAGATAT |         |   |         |
|    |              | ACGCGTTGAC |                             |            |            |            |            |         |   |         |
| 55 | CATAGCCCCAT  | 241        | ATTGATTATT                  | GACTAGTTAT | TAATAGTAAT | CAATTACGGG | GTCATTAGTT |         |   |         |

301 ATATGGAGTT CCGCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA  
 CCGCCCAACG  
 361 ACCCCCCGCCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA  
 ATAGGGACTT  
 5 421 TCCATTGACG TCAATGGGTG GAGTATTTAC GGTAAACTGC CCACTTGGCA  
 GTACATCAAG  
 481 TGTATCATAT GCCAAGTACG CCCCCCTATTG ACGTCAATGA CGGTAAATGG  
 CCCGCCTGGC  
 541 ATTATGCCCA GTACATGACC TTATGGACT TTCCTACTTG GCAGTACATC  
 10 TACGTATTAG  
 601 TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT CAATGGCGT  
 GGATAGCGGT  
 661 TTGACTCACG GGGATTTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT  
 TTGTTTGGC  
 15 721 ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC CGCCCCATTG  
 ACGCAAATGG  
 781 GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGCGC GTTTGCCTG  
 TACTGGGTCT  
 841 CTCTGGTTAG ACCAGATCTG AGCCTGGAG CTCTCTGGCT AACTAGGGAA  
 20 CCCACTGCTT  
 901 AAGCCTCAAT AAAGCTTGCC TTGAGTGCTT CAAGTAGTGT GTGCCCGTCT  
 GTTGTGTGAC  
 961 TCTGGTAACT AGAGATCCCT CAGACCCTTT TAGTCAGTGT GGAAAATCTC  
 TAGCAGTGGC  
 25 1021 GCCCGAACAG GGACTTGAAA GCGAAAGGGA AACCAAGAGGA GCTCTCTCGA  
 CGCAGGACTC  
 1081 GGCTTGCTGA AGCGCGCACG GCAAGAGGCG AGGGGCGGCG ACTGGTGAGT  
 ACGCCAAAAA  
 1141 TTTTGACTAG CGGAGGCTAG AAGGAGAGAG ATGGGTGCGA GAGCGTCAGT  
 30 ATTAAGCGGG  
 1201 GGAGAATTAG ATCGCGATGG GAAAAAATTC GGTTAAGGCC AGGGGGAAAG  
 AAAAAATATA  
 1261 AATTAAAACA TATAGTATGG GCAAGCAGGG AGCTAGAACG ATTGCGAGTT  
 AATCCTGGCC  
 35 1321 TGTTAGAAAC ATCAGAAGGC TGTAGACAAA TACTGGGACA GCTACAACCA  
 TCCCTTCAGA  
 1381 CAGGATCAGA AGAACTTAGA TCATTATATA ATACAGTAGC AACCCCTCTAT  
 TGTGTGCATC  
 1441 AAAGGATAGA GATAAAAGAC ACCAAGGAAG CTTTAGACAA GATAGAGGAA  
 40 GAGCAAAACA  
 1501 AAAGTAAGAC CACCGCACAG CAAGCGGCCG CTGATCTTC GACCTGGAGG  
 AGGAGATATG  
 1561 AGGGACAATT GGAGAAGTGA ATTATATAAA TATAAAGTAG TAAAAATTGA  
 ACCATTAGGA  
 45 1621 GTAGCACCCA CCAAGGCAA GAGAAGAGTG GTGCAGAGAG AAAAAAGAGC  
 AGTGGGAATA  
 1681 GGAGCTTGT TCCTTGGTT CTTGGGAGCA GCAGGAAGCA CTATGGCGC  
 AGCGTCAATG  
 1741 ACGCTGACGG TACAGGCCAG ACAATTATTG TCTGGTATAG TGCAGCAGCA  
 50 GAACAAATTG  
 1801 CTGAGGGCTA TTGAGGCGCA ACAGCATCTG TTGCAACTCA CAGTCTGGGG  
 CATCAAGCAG  
 1861 CTCCAGGCAA GAATCCTGGC TGTGAAAGA TACCTAAAGG ATCAACAGCT  
 CCTGGGGATT  
 55 1921 TGGGGTTGCT CTGGAAAAT CATTGACACC ACTGCTGTGC CTTGGAATGC  
 TAGTTGGAGT  
 1981 AATAAAATCTC TGGAACAGAT TTGGAATCAC ACGACCTGGA TGGAGTGGGA  
 CAGAGAAATT

2041 AACAAATTACA CAAGCTTAAT ACACCTCTTA ATTGAAGAAT CGCAAAACCA  
 GCAAGAAAAG  
 2101 AATGAACAAG AATTATTGGA ATTAGATAAA TGGGCAAGTT TGTGGAATTG  
 GTTTAACATA  
 5 2161 ACAAAATTGGC TGTGGTATAT AAAATTATTC ATAATGATAG TAGGAGGCTT  
 GGTAGGTTA  
 2221 AGAATAGTTT TTGCTGTACT TTCTATAGTG AATAGAGTTA GGCAAGGGATA  
 TTCACCATA  
 2281 TCGTTTCAGA CCCACCTCCC AACCCGAGG GGACCCGACA GGCCCGAAGG  
 10 AATAGAAGAA  
 2341 GAAGGTGGAG AGAGAGACAG AGACAGATCC ATTCGATTAG TGAACGGATC  
 GGCACGTGCGT  
 2401 GCGCCAATTG TGCAGACAAA TGGCAGTATT CATCCACAAT TTTAAAAGAA  
 AAGGGGGGAT  
 15 2461 TGGGGGGTAC AGTGCAGGGG AAAGAATAGT AGACATAATA GCAACAGACA  
 TACAAACTAA  
 2521 AGAATTACAA AAACAAATTAA CAAAAATTCA AAATTTCGG GTTTATTACA  
 GGGACAGCAG  
 2581 AGATCCAGTT TGGTTAATTAA ACTGCAGGAA TCTAGTTATT AATAGTAATC  
 20 AATTACGGGG  
 2641 TCATTAGTTC ATAGCCCATA TATGGAGTTC CGCGTTACAT AACTTACGGT  
 AAATGGCCCG  
 2701 CCTGGCTGAC CGCCCAACGA CCCCCGCCA TTGACGTCAA TAATGACGTA  
 TGTTCCATA  
 25 2761 GTAACGCCAA TAGGGACTTT CCATTGACGT CAATGGGTGG AGTATTTACG  
 GTAAACTGCC  
 2821 CACTTGGCAG TACATCAAGT GTATCATATG CCAAGTACGC CCCCTATTGA  
 CGTCAATGAC  
 2881 GGTAAATGGC CCGCCTGGCA TTATGCCAG TACATGACCT TATGGACTT  
 30 TCCTACTTGG  
 2941 CAGTACATCT ACGTATTAGT CATCGCTATT ACCATGGTCG AGGTGAGCCC  
 CACGTTCTGC  
 3001 TTCACTCTCC CCATCTCCCC CCCCTCCCCA CCCCCAATTG TGTATTTATT  
 TATTTTTAA  
 35 3061 TTATTTGTG CAGCGATGGG GGCGGGGGGG GGGGGGGGGC GCGCGCCAGG  
 CGGGGCGGGG  
 3121 CGGGCGAGG GGCGGGCGGG GGCGAGGCGG AGAGGTGCGG CGGCAGCCAA  
 TCAGAGCGGC  
 3181 GCGCTCCGAA AGTTCTTT TATGGCGAGG CGGCGGCCGG GGCGGCCCTA  
 40 TAAAAAGCGA  
 3241 AGCGCGCGGC GGGCGGGGAG TCGCTGCGAC GCTGCCTTCG CCCCGTGCCC  
 CGCTCCGCG  
 3301 CCGCCTCGCG CCGCCCCCCC CGGCTCTGAC TGACCGCGTT ACTCCCACAG  
 GTGAGCGGGC  
 45 3361 GGGACGGCCC TTCTCCTCCG GGCTGTAATT AGCGCTTGGT TTAATGACGG  
 CTTGTTTCTT  
 3421 TTCTGTGGCT GCGTAAAGC CTTGAGGGGC TCCGGGAGGG CCCTTGTGC  
 GGGGGGAGCG  
 3481 GCTCGGGGG TGCGTGCCTG TGTGTGTGCG TGGGGAGCGC CGCGTGCAGG  
 50 TCCGCGCTGC  
 3541 CCGGCGGCTG TGAGCGCTGC GGGCGCGCG CGGGGCTTTG TGCGCTCCGC  
 AGTGTGCGCG  
 3601 AGGGGAGCGC GGCGGGGGC GGTGCCCGC GGTGCAGGGGG GGGCTGCGAG  
 GGGAAACAAAG  
 55 3661 GCTGCGTGCG GGGTGTGTGC GTGGGGGGGT GAGCAGGGGG TGTGGGCGCG  
 TCGGTGCGGC  
 3721 TGCAACCCCC CCTGCACCCCC CCTCCCCGAG TTGCTGAGCA CGGCCCCGGCT  
 TCGGGTGCAG

3781 GGCTCCGTAC GGGCGTGGC GCAGGGCTCG CCGTCCGGG CGGGGGTGG  
 CGGCAGGTGG  
 3841 GGGTGCCGGG CGGGCGGGG CGCCCTCGGG CGGGGGAGGG CTGGGGGAG  
 GGGCGCGGCG  
 5 3901 GCCCCCGGAG CGCCGGCGGC TGTGAGGCG CGGGGAGCCG CAGCCATTGC  
 CTTTTATGGT  
 3961 AATCGTGCAG GAGGGCGCAG GGACTTCCTT TGTCCAAAT CTGTGCGGAG  
 CCGAAATCTG  
 4021 GGAGGCGCCG CGCACCCTCC TCTAGCGGGC GCAGGGCGAA CGGGTGCAG  
 10 GCCGGCAGGA  
 4081 AGGAAATGGG CGGGGAGGGC CTTCGTGCCT CGCCGCGCCG CGTCCTCC  
 CTCCCTCTCC  
 4141 AGCCTCGGGG CTGTCCGCAG GGGGACGGCT GCCTCGGGG GGGACGGGGC  
 AGGGCGGGGT  
 15 4201 TCGGCTTCTG GCGTGTGACC GGCGGCTCTA GAGCCTCTGC TAACCATGTT  
 CATGCCTCT  
 4261 TCTTTTCCT ACAGCTCCTG GGCAACGTGC TGGTTATTGT GCTGTCTCAT  
 CATTGGCA  
 4321 AAGAATTGAT TTGATACCGC GGGCCCGGGG TCCCCGGGTA CGGGTCGCCA  
 20 CCATGGTGA  
 4381 CAAGGGCGAG GAGCTGTTCA CGGGGGTGGT GCCCATCCTG GTCGAGCTGG  
 ACGGCGACGT  
 4441 AAACGGCCAC AAGTTCAGCG TGTCCGGCGA GGGCGAGGGC GATGCCACCT  
 ACGGCAAGCT  
 25 4501 GACCCTGAAG TTCATCTGCA CCACCGGCAA GCTGCCCGTG CCCTGGCCCA  
 CCCTCGTGAC  
 4561 CACCCCTGACC TACGGCGTGC AGTGCTTCAG CCGCTACCCC GACCACATGA  
 AGCAGCACGA  
 4621 CTTCTTCAAG TCCGCCATGC CGAAGGCTA CGTCCAGGAG CGCACCATCT  
 30 TCTTCAAGGA  
 4681 CGACGGCAAC TACAAGACCC GCGCCGAGGT GAAAGTCGAG GGGGACACCC  
 TGGTGAACCG  
 4741 CATCGAGCTG AAGGGCATCG ACTTCAAGGA GGACGGCAAC ATCCTGGGGC  
 ACAAGCTGGA  
 35 4801 GTACAACCTAC AACAGCCACA ACGTCTATAT CATGGCCGAC AAGCAGAAGA  
 ACGGCATCAA  
 4861 GGTGAACCTTC AAGATCCGCC ACAACATCGA GGACGGCAGC GTGCAGCTCG  
 CCGACCACTA  
 4921 CCAGCAGAAC ACCCCCATCG GCGACGGCCC CGTGCTGCTG CCCGACAACC  
 40 ACTACCTGAG  
 4981 CACCCAGTCC GCCCTGAGCA AAGACCCCAA CGAGAAGCGC GATCACATGG  
 TCCTGCTGGA  
 5041 GTTCGTGACC GCCGCCGGG TCACTCTCGG CATGGACGAG CTGTACAAGT  
 AAAGCGGCCG  
 45 5101 CGACTCTAGA ATTGATATC AAGCTTATCG ATAATCAACC TCTGGATTAC  
 AAAATTGTC  
 5161 AAAGATTGAC TGGTATTCTT AACTATGTTG CTCCCTTTAC GCTATGTGGA  
 TACGCTGCTT  
 5221 TAATGCCTTT GTATCATGCT ATTGCTTCCC GTATGGCTTT CATTTCCTCC  
 50 TCCTTGATA  
 5281 AATCCTGGTT GCTGTCTTT TATGAGGAGT TGTGGCCCGT TGTCAGGCAA  
 CGTGGCGTGG  
 5341 TGTGCACTGT GTTGCTGAC GCAACCCCAA CTGGTTGGGG CATTGCCACC  
 ACCTGTCAGC  
 55 5401 TCCTTCCGG GACTTCGCT TTCCCCCTCC CTATTGCCAC GGCGGAACTC  
 ATCGCCGCCT  
 5461 GCCTGCCCG CTGCTGGACA GGGGCTCGGC TGTTGGGCAC TGACAATTCC  
 GTGGTGTGTTGT

5521 CGGGGAAATC ATCGTCCTT CCTGGCTGC TCGCCTGTGT TGCCACCTGG  
 ATTCTGCGCG  
 5581 GGACGTCCTT CTGCTACGTC CCTTCGGCCC TCAATCCAGC GGACCTTCCT  
 TCCCGCGGCC  
 5 5641 TGCTGCCGGC TCTGCGGCCT CTTCCGCGTC TTGCGCTTCG CCCTCAGACG  
 AGTCGGATCT  
 5701 CCCTTGGGC CGCCTCCCCG CATCGATACC GTCGACCTCG AGACCTAGAA  
 AACATGGAG  
 5761 CAATCACAAG TAGCAATACA GCAGCTACCA ATGCTGATTG TGCGTGGCTA  
 10 GAAGCACAAG  
 5821 AGGAGGAGGA GGTGGGTTTT CCAGTCACAC CTCAGGTACC TTTAAGACCA  
 ATGACTTACA  
 5881 AGGCAGCTGT AGATCTTAGC CACTTTTAA AAGAAAAGGG GGGACTGGAA  
 15 GGGCTAAATTCA  
 5941 ACTCCAACG AAGACAAGAT ATCCTTGATC TGTGGATCTA CCACACACAA  
 GGCTACTTCC  
 6001 CTGATTGGCA GAACTACACA CCAGGGCCAG GGATCAGATA TCCACTGACC  
 TTTGGATGGT  
 6061 GCTACAAGCT AGTACCAGTT GAGCAAGAGA AGGTAGAAGA AGCCAATGAA  
 20 GGAGAGAACAA  
 6121 CCCGCTTGTGTT ACACCCTGTG AGCCTGCATG GGATGGATGA CCCGGAGAGA  
 GAAGTATTAG  
 6181 AGTGGAGGTT TGACAGCCGC CTAGCATTTC ATCACATGGC CCGAGAGCTG  
 CATCCGGACT  
 25 6241 GTACTGGGTC TCTCTGGTTA GACCAGATCT GAGCCTGGGA GCTCTCTGGC  
 TAACTAGGGAA  
 6301 ACCCACTGCT TAAGCCTCAA TAAAGCTTGC CTTGAGTGCT TCAAGTAGTG  
 TGTGCCCGTC  
 6361 TGTTGTGTGA CTCTGGTAAC TAGAGATCCC TCAGACCCTT TTAGTCAGTG  
 30 TGGAAAATCT  
 6421 CTAGCAGGGC CCGTTAAAC CCGCTGATCA GCCTCGACTG TGCCCTCTAG  
 TTGCCAGCCA  
 6481 TCTGTTGTTT GCCCCTCCCC CGTGCCTTCC TTGACCCCTGG AAGGTGCCAC  
 TCCCACGTGTC  
 35 6541 CTTTCTTAAT AAAATGAGGA AATTGCATCG CATTGTCCTGA GTAGGTGTCA  
 TTCTATTCTG  
 6601 GGGGGTGGGG TGGGGCAGGA CAGCAAGGGG GAGGATTGGG AAGACAATAG  
 CAGGCATGCT  
 6661 GGGGATGCGG TGGGCTCTAT GGCTTCTGAG GCGGAAAGAA CCAGCTGGGG  
 40 CTCTAGGGGG  
 6721 TATCCCCACG CGCCCTGTAG CGGCGCATTA AGCGCGGCCGG GTGTGGTGGT  
 TACGCGCAGC  
 6781 GTGACCGCTA CACTGCCAG CGCCCTAGCG CCCGCTCCTT TCGCTTCTT  
 CCCTTCCTTT  
 45 6841 CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC GGGGGCTCCC  
 TTTAGGGTTC  
 6901 CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAAACTTG ATTAGGGTGA  
 TGGTTCACGT  
 6961 AGTGGGCCAT CGCCCTGATA GACGGTTTT CGCCCTTGA CGTTGGAGTC  
 50 CACGTTCTTT  
 7021 AATAGTGGAC TCTTGTCCA AACTGGAACA ACACTCAACC CTATCTCGGT  
 CTATTCTTT  
 7081 GATTTATAAG GGATTTGCC GATTCGGCC TATTGGTTAA AAAATGAGCT  
 GATTTAACAA  
 55 7141 AAATTTAACG CGAATTAATT CTGTGGAATG TGTGTCAGTT AGGGTGTGGA  
 AAGTCCCCAG  
 7201 GCTCCCCAGC AGGCAGAAGT ATGCAAAGCA TGCATCTCAA TTAGTCAGCA  
 ACCAGGTGTG

7261 GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA GTATGAAAG CATGCATCTC  
 AATTAGTCAG  
 7321 CAACCATAGT CCCGCCCTA ACTCCGCCA TCCCGCCCT AACTCCGCC  
 AGTTCCGCC  
 5 7381 ATTCTCCGCC CCATGGCTGA CTAATTTTT TTATTTATGC AGAGGCCAG  
 GCCGCCCTG  
 7441 CCTCTGAGCT ATTCCAGAAG TAGTGAGGAG GCTTTTTGG AGGCCTAGGC  
 TTTGCAAAA  
 7501 AGCTCCGGG AGCTTGTATA TCCATTTCG GATCTGATCA GCACGTGTTG  
 10 ACAATTAATC  
 7561 ATCGGCATAG TATATCGCA TAGTATAATA CGACAAGGTG AGGAACTAAA  
 CCATGGCCAA  
 7621 GTTGACCAGT GCCGTTCCGG TGCTCACCGC GCGCGACGTC GCCGGAGCGG  
 TCGAGTTCTG  
 15 7681 GACCGACCGG CTCGGGTTCT CCCGGGACTT CGTGGAGGAC GACTTCGCCG  
 GTGTGGTCCG  
 7741 GGACGACGTG ACCCTGTTCA TCAGCGCGT CCAGGACCAG GTGGTGCCGG  
 ACAACACCC  
 7801 GGCCTGGGTG TGGGTGCGCG GCCTGGACGA GCTGTACGCC GAGTGGTCGG  
 20 AGGTCTGTGTC  
 7861 CACGAACCTTC CGGGACGCCT CCAGGGCCGGC CATGACCGAG ATCGGCAGC  
 AGCCGTGGGG  
 7921 GCGGGAGTTC GCCCTGCGCG ACCCGGCCGG CAACTGCGTG CACTTCGTGG  
 CCGAGGAGCA  
 25 7981 GGACTGACAC GTGCTACGAG ATTTGATTC CACCGCCGCC TTCTATGAAA  
 GGTTGGGCTT  
 8041 CGGAATCGTT TTCCGGGACG CCGGCTGGAT GATCCTCCAG CGCGGGGATC  
 TCATGCTGGA  
 8101 GTTCTTCGCC CACCCAACT TGTTTATTGC AGCTTATAAT GGTTACAAAT  
 30 AAAGCAATAG  
 8161 CATCACAAAT TTCACAAATA AAGCATTTC TTCACTGCAT TCTAGTTGTG  
 GTTTGTCCAA  
 8221 ACTCATCAAT GTATCTTATC ATGTCTGTAT ACCGTCGACC TCTAGCTAGA  
 GCTTGGCGTA  
 35 8281 ATCATGGTCA TAGCTGTTTC CTGTGTGAAA TTGTTATCCG CTCACAATT  
 CACACAAACAT  
 8341 ACGAGCCGGA AGCATAAAAGT GTAAAGCCTG GGGTGCCTAA TGAGTGAGCT  
 AACTCACATT  
 8401 AATTGCGTTG CGCTCACTGC CCGCTTCCA GTCGGGAAAC CTGTCGTGCC  
 40 AGCTGCATTA  
 8461 ATGAATCGGC CAACGCGCGG GGAGAGGCAGG TTTGCGTATT GGGCGCTCTT  
 CCGCTTCCTC  
 8521 GCTCACTGAC TCGCTGCGCT CGGTGTTCG GCTGCGCGA GCGGTATCAG  
 CTCACTCAA  
 45 8581 GGCGGTAATA CGGTTATCCA CAGAACAGG GGATAACGCA GGAAAGAAC  
 TGTGAGCAAA  
 8641 AGGCCAGCAA AAGGCCAGGA ACCGTAAAAA GGCCGCGTTG CTGGCGTTTT  
 TCCATAGGCT  
 8701 CCGCCCCCT GACGAGCATC ACAAAATCG ACGCTCAAGT CAGAGGTGGC  
 50 GAAACCCGAC  
 8761 AGGACTATAA AGATACCAGG CGTTTCCCCC TGGAAGCTCC CTGGTGCCTC  
 CTCCTGTTCC  
 8821 GACCCTGCCG CTTACCGGAT ACCTGTCCGC CTTTCTCCCT TCGGGAAAGCG  
 TGGCGCTTTC  
 55 8881 TCATAGCTCA CGCTGTAGGT ATCTCAGTTC GGTGTAGGTC GTTCGCTCCA  
 AGCTGGGCTG  
 8941 TGTGCAAGAA CCCCCCGTTG AGCCCGACCG CTGCGCCTTA TCCGGTAAC  
 ATCGTCTTGA

9001 GTCCAACCCG GTAAGACACG ACTTATGCC ACTGGCAGCA GCCACTGGTA  
 ACAGGATTAG  
 9061 CAGAGCGAGG TATGTAGGCG GTGCTACAGA GTTCTTGAAG TGGTGGCCTA  
 ACTACGGCTA  
 5 9121 CACTAGAAGA ACAGTATTG GTATCTGCC TCTGCTGAAG CCAGTTACCT  
 TCGGAAAAAG  
 9181 AGTTGGTAGC TCTTGATCCG GCAAACAAAC CACCGCTGGT AGCGGTGGTT  
 TTTTTGTTG  
 9241 CAAGCAGCAG ATTACGCGCA GAAAAAAAGG ATCTCAAGAA GATCCTTG  
 10 TCTTTTCTAC  
 9301 GGGGTCTGAC GCTCAGTGGA ACGAAAAC TCACGTTAAGGG ATTTGGTCA  
 TGAGATTATC  
 9361 AAAAAGGATC TTCACCTAGA TCCTTTAAA TTAAAAATGA AGTTTAAAT  
 CAATCTAAAG  
 15 9421 TATATATGAG TAAACTTGGT CTGACAGTTA CCAATGCTTA ATCAGTGAGG  
 CACCTATCTC  
 9481 AGCGATCTGT CTATTCGTT CATCCATAGT TGCTGACTC CCCGTCGTGT  
 AGATAACTAC  
 9541 GATACGGGAG GGCTTACCAT CTGGCCCCAG TGCTGCAATG ATACCGCGAG  
 20 ACCCACGCTC  
 9601 ACCGGCTCCA GATTTATCAG CAATAAACCA GCCAGCCGGA AGGGCCGAGC  
 GCAGAAGTGG  
 9661 TCCTGCAACT TTATCCGCCT CCATCCAGTC TATTAATTGT TGCCGGAAAG  
 CTAGAGTAAG  
 25 9721 TAGTCGCCA GTTAATAGTT TGCGCAACGT TGTTGCCATT GCTACAGGCA  
 TCGTGGTGTG  
 9781 ACGCTCGTCG TTTGGTATGG CTTCATTCACTG CTCCGGTTCC CAACGATCAA  
 GGCGAGTTAC  
 9841 ATGATCCCCC ATGTTGTGCA AAAAAGCGGT TAGCTCCTTC GGTCCTCCGA  
 30 TCGTTGTCAG  
 9901 AAGTAAGTTG GCCGCAGTGT TATCACTCAT GGTTATGGCA GCACTGCATA  
 ATTCTCTTAC  
 9961 TGTCATGCCA TCCGTAAGAT GCTTTCTGT GACTGGTGAG TACTCAACCA  
 AGTCATTCTG  
 35 10021 AGAATAGTGT ATGCCCGAC CGAGTTGCTC TTGCCCGCG TCAATACGGG  
 ATAATACCGC  
 10081 GCCACATAGC AGAACTTTAA AAGTGCTCAT CATTGGAAAA CGTTCTCGG  
 GGCGAAAAC  
 10141 CTCAAGGATC TTACCGCTGT TGAGATCCAG TTGATGTAA CCCACTCGT  
 40 CACCCAACTG  
 10201 ATCTTCAGCA TCTTTTACTT TCACCAAGCGT TTCTGGGTGA GCAAAACAG  
 GAAGGCAAAA  
 10261 TGCCGCAAAA AAGGGAATAA GGGCGACACG GAAATGTTGA ATACTCATAC  
 TCTTCCTTT  
 45 10321 TCAATATTAT TGAAGCATTG ATCAGGGTTA TTGTCTCATG AGCGGATACA  
 TATTTGAATG  
 10381 TATTTAGAAA AATAAACAAA TAGGGGTTCC GCGCACATTT CCCCCGAAAAG  
 TGCCACCTGA  
 10441 C  
 50 //  
 (SEQ ID NO: 1)

## [00345] pLL3.0

5 LOCUS PLENTILOX 6027 BP DS-DNA CIRCULAR SYN 23-JAN-  
 2002  
 DEFINITION -  
 ACCESSION -  
 KEYWORDS -  
 SOURCE -  
 10 FEATURES Location/Qualifiers  
 promoter 212..816  
 /note="CMV promoter/enhancer 1"  
 gene 5034..5894  
 /note="AmpR"  
 15 rep\_origin 4216..4889  
 /note="pUC"  
 misc\_recomb 2710..2743  
 /note="LoxP"  
 20 misc\_recomb 2827..2860  
 /note="LoxP"  
 LTR 835..1509  
 /note="5' HIV R-U5-del gag (HIV NL4-3/454-1126)"  
 misc\_feature 1539..2396  
 /note="HIV RRE (HIV NL4-3/7622-8459)"  
 25 misc\_feature 2422..2599  
 /note="HIV Flap"  
 misc\_feature 2915..3504  
 /note="WRE element"  
 LTR 3524..4213  
 /note="3' SIN LTR"  
 30 BASE COUNT 1612 A 1408 C 1518 G 1489 T 0 OTHER  
 ORIGIN -  
 1 GTCGACGGAT CGGGAGATCT CCCGATCCCC TATGGTGCAC TCTCAGTACA  
 ATCTGCTCTG  
 35 61 ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT GTTGGAGGTC  
 GCTGAGTAGT  
 121 GCGCGAGCAA AATTAAAGCT ACAACAAGGC AAGGCTTGAC CGACAATTGC  
 ATGAAGAAC  
 181 TGCTTAGGGT TAGGCCTTT GCGCTGCTTC GCGATGTACG GGCCAGATAT  
 40 ACGCGTTGAC  
 241 ATTGATTATT GACTAGTTAT TAATAGTAAT CAATTACGGG GTCATTAGTT  
 CATAGCCCCAT  
 301 ATATGGAGTT CCGCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA  
 CCGCCCCAACG  
 45 361 ACCCCCCGCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA  
 ATAGGGACTT  
 421 TCCATTGACG TCAATGGGTG GAGTATTTAC GGTAAACTGC CCACTTGGCA  
 GTACATCAAG  
 481 TGTATCATAT GCCAAGTACG CCCCCCTATTG ACGTCAATGA CGGTAAATGG  
 50 CCCGCCTGGC  
 541 ATTATGCCCA GTACATGACC TTATGGGACT TTCCTACTTG GCAGTACATC  
 TACGTATTAG  
 601 TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT CAATGGCGT  
 GGATAGCGGT  
 55 661 TTGACTCACG GGGATTTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT  
 TTGTTTTGGC  
 721 ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC CGCCCCATTG  
 ACGCAAATGG

781 GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGCGC GTTTGCCTG  
 TACTGGGTCT  
 841 CTCTGGTTAG ACCAGATCTG AGCCTGGAG CTCTCTGGCT AACTAGGGAA  
 CCCACTGCTT  
 5 901 AAGCCTCAAT AAAGCTTGCC TTGAGTGCTT CAAGTAGTGT GTGCCCGTCT  
 GTTGTGTGAC  
 961 TCTGGTAAC AGAGATCCCT CAGACCCCTT TAGTCAGTGT GGAAAATCTC  
 TAGCAGTGGC  
 1021 GCCCGAACAG GGACTTGAAA GCGAAAGGGA AACCAAGAGGA GCTCTCTCGA  
 10 CGCAGGACTC  
 1081 GGCTTGCTGA AGCGCGCACG GCAAGAGGCG AGGGGCGGCG ACTGGTGAGT  
 ACGCCAAAAA  
 1141 TTTTGACTAG CGGAGGCTAG AAGGAGAGAG ATGGGTGCGA GAGCGTCAGT  
 ATTAAGCGGG  
 15 1201 GGAGAATTAG ATCGCGATGG GAAAAAAATTC GGTAAAGGCC AGGGGGAAAG  
 AAAAAAATATA  
 1261 AATTAAAACA TATAGTATGG GCAAGCAGGG AGCTAGAACG ATTGCAGTT  
 AATCCTGGCC  
 1321 TGTTAGAAC ATCAGAAGGC TGTAGACAAA TACTGGGACA GCTACAACCA  
 20 TCCCTTCAGA  
 1381 CAGGATCAGA AGAACTTAGA TCATTATATA ATACAGTAGC AACCCCTCTAT  
 TGTGTGCATC  
 1441 AAAGGATAGA GATAAAAGAC ACCAAGGAAG CTTTAGACAA GATAGAGGAA  
 GAGCAAAACA  
 25 1501 AAAGTAAGAC CACCGCACAG CAAGCGGCCG GCCCGCCTGA TCTTCAGACC  
 TGGAGGAGGA  
 1561 GATATGAGGG ACAATTGGAG AAGTGAATTAA TATAAAATATA AAGTAGTAAA  
 AATTGAACCA  
 1621 TTAGGAGTAG CACCCACCAA GGCAAAGAGA AGAGTGGTGC AGAGAGAAAA  
 30 AAGAGCAGTG  
 1681 GGAATAGGAG CTTTGTTCCT TGGGTTCTTG GGAGCAGCAG GAAGCACTAT  
 GGGCGCAGCG  
 1741 TCAATGACGC TGACGGTACA GGCCAGACAA TTATTGTCTG GTATAGTGCA  
 GCAGCAGAAC  
 35 1801 AATTGCTGA GGGCTATTGA GGCACACAG CATCTGTTGC AACTCACAGT  
 CTGGGGCCTC  
 1861 AAGCAGCTCC AGGCAAGAAT CCTGGCTGTG GAAAGATACC TAAAGGATCA  
 ACAGCTCCTG  
 1921 GGGATTGGG GTGCTCTGG AAAACTCATT TGACCAACTG CTGTGCCTTG  
 40 GAATGCTAGT  
 1981 TGGAGTAATA AATCTCTGGA ACAGATTGG AATCACACGA CCTGGATGGA  
 GTGGGACAGA  
 2041 GAAATTAACA ATTACACAAG CTTAATACAC TCCTTAATTG AAGAATCGCA  
 AAACCAGCAA  
 45 2101 GAAAAGAATG AACAGAAATT ATTGGAATT GATAATGGG CAAGTTGTG  
 GAATTGGTTT  
 2161 AACATAACAA ATTGGCTGTG GTATATAAAA TTATTCTAA TGATAGTAGG  
 AGGCTTGGTA  
 2221 GGTTTAAGAA TAGTTTTGC TGTACTTTCT ATAGTGAATA GAGTTAGGCA  
 50 GGGATATTCA  
 2281 CCATTATCGT TTCAGACCCA CCTCCCAACC CCGAGGGGAC CCGACAGGCC  
 CGAAGGAATA  
 2341 GAAGAAGAAG GTGGAGAGAG AGACAGAGAC AGATCCATTG GATTAGTGAA  
 CGGATCGGCA  
 55 2401 CTGCGTGCAGC CAATTCTGCA GACAAATGGC AGTATTCTAC CACAATTAA  
 AAAGAAAAGG  
 2461 GGGGATTGGG GGGTACAGTG CAGGGAAAG AATAGTAGAC ATAATAGCAA  
 CAGACATACA

2521 AACTAAAGAA TTACAAAAAC AAATTACAAA AATTCAAAAT TTTGGGTTT  
 ATTACAGGGAA  
 2581 CAGCAGAGAT CCAGTTGGT TAGTACCGGG CCCGCTCTAG ACGGTTAACG  
 CGCTAGCCGT  
 5 2641 TAATTAAGCC TCGAGGTCGA CGGTATCGAT AAGCTCGCTT CACGAGATTG  
 CAGCAGGTCG  
 2701 AGGGACCTAA TAACTTCGTA TAGCATAACAT TATACGAAGT TATATTAAGG  
 GTTCCAAGCT  
 2761 TAAGCGGCCG CCGATGCATG CCCCAGGATG GCGCGCCATG GATCCGCGAA  
 10 TTCGTCGAGG  
 2821 GACCTAATAA CTTCGTATAG CATACTTAT ACGAAGTTAT ACATGTTAA  
 GGGTTCCGGT  
 2881 TCCACTAGGT ACAATTGAT ATCAAGCTTA TCGATAATCA ACCTCTGGAT  
 TACAAAATTT  
 15 2941 GTGAAAGATT GACTGGTATT CTTAACTATG TTGCTCCTTT TACGCTATGT  
 GGATACGCTG  
 3001 CTTTAATGCC TTTGTATCAT GCTATTGCTT CCCGTATGGC TTTCATTTTC  
 TCCTCCTTGT  
 3061 ATAAATCCTG GTTGTGTCT CTTTATGAGG AGTTGTGGCC CGTTGTCAAGG  
 20 CAACGTGGCG  
 3121 TGGTGTGCAC TGTGTTGCT GACGCAACCC CCACTGGTTG GGGCATTGCC  
 ACCACCTGTC  
 3181 AGCTCCTTTC CGGGACTTTTC GCTTTCCCCC TCCCTATTGC CACGGCGGAA  
 CTCATCGCCG  
 25 3241 CCTGCCTTGC CCGCTGCTGG ACAGGGGCTC GGCTGTTGGG CACTGACAAT  
 TCCGTGGTGT  
 3301 TGCGGGGAA ATCATCGTCC TTTCCCTGGC TGCTCGCCTG TGTTGCCACC  
 TGGATTCTGC  
 3361 GCGGGACGTC CTTCTGCTAC GTCCCTTCGG CCCTCAATCC AGCGGACCTT  
 30 CCTTCCCCGCG  
 3421 GCCTGCTGCC GGCTCTGCCG CCTCTTCCGC GTCTCGCCT TCGCCCTCAG  
 ACGAGTCGGA  
 3481 TCTCCCTTG GGCCGCCTCC CCGCATCGAT ACCGTCGACC TCGATCGAGA  
 CCTAGAAAAA  
 35 3541 CATGGAGCAA TCACAAGTAG CAATACAGCA GCTACCAATG CTGATTGTGC  
 CTGGCTAGAA  
 3601 GCACAAGAGG AGGAGGAGGT GGGTTTCCA GTCACACCTC AGGTACCTTT  
 AAGACCAATG  
 3661 ACTTACAAGG CAGCTGTAGA TCTTAGCCAC TTTTAAAAG AAAAGGGGGG  
 40 ACTGGAAGGG  
 3721 CTAATTCACT CCCAACGAAG ACAAGATATC CTTGATCTGT GGATCTACCA  
 CACACAAGGG  
 3781 TACTTCCCTG ATTGGCAGAA CTACACACCA GGGCCAGGGA TCAGATATCC  
 ACTGACCTT  
 45 3841 GGATGGTGCT ACAAGCTAGT ACCAGTTGAG CAAGAGAAGG TAGAAGAAGC  
 CAATGAAGGA  
 3901 GAGAACACCC GCTTGTACA CCCTGTGAGC CTGCATGGGA TGGATGACCC  
 GGAGAGAGAA  
 3961 GTATTAGAGT GGAGGTTGA CAGCCGCCTA GCATTCATC ACATGGCCCG  
 50 AGAGCTGCAT  
 4021 CGGGACTGTA CTGGGTCTCT CTGGTTAGAC CAGATCTGAG CCTGGGAGCT  
 CTCTGGCTAA  
 4081 CTAGGGAACC CACTGCTTAA GCCTCAATAA AGCTTGCCTT GAGTGTCTCA  
 AGTAGTGTGT  
 55 4141 GCCCGTCTGT TGTGTGACTC TGGTAACAG AGATCCCTCA GACCCTTTA  
 GTCAGTGTGG  
 4201 AAAATCTCTA GCAGCATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG  
 TAAAAAGGCC

4261 GCGTTGCTGG CGTTTTCCA TAGGCTCCGC CCCCCCTGACG AGCATCACAA  
 AAATCGACGC  
 4321 TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT ACCAGGCCTT  
 TCCCCCTGGA  
 5 4381 AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA CCGGATACCT  
 GTCCGCCTTT  
 4441 CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT AGCTCACGCT GTAGGTATCT  
 CAGTTCGGTG  
 4501 TAGTCGTTG GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAAGCC  
 10 CGACCGCTGC  
 4561 GCCTTATCCG GTAACTATCG TCTTGAGTCC AACCCGGTAA GACACGACTT  
 ATCGCCACTG  
 4621 GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC  
 TACAGAGTTC  
 15 4681 TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGAACAG TATTGGTAT  
 CTGCGCTCTG  
 4741 CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT GATCCGGCAA  
 ACAAAACCACC  
 4801 GCTGGTAGCG GTGGTTTTTG TGTTGCAAG CAGCAGATTA CGCGCAGAAA  
 20 AAAAGGATCT  
 4861 CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA  
 AAAACTCACGT  
 4921 TAAGGGATTG TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT  
 TTTAAATTAA  
 25 4981 AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA CTTGGTCTGA  
 CAGTTACCAA  
 5041 TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTCATC  
 CATAGTTGCC  
 5101 TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG  
 30 CCCCAGTGCT  
 5161 GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT  
 AAACCAGCCA  
 5221 GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT CCGCCTCCAT  
 CCAGTCTATT  
 35 5281 AATTGTTGCC GGGAAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTGCG  
 CAACGTTGTT  
 5341 GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTG GTATGGCTTC  
 ATTCAAGCTCC  
 5401 GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT TGTGCAAAAAA  
 40 AGCGGTTAGC  
 5461 TCCCTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG CAGTGTATTC  
 ACTCATGGTT  
 5521 ATGGCAGCAC TGCATAATTCTC TCTTACTGTC ATGCCATCCG TAAGATGCTT  
 TTCTGTGACT  
 45 5581 GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC GGCGACCGAG  
 TTGCTCTTGCG  
 5641 CCGGCGTCAA TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAAGT  
 GCTCATCATT  
 5701 GGAAAACGTT CTTGGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG  
 50 ATCCAGTTCG  
 5761 ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTCAC  
 CAGCGTTTCT  
 5821 GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAAGG GAATAAGGGC  
 GACACGGAAA  
 55 5881 TGTTGAATAC TCATACTCTT CCTTTTCAA TATTATTGAA GCATTTATCA  
 GGGTTATTGTT  
 5941 CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG  
 GTTCCCGCGC  
 6001 ACATTTCCCC GAAAAGTGCC ACCTGAC

//

(SEQ ID NO: 2)

## [00346] pLL3.1

5 LOCUS PLENTILOX 6748 BP DS-DNA CIRCULAR SYN 23-JAN-  
 2002  
 DEFINITION -  
 ACCESSION -  
 KEYWORDS -  
 SOURCE -  
 10 FEATURES Location/Qualifiers  
 promoter 212..816  
 /note="CMV promoter/enhancer 1"  
 misc\_recomb 3548..3581  
 /note="LoxP"  
 15 gene 5755..6615  
 /note="AmpR"  
 rep\_origin 4937..5610  
 /note="pUC"  
 misc\_recomb 2710..2745  
 /note="LoxP"  
 20 LTR 835..1509  
 /note="5' HIV R-U5-del gag (HIV NL4-3/454-1126)"  
 misc\_feature 1539..2396  
 /note="HIV RRE (HIV NL4-3/7622-8459)"  
 25 misc\_feature 2422..2599  
 /note="HIV Flap"  
 misc\_feature 3636..4225  
 /note="WRE element"  
 LTR 4245..4934  
 /note="3' SIN LTR"  
 30 gene 2772..3494  
 /note="EGFP"  
 BASE COUNT 1785 A 1651 C 1721 G 1591 T 0 OTHER  
 ORIGIN -  
 35 1 GTCGACGGAT CGGGAGATCT CCCGATCCCC TATGGTGCAC TCTCAGTACA  
 ATCTGCTCTG  
 61 ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT GTTGGAGGTC  
 GCTGAGTAGT  
 121 GCGCGAGCAA AATTAAAGCT ACAACAAGGC AAGGCTTGAC CGACAATTGC  
 40 ATGAAGAAC  
 181 TGCTTAGGGT TAGGCCTTT GCGCTGCTTC GCGATGTACG GGCCAGATAT  
 ACGCGTTGAC  
 241 ATTGATTATT GACTAGTTAT TAATAGTAAT CAATTACGGG GTCATTAGTT  
 CATAGCCCAT  
 45 301 ATATGGAGTT CCGCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA  
 CCGCCCAAACG  
 361 ACCCCCCGCCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA  
 ATAGGGACTT  
 421 TCCATTGACG TCAATGGGTG GAGTATTAC GGTAAACTGC CCACTTGGCA  
 50 GTACATCAAG  
 481 TGTATCATAT GCCAAGTACG CCCCCTATTG ACGTCAATGA CGGTAAATGG  
 CCCGCCTGGC  
 541 ATTATGCCCA GTACATGACC TTATGGGACT TTCCTACTTG GCAGTACATC  
 TACGTATTAG  
 55 601 TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT CAATGGCGT  
 GGATAGCGGT  
 661 TTGACTCACG GGGATTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT  
 TTGTTTGGC

721 ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC CGCCCCATTG  
 ACGCAAATGG  
 781 GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGCGC GTTTGCCTG  
 TACTGGGTCT  
 5 841 CTCTGGTTAG ACCAGATCTG AGCCTGGGAG CTCTCTGGCT AACTAGGGAA  
 CCCACTGCTT  
 901 AAGCCTCAAT AAAGCTTGCC TTGAGTGCTT CAAGTAGTGT GTGCCCGTCT  
 GTTGTGTGAC  
 961 TCTGGTAACT AGAGATCCCT CAGACCCCTT TAGTCAGTGT GGAAAATCTC  
 10 TAGCAGTGGC  
 1021 GCCCGAACAG GGACTTGAAA GCGAAAGGGA AACCAAGAGGA GCTCTCTCGA  
 CGCAGGACTC  
 1081 GGCTTGCTGA AGCGCGCACG GCAAGAGGCG AGGGGCGGCG ACTGGTGAGT  
 ACGCCAAAAA  
 15 1141 TTTTGACTAG CGGAGGCTAG AAGGAGAGAG ATGGGTGCGA GAGCGTCAGT  
 ATTAAGCGGG  
 1201 GGAGAATTAG ATCGCGATGG GAAAAAAATTC GTTAAAGGCC AGGGGGAAAG  
 AAAAAAATATA  
 1261 AATTAAAACA TATAGTATGG GCAAGCAGGG AGCTAGAACG ATTGCGAGTT  
 20 AATCCTGGC  
 1321 TGTTAGAAAC ATCAGAAGGC TGTAGACAAA TACTGGGACA GCTACAACCA  
 TCCCTTCAGA  
 1381 CAGGATCAGA AGAACCTAGA TCATTATATA ATACAGTAGC AACCCCTCTAT  
 TGTGTGCATC  
 25 1441 AAAGGATAGA GATAAAAGAC ACCAAGGAAG CTTTAGACAA GATAGAGGAA  
 GAGCAAAACA  
 1501 AAAGTAAGAC CACCGCACAG CAAGCGGCCG GCCGCGCTGA TCTTCAGACC  
 TGGAGGAGGA  
 1561 GATATGAGGG ACAATTGGAG AAGTGAATTA TATAAATATA AAGTAGTAAA  
 30 AATTGAACCA  
 1621 TTAGGAGTAG CACCCACCAA GGCAAAGAGA AGAGTGGTGC AGAGAGAAAA  
 AAGAGCAGTG  
 1681 GGAATAGGAG CTTTGTTCCT TGGGTTCTTG GGAGCAGCAG GAAGCACTAT  
 GGGCGCAGCG  
 35 1741 TCAATGACGC TGACGGTACA GGCCAGACAA TTATTGTCTG GTATAGTGCA  
 GCAGCAGAAC  
 1801 AATTGCTGA GGGCTATTGA GGCGCAACAG CATCTGTTGC AACTCACAGT  
 CTGGGGCCTAC  
 1861 AAGCAGCTCC AGGCAAGAAT CCTGGCTGTG GAAAGATACC TAAAGGATCA  
 40 ACAGCTCCTG  
 1921 GGGATTGGG GTTGCTCTGG AAAACTCATT TGCACCACTG CTGTGCCTTG  
 GAATGCTAGT  
 1981 TGGAGTAATA AATCTCTGGA ACAGATTGG AATCACACGA CCTGGATGGA  
 GTGGGACAGA  
 45 2041 GAAATTAACA ATTACACAAG CTTAATACAC TCCTTAATTG AAGAATCGCA  
 AAACCAGCAA  
 2101 GAAAAGAATG AACAAAGAATT ATTGGAATTA GATAAAATGGG CAAGTTGTG  
 GAATTGGTTT  
 2161 AACATAACAA ATTGGCTGTG GTATATAAAA TTATTCTAA TGATAGTAGG  
 50 AGGCTTGGTA  
 2221 GGTTTAAGAA TAGTTTTGC TGTACTTTCT ATAGTGAATA GAGTTAGGCA  
 GGGATATTCA  
 2281 CCATTATCGT TTCAGACCCA CCTCCCAACC CCGAGGGGAC CCGACAGGCC  
 CGAAGGAATA  
 55 2341 GAAGAAGAAG GTGGAGAGAG AGACAGAGAC AGATCCATTC GATTAGTGAA  
 CGGATCGGCA  
 2401 CTGCGTGCCTGCA ATTCTGCA GACAAATGGC AGTATTCTAC CACAATTTA  
 AAAGAAAAGG

2461 GGGGATTGGG GGGTACAGTG CAGGGAAAG AATAGTAGAC ATAATAGCAA  
 CAGACATACA  
 2521 AACTAAAGAA TTACAAAAAC AAATTACAAA AATTCAAAAT TTTCGGGTTT  
 ATTACAGGGA  
 5 2581 CAGCAGAGAT CCAGTTGGT TAGTACCGGG CCCGCTCTAG ACGGTTAACG  
 CGCTAGCCGT  
 2641 TAATTAAGCC TCGAGGTCGA CGGTATCGAT AAGCTCGCTT CACGAGATTC  
 CAGCAGGTCG  
 2701 AGGGACCTAA TAACTTCGTA TAGCATAACAT TATACGAAGT TATATTAAGG  
 10 GTTCCAAGCT  
 2761 TAAGCGGCCG CGCCACCATG GTGAGCAAGG GCGAGGAGCT GTTCACCGGG  
 GTGGTGCCCA  
 2821 TCCTGGTCGA GCTGGACGGC GACGTAAACG GCCACAAGTT CAGCGTGTCC  
 GGCGAGGGCG  
 15 2881 AGGGCGATGC CACCTACGGC AAGCTGACCC TGAAGTTCAT CTGCACCACC  
 GGCAAGCTGC  
 2941 CCGTGCCCTG GCCCACCCCTC GTGACCACCC TGACCTACGG CGTGCAGTGC  
 TTCAGCCGCT  
 3001 ACCCCGACCA CATGAAGCAG CACGACTTCT TCAAGTCCGC CATGCCGAA  
 20 GGCTACGTCC  
 3061 AGGAGCGCAC CATCTTCTTC AAGGACGACG GCAACTACAA GACCCGCGCC  
 GAGGTGAAGT  
 3121 TCGAGGGCGA CACCCTGGTG AACCGCATCG AGCTGAAGGG CATCGACTTC  
 AAGGAGGACG  
 25 3181 GCAACATCCT GGGGCACAAG CTGGAGTACA ACTACAACAG CCACAACGTC  
 TATATCATGG  
 3241 CCGACAAGCA GAAGAACGGC ATCAAGGTGA ACTTCAAGAT CCGCCACAAAC  
 ATCGAGGACG  
 3301 GCAGCGTGCA GCTCGCCGAC CACTACCAGC AGAACACCCC CATCGCGAC  
 30 GGCCCCGTGC  
 3361 TGCTGCCCGA CAACCACTAC CTGAGGCACCC AGTCCGCCCT GAGCAAAGAC  
 CCCAACGAGA  
 3421 AGCGCGATCA CATGGTCCTG CTGGAGTTCG TGACCGCCGC CGGGATCACT  
 CTCGGCATGG  
 35 3481 ACGAGCTGTA CAAGATGCAT GCCCCGGGAT GGCGCGCCAT GGATCCGCGA  
 ATTCTCGAG  
 3541 GGACCTAATA ACTTCGTATA GCATACATTA TACGAAGTTA TACATGTTTA  
 AGGGTTCCGG  
 3601 TTCCACTAGG TACAATTCCA TATCAAGCTT ATCGATAATC AACCTCTGGA  
 40 TTACAAAATT  
 3661 TGTGAAAGAT TGACTGGTAT TCTTAACTAT GTTGCTCCTT TTACGCTATG  
 TGGATACGCT  
 3721 GCTTTAATGC CTTTGTATCA TGCTATTGCT TCCC GTATGG CTTTCATTT  
 CTCCTCCTTG  
 45 3781 TATAAACCTT GGTTGCTGTC TCTTATGAG GAGTTGTGGC CCGTTGTCAG  
 GCAACGTGGC  
 3841 GTGGTGTGCA CTGTGTTGC TGACGCAACC CCCACTGGTT GGGGCATTGC  
 CACCACCTGT  
 3901 CAGCTCCTTT CGGGACTTT CGCTTTCCCC CTCCCTATTG CCACGGCGGA  
 50 ACTCATCGCC  
 3961 GCCTGCCTTG CCCGCTGCTG GACAGGGGCT CGGCTGTTGG GCACTGACAA  
 TTCCGTGGTG  
 4021 TTGTCGGGGA AATCATCGTC CTTCCATTGG CTGCTCGCCT GTGTTGCCAC  
 CTGGATTCTG  
 55 4081 CGCGGGACGT CCTTCTGCTA CGTCCCTTCG GCCCTCAATC CAGCGGACCT  
 TCCTTCCCGC  
 4141 GGCTGCTGCA CGGCTCTGCG GCCTCTTCCG CGTCTTCGCC TTGCCCTCA  
 GACGAGTCGG

4201 ATCTCCCTTT GGGCCGCCTC CCCGCATCGA TACCGTCGAC CTCGATCGAG  
 ACCTAGAAAA  
 4261 ACATGGAGCA ATCACAAAGTA GCAATACAGC AGCTACCAAT GCTGATTGTG  
 CCTGGCTAGA  
 5 4321 AGCACAAAGAG GAGGAGGAGG TGGGTTTCC AGTCACACCT CAGGTACCTT  
 TAAGACCAAT  
 4381 GACTTACAAG GCAGCTGTAG ATCTTAGCCA CTTTTAAAAA GAAAAGGGGG  
 GACTGGAAGG  
 4441 GCTAATTACAC TCCCAACGAA GACAAGATAT CCTTGATCTG TGGATCTACC  
 10 ACACACAAAGG  
 4501 CTACTTCCCT GATTGGCAGA ACTACACACC AGGGCCAGGG ATCAGATATC  
 CACTGACCTT  
 4561 TGGATGGTGC TACAAGCTAG TACCAAGTTGA GCAAGAGAAG GTAGAAGAAG  
 CCAATGAAGG  
 15 4621 AGAGAACACC CGCTTGTTAC ACCCTGTGAG CCTGCATGGG ATGGATGACC  
 CGGAGAGAGA  
 4681 AGTATTAGAG TGGAGGTTTG ACAGCCGCCT AGCATTTCAT CACATGGCCC  
 GAGAGCTGCA  
 4741 TCCGGACTGT ACTGGGTCTC TCTGGTTAGA CCAGATCTGA GCCTGGGAGC  
 20 TCTCTGGCTA  
 4801 ACTAGGGAAC CCACTGCTTA AGCCTCAATA AAGCTTGCCCT TGAGTGCTTC  
 AAGTAGTGTG  
 4861 TGCCCGTCTG TTGTGTGACT CTGGTAACTA GAGATCCCTC AGACCCTTTT  
 AGTCAGTGTG  
 25 4921 GAAAATCTCT AGCAGCATGT GAGCAAAAGG CCAGCAAAAG GCCAGGAACC  
 GTAAAAAAGGC  
 4981 CGCGTTGCTG GCGTTTTCC ATAGGCTCCG CCCCCCTGAC GAGCATTACA  
 AAAATCGACG  
 5041 CTCAAGTCAG AGGTGGCGAA ACCCGACAGG ACTATAAAGA TACCAGGCGT  
 30 TTCCCCCTGG  
 5101 AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC CCTGCCGCTT ACCGGATACC  
 TGTCCCGCTT  
 5161 TCTCCCTTCG GGAAGCGTGG CGCTTCTCA TAGCTCACGC TGTAGGTATC  
 TCAGTTCGGT  
 35 5221 GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC CCCGTTCAAGC  
 CCGACCGCTG  
 5281 CGCCTTATCC GGTAACATATC GTCTTGAGTC CAACCCGGTA AGACACGACT  
 TATCGCCACT  
 5341 GGCAGCAGCC ACTGGTAACA GGATTAGCAG AGCGAGGTAT GTAGGCGGTG  
 40 CTACAGAGTT  
 5401 CTTGAAGTGG TGGCCTAACT ACGGCTACAC TAGAAGAACAA GTATTTGGTA  
 TCTGCGCTCT  
 5461 GCTGAAGCCA GTTACCTTCG GAAAAAGAGT TGGTAGCTCT TGATCCGGCA  
 AACAAACCAC  
 45 5521 CGCTGGTAGC GGTGGTTTT TTGTTGCAA GCAGCAGATT ACGCGCAGAA  
 AAAAAGGATC  
 5581 TCAAGAAGAT CCTTTGATCT TTTCTACGGG GTCTGACGCT CAGTGGAACG  
 AAAACTCACG  
 5641 TTAAGGGATT TTGGTCATGA GATTATCAA AAGGATCTTC ACCTAGATCC  
 50 TTTTAAATTAA  
 5701 AAAATGAAGT TTTAAATCAA TCTAAAGTAT ATATGAGTAA ACTTGGTCTG  
 ACAGTTACCA  
 5761 ATGCTTAATC AGTGAGGCAC CTATCTCAGC GATCTGTCTA TTTCGTTCAT  
 CCATAGTTGC  
 55 5821 CTGACTCCCC GTCGTGTAGA TAACTACGAT ACGGGAGGGC TTACCATCTG  
 GCCCCAGTGC  
 5881 TGCAATGATA CCGCGAGACC CACGCTCACC GGCTCCAGAT TTATCAGCAA  
 TAAACCAGCC

5941 AGCCGGAAGG GCCGAGCGCA GAAGTGGTCC TGCAACTTA TCCGCCTCCA  
TCCAGTCTAT  
6001 TAATTGTTGC CGGGAAGCTA GAGTAAGTAG TTGCCAGTT AATAGTTGC  
GCAACGTTGT  
5 6061 TGCCATTGCT ACAGGCATCG TGGTGTACG CTCGTCGTTT GGTATGGCTT  
CATTCAGCTC  
6121 CGGTTCCCAA CGATCAAGGC GAGTTACATG ATCCCCCATG TTGTGCAAAA  
AAGCGGTTAG  
6181 CTCCCTCGGT CCTCCGATCG TTGTCAGAAG TAAGTTGCC GCAGTGTAT  
10 CACTCATGGT  
6241 TATGGCAGCA CTGCATAATT CTCTTACTGT CATGCCATCC GTAAGATGCT  
TTTCTGTGAC  
6301 TGGTGAGTAC TCAACCAAGT CATTCTGAGA ATAGTGTATG CGCGACCGA  
GTTGCTCTTG  
15 6361 CCCGGCGTCA ATACGGGATA ATACCGGCC ACATAGCAGA ACTTTAAAAG  
TGCTCATCAT  
6421 TGGAAAACGT TCTTCGGGGC GAAAACCTCTC AAGGATCTTA CCGCTGTTGA  
GATCCAGTTC  
6481 GATGTAACCC ACTCGTGCAC CCAACTGATC TTCAGCATCT TTTACTTTCA  
20 CCAGCGTTTC  
6541 TGGGTGAGCA AAAACAGGAA GGCAAAATGC CGCAAAAAAG GGAATAAGGG  
CGACACGGAA  
6601 ATGTTGAATA CTCATACTCT TCCTTTTCA ATATTATTGA AGCATTATC  
AGGGTTATTG  
25 6661 TCTCATGAGC GGATACATAT TTGAATGTAT TTAGAAAAAT AAACAAATAG  
GGGTTCCCG  
6721 CACATTTCCC CGAAAAGTGC CACCTGAC  
//  
30 (SEQ ID NO: 3)

## [00347] pLL3.2

5 LOCUS PLENTILOX 6706 BP DS-DNA CIRCULAR SYN 23-JAN-  
 2002  
 DEFINITION -  
 ACCESSION -  
 KEYWORDS -  
 SOURCE -  
 10 FEATURES Location/Qualifiers  
 promoter 212..816  
 /note="CMV promoter/enhancer 1"  
 misc\_recomb 3506..3539  
 /note="LoxP"  
 15 gene 5713..6573  
 /note="AmpR"  
 rep\_origin 4895..5568  
 /note="pUC"  
 misc\_recomb 2710..2745  
 /note="LoxP"  
 20 LTR 835..1509  
 /note="5' HIV R-U5-del gag (HIV NL4-3/454-1126)"  
 misc\_feature 1539..2396  
 /note="HIV RRE (HIV NL4-3/7622-8459)"  
 25 misc\_feature 2422..2599  
 /note="HIV Flap"  
 misc\_feature 3594..4183  
 /note="WRE element"  
 LTR 4203..4892  
 /note="3' SIN LTR"  
 30 gene 2772..3452  
 /note="dsRed2"  
 BASE COUNT 1755 A 1638 C 1722 G 1591 T 0 OTHER  
 ORIGIN -  
 35 1 GTCGACGGAT CGGGAGATCT CCCGATCCCC TATGGTGCAC TCTCAGTACA  
 ATCTGCTCTG  
 61 ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT GTTGGAGGTC  
 GCTGAGTAGT  
 121 GCGCGAGCAA AATTAAAGCT ACAACAAGGC AAGGCTTGAC CGACAATTGC  
 40 ATGAAGAAC  
 181 TGCTTAGGGT TAGGCGTTTT GCGCTGCTTC GCGATGTACG GGCCAGATAT  
 ACGCGTTGAC  
 241 ATTGATTATT GACTAGTTAT TAATAGTAAT CAATTACGGG GTCATTAGTT  
 CATAGCCCAT  
 45 301 ATATGGAGTT CCGCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA  
 CCGCCCAACG  
 361 ACCCCCGCCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA  
 ATAGGGACTT  
 421 TCCATTGACG TCAATGGGTG GAGTATTAC GGTAAAATGC CCACTTGGCA  
 50 GTACATCAAG  
 481 TGTATCATAT GCCAAGTACG CCCCCTATTG ACGTCAATGA CGGTAAATGG  
 CCCGCCTGGC  
 541 ATTATGCCCA GTACATGACC TTATGGACT TTCTACTTG GCAGTACATC  
 TACGTATTAG  
 55 601 TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT CAATGGCGT  
 GGATAGCGGT  
 661 TTGACTCACG GGGATTTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT  
 TTGTTTTGGC

721 ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC CGCCCCATTG  
 ACGCAAATGG  
 781 GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGCGC GTTTTGCCTG  
 TACTGGGTCT  
 5 841 CTCTGGTTAG ACCAGATCTG AGCCTGGGAG CTCTCTGGCT AACTAGGGAA  
 CCCACTGCTT  
 901 AAGCCTCAAT AAAGCTTGCC TTGAGTGCTT CAAGTAGTGT GTGCCCGTCT  
 GTTGTGTGAC  
 961 TCTGGTAACT AGAGATCCCT CAGACCCCTT TAGTCAGTGT GGAAAATCTC  
 10 TAGCAGTGGC  
 1021 GCCCCAACAG GGACTTGAAA GCGAAAGGGA AACCAGAGGA GCTCTCTCGA  
 CGCAGGACTC  
 1081 GGCTTGCTGA AGCGCGCACG GCAAGAGGCG AGGGGCGGCG ACTGGTGAGT  
 ACGCCAAAAA  
 15 1141 TTTTGACTAG CGGAGGCTAG AAGGAGAGAG ATGGGTGCGA GAGCGTCAGT  
 ATTAAGCGGG  
 1201 GGAGAATTAG ATCGCGATGG GAAAAAAATTC GGTTAAGGCC AGGGGGAAAG  
 AAAAAAATATA  
 1261 AATTAAAACA TATAGTATGG GCAAGCAGGG AGCTAGAACG ATTGCGAGTT  
 20 AATCCTGGCC  
 1321 TGTTAGAAC ATCAGAAGGC TGTAGACAAA TACTGGGACA GCTACAACCA  
 TCCCTTCAGA  
 1381 CAGGATCAGA AGAACTTAGA TCATTATATA ATACAGTAGC AACCTCTAT  
 TGTGTGCATC  
 25 1441 AAAGGATAGA GATAAAAGAC ACCAAGGAAG CTTTAGACAA GATAGAGGAA  
 GAGCAAAACA  
 1501 AAAGTAAGAC CACCGCACAG CAAGCGGCCG GCCCGCGCTGA TCTTCAGACC  
 TGGAGGAGGA  
 1561 GATATGAGGG ACAATTGGAG AAGTGAATTA TATAAATATA AAGTAGTAAA  
 30 AATTGAACCA  
 1621 TTAGGAGTAG CACCCACCAA GGCAAAGAGA AGAGTGGTGC AGAGAGAAAA  
 AAGAGCAGTG  
 1681 GGAATAGGAG CTTTGTTCCT TGGGTTCTTG GGAGCAGCAG GAAGCACTAT  
 GGGCGCAGCG  
 35 1741 TCAATGACGC TGACGGTACA GGCCAGACAA TTATTGTCIG GTATAGTGCA  
 GCAGCAGAAC  
 1801 AATTGCTGA GGGCTATTGA GGCGCAACAG CATCTGTTGC AACTCACAGT  
 CTGGGGCCTC  
 1861 AAGCAGCTCC AGGCAAGAAT CCTGGCTGTG GAAAGATACC TAAAGGATCA  
 40 ACAGCTCCTG  
 1921 GGGATTGGG GTTGCTCTGG AAAACTCATT TGCACCACTG CTGTGCCTTG  
 GAATGCTAGT  
 1981 TGGAGTAATA AATCTCTGGA ACAGATTGG AATCACACGA CCTGGATGGA  
 GTGGGACAGA  
 45 2041 GAAATTAACA ATTACACAAG CTTAATACAC TCCTTAATTG AAGAATCGCA  
 AAACCAGCAA  
 2101 GAAAAGAATG ACAAGAATT ATTGGAATTA GATAAATGGG CAAGTTGTG  
 GAATTGGTTT  
 2161 AACATAACAA ATTGGCTGTG GTATATAAAA TTATTCTAA TGATAGTAGG  
 50 AGGCTTGGTA  
 2221 GGTTTAAGAA TAGTTTTGC TGTACTTTCT ATAGTGAATA GAGTTAGGCA  
 GGGATATTCA  
 2281 CCATTATCGT TTCAGACCCA CCTCCCAACC CCGAGGGGAC CCGACAGGCC  
 CGAAGGAATA  
 55 2341 GAAGAAGAAG GTGGAGAGAG AGACAGAGAC AGATCCATTG GATTAGTGAA  
 CGGATCGGCA  
 2401 CTGCGTGCCTGA CAATTCTGCA GACAAATGGC AGTATTCTAC CACAATTTA  
 AAAGAAAAGG

2461 GGGGATTGGG GGGTACAGTG CAGGGGAAAG AATAGTAGAC ATAATAGCAA  
 CAGACATACA  
 2521 AACTAAAGAA TTACAAAAAC AAATTACAAA AATTCAAAAT TTTCGGGTTT  
 ATTACAGGGA  
 5 2581 CAGCAGAGAT CCAGTTGGT TAGTACCGGG CCCGCTCTAG ACGGTTAACG  
 CGCTAGCCGT  
 2641 TAATTAAGCC TCGAGGTCCA CGGTATCGAT AAGCTCGCTT CACGAGATTG  
 CAGCAGGTCG  
 2701 AGGGACCTAA TAACTTCGTA TAGCATAACAT TATACGAAGT TATATTAAGG  
 10 GTTCCAAGCT  
 2761 TAAGCGGCCG CGCCACCATG GCCTCCTCCG AGAACGTCAT CACCGAGTTC  
 ATGCGCTTCA  
 2821 AGGTGCGCAT GGAGGGCACC GTGAACGGCC ACGAGTTCGA GATCGAGGGC  
 GAGGGCGAGG  
 15 2881 GCCGCCCTA CGAGGGCCAC AACACCGTGA AGCTGAAGGT GACCAAGGGC  
 GGCCCCCTGC  
 2941 CCTTCGCCTG GGACATCCTG TCCCCCCAGT TCCAGTACGG CTCCAAGGTG  
 TACGTGAAGC  
 3001 ACCCCGCCGA CATCCCCGAC TACAAGAAGC TGTCCCTCCC CGAGGGCTTC  
 20 AAGTGGGAGC  
 3061 GCGTGATGAA CTTCGAGGAC GGCGCGTGG CGACCGTGAC CCAGGACTCC  
 TCCCTGCAGG  
 3121 ACGGCTGCTT CATCTACAAG GTGAAGTTCA TCGGCGTGAA CTTCCCCCTCC  
 GACGGCCCCG  
 25 3181 TGATGCAGAA GAAGACCATG GGCTGGGAGG CCTCCACCGA GCGCCTGTAC  
 CCCCGCGACG  
 3241 GCGTGCCTGAA GGGCGAGACC CACAAGGCCG TGAAGCTGAA GGACGGCGGC  
 CACTACCTGG  
 3301 TGGAGTTCAA GTCCATCTAC ATGGCCAAGA AGCCCGTGCA GCTGCCCGGC  
 30 TACTACTACG  
 3361 TGGACGCCAA GCTGGACATC ACCTCCCACA ACGAGGACTA CACCATCGTG  
 GAGCAGTACG  
 3421 AGCGCACCGA GGGCCGCCAC CACCTGTTCC TGATGCATGC CCCGGGATGG  
 CGCGCCATGG  
 35 3481 ATCCGCGAAT TCGTCGAGGG ACCTAATAAC TTCGTATAGC ATACATTATA  
 CGAAGTTATA  
 3541 CATGTTTAAG GGTTCCGGTT CCACTAGGTA CAATTCGATA TCAAGCTTAT  
 CGATAATCAA  
 3601 CCTCTGGATT ACAAAATTG TGAAAGATTG ACTGGTATTC TTAACTATGT  
 40 TGCTCCTTT  
 3661 ACGCTATGTG GATACGCTGC TTTAATGCCT TTGTATCATG CTATTGCTTC  
 CCGTATGGCT  
 3721 TTCATTTCT CCTCCTTGTAA TAAATCCTGG TTGCTGTCTC TTTATGAGGA  
 GTTGTGGCCC  
 45 3781 GTTGTCAAGC AACGTGGCGT GGTGTGCACT GTGTTGCTG ACGCAACCCC  
 CACTGGTTGG  
 3841 GGCATTGCCA CCACCTGTCA GCTCCTTCC GGGACTTTCG CTTTCCCCCT  
 CCCTATTGCC  
 3901 ACGGCGGAAC TCATGCCGC CTGCCTTGCC CGCTGCTGGA CAGGGGCTCG  
 50 GCTGTTGGGC  
 3961 ACTGACAATT CCGTGGTGTGTT GTCGGGGAAA TCATCGTCCT TTCCCTGGCT  
 GCTCGCCTG  
 4021 GTTGCCACCT GGATTCTGCG CGGGACGTCC TTCTGCTACG TCCCTTCGGC  
 CCTCAATCCA  
 55 4081 GCGGACCTTC CTTCCCGCGG CCTGCTGCCG GCTCTGCCG CTCTCCGCG  
 TCTTCGCGCTT  
 4141 CGCCCTCAGA CGAGTCGGAT CTCCCTTTGG GCCGCCTCCC CGCATCGATA  
 CGTCGACCT

4201 CGATCGAGAC CTAGAAAAAC ATGGAGCAAT CACAAGTAGC AATACAGCAG  
 CTACCAATGC  
 4261 TGATTGTGCC TGGCTAGAAG CACAAGAGGA GGAGGAGGTG GGTTTCCAG  
 TCACACCTCA  
 5 4321 GGTACCTTTA AGACCAATGA CTTACAAGGC AGCTGTAGAT CTTAGCCACT  
 TTTTAAAAGA  
 4381 AAAGGGGGGA CTGGAAGGGC TAATTCACTC CCAACGAAGA CAAGATATCC  
 TTGATCTGTG  
 4441 GATCTACAC ACACAAGGCT ACTTCCCTGA TTGGCAGAAC TACACACCAG  
 10 GCCCAGGGAT  
 4501 CAGATATCCA CTGACCTTG GATGGTGCTA CAAGCTAGTA CCAGTTGAGC  
 AAGAGAAGGT  
 4561 AGAAGAAGCC AATGAAGGAG AGAACACCCG CTTGTTACAC CCTGTGAGCC  
 TGCATGGGAT  
 15 4621 GGATGACCCG GAGAGAGAAG TATTAGAGTG GAGGTTTGAC AGCCGCCTAG  
 CATTTCATCA  
 4681 CATGGCCCGA GAGCTGCATC CGGACTGTAC TGGGTCTCTC TGGTTAGACC  
 AGATCTGAGC  
 4741 CTGGGAGCTC TCTGGCTAAC TAGGGAACCC ACTGCTTAAG CCTCAATAAA  
 20 GCTTGCCTTG  
 4801 AGTGCTTCAA GTAGTGTGTG CCCGTCTGTT GTGTGACTCT GGTAACTAGA  
 GATCCCTCAG  
 4861 ACCCTTTAG TCAGTGTGGA AAATCTCTAG CAGCATGTGA GCAAAAGGCC  
 AGCAAAAGGC  
 25 4921 CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTCCAT AGGCTCCGCC  
 CCCCTGACGA  
 4981 GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAC CCGACAGGAC  
 TATAAAGATA  
 5041 CCAGGGCGTTT CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC  
 30 TGCCGCTTAC  
 5101 CGGATACCTG TCCGCCCTTC TCCCTCGGG AAGCGTGGCG CTTTCTCATA  
 GCTCACGCTG  
 5161 TAGGTATCTC AGTCGGTGT AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC  
 ACGAACCCCC  
 35 5221 CGTCAGCCCC GACCGCTGGC CCTTATCCGG TAACTATCGT CTTGAGTCCA  
 ACCCGGTAAG  
 5281 ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG  
 CGAGGTATGT  
 5341 AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA  
 40 GAAGAACAGT  
 5401 ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG  
 GTAGCTCTTG  
 5461 ATCCGGAAA CAAACCACCG CTGGTAGCGG TGGTTTTTT GTTGCAAGC  
 AGCAGATTAC  
 45 5521 GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTT TCTACGGGT  
 CTGACGCTCA  
 5581 GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCACTGAGA TTATCAAAAA  
 GGATCTTCAC  
 5641 CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC TAAAGTATAT  
 50 ATGAGTAAAC  
 5701 TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA  
 TCTGTCTATT  
 5761 TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC  
 GGGAGGGCTT  
 55 5821 ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCGG  
 CTCCAGATT  
 5881 ATCAGCAATA AACCAAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG  
 CAACTTTATC

5941 CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT  
CGCCAGTTAA  
6001 TAGTTGCGC AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT  
CGTCGTTGCG  
5 6061 TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCAGA GTTACATGAT  
CCCCCATGTT  
6121 GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA  
AGTTGGCCGC  
6181 AGTGTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA  
10 TGCCATCCGT  
6241 AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT  
AGTGTATGCG  
6301 GCGACCGAGT TGCTCTTGC CGCGTCAAT ACGGGATAAT ACCCGGCCAC  
ATAGCAGAAC  
15 6361 TTTAAAAGTG CTCATCATTG GAAAACGTTTTC TTCGGGGCGA AAACTCTCAA  
GGATCTTACC  
6421 GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT  
CAGCATCTT  
6481 TACTTCACC AGCGTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG  
20 CAAAAAAAGGG  
6541 AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTCAAT  
ATTATTGAAG  
6601 CATTATCAG GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT  
AGAAAAATAA  
25 6661 ACAAAATAGGG GTTCCGCGCA CATTCCCCG AAAAGTGCCA CCTGAC  
//  
(SEQ ID NO: 4)

## [00348] pLL3.3

5 LOCUS PLENTILOX 7248 BP DS-DNA CIRCULAR SYN 23-JAN-  
 2002  
 DEFINITION -  
 ACCESSION -  
 KEYWORDS -  
 SOURCE -  
 10 FEATURES Location/Qualifiers  
 promoter 212..816  
 /note="CMV promoter/enhancer 1"  
 gene 6255..7115  
 /note="AmpR"  
 15 rep\_origin 5437..6110  
 /note="pUC"  
 misc\_recomb 3931..3966  
 /note="Lox 1"  
 20 misc\_recomb 4048..4081  
 /note="Lox2"  
 LTR 835..1509  
 /note="5' HIV R-U5-del gag (HIV NL4-3/454-1126)"  
 misc\_feature 1539..2396  
 /note="HIV RRE (HIV NL4-3/7622-8459)"  
 25 misc\_feature 2422..2599  
 /note="HIV Flap"  
 misc\_feature 4136..4725  
 /note="WRE element"  
 30 LTR 4745..5434  
 /note="3' SIN LTR"  
 frag 2627..3847  
 /note="13 to 1233 of pUB6/V5-HisA"  
 promoter 2632..3841  
 /note="Ubc promoter"  
 35 BASE COUNT 1815 A 1695 C 1947 G 1791 T 0 OTHER  
 ORIGIN -  
 1 GTCGACGGAT CGGGAGATCT CCCGATCCCC TATGGTGCAC TCTCAGTACA  
 ATCTGCTCTG  
 40 61 ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT GTTGGAGGTC  
 GCTGAGTAGT  
 121 GCGCGAGCAA AATTTAAGCT ACAACAAGGC AAGGCTTGAC CGACAATTGC  
 ATGAAGAAC  
 181 TGCTTAGGGT TAGGCGTTTT GCGCTGCTTC GCGATGTACG GGCCAGATAT  
 ACGCGTTGAC  
 45 241 ATTGATTATT GACTAGTTAT TAATAGTAAT CAATTACGGG GTCATTAGTT  
 CATAGCCCCAT  
 301 ATATGGAGTT CCGCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA  
 CCGCCCCAACG  
 361 ACCCCCCGCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA  
 50 ATAGGGACTT  
 421 TCCATTGACG TCAATGGGTG GAGTATTTAC GGTAAACTGC CCACCTGGCA  
 GTACATCAAG  
 481 TGTATCATAT GCCAAGTACG CCCCCTATTG ACGTCAATGA CGGTAAATGG  
 CCCGCCTGGC  
 55 541 ATTATGCCCA GTACATGACC TTATGGGACT TTCCTACTTG GCAGTACATC  
 TACGTATTAG  
 601 TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT CAATGGCGT  
 GGATAGCGGT

661 TTGACTCACG GGGATTTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT  
 TTGTTTTGGC  
 721 ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC CGCCCCATTG  
 ACGCAAATGG  
 5 781 GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGCGC GTTTGCCTG  
 TACTGGGTCT  
 841 CTCTGGTTAG ACCAGATCTG AGCCTGGAG CTCTCTGGCT AACTAGGGAA  
 CCCACTGCTT  
 901 AAGCCTCAAT AAAGCTTGCC TTGAGTGCTT CAAGTAGTGT GTGCCCGTCT  
 10 GTTGTGTGAC  
 961 TCTGGTAACT AGAGATCCCT CAGACCCCTT TAGTCAGTGT GGAAAATCTC  
 TAGCAGTGGC  
 1021 GCCCGAACAG GGACTTGAAA GCGAAAGGGA AACCAGAGGA GCTCTCTCGA  
 CGCAGGACTC  
 15 1081 GGCTTGCTGA AGCGCGCACG GCAAGAGGCG AGGGGCGGCG ACTGGTGAGT  
 ACGCCAAAAA  
 1141 TTTTGACTAG CGGAGGCTAG AAGGAGAGAG ATGGGTGCGA GAGCGTCAGT  
 ATTAAGCGGG  
 1201 GGAGAATTAG ATCGCGATGG GAAAAAATTC GGTAAAGGCC AGGGGGAAAG  
 20 AAAAAATATA  
 1261 AATTAAAACA TATAGTATGG GCAAGCAGGG AGCTAGAACG ATTTCAGATT  
 AATCCTGGCC  
 1321 TGTAGAACAC ATCAGAAGGC TGTAGACAAA TACTGGGACA GCTACAACCA  
 TCCCTTCAGA  
 25 1381 CAGGATCAGA AGAACTTAGA TCATTATATA ATACAGTAGC AACCCCTCTAT  
 TGTGTGCATC  
 1441 AAAGGATAGA GATAAAAGAC ACCAAGGAAG CTTTAGACAA GATAGAGGAA  
 GAGCAAAACA  
 1501 AAAGTAAGAC CACCGCACAG CAAGCGGCCG GCCGCGCTGA TCTTCAGACC  
 30 TGGAGGAGGA  
 1561 GATATGAGGG ACAATTGGAG AAGTGAATTA TATAAAATATA AAGTAGTAAA  
 AATTGAACCA  
 1621 TTAGGAGTAG CACCCACCAA GGCAAAGAGA AGAGTGGTGC AGAGAGAAAA  
 AAGAGCAGTG  
 35 1681 GGAATAGGAG CTTTGTTCCT TGGGTTCTTG GGAGCAGCAG GAAGCACTAT  
 GGGCGCAGCG  
 1741 TCAATGACGC TGACGGTACA GGCCAGACAA TTATTGTCTG GTATAGTGCA  
 GCAGCAGAAC  
 1801 AATTGCTGA GGGCTATTGA GGCGCAACAG CATCTGTTGC AACTCACAGT  
 40 CTGGGGCATC  
 1861 AAGCAGCTCC AGGCAAGAAT CCTGGCTGTG GAAAGATACC TAAAGGATCA  
 ACAGCTCCCTG  
 1921 GGGATTGGG GTTGCTCTGG AAAACTCATT TGCACCAC TGTCAGCTTG  
 GAATGCTAGT  
 45 1981 TGGAGTAATA AATCTCTGGA ACAGATTGG AATCACACGA CCTGGATGGA  
 GTGGGACAGA  
 2041 GAAATTAACA ATTACACAAG CTTAATACAC TCCTTAATTG AAGAATCGCA  
 AAACCAGCAA  
 2101 GAAAAGAATG AACAGAATT ATTGGAATTA GATAATGGG CAAGTTGTG  
 50 GAATTGGTTT  
 2161 AACATAACAA ATTGGCTGTG GTATATAAAA TTATTCTAA TGATAGTAGG  
 AGGCTGGTA  
 2221 GGTTTAAGAA TAGTTTTGC TGTACTTTCT ATAGTGAATA GAGTTAGGCA  
 GGGATATTCA  
 55 2281 CCATTATCGT TTCAGACCCA CCTCCCAACC CCGAGGGGAC CCGACAGGCC  
 CGAAGGAATA  
 2341 GAAGAAGAAG GTGGAGAGAG AGACAGAGAC AGATCCATTG GATTAGTGAA  
 CGGATCGGCA

2401 CTGGGTGCGC CAATTCTGCA GACAAATGGC AGTATTCATC CACAATTTA  
 AAAGAAAAGG  
 2461 GGGGATTGGG GGGTACAGTG CAGGGGAAAG AATAGTAGAC ATAATAGCAA  
 CAGACATACA  
 5 2521 AACTAAAGAA TTACAAAAAC AAATTACAAA AATTCAAAAT TTTCGGGTTT  
 ATTACAGGGA  
 2581 CAGCAGAGAT CCAGTTGGT TAGTACCGGG CCCGCTCTAG ACGGTTGATC  
 TGGCCTCCGC  
 2641 GCCGGGTTTT GGCGCCTCCC GCAGGGCGCC CCCTCCTCAC GGCGAGCGCT  
 10 GCCACGTCA  
 2701 ACGAAGGGCG CAGGAGCGTC CTGATCCTTC CGCCCGGACG CTCAGGACAG  
 CGGCCCGCTG  
 2761 CTCATAAGAC TCGGCCTTAG AACCCAGTA TCAGCAGAAG GACATTTAG  
 GACGGGACTT  
 15 2821 GGGTGACTCT AGGGCACTGG TTTTCTTCC AGAGAGCGGA ACAGGCGAGG  
 AAAAGTAGTC  
 2881 CCTTCTCGGC GATTCTGCGG AGGGATCTCC GTGGGGCGGT GAACGCCGAT  
 GATTATATAA  
 2941 GGACGCGCCG GGTGTGGCAC AGCTAGTTCC GTCGCAGCCG GGATTTGGGT  
 20 CGCGGTTCTT  
 3001 GTTGTGGAT CGCTGTGATC GTCACTTGGT GAGTAGCGGG CTGCTGGGCT  
 GGCCGGGGCT  
 3061 TTCGTGGCCG CGGGGCCGCT CGGTGGGACG GAAGCGTGTG GAGAGACCGC  
 CAAGGGCTGT  
 25 3121 AGTCTGGGTC CGCGAGCAAG GTTGCCTGA ACTGGGGGTT GGGGGGAGCG  
 CAGCAAAATG  
 3181 GCGGCTGTTG CCGAGTCTTG AATGGAAGAC GCTTGTGAGG CGGGCTGTGA  
 GGTCGTTGAA  
 3241 ACAAGGTGGG GGGCATGGTG GGCGCAAGA ACCCAAGGTC TTGAGGCCTT  
 30 CGCTAATGCG  
 3301 GGAAAGCTCT TATTGGGTG AGATGGGCTG GGGCACCATC TGGGGACCC  
 GACGTGAAGT  
 3361 TTGTCACTGA CTGGAGAACT CGGTTTGTG TCTGTTGCCG GGGCGGCAGT  
 TATGCGGTGC  
 35 3421 CGTTGGCAG TGCACCCGTA CCTTGGGAG CGCGGCCCT CGTCGTGTC  
 TGACGTCACC  
 3481 CGTTCTGTTG GCTTATAATG CAGGGTGGGG CCACCTGCCG GTAGGTGTGC  
 GGTAGGCTTT  
 3541 TCTCCGTCGC AGGACGCAGG GTTGGGCCT AGGGTAGGCT CTCCTGAATC  
 40 GACAGGCGCC  
 3601 GGACCTCTGG TGAGGGGAGG GATAAGTGAG GCGTCAGTTT CTTTGGTCGG  
 TTTTATGTAC  
 3661 CTATCTTCTT AAGTAGCTGA AGCTCCGGTT TTGAACATAG CGCTCGGGGT  
 TGGCGAGTGT  
 45 3721 GTTTGTGAA GTTTTTAGG CACTTTGAA AATGTAATCA TTTGGGTCAA  
 TATGTAATT  
 3781 TCAGTGTAG ACTAGTAAAT TGTCCGCTAA ATTCTGGCCG TTTTGGCTT  
 TTTTGTAGA  
 3841 CGAAGCTAAC GCGCTAGCCG TTAATTAAGC CTCGAGGTG ACGGTATCGA  
 50 TAAGCTCGCT  
 3901 TCACGAGATT CCAGCAGGTC GAGGGACCTA ATAACCTCGT ATAGCATACA  
 TTATACGAAG  
 3961 TTATATTAAG GTTCCAAGC TTAAGCGGCC GCCGATGCAT GCCCCGGGAT  
 GGCGCGCCAT  
 55 4021 GGATCCGCGA ATTCTGTCGAG GGACCTAATA ACTTCGTATA GCATACATTA  
 TACGAAGTTA  
 4081 TACATGTTA AGGGTTCCGG TTCCACTAGG TACAATTCGA TATCAAGCTT  
 ATCGATAATC

4141 AACCTCTGGA TTACAAAATT TGTGAAAGAT TGACTGGTAT TCTTAACTAT  
 GTTGCTCCTT  
 4201 TTACGCTATG TGGATACGCT GCTTTAATGC CTTTGTATCA TGCTATTGCT  
 TCCCGTATGG  
 5 4261 CTTTCATTTC CTCCTCCTTG TATAAACTCCT GGTTGCTGTC TCTTTATGAG  
 GAGTTGTGGC  
 4321 CCGTTGTCAG GCAACGTGGC GTGGTGTGCA CTGTGTTGTC TGACGCAACC  
 CCCACTGGTT  
 4381 GGGGCATTGC CACCACCTGT CAGCTCCTT CCGGGACTTT CGCTTCCCC  
 10 CTCCCTATTG  
 4441 CCACGGCGGA ACTCATCGCC GCCTGCCTTG CCCGCTGCTG GACAGGGGCT  
 CGGCTGTTGG  
 4501 GCACTGACAA TTCCGTGGTG TTGTCGGGGA AATCATCGTC CTTTCCTTGG  
 CTGCTCGCCT  
 15 4561 GTGTTGCCAC CTGGATTCTG CGCGGGACGT CCTTCTGCTA CGTCCCTTCG  
 GCCCTCAATC  
 4621 CAGCGGACCT TCCTTCCCGC GGCGCTGCTGC CGGCTCTGCG GCCTCTTCCG  
 CGTCTCGCC  
 4681 TTCGCCCTCA GACGAGTCGG ATCTCCCTT GGGCCGCCTC CCCGCATCGA  
 20 TACCGTGCAC  
 4741 CTCGATCGAG ACCTAGAAAA ACATGGAGCA ATCACAAGTA GCAATACAGC  
 AGCTACCAAT  
 4801 GCTGATTGTG CCTGGCTAGA AGCACAAAGAG GAGGAGGAGG TGGGTTTCC  
 AGTCACACCT  
 25 4861 CAGGTACCTT TAAGACCAAT GACTTACAAG GCAGCTGTAG ATCTTAGCCA  
 CTTTTTAAAAA  
 4921 GAAAAGGGGG GACTGGAAGG GCTAATTACAC TCCCAACGAA GACAAGATAT  
 CCTTGATCTG  
 4981 TGGATCTACC ACACACAAGG CTACTTCCCT GATTGGCAGA ACTACACACC  
 30 AGGGCCAGGG  
 5041 ATCAGATATC CACTGACCTT TGGATGGTGC TACAAGCTAG TACCAAGTGA  
 GCAAGAGAAAG  
 5101 GTAGAAGAAG CCAATGAAGG AGAGAACACC CGCTTGTAC ACCCTGTGAG  
 CCTGCATGGG  
 35 5161 ATGGATGACC CGGAGAGAGA AGTATTAGAG TGGAGGTTTG ACAGCCGCCT  
 AGCATTTCAT  
 5221 CACATGGCCC GAGAGCTGCA TCCGGACTGT ACTGGGTCTC TCTGGTTAGA  
 CCAGATCTGA  
 5281 GCCTGGGAGC TCTCTGGCTA ACTAGGGAAC CCACTGCTTA AGCCTCAATA  
 40 AAGCTTGCCT  
 5341 TGAGTGCTTC AAGTAGTGTG TGCCCGTCTG TTGTGTGACT CTGGTAACTA  
 GAGATCCCTC  
 5401 AGACCCCTTT AGTCAGTGTG GAAAATCTCT AGCAGCATGT GAGCAAAGG  
 CCAGCAAAAG  
 45 5461 GCCAGGAACC GTAAAAAGGC CGCGTTGCTG GCGTTTTCC ATAGGCTCCG  
 CCCCCCTGAC  
 5521 GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA ACCCGACAGG  
 ACTATAAAGA  
 5581 TACCAGGCGT TTCCCCCTGG AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC  
 50 CCTGCCGCTT  
 5641 ACCGGATACC TGTCCGCCTT TCTCCCTTCG GGAAGCGTGG CGCTTCTCA  
 TAGCTCACGC  
 5701 TGTAGGTATC TCAGTTCGGT GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT  
 GCACGAAACCC  
 55 5761 CCCGTTTCAGC CCGACCGCTG CGCCTTATCC GGTAACTATC GTCTTGAGTC  
 CAACCCGGTA  
 5821 AGACACGACT TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG  
 AGCGAGGTAT

5881 GTAGGCGGTG CTACAGAGTT CTTGAAGTGG TGGCCTAACT ACGGCTACAC  
 TAGAAGAACAA  
 5941 GTATTGGTA TCTGCGCTCT GCTGAAGCCA GTTACCTTCG GAAAAAGAGT  
 TGGTAGCTCT  
 5 6001 TGATCCGGCA AACAAACCAC CGCTGGTAGC GGTGGTTTT TTGTTGCAA  
 GCAGCAGATT  
 6061 ACGCGCAGAA AAAAAGGATC TCAAGAAGAT CCTTTGATCT TTTCTACGGG  
 GTCTGACGCT  
 6121 CAGTGGAACG AAAACTCACG TTAAGGGATT TTGGTCATGA GATTATCAAA  
 10 AAGGATCTTC  
 6181 ACCTAGATCC TTTTAAATTA AAAATGAAGT TTTAAATCAA TCTAAAGTAT  
 ATATGAGTAA  
 6241 ACTTGGTCTG ACAGTTACCA ATGCTTAATC AGTGAGGCAC CTATCTCAGC  
 GATCTGTCTA  
 15 6301 TTTCGTTCAT CCATAGTTGC CTGACTCCCC GTCGTGTAGA TAACTACGAT  
 ACGGGAGGGC  
 6361 TTACCATCTG GCCCCAGTGC TGCAATGATA CCGCGAGACC CACGCTCACC  
 GGCTCCAGAT  
 6421 TTATCAGCAA TAAACCAGCC AGCCGGAAGG GCCGAGCGCA GAAGTGGTCC  
 20 TGCAACCTTA  
 6481 TCCGCCTCCA TCCAGTCTAT TAATTGTTGC CGGGAAAGCTA GAGTAAGTAG  
 TTCGCCAGTT  
 6541 AATAGTTGC GCAACGTTGT TGCCATTGCT ACAGGCATCG TGGTGTACG  
 CTCGTCGTTT  
 25 6601 GGTATGGCTT CATTCAAGCTC CGGTTCCCAA CGATCAAGGC GAGTTACATG  
 ATCCCCCATG  
 6661 TTGTGCAAAA AAGCGGTTAG CTCCTTCGGT CCTCCGATCG TTGTCAGAAG  
 TAAGTTGGCC  
 6721 GCAGTGTAT CACTCATGGT TATGGCAGCA CTGCATAATT CTCTTACTGT  
 30 CATGCCATCC  
 6781 GTAAGATGCT TTTCTGTGAC TGGTGAGTAC TCAACCAAGT CATTCTGAGA  
 ATAGTGTATG  
 6841 CGCGGACCGA GTTGCTCTG CCCGGCGTCA ATACGGGATA ATACCGCGCC  
 ACATAGCAGA  
 35 6901 ACTTTAAAAG TGCTCATCAT TGGAAAACGT TCTTCGGGGC GAAAACCTCTC  
 AAGGATCTTA  
 6961 CCGCTGTTGA GATCCAGTTTC GATGTAACCC ACTCGTGCAC CCAACTGATC  
 TTCAGCATCT  
 7021 TTTACTTTCA CCAGCGTTTC TGGGTGAGCA AAAACAGGAA GGCAAAATGC  
 40 CGCAAAAAAG  
 7081 GGAATAAGGG CGACACGGAA ATGTTGAATA CTCATACTCT TCCTTTTCA  
 ATATTATTGA  
 7141 AGCATTATC AGGGTTATTG TCTCATGAGC GGATACATAT TTGAATGTAT  
 TTAGAAAAAT  
 45 7201 AAACAAATAG GGGTTCCGCG CACATTCCC CGAAAAGTGC CACCTGAC  
 //  
 (SEQ ID NO: 5)

## [00349] pLL3.4

5 LOCUS PLENTILOX 7969 BP DS-DNA CIRCULAR SYN 23-JAN-  
 2002  
 DEFINITION -  
 ACCESSION -  
 KEYWORDS -  
 SOURCE -  
 10 FEATURES Location/Qualifiers  
 promoter 212..816  
 /note="CMV promoter/enhancer 1"  
 misc\_recomb 4769..4802  
 /note="LoxP"  
 '15 promoter 2632..3841  
 /note="UbC promoter"  
 gene 6976..7836  
 /note="AmpR"  
 20 rep\_origin 6158..6831  
 /note="pUC"  
 misc\_recomb 3931..3966  
 /note="LoxP"  
 LTR 835..1509  
 /note="5' HIV R-U5-del gag (HIV NL4-3/454-1126)"  
 25 misc\_feature 1539..2396  
 /note="HIV RRE (HIV NL4-3/7622-8459)"  
 misc\_feature 2422..2599  
 /note="HIV Flap"  
 misc\_feature 4857..5446  
 30 /note="WRE element"  
 LTR 5466..6155  
 /note="3' SIN LTR"  
 gene 3993..4715  
 /note="EGFP"  
 35 BASE COUNT 1988 A 1938 C 2150 G 1893 T 0 OTHER  
 ORIGIN -  
 1 GTCGACGGAT CGGGAGATCT CCCGATCCCC TATGGTGCAC TCTCAGTACA  
 ATCTGCTCTG  
 61 ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT GTTGGAGGTC  
 40 GCTGAGTAGT  
 121 GCGCGAGCAA AATTAAAGCT ACAACAAGGC AAGGCTTGAC CGACAATTGC  
 ATGAAGAAC  
 181 TGCTTAGGGT TAGGCCTTT GCGCTGCTTC GCGATGTACG GGCCAGATAT  
 ACGCGTTGAC  
 45 241 ATTGATTATT GACTAGTTAT TAATAGTAAT CAATTACGGG GTCATTAGTT  
 CATAGCCCAT  
 301 ATATGGAGTT CCGCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA  
 CCGCCCCAACG  
 361 ACCCCCCGCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA  
 50 ATAGGGACTT  
 421 TCCATTGACG TCAATGGGTG GAGTATTTAC GGTAAACTGC CCACTTGGCA  
 GTACATCAAG  
 481 TGTATCATAT GCCAAGTACG CCCCCTATTG ACGTCAATGA CGGTAAATGG  
 CCCGCCTGGC  
 55 541 ATTATGCCCA GTACATGACC TTATGGACT TTCCTACTTG GCAGTACATC  
 TACGTATTAG  
 601 TCATCGCTAT TACCATGGTG ATGCGGTTT GGCAGTACAT CAATGGCGT  
 GGATAGCGGT

661 TTGACTCACG GGGATTTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT  
 TTGTTTTGGC  
 721 ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC CGCCCCATTG  
 ACGCAAATGG  
 5 781 GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGCGC GTTTGCCTG  
 TACTGGGTCT  
 841 CTCTGGTTAG ACCAGATCTG AGCCTGGAG CTCTCTGGCT AACTAGGGAA  
 CCCACTGCTT  
 901 AAGCCTCAAT AAAGCTTGCC TTGAGTGCTT CAAGTAGTGT GTGCCCGTCT  
 10 GTTGTGTGAC  
 961 TCTGGTAAC AGAGATCCCT CAGACCCTTT TAGTCAGTGT GGAAAATCTC  
 TAGCAGTGGC  
 1021 GCCCGAACAG GGACTTGAAA GCGAAAGGGA AACCAAGAGGA GCTCTCTCGA  
 CGCAGGACTC  
 15 1081 GGCTTGCTGA AGCGCGCACG GCAAGAGGCG AGGGCGGCG ACTGGTGAGT  
 ACGCCAAAAAA  
 1141 TTTTGACTAG CGGAGGCTAG AAGGAGAGAG ATGGGTGCGA GAGCGTCAGT  
 ATTAAGCGGG  
 1201 GGAGAATTAG ATCGCGATGG GAAAAAATTC GGTAAAGGCC AGGGGGAAAG  
 20 AAAAAATATA  
 1261 AATTAAAACA TATAGTATGG GCAAGCAGGG AGCTAGAACG ATTGCGAGTT  
 AATCCTGGCC  
 1321 TGTTAGAAC ATCAGAAGGC TGTAGACAAA TACTGGGACA GCTACAACCA  
 TCCCTTCAGA  
 25 1381 CAGGATCAGA AGAACTTAGA TCATTATATA ATACAGTAGC AACCCCTCTAT  
 TGTGTGCATC  
 1441 AAAGGATAGA GATAAAAGAC ACCAAGGAAG CTTTAGACAA GATAGAGGAA  
 GAGCAAAACA  
 1501 AAAGTAAGAC CACCGCACAG CAAGCGGCCG GCCCGCTGA TCTTCAGACC  
 30 TGGAGGAGGA  
 1561 GATATGAGGG ACAATTGGAG AAGTGAATTA TATAAAATATA AAGTAGTAAA  
 AATTGAACCA  
 1621 TTAGGAGTAG CACCCACCAA GGCAAAGAGA AGAGTGGTGC AGAGAGAAAA  
 AAGAGCAGTG  
 35 1681 GGAATAGGAG CTTTGTTCCT TGGGTTCTTG GGAGCAGCAG GAAGCACTAT  
 GGGCGCAGCG  
 1741 TCAATGACGC TGACGGTACA GGCCAGACAA TTATTGTCTG GTATAGTGCA  
 GCAGCAGAAC  
 1801 AATTGCTGA GGGCTATTGA GGCGCAACAG CATCTGTTGC AACTCACAGT  
 40 CTGGGGCATC  
 1861 AAGCAGCTCC AGGCAAGAAT CCTGGCTGTG GAAAGATACC TAAAGGATCA  
 ACAGCTCCTG  
 1921 GGGATTGGG GTTGCTCTGG AAAACTCATT TGCACCACTG CTGTGCCTTG  
 GAATGCTAGT  
 45 1981 TGGAGTAATA AATCTCTGGA ACAGATTGG AATCACACGA CCTGGATGGA  
 GTGGGACAGA  
 2041 GAAATTAACA ATTACACAAG CTTAATACAC TCCTTAATTG AAGAATCGCA  
 AAACCAGCAA  
 2101 GAAAAGAATG AACAGAATT ATTGGAATTA GATAATGGG CAAGTTGTG  
 50 GAATTGGTT  
 2161 AACATAACAA ATTGGCTGTG GTATATAAAA TTATTCTAA TGATAGTAGG  
 AGGCTTGGTA  
 2221 GGTAAAGAA TAGTTTTGC TGTACTTTCT ATAGTGAATA GAGTTAGGCA  
 GGGATATTCA  
 55 2281 CCATTATCGT TTCAGACCCA CCTCCCAACC CCGAGGGGAC CCGACAGGCC  
 CGAAGGAATA  
 2341 GAAGAAGAAG GTGGAGAGAG AGACAGAGAC AGATCCATTG GATTAGTGAA  
 CGGATCGGCA

2401 CTGCGTGCAG CAATTCTGCA GACAAATGGC AGTATTCATC CACAATTTA  
 AAAGAAAAAGG  
 2461 GGGGATTGGG GGGTACAGTG CAGGGGAAAG AATAGTAGAC ATAATAGCAA  
 CAGACATACA  
 5 2521 AACTAAAGAA TTACAAAAAC AAATTACAAA AATTCAAAAT TTTCGGGTTT  
 ATTACAGGGA  
 2581 CAGCAGAGAT CCAGTTGGT TAGTACCGGG CCCGCTCTAG ACGGTTGATC  
 TGGCCTCCGC  
 2641 GCCGGGTTT GGCGCCTCCC GCAGGCGCCC CCCTCCTCAC GGCGAGCGCT  
 10 GCCACGTCAAG  
 2701 ACGAAGGGCG CAGGAGCGTC CTGATCCTTC CGCCCGGACG CTCAGGACAG  
 CGGCCCGCTG  
 2761 CTCATAAGAC TCGGCCTTAG AACCCCAGTA TCAGCAGAAG GACATTTAG  
 GACGGGACTT  
 15 2821 GGGTGAATCT AGGGCACTGG TTTTCTTCC AGAGAGCGGA ACAGGCGAGG  
 AAAAGTAGTC  
 2881 CCTTCTCGGC GATTCTGCGG AGGGATCTCC GTGGGGCGGT GAACGCCGAT  
 GATTATATAA  
 2941 GGACGCGCCG GGTGTGGCAC AGCTAGTTCC GTCGCAGCCG GGATTTGGGT  
 20 CGCGGTTCTT  
 3001 GTTGTGGAT CGCTGTGATC GTCACCTGGT GAGTAGCGGG CTGCTGGCT  
 GGCCGGGGCT  
 3061 TTCGTGGCCG CGGGCCGCT CGGTGGGACG GAAGCGTGTG GAGAGACCGC  
 CAAGGGCTGT  
 25 3121 AGTCTGGTC CGCGAGCAAG GTTGCCTGA ACTGGGGGTT GGGGGGAGCG  
 CAGCAAAATG  
 3181 GCGGCTGTTCC CGAGTCTTG AATGGAAGAC GCTTGTGAGG CGGGCTGTGA  
 GGTCGTTGAA  
 3241 ACAAGGTGGG GGGCATGGTG GGCGCAAGA ACCCAAGGTC TTGAGGCCTT  
 30 CGCTAATGCG  
 3301 GGAAAGCTCT TATTGGGTG AGATGGGCTG GGGCACCATC TGGGGACCC  
 GACGTGAAGT  
 3361 TTGTCACTGA CTGGAGAACT CGGTTGTGCG TCTGTTGCGG GGGCGGCAGT  
 TATGCGGTGC  
 35 3421 CGTTGGCAG TGCACCCGTA CCTTGGGAG CGCGGCCCT CGTCGTGTGC  
 TGACGTCACC  
 3481 CGTTCTGTTG GCTTATAATG CAGGGTGGGG CCACCTGCCG GTAGGTGTGC  
 GGTAGGCTTT  
 3541 TCTCCGTCGC AGGACGCAGG GTTGGGCCT AGGGTAGGCT CTCCGAATC  
 40 GACAGGCGCC  
 3601 GGACCTCTGG TGAGGGGAGG GATAAGTGAG GCGTCAGTTT CTTGGTCGG  
 TTTTATGTAC  
 3661 CTATCTCTT AAGTAGCTGA AGCTCCGGTT TTGAACATAG CGCTCGGGGT  
 TGGCGAGTGT  
 45 3721 GTTTGTGAA GTTTTTAGG CACCTTTGA AATGTAATCA TTTGGTCAA  
 TATGTAATT  
 3781 TCAGTGTAG ACTAGTAAAT TGTCCGCTAA ATTCTGGCCG TTTTGGCTT  
 TTTTGTAGA  
 3841 CGAAGCTAAC GCGCTAGCCG TTAATTAAGC CTCGAGGTGCG ACGGTATCGA  
 50 TAAGCTCGCT  
 3901 TCACGAGATT CCAGCAGGTC GAGGGACCTA ATAACCTCGT ATAGCATA  
 TTATACGAAG  
 3961 TTATATTAAG GTTCCAAGC TTAAGCGGCC GCGCCACCAT GGTGAGCAAG  
 GCGCAGGAGC  
 55 4021 TGTTCACCGG GGTGGTGCCTT ATCCCTGGTCG AGCTGGACGG CGACGTAAAC  
 GGCCACAAAGT  
 4081 TCAGCGTGTGTC CGCGAGGGC GAGGGCGATG CCACCTACGG CAAGCTGACC  
 CTGAAGTTCA

4141 TCTGCACCAAC CGGCAAGCTG CCCGTGCCCT GGCCCACCCCT CGTGACCACC  
 CTGACCTACG  
 4201 GCGTGCAGTG CTTCAGCCGC TACCCCGACC ACATGAAGCA GCACGACTTC  
 TTCAAGTCCG  
 5 4261 CCATGCCCGA AGGCTACGTC CAGGAGCGCA CCATCTCTT CAAGGACGAC  
 GGCAACTACA  
 4321 AGACCCGCGC CGAGGTGAAG TTCAAGGGCG ACACCCTGGT GAACCGCAGC  
 GAGCTGAAGG  
 4381 GCATCGACTT CAAGGAGGAC GGCAACATCC TGGGGCACAA GCTGGAGTAC  
 10 AACTACAACA  
 4441 GCCACAAACGT CTATATCATG GCCGACAAGC AGAAGAACGG CATCAAGGTG  
 AACTTCAAGA  
 4501 TCCGCCACAA CATCGAGGAC GGCAGCGTGC AGCTCGCCGA CCACTACCAG  
 CAGAACACCC  
 15 4561 CCATCGGCAGA CGGCCCGGTG CTGCTGCCCG ACAACCACCA CCTGAGCACC  
 CAGTCCGCC  
 4621 TGAGCAAAGA CCCCAACGAG AAGCCGATC ACATGGTCCT GCTGGAGTTC  
 GTGACCGCCG  
 4681 CCGGGATCAC TCTCGGCATG GACGAGCTGT ACAAGATGCA TGCCCCGGGA  
 20 TGGCGCGCCA  
 4741 TGGATCCGCG AATTCTCGA GGGACCTAAT AACTTCGTAT AGCATACTATT  
 ATACGAAGTT  
 4801 ATACATGTTT AAGGGTTCCG GTTCCACTAG GTACAATTAG ATATCAAGCT  
 TATCGATAAT  
 25 4861 CAACCTCTGG ATTACAAAAT TTGTGAAAGA TTGACTGGTA TTCTTAACCA  
 TGGTGCTCCT  
 4921 TTTACGCTAT GTGGATACGC TGCTTTAATG CCTTTGTATC ATGCTATTGC  
 TTCCCGTATG  
 4981 GCTTCATTT TCTCCTCCTT GTATAATCC TGGTTGCTGT CTCTTATGA  
 30 GGAGTTGTGG  
 5041 CCCGTTGTCA GGCAACGTGG CGTGGTGTGC ACTGTGTTTG CTGACGCAAC  
 CCCCACGTGGT  
 5101 TGGGGCATTG CCACCACCTG TCAGCTCCTT TCCGGGACTT TCGCTTCCC  
 CCTCCCTATT  
 35 5161 GCCACGGCGG AACTCATCGC CGCCTGCCTT GCCCGCTGCT GGACAGGGGC  
 TCGGCTGTTG  
 5221 GGCACTGACA ATTCCGTGGT GTTGTGGGG AAATCATCGT CCTTTCCCTTG  
 GCTGCTCGCC  
 5281 TGTGTTGCCA CCTGGATTCT GCGCGGGACG TCCTTCTGCT ACGTCCCTTC  
 40 GGCCCTCAAT  
 5341 CCAGCGGACC TTCCTTCCCG CGGCCTGCTG CCGGCTCTGC GGCTCTTCC  
 CGGTCTTCGC  
 5401 CTTCGCCCTC AGACGAGTCG GATCTCCCTT TGGGCCGCCT CCCCCATCG  
 ATACCGTCGA  
 45 5461 CCTCGATCGA GACCTAGAAA AACATGGAGC AATCACAAGT AGCAATACAG  
 CAGCTACCAA  
 5521 TGCTGATTGT GCCTGGCTAG AAGCACAAGA GGAGGAGGAG GTGGGTTTTC  
 CAGTCACACC  
 5581 TCAGGTACCT TTAAGACCAA TGACTTACAA GGCAGCTGTA GATCTTAGCC  
 50 ACTTTTTAAA  
 5641 AGAAAAGGGG GGACTGGAAG GGCTAATTCA CTCCCAACGA AGACAAGATA  
 TCCTTGATCT  
 5701 GTGGATCTAC CACACACAAG GCTACTTCCC TGATTGGCAG AACTACACAC  
 CAGGGCCAGG  
 55 5761 GATCAGATAT CCACTGACCT TTGGATGGTG CTACAAGCTA GTACCAGTTG  
 AGCAAGAGAA  
 5821 GGTAGAAGAA GCCAATGAAG GAGAGAACAC CCGCTTGTAA CACCCGTGA  
 GCCTGCATGG

5881 GATGGATGAC CGGGAGAGAG AAGTATTAGA GTGGAGGTTT GACAGCCGCC  
 TAGCATTTC  
 5941 TCACATGGCC CGAGAGCTGC ATCCGGACTG TACTGGGTCT CTCTGGTTAG  
 ACCAGATCTG  
 6001 AGCCTGGGAG CTCTCTGGCT AACTAGGGAA CCCACTGCTT AAGCCTCAAT  
 AAAGCTTGCC  
 6061 TTGAGTGCTT CAAGTAGTGT GTGCCCGTCT GTTGTGTGAC TCTGGTAACT  
 AGAGATCCCT  
 6121 CAGACCCTTT TAGTCAGTGT GGAAAATCTC TAGCAGCATG TGAGCAAAAG  
 10 GCCAGCAAAA  
 6181 GGCCAGGAAC CGTAAAAAAGG CCGCGTTGCT GGCGTTTTTC CATAGGCTCC  
 GCCCCCCCTGA  
 6241 CGAGCATCAC AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG  
 GACTATAAAG  
 15 6301 ATACCAGGCG TTTCCCCCTG GAAGCTCCCT CGTGCCTCT CTGTTCCGA  
 CCCTGCCGCT  
 6361 TACCGGATAC CTGTCCGCCT TTCTCCCTTC GGGAAAGCGTG GCGCTTTCTC  
 ATAGCTCACG  
 6421 CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG  
 20 TGCACGAACC  
 6481 CCCCGTTCAAG CCCGACCGCT GCGCCTTATC CGGTAACTAT CGTCTTGAGT  
 CCAACCCGGT  
 6541 AAGACACGAC TTATGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA  
 GAGCGAGGTA  
 25 6601 TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA  
 CTAGAAGAAC  
 6661 AGTATTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG  
 TTGGTAGCTC  
 6721 TTGATCCGGC AAACAAACCA CCGCTGGTAG CGGTGGTTTT TTTGTTGCA  
 30 AGCAGCAGAT  
 6781 TACGCCAGA AAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG  
 GGTCTGACGC  
 6841 TCAGTGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA  
 AAAGGATCTT  
 35 6901 CACCTAGATC CTTTAAATT AAAAATGAAG TTTAAATCA ATCTAAAGTA  
 TATATGAGTA  
 6961 AACTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG  
 CGATCTGTCT  
 7021 ATTCGTTCA TCCATAGTTG CCTGACTCCC CGTCGTGTAG ATAACACGA  
 40 TACGGGAGGG  
 7081 CTTACCATCT GGCCCCAGTG CTGCAATGAT ACCGCGAGAC CCACGCTCAC  
 CGGCTCCAGA  
 7141 TTTATCAGCA ATAAACCAGC CAGCCGGAAG GGCGAGCGC AGAAGTGGTC  
 CTGCAACTTT  
 45 7201 ATCCGCCTCC ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA  
 GTTCGCCAGT  
 7261 TAATAGTTG CGAACGTTG TTGCCATTGC TACAGGCATC GTGGTGTAC  
 GCTCGTCGTT  
 7321 TGGTATGGCT TCATTCAAGCT CCGGTTCCCA ACGATCAAGG CGAGTTACAT  
 50 GATCCCCCAT  
 7381 GTTGTGAAA AAAGCGGTTA GCTCCTTCGG TCCTCCGATC GTTGTCAAGAA  
 GTAAGTTGGC  
 7441 CGCAGTGTAA TCACTCATGG TTATGGCAGC ACTGCATAAT TCTCTTACTG  
 TCATGCCATC  
 55 7501 CGTAAGATGC TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG  
 AATAGTGTAT  
 7561 GCGGCGACCG AGTTGCTCTT GCCCGGGCGTC AATACGGGAT AATACCGCGC  
 CACATAGCAG

7621 AACTTTAAAAA GTGCTCATCA TTGGAAAACG TTCTTCGGGG CGAAAAACTCT  
CAAGGATCTT  
5 7681 ACCGCTGTTG AGATCCAGTT CGATGTAACC CACTCGTGCA CCCAACTGAT  
CTTCAGCATC  
7741 TTTTACTTTC ACCAGCGTTT CTGGGTGAGC AAAAACAGGA AGGCAAAATG  
CCGCAAAAAA  
7801 GGGAAATAAGG GCGACACCGA AATGTTGAAT ACTCATAACTC TTCCCTTTTC  
AATATTATTG  
10 7861 AAGCATTAT CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA  
TTTAGAAAAA  
7921 TAAACAAATA GGGGTTCCGC GCACATTCC CCGAAAAGTG CCACCTGAC  
//  
15 (SEQ ID NO: 6)

## [00350] pLL3.5

5 LOCUS PLL3.5.GB 7927 BP DS-DNA CIRCULAR SYN 23-JAN-  
 2002  
 DEFINITION -  
 ACCESSION -  
 KEYWORDS -  
 SOURCE -  
 10 FEATURES Location/Qualifiers  
 promoter 212..816  
 /note="CMV promoter/enhancer 1"  
 misc\_recomb 4727..4760  
 /note="LoxP"  
 15 promoter 2632..3841  
 /note="Ubc promoter"  
 gene 6934..7794  
 /note="AmpR"  
 20 rep\_origin 6116..6789  
 /note="pUC"  
 misc\_recomb 3931..3966  
 /note="LoxP"  
 LTR 835..1509  
 /note="5' HIV R-U5-del gag (HIV NL4-3/454-1126)"  
 25 misc\_feature 1539..2396  
 /note="HIV RRE (HIV NL4-3/7622-8459)"  
 misc\_feature 2422..2599  
 /note="HIV Flap"  
 30 misc\_feature 4815..5404  
 /note="WRE element"  
 LTR 5424..6113  
 /note="3' SIN LTR"  
 gene 3993..4673  
 /note="dsRed2"  
 35 BASE COUNT 1958 A 1925 C 2151 G 1893 T 0 OTHER  
 ORIGIN -  
 1 GTCGACGGAT CGGGAGATCT CCCGATCCCC TATGGTGCAC TCTCAGTACA  
 ATCTGCTCTG  
 40 61 ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT GTTGGAGGTC  
 GCTGAGTAGT  
 121 GCGCGAGCAA AATTAAAGCT ACAACAAGGC AAGGCTTGAC CGACAATTGC  
 ATGAAGAAC  
 181 TGCTTAGGGT TAGGCCTTT GCGCTGCTTC GCGATGTACG GGCCAGATAT  
 ACGCGTTGAC  
 45 241 ATTGATTATT GACTAGTTAT TAATAGTAAT CAATTACGGG GTCATTAGTT  
 CATAGCCCCAT  
 301 ATATGGAGTT CCGCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA  
 CCGCCCCAACG  
 361 ACCCCCCGCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA  
 50 ATAGGGACTT  
 421 TCCATTGACG TCAATGGGTG GAGTATTAC GGTAAACTGC CCACTTGGCA  
 GTACATCAAG  
 481 TGTATCATAT GCCAAGTACG CCCCCCTATTG ACGTCAATGA CGGTAAATGG  
 CCCGCCTGGC  
 55 541 ATTATGCCCA GTACATGACC TTATGGACT TTCCTACTTG GCAGTACATC  
 TACGTATTAG  
 601 TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT CAATGGCGT  
 GGATAGCGGT

661 TTGACTCACG GGGATTTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT  
 TTGTTTGCGC  
 721 ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC CGCCCCATTG  
 ACGCAAATGG  
 5 781 GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGCGC GTTTGCCTG  
 TACTGGGTCT  
 841 CTCTGGTTAG ACCAGATCTG AGCCTGGAG CTCTCTGGCT AACTAGGGAA  
 CCCACTGCTT  
 901 AAGCCTCAAT AAAGCTTGCC TTGAGTGCTT CAAGTAGTGT GTGCCCGTCT  
 10 GTTGTGTGAC  
 961 TCTGGTAACT AGAGATCCCT CAGACCCTTT TAGTCAGTGT GGAAAATCTC  
 TAGCAGTGGC  
 1021 GCCCCAACAG GGACTTGAAA GCGAAAGGGA AACCAAGAGGA GCTCTCTCGA  
 CGCAGGACTC  
 15 1081 GGCTTGCTGA AGCGCGCACG GCAAGAGGCG AGGGGCGGCG ACTGGTGAGT  
 ACGCCAAAAA  
 1141 TTTTGACTAG CGGAGGCTAG AAGGAGAGAG ATGGGTGCGA GAGCGTCAGT  
 ATTAAGCGGG  
 1201 GGAGAATTAG ATCGCGATGG GAAAAAAATTC GGTAAAGGCC AGGGGGAAAG  
 20 AAAAAATATA  
 1261 AATTAAAACA TATAGTATGG GCAAGCAGGG AGCTAGAACG ATTGCAGTT  
 AATCCTGGCC  
 1321 TGTTAGAAC ATCAGAAGGC TGAGACAAA TACTGGACA GCTACAACCA  
 TCCCTTCAGA  
 25 1381 CAGGATCAGA AGAACTTAGA TCATTATATA ATACAGTAGC AACCTCTAT  
 TGTGTGCATC  
 1441 AAAGGATAGA GATAAAAGAC ACCAAGGAAG CTTTAGACAA GATAGAGGAA  
 GAGCAAAACA  
 1501 AAAGTAAGAC CACCGCACAG CAAGCGGCCG GCCCGCCTGA TCTTCAGACC  
 30 TGGAGGAGGA  
 1561 GATATGAGGG ACAATTGGAG AAGTGAATTA TATAAATATA AAGTAGTAAA  
 AATTGAACCA  
 1621 TTAGGAGTAG CACCCACCAA GGCAAAGAGA AGAGTGGTGC AGAGAGAAAA  
 AAGAGCAGTG  
 35 1681 GGAATAGGAG CTTTGTCTCT TGTTGCTCTTG GGAGCAGCAG GAAGCACTAT  
 GGGCGCAGCG  
 1741 TCAATGACGC TGACGGTACA GGCCAGACAA TTATTGTCTG GTATAGTGCA  
 GCAGCAGAAC  
 1801 AATTGCTGA GGGCTATTGA GGCGAACAG CATCTGTTGC AACTCACAGT  
 40 CTGGGGCATC  
 1861 AAGCAGCTCC AGGCAAGAAT CCTGGCTGTG GAAAGATACC TAAAGGATCA  
 ACAGCTCTG  
 1921 GGGATTGGGG GTTGCTCTGG AAAACTCATT TGCAACCACTG CTGTGCCTTG  
 GAATGCTAGT  
 45 1981 TGGAGTAATA AATCTCTGGA ACAGATTGG AATCACACGA CCTGGATGGA  
 GTGGGACAGA  
 2041 GAAATTAACA ATTACACAAG CTTAATACAC TCCTTAATTG AAGAATCGCA  
 AAACCAGCAA  
 2101 GAAAAGAATG AACAGAATT ATTGGAATTA GATAAATGGG CAAGTTGTG  
 50 GAATTGGTTT  
 2161 AACATAACAA ATTGGCTGTG GTATATAAAA TTATTCTAA TGATAGTAGG  
 AGGCTTGGTA  
 2221 GGTGTTAAGAA TAGTTTTGC TGTACTTTCT ATAGTGAATA GAGTTAGGCA  
 GGGATATTCA  
 55 2281 CCATTATCGT TTCAGACCCA CCTCCCAACC CCGAGGGGAC CCGACAGGCC  
 CGAAGGAATA  
 2341 GAAGAAGAAG GTGGAGAGAG AGACAGAGAC AGATCCATTG GATTAGTGAA  
 CGGATCGGCA

2401 CTGCGTGCAG CAATTCTGCA GACAAATGGC AGTATTCAATC CACAATTTA  
 AAAGAAAAGG  
 2461 GGGGATTGGG GGGTACAGTG CAGGGGAAAG AATAGTAGAC ATAATAGCAA  
 CAGACATACA  
 5 2521 AACTAAAGAA TTACAAAAAC AAATTACAAA AATTCAAAAT TTTCGGGTTT  
 ATTACAGGAA  
 2581 CAGCAGAGAT CCAGTTGGT TAGTACCGGG CCCGCTCTAG ACGGTTGATC  
 TGGCCTCCGC  
 2641 GCCGGGTTTT GGCGCCTCCC GCAGGGCGCCC CCCTCCTCAC GGCGAGCGCT  
 10 GCCACGTCAG  
 2701 ACGAAGGGCG CAGGAGCGTC CTGATCCTTC CGCCCGGACG CTCAGGACAG  
 CGGCCCGCTG  
 2761 CTCATAAGAC TCGGCCTAG AACCCAGTA TCAGCAGAAG GACATTTAG  
 GACGGGACTT  
 15 2821 GGGTGACTCT AGGGCACTGG TTTTCTTCC AGAGAGCGGA ACAGGCGAGG  
 AAAAGTAGTC  
 2881 CCTTCTCGGC GATTCTGCAG AGGGATCTCC GTGGGGCGGT GAACGCCGAT  
 GATTATATAA  
 2941 GGACCGCGCCG GGTGTGGCAC AGCTAGTTCC GTGCAGCCG GGATTTGGGT  
 20 CGCGGTTCTT  
 3001 GTTTGTGGAT CGCTGTGATC GTCACTTGGT GAGTAGCGGG CTGCTGGGCT  
 GGCCGGGGCT  
 3061 TTCTGGCCG CCGGGCCGCT CGGTGGGACG GAAGCGTGTG GAGAGACCGC  
 CAAGGGCTGT  
 25 3121 AGTCTGGTC CGCGAGCAAG GTTGCCTGA ACTGGGGTT GGGGGGAGCG  
 CAGCAAAATG  
 3181 GCGGCTGTT CCGAGTCTTG AATGGAAGAC GCTTGTGAGG CGGGCTGTGA  
 GGTCGTTGAA  
 3241 ACAAGGTGGG GGGCATGGTG GGCGGCAAGA ACCCAAGGTC TTGAGGCCTT  
 30 CGCTAATGCG  
 3301 GGAAAGCTCT TATTGGGTG AGATGGGCTG GGGCACCATC TGGGGACCC  
 GACGTGAAGT  
 3361 TTGTCACTGA CTGGAGAACT CGGTTGTCG TCTGTTGCAG GGGCGGCAGT  
 35 TATGCGGTGCA  
 3421 CGTTGGGCAG TGCACCCGTA CCTTTGGGAG CGCGCGCCCT CGTCGTGTG  
 TGACGTCACC  
 3481 CGTTCTGTTG GCTTATAATG CAGGGTGGGG CCACCTGCCG GTAGGTGTGC  
 GGTAGGCTTT  
 3541 TCTCCGTCGC AGGACGCAGG GTTCGGGCCT AGGGTAGGCT CTCCTGAATC  
 40 GACAGGCGCC  
 3601 GGACCTCTGG TGAGGGGAGG GATAAGTGAG GCGTCAGTTT CTTTGGTCGG  
 TTTTATGTAC  
 3661 CTATCTCTT AAGTAGCTGA AGCTCCGGTT TTGAACATAG CGCTCGGGGT  
 TGGCGAGTGT  
 45 3721 GTTTTGAA GTTTTTAGG CACTTTGAA AATGTAATCA TTTGGGTCAA  
 TATGTAATT  
 3781 TCAGTGTAG ACTAGTAAAT TGTCCGCTAA ATTCTGGCCG TTTTTGGCTT  
 TTTTGTAGA  
 3841 CGAAGCTAAC GCGCTAGCCG TTAATTAAGC CTCGAGGTGCG ACGGTATCGA  
 50 TAAGCTCGCT  
 3901 TCACGAGATT CCAGCAGGTC GAGGGACCTA ATAACCTCGT ATAGCATA  
 TTATACGAAG  
 3961 TTATATTAAG GTTCCAAGC TTAAGCGGCC GCGCCACCAG GGCCTCCTCC  
 GAGAACGTCA  
 55 4021 TCACCGAGTT CATGCGCTTC AAGGTGCGCA TGGAGGGCAC CGTGAACGGC  
 CACGAGTTCG  
 4081 AGATCGAGGG CGAGGGCGAG GGCGCCCCCT ACGAGGGCCA CAACACCGTG  
 AAGCTGAAGG

4141 TGACCAAGGG CGGCCCTG CCCTCGCCT GGGACATCCT GTCCCCCAG  
 TTCCAGTACG  
 4201 GCTCCAAGGT GTACGTGAAG CACCCCGCCG ACATCCCCGA CTACAAGAAG  
 CTGTCCCTTC  
 5 4261 CCGAGGGCTT CAAGTGGAG CGCGTGATGA ACTTCGAGGA CGCGGGCGTG  
 GCGACCGTGA  
 4321 CCCAGGACTC CTCCCTGCAG GACGGCTGCT TCATCTACAA GGTGAAGTTC  
 ATCGGCGTGA  
 4381 ACTTCCCCCTC CGACGGCCCC GTGATGCAGA AGAAGACCAT GGGCTGGAG  
 10 GCCTCCACCG  
 4441 AGCGCCTGTA CCCCCCGCAG GGCCTGCTGA AGGGCGAGAC CCACAAGGCC  
 CTGAAGCTGA  
 4501 AGGACGGCGG CCACTACCTG GTGGAGTTCA AGTCCATCTA CATGGCCAAG  
 AAGCCCGTGC  
 15 4561 AGCTGCCCGG CTACTACTAC GTGGACGCCA AGCTGGACAT CACCTCCAC  
 AACGAGGACT  
 4621 ACACCATCGT GGAGCAGTAC GAGCGCACCG AGGGCCGCCA CCACCTGTT  
 CTGATGCATG  
 4681 CCCCGGGATG GCGCGCCATG GATCCCGAA TTCGTCGAGG GACCTAATAA  
 20 CTTCGTATAG  
 4741 CATACTATTACGAAAGTTAT ACATGTTAA GGGTTCCGGT TCCACTAGGT  
 ACAATTGAT  
 4801 ATCAAGCTTA TCGATAATCA ACCTCTGGAT TACAAAATTT GTGAAAGATT  
 GACTGGTATT  
 25 4861 CTTAACTATG TTGCTCCTTT TACGCTATGT GGATACGCTG CTTTAATGCC  
 TTTGTATCAT  
 4921 GCTATTGCTT CCCGTATGGC TTTCAATTTC TCCTCCTTGT ATAAATCCTG  
 GTTGCTGTCT  
 4981 CTTTATGAGG AGTTGTGGCC CGTTGTCAGG CAACGTGGCG TGGTGTGCAC  
 30 TGTGTTGCT  
 5041 GACGCAACCC CCACTGGTTG GGGCATTGCC ACCACCTGTC AGCTCCTTTC  
 CGGGACTTT  
 5101 GCTTTCCCCC TCCCTATTGC CACGGCGAA CTCATGCCG CCTGCCCTGC  
 CCGCTGCTGG  
 35 5161 ACAGGGGCTC GGCTGTTGGG CACTGACAAT TCCGTGGTGT TGTCGGGAA  
 ATCATCGTCC  
 5221 TTTCTTGGC TGCTCGCCTG TGTTGCCACC TGGATTCTGC GCGGACGTC  
 CTTCTGCTAC  
 5281 GTCCCTTCGG CCCTCAATCC AGCGGACCTT CCTTCCCGCG GCCTGCTGCC  
 40 GGCTCTGCGG  
 5341 CCTCTTCCGC GTCTTCGCCT TCGCCCTCAG ACGAGTCGGA TCTCCCTTG  
 GGCCGCCTCC  
 5401 CCGCATCGAT ACCGTCGACC TCGATCGAGA CCTAGAAAAA CATGGAGCAA  
 TCACAAGTAG  
 45 5461 CAATACAGCA GCTACCAATG CTGATTGTGC CTGGCTAGAA GCACAAGAGG  
 AGGAGGAGGT  
 5521 GGGTTTCCA GTCACACCTC AGGTACCTTT AAGACCAATG ACTTACAAGG  
 CAGCTGTAGA  
 5581 TCTTAGCCAC TTTTAAAAG AAAAGGGGG ACTGGAAGGG CTAATTCACT  
 50 CCCAACGAAG  
 5641 ACAAGATATC CTTGATCTGT GGATCTACCA CACACAAGGC TACTCCCTG  
 ATTGGCAGAA  
 5701 CTACACACCA GGGCCAGGGA TCAGATATCC ACTGACCTT GGATGGTGCT  
 55 ACAAGCTAGT  
 5761 ACCAGTTGAG CAAGAGAAGG TAGAAGAAGC CAATGAAGGA GAGAACACCC  
 GCTTGTACA  
 5821 CCCTGTGAGC CTGCATGGGA TGGATGACCC GGAGAGAGAA GTATTAGAGT  
 GGAGGTTGA

5881 CAGCCGCCTA GCATTTCATC ACATGGCCCG AGAGCTGCAT CCGGACTGTA  
 CTGGGTCTCT  
 5941 CTGGTTAGAC CAGATCTGAG CCTGGGAGCT CTCTGGCTAA CTAGGGAAACC  
 CACTGCTTAA  
 5 6001 GCCTCAATAA AGCTTGCCCTT GAGTGCTTCA AGTAGTGTGT GCCCGTCTGT  
 TGTGTGACTC  
 6061 TGGTAACTAG AGATCCCTCA GACCCTTTA GTCAGTGTGG AAAATCTCTA  
 GCAGGCATGTG  
 6121 AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAAGGCC GCGTTGCTGG  
 10 CGTTTTTCCA  
 6181 TAGGCTCCGC CCCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA  
 GGTGGCGAAA  
 6241 CCCGACAGGA CTATAAAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG  
 TGCCTCTCC  
 15 6301 TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG  
 GAAGCGTGGC  
 6361 GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTCGGTG TAGGTCGTT  
 GCTCCAAGCT  
 6421 GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG  
 20 GTAACTATCG  
 6481 TCTTGAGTCC AACCCGGTAA GACACGACTT ATGCCACTG GCAGCAGCCA  
 CTGGTAACAG  
 6541 GATTAGCAGA GCGAGGTATG TAGGCAGGTGC TACAGAGTTC TTGAAGTGGT  
 GGCCTAACTA  
 25 6601 CGGCTACACT AGAAGAACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG  
 TTACCTTCGG  
 6661 AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAAACCACC GCTGGTAGCG  
 GTGGTTTTTT  
 6721 TGTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC  
 30 CTTTGATCTT  
 6781 TTCTACGGGG TCTGACGCTC AGTGGAACGA AAAACTCACGT TAAGGGATTT  
 TGGTCATGAG  
 6841 ATTATCAAAA AGGATCTTCAGA CCTAGATCCT TTTAAATTAA AAATGAAGTT  
 TTAAATCAAT  
 35 6901 CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA  
 GTGAGGCACC  
 6961 TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC TGACTCCCCG  
 TCGTGTAGAT  
 7021 AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT GCAATGATAC  
 40 CGCGAGACCC  
 7081 ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGGAAGGG  
 CCGAGCGCAG  
 7141 AAGTGGCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT AATTGTTGCC  
 GGGAAAGCTAG  
 7201 AGTAAGTAGT TCGCCAGTTA ATAGTTGCG CAACGTTGTT GCCATTGCTA  
 45 CAGGCATCGT  
 7261 GGTGTCACGC TCGTCGTTG GTATGGCTTC ATTCAAGCTCC GGTTCCCAAC  
 GATCAAGGCG  
 7321 AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC  
 50 CTCCGATCGT  
 7381 TGTCAGAAAGT AAGTTGGCCG CAGTGTATC ACTCATGGTT ATGGCAGCAC  
 TGCATAATTG  
 7441 TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT  
 CAACCAAGTC  
 55 7501 ATTCTGAGAA TAGTGTATGC GGCGACCGAG TTGCTCTTGC CCGGCGTCAA  
 TACGGGATAA  
 7561 TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAAACGTT  
 CTTCGGGGCG

7621 AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA  
CTCGTGCACC  
5 7681 CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTCT GGGTGAGCAA  
AACAGGAAG  
7741 GCAAAATGCC GCAAAAAAGG GAATAAGGGC GACACGGAAA TGTGAATAC  
TCATACTCTT  
7801 CCTTTTCAA TATTATTGAA GCATTATCA GGGTTATTGT CTCATGAGCG  
GATACATATT  
10 7861 TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC  
GAAAAGTGCC  
7921 ACCTGAC  
//  
15 (SEQ ID NO: 7)

## [00351] pLL3.6

|       |              |  |          |        |         |         |
|-------|--------------|--|----------|--------|---------|---------|
| LOCUS | PLENTILOX    | 7350 BP DS-DNA   | CIRCULAR | SYN    | 23-JAN- |         |
| 2002  |              |  |          |        |         |         |
| 5     | DEFINITION   | -  |          |        |         |         |
|       | ACCESSION    | -  |          |        |         |         |
|       | KEYWORDS     | -  |          |        |         |         |
|       | SOURCE       | -  |          |        |         |         |
| 10    | FEATURES     | Location/Qualifiers  |          |        |         |         |
|       | promoter     | 212..816   |          |        |         |         |
|       |              | /note="CMV promoter/enhancer 1"                            |          |        |         |         |
|       | promoter     | 2799..3387   |          |        |         |         |
|       |              | /note="CMV"  |          |        |         |         |
| 15    | gene         | 6357..7217   |          |        |         |         |
|       |              | /note="AmpR"   |          |        |         |         |
|       | rep_origin   | 5539..6212   |          |        |         |         |
|       |              | /note="pUC"  |          |        |         |         |
|       | misc_recomb  | 2710..2745   |          |        |         |         |
|       |              | /note="Lox 1"  |          |        |         |         |
| 20    | misc_recomb  | 4150..4183   |          |        |         |         |
|       |              | /note="LoxP"   |          |        |         |         |
|       | LTR          | 835..1509  |          |        |         |         |
|       |              | /note="5' HIV R-U5-del gag (HIV NL4-3/454-1126)"           |          |        |         |         |
| 25    | misc_feature | 1539..2396   |          |        |         |         |
|       |              | /note="HIV RRE (HIV NL4-3/7622-8459)"                      |          |        |         |         |
|       | misc_feature | 2422..2599   |          |        |         |         |
|       |              | /note="HIV Flap"   |          |        |         |         |
|       | misc_feature | 4238..4827   |          |        |         |         |
| 30    | LTR          | 4847..5536   |          |        |         |         |
|       |              | /note="3' SIN LTR"   |          |        |         |         |
|       | frag         | 2772..4130   |          |        |         |         |
|       |              | /note="1 to 1359 of Untitled1"                             |          |        |         |         |
| 35    | frag         | 2772..2798   |          |        |         |         |
|       |              | /note="4705 to 4731 of pEGFP-C1"                           |          |        |         |         |
|       | frag         | 2799..4127   |          |        |         |         |
|       |              | /note="1 to 1329 of pEGFP-C1"                              |          |        |         |         |
|       | gene         | 3404..4127   |          |        |         |         |
|       |              | /note="EGFP"   |          |        |         |         |
| 40    | BASE COUNT   | 1939 A   | 1795 C   | 1862 G | 1754 T  | 0 OTHER |
|       | ORIGIN       | -  |          |        |         |         |
|       |              | 1 GTCGACGGAT CGGGAGATCT CCCGATCCCC TATGGTGCAC TCTCAGTACA   |          |        |         |         |
|       |              | ATCTGCTCTG   |          |        |         |         |
|       |              | 61 ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT GTTGGAGGTC  |          |        |         |         |
| 45    | GCTGAGTAGT   |  |          |        |         |         |
|       |              | 121 GCGCGAGCAA AATTTAAGCT ACAACAAGGC AAGGCTTGAC CGACAATTGC |          |        |         |         |
|       |              | ATGAAGAAC  |          |        |         |         |
|       |              | 181 TGCTTAGGGT TAGGCGTTTT GCGCTGCTTC GCGATGTACG GGCCAGATAT |          |        |         |         |
|       |              | ACGCCTTGAC   |          |        |         |         |
| 50    |              | 241 ATTGATTATT GACTAGTTAT TAATAGTAAT CAATTACGGG GTCATTAGTT |          |        |         |         |
|       |              | CATAGCCCCAT  |          |        |         |         |
|       |              | 301 ATATGGAGTT CCGCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA |          |        |         |         |
|       |              | CCGCCCAACG   |          |        |         |         |
|       |              | 361 ACCCCCCGCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA |          |        |         |         |
| 55    | ATAGGGACTT   |  |          |        |         |         |
|       |              | 421 TCCATTGACG TCAATGGGTG GAGTATTAC GGTAAACTGC CCACTTGGCA  |          |        |         |         |
|       |              | GTACATCAAG   |          |        |         |         |

481 TGTATCATAT GCCAAGTACG CCCCCTATTG ACGTCAATGA CGGTAAATGG  
 CCCGCCTGGC  
 541 ATTATGCCCA GTACATGACC TTATGGGACT TTCCTACTTG GCAGTACATC  
 TACGTATTAG  
 5 601 TCATCGCTAT TACCATGGTG ATGCCGTTTT GGCAGTACAT CAATGGCGT  
 GGATAGCGGT  
 661 TTGACTCACG GGGATTTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT  
 TTGTTTGGC  
 721 ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC CGCCCCATTG  
 10 ACGCAAATGG  
 781 GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGCGC GTTTGCCTG  
 TACTGGGTCT  
 841 CTCTGGTTAG ACCAGATCTG AGCCTGGAG CTCTCTGGCT AACTAGGGAA  
 CCCACTGCTT  
 15 901 AAGCCTCAAT AAAGCTTGCC TTGAGTGCTT CAAGTAGTGT GTGCCCGTCT  
 GTTGTGTGAC  
 961 TCTGGTAAC AGAGATCCCT CAGACCCTTT TAGTCAGTGT GGAAAATCTC  
 TAGCAGTGGC  
 1021 GCCCCAACAG GGACTTGAAA GCGAAAGGGA AACCAGAGGA GCTCTCTCGA  
 20 CGCAGGACTC  
 1081 GGCTTGCTGA AGCGCGCACG GCAAGAGGCG AGGGGCGGCG ACTGGTGAGT  
 ACGCCAAAAA  
 1141 TTTTGACTAG CGGAGGCTAG AAGGAGAGAG ATGGGTGCGA GAGCGTCAGT  
 ATTAAGCGGG  
 25 1201 GGAGAATTAG ATCGCGATGG GAAAAAAATTC GGTAAAGGCC AGGGGGAAAG  
 AAAAAAATATA  
 1261 AATTAAAACA TATAGTATGG GCAAGCAGGG AGCTAGAACG ATTGCGAGTT  
 AATCCTGGCC  
 1321 TGTTAGAAC ATCAGAAGGC TGTAGACAAA TACTGGGACA GCTACAACCA  
 30 TCCCTTCAGA  
 1381 CAGGATCAGA AGAACTTAGA TCATTATATA ATACAGTAGC AACCTCTAT  
 TGTGTGCATC  
 1441 AAAGGATAGA GATAAAAGAC ACCAAGGAAG CTTTAGACAA GATAGAGGAA  
 GAGCAAAACA  
 35 1501 AAAGTAAGAC CACCGCACAG CAAGCGGCCG GCCCGCCTGA TCTTCAGACC  
 TGGAGGAGGA  
 1561 GATATGAGGG ACAATTGGAG AAGTGAATTA TATAAAATATA AAGTAGTAAA  
 AATTGAACCA  
 1621 TTAGGAGTAG CACCCACCAA GGCAAAGAGA AGAGTGGTGC AGAGAGAAAA  
 40 AAGAGCAGTG  
 1681 GGAATAGGAG CTTTGTTCCT TGGGTTCTTG GGAGCAGCAG GAAGCACTAT  
 GGGCGCAGCG  
 1741 TCAATGACGC TGACGGTACA GGCCAGACAA TTATTGTCTG GTATAGTGCA  
 GCAGCAGAAC  
 45 1801 AATTTGCTGA GGGCTATTGA GGCGAACAG CATCTGTTGC AACTCACAGT  
 CTGGGGCATC  
 1861 AAGCAGCTCC AGGCAAGAAT CCTGGCTGTG GAAAGATACC TAAAGGATCA  
 ACAGCTCTG  
 1921 GGGATTTGGG GTTGCTCTGG AAAACTCATT TGCACCACTG CTGTGCCTTG  
 50 GAATGCTAGT  
 1981 TGGAGTAATA AATCTCTGGA ACAGATTGG AATCACACGA CCTGGATGGA  
 GTGGGACAGA  
 2041 GAAATTAACA ATTACACAAG CTTAATACAC TCCTTAATTG AAGAATCGCA  
 AAACCAACAA  
 55 2101 GAAAAGAATG AACAAAGAATT ATTGGAATTA GATAAAATGGG CAAGTTTGTG  
 GAATTGGTTT  
 2161 AACATAACAA ATTGGCTGTG GTATATAAAA TTATTCTAA TGATAGTAGG  
 AGGCTTGGTA

2221 GGTTTAAGAA TAGTTTTGC TGTACTTCT ATAGTGAATA GAGTTAGGCA  
 GGGATATTCA  
 2281 CCATTATCGT TTCAGACCCA CCTCCCAACC CCGAGGGGAC CCGACAGGCC  
 CGAAGGAATA  
 5 2341 GAAGAAGAAG GTGGAGAGAG AGACAGAGAC AGATCCATTG GATTAGTGAA  
 CGGATCGGCA  
 2401 CTGCGTGCAG CAATTCTGCA GACAAATGGC AGTATTGATC CACAATTAA  
 AAAGAAAAGG  
 2461 GGGGATTGGG GGGTACAGTG CAGGGAAAG AATAGTAGAC ATAATAGCAA  
 10 CAGACATACA  
 2521 AACTAAAGAA TTACAAAAAC AAATTACAAA AATTCAAAAT TTTCGGGTTT  
 ATTACAGGGA  
 2581 CAGCAGAGAT CCAGTTGGT TAGTACCGGG CCCGCTCTAG ACGGTTAACG  
 CGCTAGCCGT  
 15 2641 TAATTAAGCC TCGAGGTCGA CGGTATCGAT AAGCTCGCTT CACGAGATTC  
 CAGCAGGTG  
 2701 AGGGACCTAA TAACCTCGTA TAGCATACAT TATACGAAGT TATATTAAGG  
 GTTCCAAGCT  
 2761 TAAGCGGCCG CGTGGATAAC CGTATTACCG CCATGCATTA GTTATTAATA  
 20 GTAATCAATT  
 2821 ACGGGGTCAT TAGTTCATAG CCCATATATG GAGTTCCGCG TTACATAACT  
 TACGGTAAAT  
 2881 GGCCCGCCTG GCTGACCGCC CAACGACCCC CGCCCATTGA CGTCAATAAT  
 GACGTATGTT  
 25 2941 CCCATAGTAA CGCCAATAGG GACTTCCAT TGACGTCAAT GGGTGGAGTA  
 TTACGGTAA  
 3001 ACTGCCACT TGGCAGTACA TCAAGTGTAT CATATGCCAA GTACGCCCC  
 TATTGACGTC  
 3061 AATGACGGTA AATGGCCCGC CTGGCATTAT GCCCAGTACA TGACCTTATG  
 30 GGACTTTCCCT  
 3121 ACTTGGCAGT ACATCTACGT ATTAGTCATC GCTATTACCA TGGTGATGCG  
 GTTTTGGCAG  
 3181 TACATCAATG GGCCTGGATA GCGGTTTGAC TCACGGGAT TTCCAAGTCT  
 CCACCCATT  
 3241 GACGTCAATG GGAGTTGTT TTGGCACCAA AATCAACGGG ACTTTCCAAA  
 35 ATGTCGTAAC  
 3301 AACTCCGCC CATTGACGCA AATGGCGGT AGGCGTGTAC GGTGGGAGGT  
 CTATATAAGC  
 3361 AGAGCTGGTT TAGTGAACCG TCAGATCCGC TAGCGCTACC GGTGCCACC  
 40 ATGGTGAGCA  
 3421 AGGGCGAGGA GCTGTTCACC GGGGTGGTGC CCATCCTGGT CGAGCTGGAC  
 GGGCAGCTAA  
 3481 ACGGCCACAA GTTCAGCGTG TCCGGCGAGG GCGAGGGCGA TGCCACCTAC  
 GGCAAGCTGA  
 45 3541 CCCTGAAGTT CATCTGCACC ACCGGCAAGC TGCCCGTGCC CTGGCCACC  
 CTCGTGACCA  
 3601 CCCTGACCTA CGCGTGCAG TGCTTCAGCC GCTACCCCGA CCACATGAAG  
 CAGCAGCTGA  
 3661 TCTTCAAGTC CGCCATGCC GAAGGCTACG TCCAGGAGCG CACCATCTTC  
 50 TTCAAGGACG  
 3721 ACGGCAACTA CAAGACCCGC GCCGAGGTGA AGTCGAGGG CGACACCTG  
 GTGAACCGCA  
 3781 TCGAGCTGAA GGGCATCGAC TTCAAGGAGG ACGGCAACAT CCTGGGGCAC  
 AAGCTGGAGT  
 55 3841 ACAACTACAA CAGCCACAAC GTCTATATCA TGGCCGACAA GCAGAAGAAC  
 GGCATCAAGG  
 3901 TGAACCTCAA GATCCGCCAC AACATCGAGG ACGGCAGCGT GCAGCTCGCC  
 GACCACTACC

3961 AGCAGAACAC CCCCCATCGGC GACGGCCCCG TGCTGCTGCC CGACAACCAC  
 TACCTGAGCA  
 4021 CCCAGTCCGC CCTGAGCAAA GACCCCAACG AGAAGCGCGA TCACATGGTC  
 CTGCTGGAGT  
 5 4081 TCGTGACCGC CGCCGGGATC ACTCTCGGCA TGGACGAGCT GTACAAGTAG  
 GAATTCTCGC  
 4141 AGGGACCTAA TAACTTCGTA TAGCATAACAT TATACTGAAGT TATACTGTT  
 TAAGGGTTCC  
 4201 GGTTCCACTA GGTACAATTG GATATCAAGC TTATCGATAA TCAACCTCTG  
 10 GATTACAAAA  
 4261 TTTGTGAAAG ATTGACTGGT ATTCTTAACT ATGTTGCTCC TTTTACGCTA  
 TGTGGATACG  
 4321 CTGCTTTAAT GCCTTTGTAT CATGCTATTG CTTCCCGTAT GGCTTTCATT  
 TTCTCCTCCT  
 15 4381 TGTATAAACAT CTGGTTGCTG TCTCTTATG AGGAGTTGTG GCCCGTTGTC  
 AGGCAACGTG  
 4441 GCGTGGTGTG CACTGTGTT GCTGACGCAA CCCCCACTGG TTGGGGCATT  
 GCCACCACCT  
 4501 GTCAGCTCCT TTCCGGGACT TTCGCTTCC CCCTCCCTAT TGCCACGGCG  
 20 GAACTCATCG  
 4561 CGGCCTGCCT TGCCCGCTGC TGGACAGGGG CTCGGCTGTT GGGCACTGAC  
 AATTCCGTGG  
 4621 TGTTGTCGGG GAAATCATCG TCCTTCCTT GGCTGCTCGC CTGTGTTGCC  
 ACCTGGATTC  
 25 4681 TGCAGGGGAC GTCCTCTGC TACGTCCCTT CGGCCCTCAA TCCAGCGGAC  
 CTTCCCTCCCC  
 4741 GCGGCCTGCT GCCGGCTCTG CGGCCTCTTC CGCGTCTTCG CCTTCGCCCT  
 CAGACGAGTC  
 4801 GGATCTCCCT TTGGGCCGCC TCCCCGCATC GATACCGTCG ACCTCGATCG  
 30 AGACCTAGAA  
 4861 AAACATGGAG CAATCACAAG TAGCAATACA GCAGCTACCA ATGCTGATTG  
 TGCCTGGCTA  
 4921 GAAGCACAAG AGGAGGAGGA GGTGGGTTTT CCAGTCACAC CTCAGGTACC  
 TTTAAGACCA  
 35 4981 ATGACTTACA AGGCAGCTGT AGATCTTAGC CACTTTTAA AAGAAAAGGG  
 GGGACTGGAA  
 5041 GGGCTAATTC ACTCCCAACG AAGACAAGAT ATCCTTGATC TGTGGATCTA  
 CCACACACAA  
 5101 GGCTACTTCC CTGATTGGCA GAACTACACA CCAGGGCCAG GGATCAGATA  
 40 TCCACTGACC  
 5161 TTTGGATGGT GCTACAAGCT AGTACCAAGTT GAGCAAGAGA AGGTAGAAGA  
 AGCCAATGAA  
 5221 GGAGAGAACCA CCCGCTTGTT ACACCCGTG AGCCTGCATG GGATGGATGA  
 CCCGGAGAGA  
 45 5281 GAAGTATTAG AGTGGAGGTT TGACAGCCGC CTAGCATTTC ATCACATGGC  
 CCGAGAGCTG  
 5341 CATCCGGACT GTACTGGTC TCTCTGGTTA GACCAGATCT GAGCCTGGGA  
 GCTCTCTGGC  
 5401 TAACTAGGGA ACCCACTGCT TAAGCCTCAA TAAAGCTTGC CTTGAGTGCT  
 50 TCAAGTAGTC  
 5461 TGTGCCCGTC TGGTGTGTGA CTCTGGTAAC TAGAGATCCC TCAGACCCTT  
 TTAGTCAGTG  
 5521 TGGAAAATCT CTAGCAGCAT GTGAGCAAAA GGCCAGCAAA AGGCCAGGAA  
 CCGTAAAAAG  
 5581 GCCGCCTTGC TGGCGTTTT CCATAGGCTC CGCCCCCCTG ACGAGCATCA  
 CAAAAATCGA  
 5641 CGCTCAAGTC AGAGGTGGCG AAACCCGACA GGACTATAAA GATACCAGGC  
 GTTCCCCCT

5701 GGAAGCTCCC TCGTGCCTC TCCTGTTCCG ACCCTGCCGC TTACCGGATA  
 CCTGTCCGCC  
 5761 TTTCTCCCTT CGGGAAAGCGT GGCGCTTCT CATAGCTCAC GCTGTAGGTA  
 TCTCAGTTCG  
 5 5821 GTGTAGGTCTG TTCGCTCCAA GCTGGGCTGT GTGCACGAAC CCCCCGTTCA  
 GCCCGACCGC  
 5881 TGCGCCTTAT CCGGTAACTA TCGTCTTGAG TCCAACCCGG TAAGACACGA  
 CTTATCGCCA  
 5941 CTGGCAGCAG CCACTGGTAA CAGGATTAGC AGAGCGAGGT ATGTAGGCAG  
 10 TGCTACAGAG  
 6001 TTCTTGAAGT GGTGGCCTAA CTACGGCTAC ACTAGAAGAA CAGTATTG  
 TATCTGCGCT  
 6061 CTGCTGAAGC CAGTTACCTT CGGAAAAAGA GTTGGTAGCT CTTGATCCGG  
 15 CAAACAAACC  
 6121 ACCGCTGGTA GCGGTGGTTT TTTTGTTCG AAGCAGCAGA TTACGCGCAG  
 AAAAAAAAGGA  
 6181 TCTCAAGAAG ATCCTTTGAT CTTTTCTACG GGGTCTGACG CTCAGTGGAA  
 CGAAAACCTCA  
 6241 CGTTAAGGGA TTTTGGTCAT GAGATTATCA AAAAGGATCT TCACCTAGAT  
 20 CCTTTTAAAT  
 6301 TAAAAATGAA GTTTTAAATC AATCTAAAGT ATATATGAGT AAAACTGGTC  
 TGACAGTTAC  
 6361 CAATGCTTAA TCAGTGAGGC ACCTATCTCA GCGATCTGTC TATTCGTT  
 ATCCATAGTT  
 25 6421 GCCTGACTCC CCGTCGTGTA GATAACTACG ATACGGGAGG GCTTACCATC  
 TGGCCCCAGT  
 6481 GCTGCAATGA TACCGCGAGA CCCACGCTCA CCGGCTCCAG ATTTATCAGC  
 AATAAACCG  
 6541 CCAGCCGAA GGGCCGAGCG CAGAAGTGGT CCTGCAACTT TATCCGCCTC  
 30 CATCCAGTCT  
 6601 ATTAATTGTT GCCGGGAAGC TAGAGTAAGT AGTTGCCAG TTAATAGTT  
 GCGCAACGTT  
 6661 GTGCCATTG CTACAGGCAT CGTGGTGTCA CGCTCGTCGT TTGGTATGGC  
 TTCATTCAAGC  
 35 6721 TCCGGTCCC AACGATCAAG GCGAGTTACA TGATCCCCA TGTGTGCAA  
 AAAAGCGGTT  
 6781 AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA AGTAAGTTGG CCGCAGTGT  
 ATCACTCATG  
 6841 GTTATGGCAG CACTGCATAA TTCTCTTACT GTCATGCCAT CCGTAAGATG  
 40 CTTTTCTGTG  
 6901 ACTGGTGAGT ACTCAACCAA GTCATTCTGA GAATAGTGTGTA TGCGGCGACC  
 GAGTTGCTCT  
 6961 TGCCCGCGT CAATACGGGA TAATACCGCG CCACATAGCA GAACTTTAAA  
 AGTGCTCATC  
 45 7021 ATTGGAAAAC GTTCTCGGG GCGAAAACTC TCAAGGATCT TACCGCTGTT  
 GAGATCCAGT  
 7081 TCGATGTAAC CCACTCGTGC ACCCAACTGA TCTTCAGCAT CTTTACTTT  
 CACCAGCGTT  
 7141 TCTGGGTGAG CAAAAACAGG AAGGCAAAAT GCGCAAAAAA AGGGAATAAG  
 50 GGCGACACGG  
 7201 AAATGTTGAA TACTCATACT CTTCTTTTT CAATATTATT GAAGCATTAA  
 TCAGGGTTAT  
 7261 TGTCTCATGA GCGGATACAT ATTTGAATGT ATTTAGAAAA ATAAACAAAT  
 AGGGGTTCCG  
 55 7321 CGCACATTTC CCCGAAAAGT GCCACCTGAC  
 //  
 (SEQ ID NO: 8)

## [00352] pLL3.7

|       |              |             |  |          |     |         |
|-------|--------------|-------------|--|----------|-----|---------|
| LOCUS | PLL3.7.GB    | 7650 BP     | DS-DNA   | CIRCULAR | SYN | 23-JAN- |
| 2002  |              |             |  |          |     |         |
| 5     | DEFINITION   | -           |  |          |     |         |
|       | ACCESSION    | -           |  |          |     |         |
|       | KEYWORDS     | -           |  |          |     |         |
|       | SOURCE       | -           |  |          |     |         |
|       | FEATURES     |             | Location/Qualifiers                              |          |     |         |
| 10    | promoter     | 212..816    | /note="CMV promoter/enhancer 1"                  |          |     |         |
|       | misc_recomb  | 4450..4483  | /note="Lox 2"                                    |          |     |         |
| 15    | promoter     | 3099..3687  | /note="CMV"                                      |          |     |         |
|       | gene         | 6657..7517  | /note="AmpR"                                     |          |     |         |
|       | rep_origin   | 5839..6512  | /note="pUC"                                      |          |     |         |
| 20    | misc_recomb  | 3010..3045  | /note="Lox 1"                                    |          |     |         |
|       | LTR          | 835..1509   | /note="5' HIV R-U5-del gag (HIV NL4-3/454-1126)" |          |     |         |
| 25    | misc_feature | 1539..2396  | /note="HIV RRE (HIV NL4-3/7622-8459)"            |          |     |         |
|       | misc_feature | 2422..2599  | /note="HIV Flap"                                 |          |     |         |
|       | misc_feature | 4538..5127  | /note="WRE element"                              |          |     |         |
| 30    | LTR          | 5147..5836  | /note="3' SIN LTR"                               |          |     |         |
|       | frag         | 3072..4430  | /note="1 to 1359 of Untitled1"                   |          |     |         |
| 35    | frag         | 3072..3098  | /note="4705 to 4731 of pEGFP-C1"                 |          |     |         |
|       | frag         | 3099..4427  | /note="1 to 1329 of pEGFP-C1"                    |          |     |         |
|       | gene         | 3704..4427  | /note="EGFP"                                     |          |     |         |
| 40    | frag         | 2617..2950  | /note="1 to 334 of Untitled2"                    |          |     |         |
|       | frag         | 2622..2935  | /note="1 to 314 of mouseu6"                      |          |     |         |
| 45    | source       | 2622..>2935 | /organism="Mus musculus"                         |          |     |         |
|       |              |             | /db_xref="taxon:10090"                           |          |     |         |
|       |              |             | /clone="pmU6-52BE [Split]"                       |          |     |         |
|       | promoter     | 2622..>2935 | /note="U6 Promoter [Split]"                      |          |     |         |
| 50    | misc_feature | 2648..2658  | /note="pot. SPI binding site"                    |          |     |         |
|       | misc_feature | 2692..2701  | /note="pot. SPI binding site"                    |          |     |         |
|       | misc_feature | 2707..2714  | /note="pot. enhancer"                            |          |     |         |
| 55    | promoter     | 2869..2888  | /note="pot. promoter region; sequence homologous |          |     |         |
|       | to PSE or    |             |  |          |     |         |

element 'B'  
 promoter 2906..2911  
 /note="put. TATA-box"  
 5 BASE COUNT 2032 A 1861 C 1917 G 1840 T 0 OTHER  
 ORIGIN -  
 1 GTCGACGGAT CGGGAGATCT CCCGATCCCC TATGGTGCAC TCTCAGTACA  
 ATCTGCTCTG  
 61 ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT GTTGGAGGTC  
 GCTGAGTAGT  
 10 121 GCGCGAGCAA AATTAAAGCT ACAACAAGGC AAGGCTTGAC CGACAATTGC  
 ATGAAGAAC  
 181 TGCTTAGGGT TAGGCCTTT GCGCTGCTTC GCGATGTACG GGCCAGATAT  
 ACGCGTTGAC  
 241 ATTGATTATT GACTAGTTAT TAATAGTAAT CAATTACGGG GTCATTAGTT  
 15 CATAGCCCCAT  
 301 ATATGGAGTT CCGCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA  
 CCGCCCCAACG  
 361 ACCCCCCGCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA  
 ATAGGGACTT  
 20 421 TCCATTGACG TCAATGGGTG GAGTATTTAC GGTAAACTGC CCACTTGGCA  
 GTACATCAAG  
 481 TGTATCATAT GCCAAGTACG CCCCCTATTG ACGTCAATGA CGGTAAATGG  
 CCCGCCTGGC  
 541 ATTATGCCCA GTACATGACC TTATGGACT TTCCTACTTG GCAGTACATC  
 25 TACGTATTAG  
 601 TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT CAATGGCGT  
 GGATAGCGGT  
 661 TTGACTCACG GGGATTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT  
 TTGTTTTGGC  
 30 721 ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC CGCCCCATTG  
 ACGCAAATGG  
 781 GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGCGC GTTTGCCTG  
 TACTGGGTCT  
 841 CTCTGGTTAG ACCAGATCTG AGCCTGGAG CTCTCTGGCT AACTAGGGAA  
 35 CCCACTGCTT  
 901 AAGCCTCAAT AAAGCTTGCC TTGAGTGCTT CAAGTAGTGT GTGCCCGTCT  
 GTTGTGTGAC  
 961 TCTGGTAACT AGAGATCCCT CAGACCCTTT TAGTCAGTGT GGAAAATCTC  
 TAGCAGTGGC  
 40 1021 GCCCGAACAG GGACTTGAAA GCGAAAGGGA AACCAGAGGA GCTCTCTCGA  
 CGCAGGACTC  
 1081 GGCTTGCTGA AGCGCGCACG GCAAGAGGCG AGGGGCGGCG ACTGGTGAGT  
 ACGCCAAAAA  
 1141 TTTTGACTAG CGGAGGCTAG AAGGAGAGAG ATGGGTGCGA GAGCGTCAGT  
 45 ATTAAGCGGG  
 1201 GGAGAATTAG ATCGCGATGG GAAAAAATTC GGTAAAGGCC AGGGGGAAAG  
 AAAAAATATA  
 1261 ATTAAAAACA TATAGTATGG GCAAGCAGGG AGCTAGAACG ATTGCGAGTT  
 AATCCTGGCC  
 50 1321 TGTTAGAAAC ATCAGAAGGC TGTAGACAAA TACTGGGACA GCTACAACCA  
 TCCCTTCAGA  
 1381 CAGGATCAGA AGAACTTAGA TCATTATATA ATACAGTAGC AACCCCTCTAT  
 TGTGTGCATC  
 1441 AAAGGATAGA GATAAAAGAC ACCAAGGAAG CTTTAGACAA GATAGAGGAA  
 55 GAGCAAAACA  
 1501 AAAGTAAGAC CACCGCACAG CAAGCGGCCG GCCCGCGCTGA TCTTCAGACC  
 TGGAGGAGGA  
 1561 GATATGAGGG ACAATTGGAG AAGTGAATTA TATAAAATATA AAGTAGTAAA  
 AATTGAACCA

1621 TTAGGAGTAG CACCCACCAA GGCAAAGAGA AGAGTGGTGC AGAGAGAAAA  
 AAGAGCAGTG  
 1681 GGAATAGGAG CTTTGTTCCT TGGGTTCTTG GGAGCAGCAG GAAGCACTAT  
 GGGCGCAGCG  
 5 1741 TCAATGACGC TGACGGTACA GGCCAGACAA TTATTGTCTG GTATAGTGCA  
 GCAGCAGAAC  
 1801 AATTTGCTGA GGGCTATTGA GGCGCAACAG CATCTGTTGC AACTCACAGT  
 CTGGGGCATC  
 1861 AAGCAGCTCC AGGCAAGAAT CCTGGCTGTG GAAAGATACC TAAAGGATCA  
 10 ACAGCTCCTG  
 1921 GGGATTGGG GTTGCTCTGG AAAACTCATT TGCACCACTG CTGTGCCTTG  
 GAATGCTAGT  
 1981 TGGAGTAATA AATCTCTGGA ACAGATTGG AATCACACGA CCTGGATGGA  
 GTGGGACAGA  
 15 2041 GAAATTAACA ATTACACAAG CTTAATACAC TCCTTAATTG AAGAATCGCA  
 AAACCAGCAA  
 2101 GAAAAGAATG AACAGAAATT ATTGGAATTA GATAAATGGG CAAGTTGTG  
 GAATTGGTTT  
 2161 AACATAACAA ATTGGCTGTG GTATATAAAA TTATTCTAA TGATAGTAGG  
 20 AGGCTTGGTA  
 2221 GGTTTAAGAA TAGTTTTGC TGTACTTCT ATAGTGAATA GAGTTAGGCA  
 GGGATATTCA  
 2281 CCATTATCGT TTCAGACCCA CCTCCCAACC CCGAGGGAC CCGACAGGCC  
 CGAAGGAATA  
 2341 GAAGAAGAAG GTGGAGAGAG AGACAGAGAC AGATCCATTG GATTAGTGAA  
 CGGATCGGCA  
 2401 CTGCGTGCAC CAATTCTGCA GACAAATGGC AGTATTCTAC CACAATTTTA  
 AAAGAAAAGG  
 2461 GGGGATTGGG GGGTACAGTG CAGGGAAAG AATAGTAGAC ATAATAGCAA  
 30 CAGACATACA  
 2521 AACTAAAGAA TTACAAAAAC AAATTACAAA AATTCAAAAT TTTCGGGTTT  
 ATTACAGGGA  
 2581 CAGCAGAGAT CCAGTTGGT TAGTACCGGG CCCGCTCTAG AGATCCGACG  
 CCGCCATCTC  
 35 2641 TAGGCCCGCG CGGGCCCCCT CGCACAGACT TGTGGGAGAA GCTCGGCTAC  
 TCCCCCTGCC  
 2701 CGGTTAATT GCATATAATA TTTCTAGTA ACTATAGAGG CTTAATGTGC  
 GATAAAAGAC  
 2761 AGATAATCTG TTCTTTTAA TACTAGCTAC ATTTTACATG ATAGGCTTGG  
 40 ATTTCTATAA  
 2821 GAGATACAAA TACTAAATTA TTATTTAAA AAACAGCACA AAAGGAAACT  
 CACCCCTAACT  
 2881 GTAAAGTAAT TGTGTGTTT GAGACTATAA ATATCCCTTG GAGAAAAGCC  
 TTGTTAACGCG  
 45 2941 GCGGTGACCC TCGAGGTCGA CGGTATCGAT AAGCTCGCTT CACGAGATTG  
 CAGCAGGTGCG  
 3001 AGGGACCTAA TAACTTCGTA TAGCATAACAT TATACGAAGT TATATTAAGG  
 GTTCCAAGCT  
 3061 TAAGCGGCCG CGTGGATAAC CGTATTACCG CCATGCATTA GTTATTAATA  
 50 GTAATCAATT  
 3121 ACGGGGTCAT TAGTTCATAG CCCATATATG GAGTTCCGCG TTACATAACT  
 TACGGTAAAT  
 3181 GGCCCGCCTG GCTGACCGCC CAACGACCCC CGCCCATGTA CGTCAATAAT  
 GACGTATGTT  
 3241 CCCATAGTAA CGCCAATAGG GACTTTCCAT TGACGTCAAT GGGTGGAGTA  
 TTTACGGTAA  
 3301 ACTGCCACT TGGCAGTACA TCAAGTGTAT CATATGCCAA GTACGCCCC  
 TATTGACGTC

3361 AATGACGGTA AATGGCCCCC CTGGCATTAT GCCCAGTACA TGACCTTATG  
 GGACTTTCCCT  
 3421 ACTTGGCAGT ACATCTACGT ATTAGTCATC GCTATTACCA TGGTGATGCG  
 GTTTTGGCAG  
 5 3481 TACATCAATG GGC GTGGATA GCGGTTGAC TCACGGGGAT TTCCAAGTCT  
 CCACCCCCATT  
 3541 GACGTCAATG GGAGTTTGTGTT TTGGCACCAA AATCAACGGG ACTTTCCAAA  
 ATGTCGTAAC  
 3601 AACTCCGCC CATTGACGCA AATGGCGGT AGGCGTGTAC GGTGGGAGGT  
 10 CTATATAAGC  
 3661 AGAGCTGGTT TAGTGAACCG TCAGATCCGC TAGCGCTACC GGTCGCCACC  
 ATGGTGAGCA  
 3721 AGGGCGAGGA GCTGTTCACC GGGGTGGTGC CCATCCTGGT CGAGCTGGAC  
 GGCGACGTAA  
 15 3781 ACGGCACCAA GTTCAGCGTG TCCGGCGAGG GCGAGGGCGA TGCCACCTAC  
 GGCAAGCTGA  
 3841 CCCTGAAGTT CATCTGCACC ACCGGCAAGC TGCCCGTGCC CTGGCCCACC  
 CTCGTGACCA  
 3901 CCCTGACCTA CGGCGTGCAG TGCTTCAGCC GCTACCCCGA CCACATGAAG  
 20 CAGCACGACT  
 3961 TCTTCAAGTC CGCCATGCC GAAGGCTACG TCCAGGAGCG CACCATCTTC  
 TTCAAGGACG  
 4021 ACGGCAACTA CAAGACCCGC GCCGAGGTGA AGTCGAGGG CGACACCCCTG  
 GTGAACCGCA  
 25 4081 TCGAGCTGAA GGGCATCGAC TTCAAGGAGG ACGGCAACAT CCTGGGGCAC  
 AAGCTGGAGT  
 4141 ACAACTACAA CAGCCACAAAC GTCTATATCA TGGCCGACAA GCAGAAGAAC  
 GGCATCAAGG  
 4201 TGAACTTCAA GATCCGCCAC AACATCGAGG ACGGCAGCGT GCAGCTCGCC  
 30 GACCACTACC  
 4261 AGCAGAACAC CCCCATCGGC GACGGCCCCG TGCTGCTGCC CGACAACCAC  
 TACCTGAGCA  
 4321 CCCAGTCCGC CCTGAGCAAAC GACCCCAACG AGAAGCGCGA TCACATGGTC  
 CTGCTGGAGT  
 35 4381 TCGTGACCGC CGCCGGGATC ACTCTCGGCA TGGACGAGCT GTACAAGTAG  
 GAATTCTCG  
 4441 AGGGACCTAA TAACTTCGTA TAGCATAACAT TATACGAAGT TATACATGTT  
 TAAGGGTTCC  
 45 4501 GGTTCCACTA GGTACAATTG GATATCAAGC TTATCGATAA TCAACCTCTG  
 GATTACAAA  
 4561 TTTGTGAAAG ATTGACTGGT ATTCTTAACG ATGTTGCTCC TTTTACGCTA  
 TGTGGATACG  
 4621 CTGCTTTAAT GCCTTTGTAT CATGCTATTG CTTCCCGTAT GGCTTTCATT  
 TTCTCCTCCT  
 4681 TGTATAAACCTC CTGGTTGCTG TCTCTTATG AGGAGTTGTG GCCCGTTGTC  
 40 AGGCAACGTG  
 4741 GCGTGGTGTG CACTGTGTTT GCTGACGCAA CCCCCACTGG TTGGGGCATT  
 GCCACCACCT  
 4801 GTCAGCTCCT TTCCGGGACT TTGCTTTCC CCCTCCCTAT TGCCACGGCG  
 50 GAACTCATCG  
 4861 CGGCCTGCCT TGCCCCGCTGC TGGACAGGGG CTCGGCTGTT GGGCACTGAC  
 AATTCCGTGG  
 4921 TGTTGTGCGGG GAAATCATCG TCCTTTCCCTT GGCTGCTCGC CTGTGTTGCC  
 ACCTGGATTC  
 4981 TGCGCGGGAC GTCCTTCTGC TACGTCCCTT CGGCCCTCAA TCCAGCGGAC  
 55 CTTCCCTTCCC  
 5041 CGGGCCTGCT GCCGGCTCTG CGGCCTCTTC CGCGTCTCG CCTTCGCCCT  
 CAGACGAGTC

5101 GGATCTCCCT TTGGGCCGCC TCCCCGCATC GATACCGTCG ACCTCGATCG  
 AGACCTAGAA  
 5161 AAACATGGAG CAATCACAAAG TAGCAATACA GCAGCTACCA ATGCTGATTG  
 TGCCTGGCTA  
 5 5221 GAAGCACAAG AGGAGGAGGA GGTGGGTTTT CCAGTCACAC CTCAGGTACC  
 TTTAAGACCA  
 5281 ATGACTTACA AGGCAGCTGT AGATCTTAGC CACTTTTAA AAGAAAAGGG  
 GGGACTGGAA  
 5341 GGGCTAATTG ACTCCCAACG AAGACAAGAT ATCCTTGATC TGTGGATCTA  
 10 CCACACACAA  
 5401 GGCTACTTCC CTGATTGGCA GAACTACACA CCAGGGCCAG GGATCAGATA  
 TCCACTGACC  
 5461 TTTGGATGGT GCTACAAGCT AGTACCAGTT GAGCAAGAGA AGGTAGAAGA  
 AGCCAATGAA  
 15 5521 GGAGAGAACCA CCCGCTTGT ACACCCCTGTG AGCCTGCATG GGATGGATGA  
 CCCGGAGAGA  
 5581 GAAGTATTAG AGTGGAGGTT TGACAGCCGC CTAGCATTTC ATCACATGGC  
 CCGAGAGCTG  
 5641 CATCCGGACT GTACTGGGTC TCTCTGGTTA GACCAGATCT GAGCCTGGGA  
 20 GCTCTCTGGC  
 5701 TAACTAGGGA ACCCACTGCT TAAGCCTCAA TAAAGCTTGC CTTGAGTGCT  
 TCAAGTAGTG  
 5761 TGTGCCGTC TGTGTGTGA CTCTGGTAAC TAGAGATCCC TCAGACCCCTT  
 TTAGTCAGTG  
 25 5821 TGGAAAATCT CTAGCAGCAT GTGAGCAAAA GGCCAGCAAA AGGCCAGGAA  
 CCGTAAAAAG  
 5881 GCCCGCTTGC TGGCGTTTTT CCATAGGCTC CGCCCCCTG ACGAGCATCA  
 CAAAAATCGA  
 5941 CGCTCAAGTC AGAGGTGGCG AAACCCGACA GGACTATAAA GATACCAGGC  
 30 GTTTCCCCCT  
 6001 GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG ACCCTGCCGC TTACCGGATA  
 CCTGTCCGCC  
 6061 TTTCTCCCTT CGGGAAAGCGT GGCGCTTCT CATAGCTCAC GCTGTAGGTA  
 TCTCAGTTG  
 35 6121 GTGTAGGTCG TTCGCTCAA GCTGGGCTGT GTGCACGAAC CCCCCGTTCA  
 GCCCGACCGC  
 6181 TGCGCCTTAT CCGGTAACTA TCGTCTTGAG TCCAACCCGG TAAGACACGAA  
 CTTATCGCCA  
 6241 CTGGCAGCAG CCACTGGTAA CAGGATTAGC AGAGCGAGGT ATGTAGGCGG  
 40 TGCTACAGAG  
 6301 TTCTTGAAGT GGTGGCCTAA CTACGGCTAC ACTAGAAGAA CAGTATTG  
 TATCTGCGCT  
 6361 CTGCTGAAGC CAGTTACCTT CGGAAAAAGA GTTGGTAGCT CTTGATCCGG  
 CAAACAAACC  
 45 6421 ACCGCTGGTA GCGGTGGTTT TTTTGTTC AAGCAGCAGA TTACGCGCAG  
 AAAAAAAAGGA  
 6481 TCTCAAGAAG ATCCTTTGAT CTTTCTACG GGGTCTGACG CTCAGTGGAA  
 CGAAAAACTCA  
 6541 CGTTAAGGGA TTTTGGTCAT GAGATTATCA AAAAGGATCT TCACCTAGAT  
 50 CCTTTAAAT  
 6601 TAAAAATGAA GTTTTAAATC AATCTAAAGT ATATATGAGT AAACCTGGTC  
 TGACAGTTAC  
 6661 CAATGCTTAA TCAGTGAGGC ACCTATCTCA GCGATCTGTC TATTCGTT  
 ATCCATAGTT  
 55 6721 GCCTGACTCC CCGTCGTGTA GATAACTACG ATACGGGAGG GCTTACCATC  
 TGGCCCCAGT  
 6781 GCTGCAATGA TACCGCGAGA CCCACGCTCA CCGGCTCCAG ATTTATCAGC  
 AATAAACCAAG

6841 CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT CCTGCAACTT TATCCGCCTC  
CATCCAGTCT  
6901 ATTAATTGTT GCCGGGAAGC TAGAGTAAGT AGTTGCCAG TTAATAGTTT  
GCGCAACGTT  
5 6961 GTTGCCATTG CTACAGGCAT CGTGGTGTCA CGCTCGTCGT TTGGTATGGC  
TTCATTCAAG  
7021 TCCGGTTCCC AACGATCAAG GCGAGTTACA TGATCCCCA TGTTGTGCAA  
AAAAGCGGTT  
7081 AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA AGTAAGTTGG CCGCAGTGT  
10 ATCACTCATG  
7141 GTTATGGCAG CACTGCATAA TTCTCTTACT GTCATGCCAT CCGTAAGATG  
CTTTCTGTG  
7201 ACTGGTGAGT ACTCAACCAA GTCATTCTGA GAATAGTGTA TGCGGCGACC  
GAGTTGCTCT  
15 7261 TGCCCGCGT CAATACGGGA TAATACCGCG CCACATAGCA GAACTTTAAA  
AGTGCTCATC  
7321 ATTGGAAAAC GTTCTTCGGG GCGAAAACTC TCAAGGATCT TACCGCTGTT  
GAGATCCAGT  
7381 TCGATGTAAC CCACTCGTGC ACCCAACTGA TCTTCAGCAT CTTTACTTT  
20 CACCAGCGTT  
7441 TCTGGGTGAG CAAAAACAGG AAGGCAAAAT GCCGAAAAAA AGGGAATAAG  
GGCGACACGG  
7501 AAATGTTGAA TACTCATACT CTTCTTTTT CAATATTATT GAAGCATTAA  
TCAGGGTTAT  
25 7561 TGTCTCATGA GCGGATACAT ATTTGAATGT ATTTAGAAAA ATAAACAAAT  
AGGGGTTCCG  
7621 CGCACATTTC CCCGAAAAGT GCCACCTGAC  
//  
30 (SEQ ID NO: 9)

## References

1. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* 391, 806-11. (1998).
- 5 2. McManus, M. T. & Sharp, P. A. Gene Silencing in Mammals by siRNAs. *Nature Genetics Reviews In Press* (2002).
3. Reinhart, B. J. et al. The 21-nucleotide let-7 RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature* 403, 901-6. (2000).
4. Olsen, P. H. & Ambros, V. The lin-4 regulatory RNA controls developmental timing in *Caenorhabditis elegans* by blocking LIN-14 protein synthesis after the initiation of translation. *Dev Biol* 216, 671-80. (1999).
- 10 5. Moss, E. G., Lee, R. C. & Ambros, V. The cold shock domain protein LIN-28 controls developmental timing in *C. elegans* and is regulated by the lin-4 RNA. *Cell* 88, 637-46. (1997).
- 15 6. Wightman, B., Ha, I. & Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in *C. elegans*. *Cell* 75, 855-62. (1993).
7. Kennerdell, J. R. & Carthew, R. W. Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. *Cell* 95, 1017-26. (1998).
- 20 8. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. *Annu Rev Biochem* 67, 227-64 (1998).
9. Elbashir, S. M., Lendeckel, W. & Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. *Genes Dev* 15, 188-200. (2001).
- 25 10. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 411, 494-8. (2001).
11. McManus, M. T., Haines, B. B., Dillon, C.P., Whitehurst, C.E., van Parijs, L., Chen, J. & Sharp, P. A. siRNA-mediated gene silencing in T-cells. *The Journal of Immunology*, 2002, 169: 5754-5760.
- 30 12. Brummelkamp, T. R., Bernards, R. & Agami, R. A System for Stable Expression of Short Interfering RNAs in Mammalian Cells. *Science* 21, 21 (2002).

13. Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J. & Conklin, D. S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. *Genes Dev* 16, 948-58. (2002).
14. Sui, G. et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. *Proc Natl Acad Sci U S A* 99, 5515-20. (2002).
- 5 15. Yu, J. Y., DeRuiter, S. L. & Turner, D. L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. *Proc Natl Acad Sci U S A* 23, 23 (2002).
- 10 16. Paul, C. P., Good, P. D., Winer, I. & Engelke, D. R. Effective expression of small interfering RNA in human cells. *Nat Biotechnol* 20, 505-8. (2002).
17. Bernstein, E., Caudy, A. A., Hammond, S. M. & Hannon, G. J. Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature* 409, 363-6. (2001).
- 15 18. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi. *Cell* 110, 563-574 (2002).
19. Brummelkamp, T. R., Bernards, R., and Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. *Cancer Cell* (2002).
- 20 20. Naldini, L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. *Curr Opin Biotechnol* 9, 457-63 (1998).
21. Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. *Science* 272, 263-7 (1996).
22. Jaenisch, R., Fan, H. & Croker, B. Infection of preimplantation mouse embryos and of newborn mice with leukemia virus: tissue distribution of viral DNA and RNA and leukemogenesis in the adult animal. *Proc Natl Acad Sci U S A* 72, 4008-12 (1975).
- 25 23. Pfeifer, A., Ikawa, M., Dayn, Y. & Verma, I. M. Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. *Proc Natl Acad Sci U S A* 99, 2140-5 (2002).

30

24. Lois, C., Hong, E. J., Pease, S., Brown, E. J. & Baltimore, D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. *Science* 295, 868-72 (2002).

5 25. Hacein-Bey-Abina, S. et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. *N Engl J Med* 346, 1185-93 (2002).

26. Tuschl, T. Expanding small RNA interference. *Nat Biotechnol* 20, 446-8 (2002).

10 27. Schmidt, E. V., Christoph, G., Zeller, R. & Leder, P. The cytomegalovirus enhancer: a pan-active control element in transgenic mice. *Mol Cell Biol* 10, 4406-11 (1990).

28. McManus, M. T., Petersen, C. P., Haines, B. B., Chen, J. & Sharp, P. A. Gene silencing using micro-RNA designed hairpins. *Rna* 8, 842-50. (2002).

15 29. Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H. & Verma, I. M. Development of a self-inactivating lentivirus vector. *J Virol* 72, 8150-7 (1998).

30. Devroe, E. a. S., PA. Retrovirus-delivered siRNA. *BMC Biotechnology* 2 (2002).

20 31. Willerford, D. M. et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. *Immunity* 3, 521-30 (1995).

32. Chen, J., Lansford, R., Stewart, V., Young, F. & Alt, F. W. RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. *Proc Natl Acad Sci U S A* 90, 4528-32 (1993).

25 33. Paddison, P. J. & Hannon, G. J. RNA interference: the new somatic cell genetics? *Cancer Cell* 2, 17-23. (2002).

34. Hannon, G. J. RNA interference. *Nature* 418, 244-51. (2002).

35. Mitchell, T. C. et al. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. *Nat Immunol* 2, 397-402 (2001).

30 36. Eszterhas, S. K., Bouhassira, E. E., Martin, D. I. & Fiering, S. Transcriptional interference by independently regulated genes occurs in any relative

arrangement of the genes and is influenced by chromosomal integration position. *Mol Cell Biol* 22, 469-79 (2002).

37. Fung-Leung, W. P. et al. CD8 is needed for development of cytotoxic T cells but not helper T cells. *Cell* 65, 443-9 (1991).

5 38. Hogquist, K. A. Signal strength in thymic selection and lineage commitment. *Curr Opin Immunol* 13, 225-31 (2001).

39. Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J. & Conklin, D. S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. *Genes Dev* 16, 948-58 (2002).

10 40. Dull, T., Zufferey, R., Kelly, M., Mandel, R.J., Nguyen, M., Trono, D., & Naldini, L., A Third-Generation Lentivirus Vector with a Conditional Packaging System. *Journal of Virology*, 72(11), 8463-8471 (1998).

41. Zufferey, R., D. Nagy, R. J. Mandel, L. Naldini, and D. Trono. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. *Nat. Biotechnol.* 15:871-875

#### Equivalents

20 [00353] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The Examples below are provided to illustrate the invention and are not limiting. Alternative procedures known to one of ordinary skill in the art might also be used. The scope of the present invention is not intended to be limited to the above Description, but rather is as set forth in the appended claims.

25

26

1 We claim:

- 2 1. A lentiviral vector comprising the following elements: a nucleic acid whose  
3 sequence includes (i) a functional packaging signal; (ii) a multiple cloning site  
4 (MCS); and (iii) at least one additional element selected from the group  
5 consisting of: a second MCS, a second MCS into which a heterologous nucleic  
6 acid is inserted, an HIV FLAP element, an expression-enhancing  
7 posttranscriptional regulatory element, a target site for a site-specific  
8 recombinase, and a self-inactivating (SIN) LTR, wherein the lentiviral vector  
9 is a lentiviral transfer plasmid or an infectious lentiviral particle.
- 10 2. The lentiviral vector of claim 1, wherein the vector comprises at least two  
11 elements selected from the group consisting of: a second MCS, a second MCS  
12 into which a heterologous nucleic acid is inserted, an HIV FLAP element, an  
13 expression-enhancing posttranscriptional regulatory element, a target site for a  
14 site-specific recombinase, and a self-inactivating (SIN) LTR.
- 15 3. The lentiviral vector of claim 1, wherein the vector comprises at least three  
16 elements selected from the group consisting of: a second MCS, a second MCS  
17 into which a heterologous nucleic acid is inserted, an HIV FLAP element, an  
18 expression-enhancing posttranscriptional regulatory element, a target site for a  
19 site-specific recombinase, and a self-inactivating (SIN) LTR.
- 20 4. The lentiviral vector of claim 1, wherein the vector comprises at least four  
21 elements selected from the group consisting of: a second MCS, a second MCS  
22 into which a heterologous nucleic acid is inserted, an HIV FLAP element, an  
23 expression-enhancing posttranscriptional regulatory element, a target site for a  
24 site-specific recombinase, and a self-inactivating (SIN) LTR.
- 25 5. The lentiviral vector of claim 1, wherein the vector comprises a second MCS,  
26 an HIV FLAP element, an expression-enhancing posttranscriptional regulatory  
27 element, a target site for a site-specific recombinase, and a self-inactivating  
28 (SIN) LTR.

- 1 6. The lentiviral vector of claim 1, wherein the vector comprises a second MCS  
2 into which a heterologous nucleic acid is inserted, an HIV FLAP element, an  
3 expression-enhancing posttranscriptional regulatory element, a target site for a  
4 site-specific recombinase, and a self-inactivating (SIN) LTR.
- 5 7. The lentiviral vector of claim 1, wherein the additional element is a second  
6 MCS.
- 7 8. The lentiviral vector of claim 1, wherein the additional element is a second  
8 MCS into which a heterologous nucleic acid is inserted.
- 9 9. The lentiviral vector of claim 1, wherein the vector has unique restriction sites  
10 for at least 4 enzymes selected from the group consisting of NotI, ApaI, XhoI,  
11 XbaI, HpaI, NheI, PacI, NsiI, SphI, Sma/Xma, AccI, BamHI, and SphI.
- 12 10. The lentiviral vector of claim 1, wherein the vector has unique restriction sites  
13 for at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at  
14 least 12, or at least 13 enzymes selected from the group consisting of NotI,  
15 ApaI, XhoI, XbaI, HpaI, NheI, PacI, NsiI, SphI, Sma/Xma, AccI, BamHI, and  
16 SphI.
- 17 11. The lentiviral vector of claim 1, wherein the additional element is an HIV  
18 FLAP element.
- 19 12. The lentiviral vector of claim 1, wherein the additional element is an  
20 expression-enhancing posttranscriptional regulatory element.
- 21 13. The lentiviral vector of claim 12, wherein the expression-enhancing  
22 posttranscriptional regulatory element is a WRE.
- 23 14. The lentiviral vector of claim 1, wherein the additional element is a target site  
24 for a site-specific recombinase.
- 25 15. The lentiviral vector of claim 14, wherein the site is a loxP site.

- 1 16. The lentiviral vector of claim 1, wherein the lentiviral  
2 transfer plasmid.
- 3 17. The lentiviral transfer plasmid of claim 16, wherein the plasmid has a size of  
4 less than 10 kB.
- 5 18. The lentiviral transfer plasmid of claim 16, wherein the plasmid has a size of  
6 less than 9 kB.
- 7 19. The lentiviral transfer plasmid of claim 16, wherein the plasmid has a size of  
8 less than 8 kB.
- 9 20. The lentiviral transfer plasmid of claim 16, wherein the plasmid has a size of  
10 less than 7 kB.
- 11 21. The lentiviral transfer plasmid of claim 16, wherein the plasmid has a size of  
12 approximately 6 kB.
- 13 22. The lentiviral vector of claim 1, wherein the lentiviral vector is an infectious  
14 lentiviral particle.
- 15 23. The lentiviral vector of claim 1, further comprising: a heterologous promoter  
16 or promoter-enhancer.
- 17 24. The lentiviral vector of claim 23, wherein the heterologous promoter or  
18 promoter-enhancer is selected from the group consisting of: the CMV  
19 promoter, the CMV promoter-enhancer, and the ubiquitin C promoter.
- 20 25. The lentiviral vector of claim 24, wherein the heterologous promoter is an  
21 inducible promoter.
- 22 26. The lentiviral vector of claim 24, wherein the heterologous promoter is a cell  
23 type specific or tissue specific promoter.
- 24 27. The lentiviral vector of claim 23, wherein the heterologous promoter is an  
25 RNA polymerase promoter.

- 1 28. The lentiviral vector of claim 27, wherein the RNA polymerase promoter is an
- 2 RNA polymerase III promoter.
- 3 29. The lentiviral vector of claim 28, wherein the RNA polymerase III promoter is
- 4 a U6 promoter.
- 5 30. The lentiviral vector of claim 28, wherein the RNA polymerase III promoter is
- 6 an H1 promoter.
- 7 31. The lentiviral vector of claim 27, wherein the RNA polymerase promoter is an
- 8 RNA polymerase II promoter.
- 9 32. The lentiviral vector of claim 23, further comprising a second heterologous
- 10 promoter or promoter-enhancer.
- 11 33. The lentiviral vector of claim 1, further comprising a heterologous nucleic acid
- 12 encoding a selectable marker operably linked to a promoter.
- 13 34. The lentiviral vector of claim 1, further comprising a heterologous nucleic acid
- 14 encoding a reporter molecule operably linked to a promoter.
- 15 35. The lentiviral vector of claim 34, wherein the reporter molecule is selected
- 16 from the group consisting of: GFP, EGFP, dsRed, dsRed2, cyan fluorescent
- 17 protein, yellow fluorescent protein, blue fluorescent protein, dsRed, dsRed2,
- 18 luciferase, and aequorin.
- 19 36. The lentiviral vector of claim 34, further comprising an RNA polymerase
- 20 promoter.
- 21 37. The lentiviral vector of claim 36, wherein the RNA polymerase promoter is an
- 22 RNA polymerase III promoter.
- 23 38. The lentiviral vector of claim 1, wherein the lentiviral vector is a transfer
- 24 plasmid, further comprising a genetic element sufficient for stable
- 25 maintenance of the transfer plasmid as an episome within mammalian cells.
- 26 39. A lentiviral vector comprising an RNA polymerase III promoter.

- 1 40. The lentiviral vector of claim 39, wherein the RNA polymerase III promoter is
- 2 a U6 promoter.
- 3 41. The lentiviral vector of claim 39, wherein the RNA polymerase III promoter is
- 4 an H1 promoter.
- 5 42. The lentiviral vector of claim 39, further comprising a heterologous nucleic
- 6 acid encoding a reporter molecule.
- 7 43. A lentiviral vector having a sequence as set forth in SEQ ID NO: 2, SEQ ID
- 8 NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ
- 9 ID NO: 8, or SEQ ID NO: 9.
- 10 44. A collection of at least two of the lentiviral vectors of claim 43.
- 11 45. The collection of claim 44, wherein the collection includes a vector
- 12 comprising a first heterologous promoter element and a vector comprising a
- 13 second heterologous promoter element different from the first promoter
- 14 element.
- 15 46. The collection of claim 44, wherein the collection includes a vector
- 16 comprising a first heterologous reporter gene and a vector comprising a
- 17 second reporter gene different from the first reporter gene.
- 18 47. A lentiviral vector having a sequence that differs by not more than 100
- 19 nucleotides from the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 3,
- 20 SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO:
- 21 8, or SEQ ID NO: 9.
- 22 48. A collection of at least two of the lentiviral vectors of claim 47.
- 23 49. The collection of claim 47, wherein the collection includes a vector
- 24 comprising a first heterologous promoter element and a vector comprising a
- 25 second heterologous promoter element different from the first promoter
- 26 element.

- 1 50. The collection of claim 47, wherein the collection includes a vector
- 2 comprising a first heterologous reporter gene and a vector comprising a
- 3 second reporter gene different from the first reporter gene.
- 4 51. A lentiviral vector having a sequence that differs by not more than X
- 5 nucleotides from the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 3,
- 6 SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO:
- 7 8, or SEQ ID NO: 9, where X represents any number between 1 and 99,
- 8 inclusive.
- 9 52. A collection of at least two of the lentiviral vectors of claim 51.
- 10 53. A collection of at least two of the lentiviral vectors of claim 51.
- 11 54. The collection of claim 53, wherein the collection includes a vector
- 12 comprising a first heterologous promoter element and a vector comprising a
- 13 second heterologous promoter element different from the first promoter
- 14 element.
- 15 55. The collection of claim 53, wherein the collection includes a vector
- 16 comprising a first heterologous reporter gene and a vector comprising a
- 17 second reporter gene different from the first reporter gene.
- 18 56. A three-plasmid lentiviral expression system comprising:
  - 19 (a) a first plasmid whose sequence comprises a nucleic acid sequence
  - 20 of at least part of a lentiviral genome, wherein the plasmid (i) contains at least
  - 21 one defect in at least one gene encoding a lentiviral structural protein, and (ii)
  - 22 lacks a functional packaging signal;
  - 23 (b) a second plasmid whose sequence comprises a nucleic acid
  - 24 sequence of a virus, wherein the plasmid (i) expresses a viral envelope protein,
  - 25 and (ii) lacks a functional packaging signal; and
  - 26 (c) a third plasmid whose nucleic acid sequence includes (i) a
  - 27 functional packaging signal; (ii) a multiple cloning site (MCS); and (iii) at
  - 28 least one additional element selected from the group consisting of: a second
  - 29 MCS, a second MCS into which a heterologous nucleic acid is inserted; an

1           HIV FLAP element, an expression-enhancing posttranscriptional regulatory  
2           element, a target site for a site-specific recombinase, and a self-inactivating  
3           (SIN) LTR.

4    57.    A four plasmid lentiviral expression system comprising the three plasmid  
5           lentiviral expression system of claim 56, further comprising a fourth plasmid  
6           comprising a nucleic acid segment that encodes Rev, operably linked to a  
7           promoter.

8    58.    A cell comprising the lentiviral vector of claim 1.

9    59.    The cell of claim 58, wherein the cell comprises a nucleic acid or nucleic acids  
10           having sequences encoding Gag, Pol, and Env proteins.

11   60.    A cell comprising a provirus derived from the lentiviral vector of claim 1.

12   61.    A transgenic animal, at least some of whose cells contain the lentiviral vector  
13           of claim 1.

14   62.    A transgenic animal, at least some of whose cells contain a provirus derived  
15           from the lentiviral vector of claim 1.

16   63.    A method of creating a producer cell line comprising introducing the lentiviral  
17           vector of claim 1 into a host cell, wherein the lentiviral vector is a transfer  
18           plasmid; and introducing a packaging plasmid and an envelope plasmid into  
19           the host cell.

20   64.    A method of producing lentiviral particles comprising  
21                (i) introducing the lentiviral vector of claim 1 into a helper cell,  
22                wherein the lentiviral vector is a transfer plasmid comprising a genetic  
23                element sufficient for stable maintenance of the plasmid as an episome in  
24                mammalian cells, into a helper cell that expresses proteins required for  
25                production of infectious lentiviral particles; and  
26                (ii) culturing the cell for a period sufficient to allow production of  
27                lentiviral particles.

1 65. A method of producing lentiviral particles comprising  
2 (i) introducing the lentiviral vector of claim 1, which lentiviral vector  
3 is a lentiviral transfer plasmid comprising a genetic element sufficient for  
4 stable maintenance of the transfer plasmid as an episome in mammalian cells,  
5 into a helper cell that expresses a protein required for production of lentiviral  
6 particles, wherein expression of the protein is under control of an inducible  
7 promoter;  
8 (ii) inducing expression of the protein required for production of  
9 lentiviral particles; and  
10 (iii) culturing the cell for a period sufficient to allow production of  
11 lentiviral particles.

12 66. A method of expressing a heterologous nucleic acid in a target cell comprising  
13 introducing a lentiviral vector of claim 1 into the target cell, wherein  
14 the lentiviral vector comprises a heterologous nucleic acid operably linked to a  
15 promoter; and  
16 expressing the heterologous nucleic acid therein.

17 67. A method for achieving controlled expression of a heterologous nucleic acid  
18 in a cell comprising steps of:  
19 (i) providing a modified lentiviral vector comprising a heterologous  
20 nucleic acid inserted between sites for a recombinase;  
21 (ii) introducing the modified lentiviral vector or a portion thereof  
22 including at least the sites for the recombinase and the region between the sites  
23 into the cell and;  
24 (iii) subsequently inducing expression of the recombinase within the  
25 cell, thereby preventing expression of the heterologous nucleic acid within the  
26 cell.

27 68. The method of claim 67, wherein the providing step comprises inserting the  
28 heterologous nucleic acid into a lentiviral vector between sites for a  
29 recombinase, thereby producing a modified lentiviral vector.

30 69. The method of claim 67, wherein the cell is a mammalian cell.

1 70. A method for expressing a transcript in a mammal in a cell type or tissue-  
2 specific manner comprising:  
3 (i) delivering a lentiviral vector to cells of the mammal, wherein the  
4 lentiviral vector comprises a heterologous nucleic acid operably linked to a  
5 promoter so that transcription from the promoter results in synthesis of the  
6 transcript, and wherein the heterologous nucleic acid is located between sites  
7 for a site-specific recombinase; and  
8 (ii) inducing expression of the site-specific recombinase in a subset of  
9 the cells of the mammal, thereby preventing synthesis of the transcript within  
10 those cells.

11 71. The method of claim 67 or claim 70, wherein the step of inducing the site-  
12 specific recombinase comprises introducing a vector encoding the site-specific  
13 recombinase into the cell.

14 72. The method of claim 67 or claim 70, wherein expression of the site-specific  
15 recombinase is under control of a cell type specific or tissue specific promoter.

16 73. The method of claim 67 or claim 70, wherein the sites are loxP sites and the  
17 site-specific recombinase is loxP.

18 74. A lentiviral vector whose presence within a cell results in transcription of one  
19 or more ribonucleic acids (RNAs) that self-hybridize or hybridize to each  
20 other to form a short hairpin RNA or short interfering RNA that inhibits  
21 expression of at least one target transcript in the cell.

22 75. The lentiviral vector of claim 74, wherein the vector provides a template for  
23 synthesis of an RNA that self-hybridizes to form an shRNA that is targeted to  
24 the transcript.

25 76. The lentiviral vector of claim 75, wherein the shRNA comprises a loop having  
26 a sequence set forth in SEQ ID NO: 10.

- 1 77. The lentiviral vector of claim 74, wherein the vector provides a template for  
2 synthesis of complementary RNAs that hybridize with each other to form an  
3 siRNA that is targeted to the transcript.
- 4 78. The lentiviral vector of claim 74, wherein the vector comprises a nucleic acid  
5 segment operably linked to a promoter, so that transcription from the promoter  
6 results in synthesis of one or more RNAs that self-hybridize or hybridize with  
7 each other to form an shRNA or siRNA targeted to the transcript.
- 8 79. The composition of claim 74, wherein the lentiviral vector is a lentiviral  
9 transfer plasmid.
- 10 80. The composition of claim 74, wherein the lentiviral vector is an infectious  
11 lentiviral particle.
- 12 81. The lentiviral vector of claim 74, wherein:  
13 the shRNA or siRNA comprises a base-paired region approximately 19  
14 nucleotides long.
- 15 82. The lentiviral vector of claim 74, wherein:  
16 the shRNA or siRNA comprises a base-paired region and at least one  
17 single-stranded overhang.
- 18 83. The lentiviral vector of claim 74 wherein:  
19 the siRNA or shRNA comprises a 3' overhang consisting of at least  
20 two pyrimidines.
- 21 84. The lentiviral vector of claim 83, wherein the 3' overhang is UU.
- 22 85. The lentiviral vector of claim 74, wherein:  
23 the shRNA or siRNA comprises a region that is precisely  
24 complementary with a region of the target transcript.
- 25 86. The lentiviral vector of claim 74, wherein the siRNA or shRNA is present at a  
26 level sufficient to reduce the level of the target transcript or its encoded  
27 protein by at least about 2 fold.

- 1 87. The lentiviral vector of claim 74, wherein the siRNA or shRNA is present at a  
2 level sufficient to reduce the level of the target transcript or its encoded  
3 protein by at least about 5 fold.
- 4 88. The lentiviral vector of claim 74, wherein the siRNA or shRNA is present at a  
5 level sufficient to reduce the level of the target transcript or its encoded  
6 protein by at least about 10 fold.
- 7 89. The lentiviral vector of claim 74, wherein the siRNA or shRNA is present at a  
8 level sufficient to reduce the level of the target transcript or its encoded  
9 protein by at least about 25 fold.
- 10 90. The lentiviral vector of claim 74, wherein the lentiviral vector comprises:
  - 11 (i) a functional packaging signal;
  - 12 (ii) a multiple cloning site (MCS); and
  - 13 (iii) at least one additional element selected from the group consisting  
14 of: a second MCS, a second MCS into which a heterologous promoter or  
15 promoter-enhancer is inserted, an HIV FLAP element, an expression-  
16 enhancing posttranscriptional regulatory element, a target site for a site-  
17 specific recombinase, and a self-inactivating (SIN) LTR.
- 18 91. A composition comprising:
  - 19 the lentiviral vector of claim 74; and
  - 20 a delivery agent that enhances delivery of the vector to cells.
- 21 92. A pharmaceutical composition comprising:
  - 22 the lentiviral vector of claim 74; and
  - 23 a pharmaceutically acceptable carrier.
- 24 93. A three plasmid lentiviral expression system comprising (i) a lentiviral transfer  
25 plasmid comprising a heterologous nucleic acid operably linked to a promoter,  
26 so that transcription of the heterologous nucleic acid produces one or more  
27 RNAs that self-hybridize or hybridize with each other to form an shRNA or  
28 siRNA targeted to a target transcript; (ii) a packaging plasmid; and (iii) an  
29 Env-coding plasmid.

- 1 94. A four plasmid lentiviral expression system comprising the three plasmid  
2 lentiviral expression system of claim 93, further comprising a fourth plasmid  
3 comprising a nucleic acid segment that encodes Rev, operably linked to a  
4 promoter.
- 5 95. A method of inhibiting or reducing the expression of a target transcript in a  
6 cell comprising delivering the lentiviral vector of claim 74 to the cell.
- 7 96. The method of claim 95, wherein the lentiviral vector comprises:
  - 8 (i) a functional packaging signal;
  - 9 (ii) a multiple cloning site (MCS); and
  - 10 (iii) at least one additional element selected from the group consisting  
11 of: a second MCS, a second MCS into which a heterologous promoter or  
12 promoter-enhancer is inserted, an HIV FLAP element, an expression-  
13 enhancing posttranscriptional regulatory element, a target site for a site-  
14 specific recombinase, and a self-inactivating (SIN) LTR .
- 15 97. The method of claim 95, wherein the cell is a mammalian cell.
- 16 98. The method of claim 95, wherein the cell is a primary cell.
- 17 99. The method of claim 95, wherein the primary cell is a T cell.
- 18 100. The method of claim 95, wherein the cell is a non-dividing cell.
- 19 101. The method of claim 95, wherein the cell is an embryonic stem cell.
- 20 102. The method of claim 95, wherein the cell is a single-cell embryo.
- 21 103. The method of claim 95, wherein the lentiviral vector is a lentiviral transfer  
22 plasmid.
- 23 104. The method of claim 95, wherein the lentiviral vector is an infectious lentiviral  
24 particle.

1 105. The method of claim 95, wherein the ribonucleic acid comprises  
2 complementary regions that self-hybridize to form a short hairpin RNA  
3 targeted to the transcript.

4 106. A method of reversibly inhibiting or reducing expression of a target transcript  
5 in a cell comprising steps of:  
6 (i) delivering a lentiviral vector to the cell, wherein presence of the  
7 lentiviral vector within the cell results in synthesis of one or more RNAs that  
8 self-hybridize or hybridize with each other to form an shRNA or siRNA that  
9 inhibits expression of the target transcript, wherein the lentiviral vector  
10 comprises a nucleic acid segment located between sites for a site-specific  
11 recombinase, which nucleic acid segment provides a template for transcription  
12 of the one or more RNAs; and (ii) inducing expression of the site-specific  
13 recombinase within the cell, thereby preventing synthesis of at least one of the  
14 RNAs.

15 107. The method of claim 105, wherein the cell is a mammalian cell.

16 108. The method of claim 105, wherein the recombinase is Cre and the sites are  
17 loxP sites.

18 109. The method of claim 105, wherein the lentiviral vector is a lentiviral transfer  
19 plasmid.

20 110. The method of claim 105, wherein the lentiviral vector is a lentiviral particle.

21 111. The method of claim 105, wherein the lentiviral vector provides a template for  
22 synthesis of an RNA comprising complementary portions that hybridize to  
23 form an shRNA.

24 112. A method for reversibly inhibiting or reducing expression of a transcript in a  
25 mammal in a cell type or tissue-specific manner comprising:  
26 (i) delivering to the mammal a lentiviral vector whose presence within  
27 a cell results in synthesis of one or more RNAs that self-hybridize or hybridize  
28 with each other to form an shRNA or siRNA that inhibits expression of the

1 target transcript, wherein the lentiviral vector comprises a nucleic acid  
2 segment located between sites for a site-specific recombinase, which nucleic  
3 acid segment provides a template for transcription of the RNA; and  
4 (ii) inducing expression of the site-specific recombinase in a subset of  
5 the cells of the mammal, thereby preventing synthesis of at least one of the  
6 RNAs within the subset of cells.

7 113. The method of claim 112, wherein the recombinase is Cre and the sites are  
8 loxP sites.

9 114. The method of claim 112, wherein the lentiviral vector is a lentiviral transfer  
10 plasmid.

11 115. The method of claim 112, wherein the lentiviral vector is a lentiviral particle.

12 116. The method of claim 112, wherein the lentiviral vector provides a template for  
13 synthesis of an RNA comprising complementary portions that hybridize to  
14 form an shRNA.

15 117. A method of treating or preventing infection by an infectious agent, the  
16 method comprising steps of:  
17 administering to a subject prior to, simultaneously with, or after  
18 exposure of the subject to the infectious agent, a composition comprising an  
19 effective amount of a lentiviral vector, wherein presence of the lentiviral  
20 vector in a cell results in synthesis of one or more RNAs that self-hybridize or  
21 hybridize with each other to form an shRNA or siRNA that is targeted to a  
22 transcript produced during infection by the infectious agent, which transcript  
23 is characterized in that reduction in levels of the transcript delays, prevents, or  
24 inhibits one or more aspects of infection by or replication of the infectious  
25 agent.

26 118. The method of claim 117, wherein the lentiviral vector provides a template for  
27 synthesis of an RNA that comprises complementary portions that hybridize to  
28 form an shRNA.

1 119. A method of treating or preventing a disease or clinical condition, the method  
2 comprising:

3 removing a population of cells from a subject at risk of or suffering  
4 from disease or clinical condition;

5 engineering or manipulating the cells to contain an effective amount of  
6 an siRNA or shRNA targeted to a transcript, which transcript is characterized  
7 in that its degradation delays, prevents, or inhibits one or more aspects of the  
8 disease or clinical condition; and

9 returning at least a portion of the cells to the subject.

10 120. The method of claim 119 wherein:

11 the engineering or manipulating step comprises introducing a lentiviral  
12 vector into the cells, wherein presence of the lentiviral vector in a cell results  
13 in synthesis of one or more RNAs that self-hybridize or hybridize with each  
14 other to form an shRNA or siRNA targeted to the transcript.

15 121. The method of claim 119, wherein:

16 the cells comprise stem cells.

17 122. The method of claim 121, wherein:

18 the stem cells are peripheral blood stem cells.

19 123. The method of claim 119, further comprising:

20 expanding at least a portion of the cells in culture.

21 124. A kit comprising (a) a lentiviral transfer plasmid comprising a nucleic acid  
22 sequence including (i) a functional packaging signal; (ii) a multiple cloning  
23 site (MCS) into which a heterologous gene may be inserted; and (iii) at least  
24 one additional element selected from the group consisting of: a second MCS,  
25 an HIV FLAP element, a heterologous promoter, a heterologous enhancer, an  
26 expression-enhancing posttranscriptional regulatory element, a target site for a  
27 site-specific recombinase, and a self-inactivating (SIN) LTR; and one or more  
28 of the following items: (b) a packaging mix comprising one or more plasmids  
29 that collectively provide nucleic acid sequences coding for retroviral or

1           lentiviral Gag and Pol proteins and an envelope protein; (c) cells (e.g., a cell  
2           line) that are permissive for production of lentiviral particles such as 293T  
3           cells; (d) packaging cells, e.g., a cell line that is permissive for production of  
4           lentiviral particles and provides the proteins Gag, Pol, Env, and, optionally,  
5           Rev; (e) cells suitable for use in titering lentiviral particles; a transfection-  
6           enhancing agent such as Lipofectamine; (f) a selection agent such as an  
7           antibiotic, preferably corresponding to an antibiotic resistance gene in the  
8           lentiviral transfer plasmid; (g) instructions for use; (h) a positive control  
9           plasmid.  
10




Figure 1






FIGURE 2

## pLentiLox 3.1








FIGURE 5

## pLentiLox 3.4




FIGURE 6




FIGURE 7




FIGURE 8

## pLentiLox 3.7




FIGURE 9








Figure 10 A

HIV Provinces

Packaging  
ConstructRev-coding  
Plasmid

RSV REV polyA

RSV-Rev


Env-coding  
Plasmid

Figure 10B




Figure 11

## RNAi in *Drosophila*







Figure 12




A



B



C



D

FIGURE 13




Figure 14




Figure 15





Figure 16

Figure 17



**B CD8 Stem Loop Sequence**

+1  
 TGCTACAACTACATGACCTCAAGAGAGTCATGTTAGTTGAGCTTTTG  
 ACGATGTTGATGATGACTGAAAGTTCTCTCAGTACATCATCAACATCGAAAAAACATTG

Terminator  
 Loop

**C Predicted CD8 Stem Loop**

+1  
 GCUACAAACUACUACAUAGAC UU A  
 ||||| ||||| ||||| A  
 CGAUGUUGAUGAUACUG AG G  
 uu

Figure 18




Figure 19






Figure 20




Figure 21






FIGURE 22




A 50% confluent 10cm plate of D7 cells (Bear et al. 2000), was infected with 100ul of concentrated PLL3.7 B-catenin lentivirus, which expressed GFP as a transgene between two LoxP sites. Infected cells were sorted based upon expression of EGFP (**A, green line**). A 50% confluent 6cm-plate of sorted D7 pLL3.7 b-catenin cells was infected with adenovirus expressing the Cre recombinase.  $1 \times 10^5$  infectious units were used in the infection. Cells were expanded for 10 days to allow for expression of Cre protein, deletion of lox-CMVgfp-lox, and depletion of EGFP protein pools. Cells were then analyzed by flow cytometry for expression of EGFP (**B, pink line**). Cells were also sorted based upon loss of EGFP expression and expanded. Purple solid peak in A and B represent uninfected control. Percentage GFP<sup>+</sup> cells are shown on each plot. A direct comparison between PLL3.7 infected D7 cells before (**green line**) and after (**pink line**) Cre delivery is seen in **C**.


Figure 23



untransfected



transfected w/  
irrelevant stem loop



cd8 stem loop in LL2.7





Figure 24

Figure 25



(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number  
WO 2004/022722 A3

(51) International Patent Classification<sup>7</sup>: A61K 48/00, C12N 5/10, 7/01, 15/09, 15/63, 15/64, 15/867

(74) Agent: GERBER, Monica, R.; Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA 02109 (US).

(21) International Application Number:  
PCT/US2003/028111

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:  
5 September 2003 (05.09.2003)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language:  
English

(26) Publication Language:  
English

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(30) Priority Data:  
60/408,558 6 September 2002 (06.09.2002) US  
60/414,195 27 September 2002 (27.09.2002) US  
60/428,039 21 November 2002 (21.11.2002) US

(71) Applicant (for all designated States except US): MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; Five Cambridge Center, Cambridge, MA 02142-1493 (US).

(88) Date of publication of the international search report:  
25 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/022722 A3

(54) Title: LENTIVIRAL VECTORS, RELATED REAGENTS, AND METHODS OF USE THEREOF

(57) Abstract: The present invention provides new lentiviral vectors, including lentiviral transfer plasmids and infectious lentiviral particles. Lentiviral vectors of the invention were designed to offer a number of desirable features including reduced size, convenient cloning sites (including multiple cloning sites and sites for particularly useful restriction enzymes), loxP sites, self-inactivating LTRs, etc. Certain of the vectors are optimized for expression of reporter genes and/or for expression of siRNAs or shRNAs within eukaryotic cells. The invention also provides three and four plasmid lentiviral expression systems. In addition, the invention provides a variety of methods for using the vectors including gene silencing in cells and transgenic animals, and methods of treating disease.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/28111

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 48/00; C12N 5/10, 7/01, 15/09, 15/63, 15/64, 15/867  
 US CL : 435/320.1, 69.1, 455, 456, 457, 325, 366; 424/93.1, 93.2, 93.6

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 69.1, 455, 456, 457, 325, 366; 424/93.1, 93.2, 93.6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.                           |
|------------|--|---|
| X          | US 6,312,683 B1 (KINGSMAN et al.) 06 November 2001 (06.11.2001), Figures 1-12, columns 5-7, 16, 20 and 29.   | 1-2, 16, 24-26, 34-35, 58-60, 63-66 and 124     |
| X          | US 6,423,544 B1 (HARDY) 23 July 2002 (23.07.2002), Figure 9, columns 2, 7, 14, 33-34.  | 1-2, 16, 24-26, 34-35, 38, 58-60, 63-66 and 124 |
| A          | ZUFFEREY et al. Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery. Journal of Virology, December 1998, Vol. 72, No. 12, pages 9873-9880, especially the Abstract, page 9874 and Figure 1.   | 1-124   |
| A          | CISTERNI et al. Efficient Gene Transfer and Expression of Biologically Active Glial Cell Line-Derived Neurotrophic Factor in Rat Motoneurons Transduced with Lentiviral Vectors. Journal of Neurochemistry, 2000, Vol. 74, pages 1820-1828, especially page 1821 and Figure 1. | 1-124   |

Further documents are listed in the continuation of Box C.

See patent family annex.

|   |     |  |
|---|-----|--|
| Special categories of cited documents:  |     |  |
| "A" document defining the general state of the art which is not considered to be of particular relevance  | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| "E" earlier application or patent published on or after the international filing date   | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "U" document referring to an oral disclosure, use, exhibition or other means  | "&" | document member of the same patent family  |
| "P" document published prior to the international filing date but later than the priority date claimed  |     |  |

Date of the actual completion of the international search

19 April 2004 (19.04.2004)

Date of mailing of the international search report

12 OCT 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 Facsimile No. (703) 305-3230

Authorized officer

David Guzo

Telephone No. (571) 272-1600

*C. Roberts, Jr.*

**INTERNATIONAL SEARCH REPORT**

PCT/US03/0711

**Continuation of B. FIELDS SEARCHED Item 3:**

WEST, Dialog, Medline, Biosis, Biotech

Search terms: lentivirus, lentiviral vector, multiple cloning site, HIV FLAP, self-inactivating LTR, CMV, RNA polymerase promoter, sequence search